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The tumour necrosis factor (TNF) superfamily is a group of cytokines that 
orchestrate a variety of functions, both in the development of the architecture of 
immune organs and of the immune response. The mammalian TNF superfamily 
consists of 19 ligands and 29 receptors, whereas in the chicken only 10 ligands and 
15 receptors are present. Chickens do not develop lymph nodes, possibly due to the 
absence of the lymphotoxin genes (TNF superfamily members) in their genome. 
New members of the chicken TNF superfamily have recently been identified in the 
genome, namely chicken receptor activator of NF-κB ligand (chRANKL), its 
signalling receptor, chRANK, and its decoy receptor, osteoprotegerin (chOPG). In 
mammals, RANKL and RANK are transmembrane proteins expressed on the surface 
of Th1 cells and mature dendritic cells (DC), respectively. OPG is expressed as a 
soluble protein from osteoblasts and DC, regulating the interaction between RANKL 
and RANK. To investigate the bioactivity of this triad of molecules, the extracellular 
soluble domains of chRANKL and chRANK and full-length chOPG were identified 
and cDNAs cloned. ChRANKL, chRANK and chOPG mRNA are ubiquitously 
expressed across non-lymphoid and lymphoid tissues and immune cells in the 
chicken. Similar to mammals, chRANK and chOPG mRNA expression levels are 
upregulated in mature bone marrow-derived DC (BMDC). ChRANKL transcription 
is regulated by Ca
2+
-mobilisation and is further enhanced by the activation of the 
protein kinase C pathway, as seen in mammals. 
 The biological activities of chRANKL, chRANK and chOPG were 
investigated by the production of recombinant soluble fusion proteins. The 
extracellular, TNF-homology, domain of chRANKL (schRANKL) was sub-cloned 
into a modified pCI-neo vector expressing an in-frame isoleucine zipper to encourage 
trimer formation. FLAG-tagged schRANKL produced in COS-7 cells predominantly 
forms homotrimers and chOPG is expressed as homodimers, both signatures of their 
mammalian TNF superfamily orthologues. SchRANKL enhances the mRNA 
expression levels of pro-inflammatory cytokines in mature BMDC and BM-derived 
macrophages (BMDM). Pre-incubation with soluble chRANK-Fc or chOPG-Fc 
blocked the schRANKL-mediated increase in pro-inflammatory cytokine mRNA 
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expression levels in BMDC. Expression of surface markers on BMDC and BMDM 
were not affected by schRANKL treatment. SchRANKL enhances the survival rates 
of BMDC and BMDM and can drive osteoclast differentiation from 
monocyte/macrophage progenitor cells. 
The chRANKL signalling receptor, chRANK, does not contain an 
intracellular catalytic domain but requires the binding of intracellular TNF receptor-
associated factors (TRAF) to initiate signalling. TRAFs are a family of seven 
proteins (TRAF1-7) grouped due to their highly conserved RING domains, zinc 
finger domains, TRAF-N and TRAF-C domains. ChRANK possesses four of the five 
TRAF peptide-binding motifs found in mammalian RANK. The “missing” chRANK 
TRAF peptide-binding motif is TRAF6-specific, a vital protein for RANKL-
mediated osteoclastogenesis. All seven members of the mammalian TRAF family are 
present in the chicken genome. To investigate the conservation of RANK-specific 
TRAF signalling proteins, chicken TRAF2 (chTRAF2), chTRAF5, chTRAF6 and a 
newly found member, chTRAF7, were identified and their cDNAs cloned. 
ChTRAF5, chTRAF6 and chTRAF7 had mRNA expression patterns, in non-
lymphoid and lymphoid tissues and in a number of immune cells, similar to their 
orthologues in mammals. Interestingly, chTRAF2 has two variants, the full-length 
chTRAF2 and a novel isoform (chTRAF2S) lacking exon 4. ChTRAF2S lacks a 
portion of zinger finger one, all of zinc finger two and a portion of zinc finger three, 
producing a protein with a hybrid of zinc fingers 1 and 3 and intact zinc fingers 4 and 
5. RT-PCR analyses indicated differential expression of both of the chTRAF2 
isoforms in a number of non-lymphoid and lymphoid tissues, splenocyte subsets and 
in a kinetic study of ConA-stimulated splenocytes. ChTRAF2S is biologically active 
compared to chTRAF2, inducing higher levels of NF-κB activation. Co-transfections 
indicate that chTRAF2 may regulate chTRAF2S bioactivity as no synergistic effect 
was identified when cells were transfected with both isoforms.  
Knowledge gained from this study will help work to further dissect the 
interactions between chRANKL-expressing T cells and chRANK-expressing DC to 
drive Th1 immune responses and to understand how the chicken mounts an effective 
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1.1  Chicken health 
The poultry industry is growing in size. In the EU, there are over 350 million 
laying hens producing 100 billion eggs, annually (Tarlton et al., 2013). Chicken meat 
production has increased to around 91 million tonnes in 2012 and the average 
consumption of chicken meat has substantially increased from 11.1 kg in 2000 to 
14.6 kg in 2012 (http://www.thepoultrysite.com/articles/2640/global-poultry-trends-
2012). In order to raise as many birds, chickens are reared under intensive 
conditions. Chickens are selectively bred based on weight gain, feed conversion, 
muscle colour and egg production. For example, broilers selected to grow quickly 
can now reach 2 kg in body weight in only 35 days. This advancement in breeding 
has both positive and negative effects; poultry farmers can produce large quantities 
of eggs and chicken meat but the birds have decreased reproductive success and 
susceptible to a wide range of immune diseases (Harford et al., 2014; reviewed in 
Hocking, 2014).  
The development of bacterial antibiotic resistance led to the ban on the use of 
antibiotics in Europe, increasing the risk of outbreaks of bacterial and parasitic 
infections in poultry flocks. Newcastle disease virus (NDV), Marek’s disease virus 
(MDV) and avian influenza virus are now recognised as major destructive diseases in 
the poultry industry. NDV has a wide host range, infecting over 236 species of birds 
(Kaleta & Baldauf, 1988). Low virulent NDV induces subclinical disease with low 
morbidity whereas high virulent NDV causes rapid onset of disease and mortality. 
Marek’s disease is a highly contagious viral infection that causes major economic 
loss to the poultry industry (Biggs & Nair, 2012). It is not just poultry health that 
requires protection but also public health. Chickens are a source of zoonotic 
infection, with 60% of emerging human diseases from 1940 to 2004 being linked to a 
wildlife origin (Jones et al., 2008). The highly pathogenic avian influenza virus, 
H5N1, causes 100% mortality in infected birds and can also infect humans (Peiris et 
al., 2007).  
Vaccines have been successfully used for the last 30 years to prevent clinical 
disease and mortality. However, there is increasing evidence that vaccination is 
driving the evolution of viruses to overcome the immune response. It is evident that 
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the vaccination regime against MDV has increased the virulence of the virus with 
time (reviewed in Nair, 2005).  
The increase in zoonotic infections poses a serious threat to human and 
animal health. Understanding emerging disease outbreaks is hindered by their 
unpredictability, absence of effective control measures and lack of essential 
knowledge of the immune responses induced by zoonotic infections (Bean et al., 
2013). Progress in characterising the avian equivalent of mammalian immune genes 
has been slow due to the evolutionary distance between birds and mammals. For 
example, birds lack lymph nodes, create antibody diversity with a mechanism 
different to mammals (Glick, 1991) and have a reduced number of genes in their 
MHC (Kaufman et al., 1999). Amino acid identity can be as low as 25% between 
mammalian and avian immune proteins and therefore little or no cross-reactivity 
occurs with reagents and bioassays used for mammalian research (Kaiser, 2010). The 
greatest advance leading to the identification and cloning of avian immune genes was 
the release of the chicken genome sequence (Wallis et al., 2004). This, along with 
the availability of other avian genomes, such as the turkey (Dalloul et al., 2010), 
zebra finch (Warren et al., 2010) and duck (Huang et al., 2013), has provided a 
larger platform to identify chicken orthologues of mammalian immune genes and 
also avian-specific immune genes.  
1.2  Overview of the mammalian immune system  
The immune system encounters millions of different antigens daily which are 
constantly recognised by cells of the immune system. The immune system can be 
divided into two arms, innate and adaptive immunity. The innate immune system 
requires a number of cells, such as mast cells, dendritic cells (DC), macrophages, 
natural killer (NK) cells, basophils, eosinophils and γδ T cells, to recognize and kill 
invading pathogens. Cell receptors called pattern-recognition receptors (PRR) are 
required for the detection of components of bacteria, fungi and viruses and for the 
innate immune response to mould the adaptive immune response. The sites of 
lymphoid cell accumulations are termed primary and secondary lymphoid organs. 
Primary lymphoid organs (e.g. bone marrow, thymus and foetal liver) are the sites 
where naïve but functionally mature lymphocytes are generated in the absence of 
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antigen.  Cells from the primary lymphoid organs seed the secondary lymphoid 
organs (e.g. spleen, lymph nodes, Peyer’s patches and tonsils). During infection, 
specialised lymphoid organs appear in the lung, bronchus-associated lymphoid 
tissues (BALT), and in the intestine, intestinal lymphoid tissues (ILT) (Ruddle & 
Akirav, 2009). Lymph nodes are located at vascular junctions and have lymphatic 
vessels which allow the transport of antigens and cells from the blood into the lymph 
nodes. Another important lymphoid system is the mucosal-associated lymphoid 
tissues (MALT) which are a major producer of IgA and responsible for maintaining 
tolerance to commensal bacteria and food allergens. The MALT accounts for ~60% 
of the total body’s immune system and produces over ~80% of the body’s 
immunoglobulin per day (Brandtzaeg et al., 1989). The MALT protects the host 
against pathogen invasion in the gastrointestinal tract, respiratory tract, nasal 
passages, uro-genital tract and mammary glands (Kudsk, 2002).  
1.2.1  Pattern Recognition Receptors  
The innate immune system was once thought to be non-specific. However, it 
is able to discriminate between “self” and a variety of pathogens. The innate immune 
system can recognise pathogens by germline-encoded PRR. These have the 
advantage of being independent of immunological memory and they recognise 
pathogen-associated molecular patterns (PAMP), small molecular molecules 
common within a class of microbes which are usually vital for the survival of the 
incoming pathogens and therefore rarely able to be mutated. PRR are constitutively 
expressed in the host and can recognise the pathogen at any stage of their cell cycle 
(Kaisho & Akira, 2006). Different PRR react with different PAMP, leading to the 
activation of specific downstream signalling pathways that drive distinct immune 
responses. The most studied PRRs are the Toll-like receptor (TLR) family. TLRs are 
evolutionarily conserved from Caenorhabditis elegans to mammals. Toll, the 
founding member of the family, was first identified in Drosophila and is vital for 
antifungal immunity (Lemaitre et al., 1996). Humans express 10 TLRs (TLR1-10) 
while mice express 12 (TLR1-9, TLR11-13), each of which differs in their 
recognition of PAMPs, their subcellular location and the nature of their responses. 
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TLRs are type I transmembrane glycoproteins which are expressed on the cell 
membrane (TLR1, TLR2, TLR4, TLR5 and TLR6) or intracellularly, such as in 
endosomes (TLR3, TLR7, TLR8 and TLR9). Their extracellular domains are 
characterised by leucine-rich repeats (LRR), with 19-25 LRR motifs, each of which 
are 24-29 amino acids in length, responsible for pathogen recognition. This is 
followed by the transmembrane domain and the intracellular region containing 
Toll/interleukin (IL)-1R homology domains (TIR), that are responsible for recruiting 
adaptor proteins, such as myeloid differentiation primary response gene 88 (MyD88) 
and other adaptor proteins that activate signal transduction cascades. Surface TLRs 
engage a core signalling pathway, leading to the activation of nuclear factor kappa- 
light-chain-enhancer of activated B cells (NF-κB), activator protein-1 (AP-1) and 
other transcription factors involved in pro-inflammatory cytokine and chemokine 
expression (O’Neill & Bowie, 2007). TLRs are expressed on a number of 
lymphocytes and epithelial cells of mucosal surfaces (Muzio et al., 2000; Zarember 
et al., 2002) and are expressed in macrophages and subsets of DC (Kadowaki et al., 
2001).  
The TLR family can be sub-divided into six families based on sequence 
homology; TLR1, TLR2, TLR4, TLR5, TLR7 and TLR11 sub-families. The TLR1 
family is made up of TLR1, TLR6 and TLR10, each residing on the cell membrane. 
In mammals TLR1, TLR6 and TLR10 genes are tandemly arranged and seem to have 
arisen due to gene duplication events. Each recognises components of microbial cell 
walls, such as lipoproteins and peptidoglycans, with only the TLR10 agonist not yet 
fully identified (Guan et al., 2010). All members of the TLR1 family can form 
heterodimers with TLR2 (Ozinsky et al., 2000). Ben-Ali et al. (2011) carried out an 
extensive analysis of the extent of amino acid sequence-altering variation on the 
effects of TLR1, TLR2 and TLR6 functions and host genetics in disease susceptibly 
and progression in humans. Their work suggested that amino acid alterations are a 
constraint for TLR2 compared to TLR1 and TLR6. Evolutionary and functional data 
suggest that TLR2 fulfils an essential function in innate immune responses and its 
ability to form heterodimers with TLR1 and TLR6 broadens the ability of the host to 
recognise PAMPs (Farhat et al., 2008). TLR4 and TLR5 are cell surface proteins that 
recognise bacterial LPS and flagella, respectively. TLR4, upon binding to LPS, is 
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trafficked to endosomal membranes where it can activate the production of type I 
interferon (IFN) (Husebye et al., 2006).  
TLR3, TLR7, TLR9 and TLR11 are intracellular TLRs found in endosomes 
and lysosomes, which are more suitable locations to detect viruses. All four require 
the protein UNC93B1 for transportation from the endoplasmic reticulum to the 
endolysosomal compartments where they are processed by proteases to become 
functional receptors (Brinkmann et al., 2007; Kim et al., 2008; Lee et al., 2013). 
TLR3 recognises double-stranded RNA (dsRNA) to induce pro-inflammatory 
cytokines and IFNs production (Alexopoulou et al., 2001). The TLR7 family is made 
up of TLR7, TLR8 and TLR9. Both TLR7 and TLR8 detect single-stranded RNA 
(ssRNA) while TLR9 detects unmethylated CpG DNA (Kreig & Vollmer, 2007). 
The TLR11 family consists of TLR11, TLR12 and TLR13 (Zhang et al., 2004). 
TLR11 and TLR12 can form heterodimers which are vital for the detection of and 
immune responses against profilin from Toxoplasma gondii (Andrade et al., 2013). 
TLR13 can detect bacterial 23S ribosomal RNA (Li & Chen, 2012). Humans do not 
possess orthologues of TLR11, TLR12 and TLR13. In fish and frogs the TLR11 
family members are called TLR21-TLR23 (Roach et al., 2005).  
In addition to TLRs, the innate immune system in vertebrate animals consists 
of other PAMP receptors, including retinoic acid-inducible gene-1 (RIG-I)-like 
receptors (RLR), nucleotide-binding oligomerisation domain (NOD)-like receptors 
(NLR) and C-type lectin receptors (CLR). The type I IFN system is a powerful and 
vital strategy against viral infection (Samuel, 2001). RLR specifically detect viral 
RNA in the cytoplasm and there are three family members. RIG-I possesses a central 
DExD/H box RNA helicase domain involved in RNA binding and two caspase 
recruitment domains (CARD) at its NH2-terminus required for the recruitment of 
downstream IFN-β promoter stimulator-1 (IPS-1) (Yoneyama et al., 2004). 
Melanoma differentiation-associated gene-5 (MDA-5) is the second member of the 
RLR family and is similar to RIG-I, possessing two CARD (Kang et al., 2002). RIG-
I and MDA-5 recognize different types of RNA; RIG-I detects short dsRNA (<1 kb) 
or RNA in complex secondary structures whereas MDA-5 detects long dsRNA (>1 
kb) (Loo et al., 2008). The CARD regions of RLR interact with the CARD regions of 
6 
 
the mitochondrial antiviral-signalling protein (MAVS), which recruits multiple 
proteins to assemble a multiprotein complex anchored to the mitochondria where it 
coordinates signalling events initiated by RIG-I and MDA-5 (Belgnaoui et al., 2011). 
The third member, called laboratory of genetics and physiology 2 (LGP2) (Kang et 
al., 2002), does not possess CARD regions and negatively regulates RIG-I and 
MDA-5 signalling (Rothenfusser et al., 2005). However, LPG2 can detect dsRNA 
but its role in antiviral activity remains unclear. LPG2 overexpression does not 
activate IFN-α or IFN-β transcription and can block RIG-I-mediated IFN induction 
(Rothenfusser et al., 2005) but is required for MDA-5 signalling (Pippig et al., 
2009). More studies are required to understand the role of mammalian LPG2 in 
antiviral immune responses.   
The NLR family members work as cytosolic receptors that sense intracellular 
PAMPs. These proteins are characterised by the presence of a NACHT nucleotide-
binding domain with a COOH-terminal domain containing multiple LRR motifs that 
sense their ligands (Ting et al., 2010). There are at least 23 NLR members in humans 
and 34 members in mice (Liu et al., 2013). NOD1 and NOD2 are the prototypical 
members of the NOD-like receptor family and sense various bacterial peptidoglycan 
fragments inducing pro-inflammatory cytokine expression and autophagy (Travassos 
et al., 2010; Boyle et al., 2013). The well-studied pathway of several NLR is the 
assembly of the multi-protein complex, the inflammasome, which includes caspase 1. 
Inflammasome complexes induce the proteolytic cleavage of pro-IL-1β and pro-IL-
18 allowing release of the soluble pro-inflammatory cytokines IL-1β and IL-18 
(Elinav et al., 2011). These cytokines can initiate a number of biological processes, 
such as neutrophil influx and the activation of T helper (Th) cells, depending on the 
presence of other cytokines, such as IL-17, IL-4 or IL-12 and IFN-γ (reviewed by 
Keyel, 2014). 
CLR are a large superfamily of proteins that possess one or more structurally 
related C-type lectin-like domains. Extracellular and transmembrane members are 
involved in antifungal immunity by binding to the fungus and mediating its uptake, 
subsequent killing and appropriate modulation of the immune response. The best 
characterised members of the CLR superfamily are the mannose receptor (MR), 
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dectin-1 and DC-specific intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN) (Willment & Brown, 2008). MR is a transmembrane protein with eight 
extracellular C-type lectin-like domains. MR can recognise both bacterial pathogens 
and fungi and induces a variety of cellular responses upon recognition of fungi, such 
as activation of the NF-κB pathway which induces pro-inflammatory cytokine 
expression (Zhang et al., 2005). Dectin-1 has a single carbohydrate-recognition 
domain and an intracellular tyrosine-based activation motif-like domain (Brown, 
2006). It can recognise a number of fungal species mediating their uptake and killing 
by inducing the expression of tumour necrosis factor (TNF)-α, IL-2, IL-10, IL-6 and 
IL-23 (LeibundGut-Landmann et al., 2007). DC-SIGN is found primarily in 
microdomains of immature DC (Cambi et al., 2003). Eight orthologues have been 
identified in mice, each one is differentially distributed and all are structurally 
different. DC-SIGN detects carbohydrates with high mannose structures in a calcium 
ion (Ca
2+
)-dependent fashion (Powlesland et al., 2006). 
1.2.2  Cells of the innate immune system 
PRR are expressed on a number of innate immune cells, such as NK, DC and 
macrophages. NK cells are large granular lymphocytes that are involved in innate 
immunity against bacteria, viruses and parasites. These cells share many features 
with T cells. NK cells have two major effector functions: direct cytolysis and 
production of pro-inflammatory chemokines and cytokines (Martin-Fontecha et al., 
2004).  The ability of cells to undergo cytotoxicity has been due to the development 
of a sophisticated and robust system to control cellular processes while not damaging 
healthy tissue. NK cells can detect the presence of both negative and positive signals 
which may cooperate or antagonise each other, called the dynamic equilibrium 
concept (Vivier et al., 2004). NK cells use inhibitory receptors to gauge the absence 
of constitutively expressed self-molecules on target cells. NK cells express inhibitors 
for MHC class I molecules that include killer cell Ig-like receptors (KLR) in humans, 
Ly49 in mice and NKG2A conserved in both species. A conserved feature of these 
molecules is the presence of one or two intracytoplasmic domains called 
immunoreceptor tyrosine-based activation motifs (ITAM) (Anfossi et al., 2006).  
These molecules interact with constitutively expressed MHC class I molecules on the 
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surface of healthy cells which may be lost when cells undergo stress or infection. NK 
cells lose their inhibitory characteristics when they come into contact with “missing 
self” cells and activate their effector functions.  
B and T lymphocytes are mediators of adaptive immunity but their activation 
and effector functions are controlled by antigen-presenting cells (APC), such as DC 
and macrophages. DC are a heterogeneous cell population which have the capacity to 
present antigen to B and T lymphocytes (Steinman, 1991). DC capture antigen by 
three approaches: phagocytosis, macropinocytosis and receptor-mediated endocytosis 
(Sallusto et al., 1995). During non-inflammatory conditions there are two types of 
DC, plasmacytoid DC (pDC) and conventional DC (cDC). pDC circulate through 
tissues and produce large amounts of type I IFN at sites of viral infection (Yang et 
al., 2005). cDC consist of both lymph node-resident and migratory cells. Resident 
cDC are maintained in a steady state of immaturity in the lymph node tissues where 
they survey the surrounding environment and the blood for signs of infection 
(Wilson et al., 2003). In the mouse, resident cDC can be subdivided by their surface 













 cDC. Each cell type differs in their 
cytokine and chemokine production profiles upon antigenic exposure (Proietto et al., 
2004). Migratory cDC circulate in the peripheral tissues and upon detection and 
phagocytosis of the antigen they migrate to the draining lymph nodes where they 
present antigenic peptides in the context of MHC molecules to the T cell receptor 
(TCR) (Banchereau & Steinman, 1998). Again these cells can be further categorised 




 cDC are potent presenters of antigen by 





 cDC are characterised by their ability to present antigenic 
peptides to CD8
+
 T cells by MHC class I molecules and the initiation of a Th1 
immune response (Proietto et al., 2004). 
Macrophages are found in all tissues where they display functional diversity 
and have roles in every aspect of an organism’s biology, such as development, repair, 
homeostasis and immune response to pathogens (Wynn et al., 2013).  Macrophages 
are a heterogeneous family of phagocytic cells. In response to pathogens, 
9 
 
macrophages are polarised phenotypically. For example, when activated by IFN-γ or 
TLR interaction, macrophages undergo classical activation (M1), whereas 
alternatively activated macrophages (M2) are elicited by Th2-type cytokines, such as 
IL-4, IL-13 and IL-21, which are produced during helminth infection (Biswas & 
Mantovani, 2010). M1 cells produce large amounts of pro-inflammatory cytokines, 
such as IL-12, TNF-α and IL-23, express MHC class II molecules and produce 
reactive nitrogen intermediates. M2 cells are more potent phagocytes and express 
higher levels of mannose and galactose receptors, low expression of IL-12 and high 
expression of IL-10 and IL-1RN (Mantovani et al., 2002).   
The most important characteristic of APC is their ability to present antigen to 
the effector cells of adaptive immunity. Antigens phagocytosed by APC are 
processed by degradation to small peptides that dock with and are presented by MHC 
molecules. MCH class I and class II molecules are similar in function; they present 




 T cells, respectively. MHC class I 
molecules present peptides from intracellular sources whereas MHC class II 
molecules present exogenous peptides (reviewed in Vyas et al., 2008). Intracellular 
antigens are degraded by cytosolic proteasomes and peptide fragments are then 
transported to the endoplasmic reticulum (ER) by the transporter-associated with 
antigen presentation (TAP) proteins where they encounter the MHC class I 
molecules. Within the ER, the MHC class I heterodimer is assembled with a 
polymorphic heavy chain and a light chain called β2-microglobulin. This heterodimer 
complex is stabilised by the docking of the 8-9 amino acid antigen peptide fragment 
whereupon the MHC class I complex exits the ER to present the peptide at the cell 
surface (reviewed by Neefjes et al., 2011). MHC class II molecules are assembled in 
the ER where the transmembrane α and β chains associate with the invariant chain. 
This complex is transported to the late endosomal compartment where the invariant 
chain is digested and the class II-associated invariant chain peptide (CLIP) resides in 
the peptide-binding groove of the MHC class II molecule. MHC class II molecules 
will dissociate CLIP to allow peptide fragments degraded in the endosomal 
compartments to bind and then travel to the plasma membrane for presentation to T 
cells (reviewed by Neefjes et al., 2011). Although both MHC class I and II molecules 
are assembled in the ER, MHC class I molecules require the binding of a peptide to 
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exit the ER, whereas MHC class II molecules associate with the invariant chain 
allowing their transport from the ER.  
1.2.3  B and T cell receptors  
Adaptive immunity is required for the late phase of infection that is 
characterised by its exquisite specificity, clonal expansion of lymphocytes expressing 
antigen-specific receptors and generation of immunological memory. B and T cells 
have major roles in the development and organisation of adaptive immunity. In the 
adaptive immune response, antigen is recognised by two distinct sets of highly 
variable receptors, the B cell receptor (BCR) and the TCR. To protect against 
pathogens, the host needs to generate a diverse pool of BCR that will recognize a 
broad range of antigens. Human and mouse B cell development occur in the bone 
marrow where stromal cells induce the differentiation of common lymphoid 
progenitor cells (CLP) into multi-potential pre-B cells (Izon et al., 2001). These B 
cell progenitors go through a process of assembling their BCR and signalling 




 B cells. The basic subunits 
of a Y-shaped antibody molecule are a pair of identical heavy-chains and a pair of 
identical light-chains that are bound by non-covalent bonds and disulphide bridges. 
The NH2-terminal region of an antibody molecule is called the variable region, as it 
has a unique amino acid sequence that is involved in binding with the antigen. The 
COOH-terminal region is known as the constant region and only comes in a few 
forms. The constant region provides the class and the function of the antibody. The 
variable regions of the heavy chain are assembled from germline-encoded variable 
(V), diversity (D) and joining (J) gene segments, whereas the light chain is 
assembled using V and J segments, by a process called V(D)J recombination 
(Tonegawa, 1983). While the light chain may be less diverse by not encoding D 
segments, its diversity is derived from the presence of two independent genes, κ and 
λ, either of which can be recombined to form light chains. Recombination occurs 
between two segments expressing recombination signals (RS). The RS are highly 
conserved heptamer and nonamer sequences separated by 12 bp and 23 bp spacer 
sequences (12/23 bp rule). Therefore rearrangement takes place between a RS with a 
12 bp spacer and a 23 bp spacer allowing for the docking and activation of the 
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recombination activating gene-1 (RAG-1) and RAG-2, forming the RAG 
endonuclease complex which introduces single-strand nicks to form a hairpin 
structure (Oettinger et al., 1990). The RS regions are joined together while the 
coding ends are modified by potential nucleotide loss or addition (Tonegawa, 1983).  
The potential of variation within the variable region of the antibody can been 
seen in the mouse heavy chain locus that spans 3 Mb and consists of over 150 VH 
genes, 4-5 DH genes and 4 JH genes. Somatic hypermutation also induces more 
diversity into the variable regions of immunoglobulins by introducing point 
mutations into the V exons and into the introns upstream of the J regions. This 
increases DNA sequence diversity but also allows for the selection of B cell clones 
with stronger affinity for the antigen (Di Noia et al., 2007).  
Antigen recognition by T cells requires the expression of TCR. TCR are 
heterodimeric proteins expressed on the membrane surface composed of two 
immunoglobulin domains. Vertebrates possess four TCR chains, α, β, γ and δ, which 
form αβ or γδ heterodimers connected by a disulphide chain. The variable region 
consists of a V-type Ig domain linked to a D and J segment (TCRβ and TCRδ) or a V 
domain linked to a J segment (TCRα and TCRγ). As with antibodies, TCR diversity 
occurs via the recombination of the heavy and light chains and within the area of the 
V(D)J joins, called the complementarity-determining region 3 (CDR3), various 
deletions/additions of nucleotides introduce additional variability. T cells migrate 








) when they undergo β, γ or δ chain rearrangement (Burtrum et 
al., 1996) expressing a single chain at their surface. When the β chain is expressed, 









) becoming double-positive (DP) cells leading to the 
rearrangement of the α-chain. These DP cells undergo positive and negative selection 




 single-positive αβ T cells. CD4
+
 αβ T cells 
recognise peptide complexed to MHC class II molecules and CD8
+
 cells recognise 
peptide complexed to MHC class I molecules. The mature TCR has no catalytic 
function but signals through intracellular tyrosine-based ITAM motif-containing 
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TCR-associated molecules, CD3γε, CD3δε and CD3ζζ (Samelson, 2002), which 
ultimately activate the T lymphocytes after the initial recognition steps. 
As for γδ T cells, after productive recombination and correct pairing, a subset 
of these cells leave the thymus and populate secondary lymphoid organs 
(Turchinovich & Pennington, 2011), as another subset of γδ T cells undergo further 
differentiation in the thymus to become IL-17A-producing γδ T cells, dendritic 
epithermal γδ T cells and NK γδ T cells (Haas et al., 2009). γδ T cells can be further 
sub-categorised by the expression of different TCR segments. In the mouse, 
subpopulations of γδ T cells can be distinguished in the skin (Vδ5), spleen and 
intestine (Vδ1) (Haas et al., 1993). γδ T cells have both activating and regulatory 
roles in controlling both the innate and adaptive immune system (He et al., 2014). 
1.2.4  T helper cells 
A protective immune response often relies on the ability of conventional 
CD4
+
 T cells to accumulate high numbers of effector cells to activate a strong 
reaction against the invading pathogen. The primary response of T cells takes place 
over 3-7 days. They can also differentiate into follicular T (TFh) cells to promote B 
cell immunity and antibody production, generally taking 5-15 days. During this 
period T cells have the opportunity to come into contact with both lymphoid (DC, B 
cells) and non-lymphoid (stromal, epithelial cells) cells and each surface receptor 
contact may direct, modulate or control the activity of the T cell. The existence of 
distinctive populations of differentiated CD4
+
 T cells was first demonstrated by 
Mosmann & Coffmann in 1986 from in vitro murine T cell clones. Each cell type can 
be distinguished by their signature cytokine expression and pattern of cell surface 
markers (Mosmann & Coffmann, 1986; Killar et al., 1986). These effector T helper 
cells were named Th1 and Th2 cells and investigations into their roles in immunity 
dominated the field of immunology for over 15 years.  
The differentiation and activation of CD4
+
 T cells is regulated by three 
signalling components: the TCR (Signal 1), costimulatory molecules (Signal 2) and 
the cytokine receptors (Signal 3) on the surface of cells (Nagashima et al., 2014). 
Binding of the cytokine receptors serves an essential role in the lineage decision of 
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the Th subsets. However, it has been proposed that the antigen dosage, co-
stimulators, genetic modifiers and non-cytokine factors can have a role in the lineage 
pathway (Murphy & Reiner, 2002). The presentation of antigen by MHC class II to 
naïve CD4
+
 T cells leads to the upregulation of certain transcriptional machinery that 
activates the appropriate effector T cells. The T box expressed in T cells (T-bet) 
transcription factor has a central role in Th1 differentiation, required to control 
infection with intracellular pathogens. T-bet induces the transcription of the loci 
encoding IFN-γ and lymphotoxin and increases the cells responsiveness to IL-12 by 
inducing the expression of the IL-12βR (Szabo et al., 2002).  
Th2 differentiation is dependent on the expression of IL-4 which is controlled 
by c-MAF, a member of the basic leucine zipper family of proteins (Ho et al., 1998). 
The activation and increase in signal transducer and activator of transcription 
(STAT)-6 expression is quickly followed by the expression of IL-4 and leads to 
GATA-binding protein 3 (GATA3) expression. GATA3 transactivates the IL-5 
promoter and also drives the expression of IL-4, IL-13 and IL-25, producing Th2 
cells (Zhang et al., 1997; Ouyang et al., 2000). These cytokines protect against 
extracellular pathogens by orchestrating a humoral response through the induction of 
immunoglobulin class switching of IgG and IgE. The cytokines produced by either 
Th subsets negatively regulate the other. For example, IL-12 signalling via STAT4 is 
required for the repression of GATA3 (Ouyang et al, 1998) whereas IL-4 represses 
the expression of IL-12 receptors on the surface of naïve T cells (Murphy et al., 
1997). Terminally differentiated T cells can be driven to induce their signature 
cytokines by the presence of other cytokines. For example, IL-12 and IL-18 
synergise to drive Th1 cells to produce IFN-γ (Robinson et al., 1997; Neighbors et 
al., 2001).  
Since the identification of the Th1 and Th2 paradigm, various other Th 
subsets have been identified in mammals (Figure 1.1). As mentioned previously, IL-
12 is a signature cytokine of Th1 cells. This is a heterodimeric protein consisting of 
two chains, α (p35) and β (p40). p35 or p40 knockout mice differed in their ability to 
clear an infection (Brombacher et al., 1999). Soon after, it was demonstrated that the 




Figure 1.1 Overview of mammalian Th cells.  Naïve Th0 cells differentiate under 
various immunological conditions that produce their driving cytokines and activate 
the transcription factors required for their maintenance and the expression of their 
effector cytokines.  
 
IL-23 (Oppmann et al., 2000). In 2003, IL-23 was identified as the cytokine 
responsible for joint autoimmune inflammation (Murphy et al., 2003). IL-23
-/-
 (p19) 
mice were immune to collagen-induced arthritis and lacked IL-17-producing T cells 
at the site of infection (Murphy et al., 2003). The development of IL-17-producing 
CD4
+
 T cells was inhibited by the presence of IL-4 or IFN-γ, indicating a T cell 
lineage not associated with Th1 or Th2 (Harrington et al., 2005). The newly 
identified IL-17A-, IL-17F-, IL-21- and IL-22-producing Th17 cells require the 
presence of IL-6 and TGF-β to activate STAT3 and induce the expression of 
transcription factors, RAR-related orphan receptor-γt (RORγt) and RORα (Ivanov et 
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al., 2007). IL-23 is required to sustain Th17 cells but not their differentiation (Ivanov 
et al., 2007). Th17 cells are required for the control of a variety of bacterial and 
fungal infections in the mucosa (Liang et al., 2006). Th1/Th17 pathogenesis has been 
linked to a number of autoimmune diseases, with IFN-γ and IL-17 expression 
associated with prolonged and uncontrolled inflammation. The pathogenesis of these 
cytokines contributes to disorders such as experimental autoimmune 
encephalomyelitis (EAE), a model for multiple sclerosis (MS), and collagen-induced 
arthritis (CIA), a model for rheumatoid arthritis (RA) in mice. These diseases arise 
from a break in tolerance of self-antigens and the development of auto-aggressive 
effector T cells infiltrating the target tissues (Leung et al., 2010).  
T cells can also differentiate into regulatory cells where they can have 
immunosuppressive functions to control against damaging self-reactivity. Self-
reactive T and B cells are exposed to self-antigens during stages of their development 
and this is one of the major mechanisms of discriminating between self and non-self 
(self-tolerance). Activation and expansion of T cells that have escaped clonal 
deletion during the thymus selection process are actively suppressed in the periphery 




 regulatory T (Treg) cells (Sakaguchi et 





 T cells (Apostolou et al., 2002). A number of diseases are attributed to the 
loss or malfunction of Treg cells, such as immune dysregulation, polyendocrinopathy 
enteropathy X-linked syndrome and scurfy. These autoimmune diseases are linked to 
uncontrolled expansion of CD4
+
 T cells and further analysis identified a common 
mutation in one gene, a forkhead-winged helix transcription factor called Forkhead 
box P3 (FoxP3) (Hori et al., 2003). The FoxP3 transcription factor is necessary for 




 Treg cells in the thymus (Fontenot et al., 2003). 
Treg cells inhibit the activation and production of IL-2 by a contact-dependent 
mechanism and produce huge amounts of the anti-inflammatory cytokine, IL-10 
(Dieckmann et al., 2001). Recently, two further Treg cell populations have been 
identified in mammals, FoxP
-
 Treg cells that are found in the periphery called pTreg 
and inducible Treg cells (iTregs) which are differentiated independent of the thymus 
in the presence of TGF-β (Chen et al., 2003). Treg cells have also been implicated in 
targeting DC by expressing the cytotoxic T-lymphocyte antigen-4 (CTLA-4). Studies 
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suggest that CTLA-4-expressing Treg cells interact with CD80/CD86 on the surface 
of DC and inhibit effective T cell activation (Larsson et al., 2009). Treg cells also 
express lymphocyte activation gene-3 (LAG-3), a CD4 homologue that can bind to 
MHC class II on DC and suppress their maturation (Bruniquel et al., 1998). Tr1 is 
another subfamily of regulatory T cell subsets that can suppress immune responses 
through a contact-independent approach by producing large amounts of IL-10. Tr1 
cell differentiation is driven by IL-27 and TGF-β and they do not express the FoxP3 
transcription factor (Awasthi et al., 2007) 
IL-9- (Th9) and IL-22- (Th22) producing Th cells have recently been added 
to the list of CD4
+
 T cells. IL-4 inhibits TGF-β-mediated upregulation of FoxP3 
expression. The stimulation of CD4
+
 T cells with both IL-4 and TGF-β led to 
unexpected Th cells, expressing both IL-9 and IL-10, now called Th9 cells. Th9 cells 
have the ability to enhance proliferation of fellow Th cells but also have a role in 
autoimmune disease (Dardalhon et al., 2008). Th22 cells produce IL-22 without IL-
17 production and express the skin cell-homing chemokines, CCR4 and CCR10 
(Duhen et al., 2009). IL-6 and TNF-α synergise to enhance IL-22 production in these 
cells (Duhen et al., 2009). TFh cells are an important Th cell subset involved in T-
dependent B cell responses. These CXCR5-expressing cells are less dependent on 
cytokines and transcription factors for their differentiation (Nurieva et al., 2008). 
TFh cell differentiation is driven by the transcriptional repressor B cell lymphoma-6 
(Bcl-6) (Yu et al., 2009) and they produce copious amounts of the plasma cell 
inducer cytokine, IL-21 (Zotos et al., 2010).  
1.3  Overview of the chicken’s immune system  
Like mammals, chickens have developed innate and adaptive immune 
responses to protect against a range of pathogens. Major differences have been 
identified between the mammalian immune system and that of chickens. Chickens 
lack lymph nodes and functional eosinophils, possess a unique organ for B cell 
development, perform BCR repertoire variation using a different mechanism to that 
seen in mammals and possess only three Ig isotypes. Although mammals and birds 
arose from a common ancestor over 300 million years ago, the chicken represents a 
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species with a more primitive immune system that carries out an immune response 
with much less architecture and sophistication than the mammalian immune system. 
1.3.1  Chicken PRRs 
Like mammals, the chicken innate immune system relies on the detection of 
PAMPs with germline-encoded PRR, such as TLR, RLR, NLR and CLR family 
members. The avian repertoire of TLR comprises mammalian orthologues and avian-
specific members (Table 1.1). The mammalian TLR1 family (TLR1, TLR6 & 
TLR10) can form heterodimers with TLR2 to increase the capacity of the innate 
immune system to detect invading pathogens (Ozinsky et al., 2000). In the chicken, 
the TLR1 family is represented by tandemly duplicated TLR1-like genes, chTLR1-
like a (TLR1La), chTLR1Lb and two TLR2-like genes, chTLR2a and chTLR2b 
(Boyd et al., 2001; Fukui et al., 2001). These molecules, like mammalian TLR2, can 
form heterodimers to increase the capacity of the chicken’s innate immune system to 
detect PAMPs (Higuchi et al., 2008). ChTLR2a and chTLR2b vary in their capacities 
to respond to TLR2 antagonists. For example, the chTLR2a and chTLR1b 
heterodimer exclusively recognises peptidoglycan of mycobacterial origin and react 
more robustly to Mycobacterium avium exposure (Higuchi et al., 2008). Chickens 
have orthologues of TLR3 (Schwarz et al., 2007), TLR4 (Leveque et al., 2003), 
TLR5 (Iqbal et al., 2005) and TLR7 (Philbin et al., 2005) which are encoded within 
genomic regions with conserved synteny (Roach et al., 2005). ChTLR4 is linked to 
the early regulation of Salmonella infection (Leveque et al., 2003) and chTLR5 can 
detect flagellated Salmonella (Iqbal et al., 2005).   
Both chTLR3 and chTLR7 are intracellular receptors that detect viral RNA 
(Schwarz et al., 2005; Philbin et al., 2005). However, certain members of the chicken 
TLR7 family are non-functional or missing. ChTLR8 is a pseudogene, fragmented 
and disrupted by a chicken repeat-1 (CR1) retrovirus-like element (Philbin et al., 
2005). The disruption of  the avian TLR8 gene was found in galliform birds but not 
in non-galliform bird species, perhaps due to the differences in susceptibility of 
galliform bird species to highly pathogenic viral infections (Boyd et al., 2007). TLR9 




Table 1.1 TLR family members and their antagonists in humans and chickens.  
 
motifs (Vleugels et al., 2002; St Paul et al., 2011), which are detected by chTLR21 
(Brownlie et al., 2009; Keestra et al., 2010). ChTLR21 is an intracellular nucleotide 
receptor that shares many functional characteristics with mammalian TLR9 
(Brownlie et al., 2009; Keestra et al., 2010; Chrząstek et al., 2014). Orthologues of 
TLR21 have been identified in fish and reptile species (Gao et al., 2013; Yeh et al., 
2013).  
TLR15 is unique to avian species having been identified in the chicken 
(Higgs et al., 2006), turkey (Ramasamy et al., 2012) and goose genomes (Genbank 
Accession Number JQ014619.1). ChTLR15 may have been gained over evolutionary 
time to compensate for the loss of TLR members in the chicken genome (Table 1.1). 
ChTLR15 has the closest identity to chTLR2 and its mRNA expression levels were 
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increased in chicken fibroblast cells infected with heat-killed Salmonella 
Typhimurium and Salmonella Enteritidis, intestinal cells and heterophils (Higgs et 
al., 2006; Shaughnessy et al., 2009; Nerren et al., 2010). In another study, the TLR9 
agonist, CpG, the TLR1 agonist, PAM3CSK4 and the TLR4 and the TLR5 agonists, 
LPS and flagella, significantly upregulated chTLR15 mRNA expression levels in 
stimulated HD11 cells but levels were not affected by stimulation with poly I:C 
(TLR3), peptidoglycan (TLR2) or CL075 (TLR7) (Ciraci & Lamont, 2011). 
ChTLR15 can be activated by proteolytic cleavage of its receptor ectodomain and 
can sense virulence-associated fungal and bacterial proteases (De Zoete et al., 2011). 
When HEK293-T cells were transfected with chTLR15, NF-κB levels were increased 
when cells were exposed to yeast-derived lysates (Boyd et al., 2012). The NH2-
terminal portion of the haemagglutinin protein from Mycoplasma synoviae induced 
increased chTLR15 mRNA expression levels which mediated activation of NF-κB in 
chicken macrophages (Oven et al., 2013). Eimeria tenella sporozoites stimulated 
heterophils and monocyte-derived macrophages increased chTLR15 mRNA 
expression levels (Zhou et al., 2013). In MDV infected chickens, chTLR15 mRNA 
expression levels were increased in the spleen 4, 14 and 21 days post-infection (Jie et 
al., 2013). It seems chTLR15 can detect a range of PAMPs.  
A RIG-I orthologue has not been identified in the chicken genome (Karpala 
et al., 2011) but it is present in both the duck and goose genomes (Barber et al., 
2010; Sun et al., 2013). Waterfowl are the natural reservoir of avian influenza virus 
but do not normally succumb to severe disease. Ducks infected with the highly 
pathogenic H5N1 virus produce huge amounts of RIG-I in their lungs. DF-1 cells also 
produced IFN-β upon H5N1 infection (Barber et al., 2010). Geese are also resistant to 
the highly pathogenic NDV and RIG-I expression has been demonstrated in infected 
birds (Sun et al., 2013). The absence of RIG-I from the chicken genome may be the 
reason why chickens are highly susceptible to highly pathogenic influenza virus and 
NDV. An ortholog of MDA-5 has been identified and characterised in the chicken 
(Karpala et al., 2011; Liniger et al., 2012) and the duck (Wei et al., 2014). LPG2 is 
also present in the chicken genome and its RNA silencing reduces H5N1-mediated 
type I IFN secretion (Childs et al., 2007). The chicken genome contains NOD1 but 
does not possess a NOD2 gene. Recently an antibody was generated against the 
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chicken C type-lectin DEC-205 (Staines et al., 2013) and mRNA transcripts of MR 
and DC-SIGN have been detected in BMDC treated with avian influenza-derived 
glycans (De Geus et al., 2013). 
1.3.2  Cells of the chicken innate immune system 
Various cells of both the innate and adaptive immune responses have been 
described in chickens. Polymorphonuclear leukocytes are vital components of the 
innate immune system. They function to kill microbes by expressing Fcγ and 
complement receptors that mediate the opsonisation-dependent phagocytosis of 
invading pathogens. Heterophils are the chicken functional equivalent of mammalian 
neutrophils and are the most abundant granulocytes circulating in the chicken’s 
blood. These cells are highly phagocytic. Phagocytosis is generally followed by 
degranulation and production of oxidative burst to kill pathogens (Kogut et al., 
1994). Heterophils, like mammalian neutrophils, have the capacity to release fibrous 
structures called heterophil extracellular traps (Chuammitri et al., 2009). The one 
major difference between neutrophils and heterophils is the lack of myeloperoxidase 
in chickens, meaning that heterophils generate a relatively weak oxidative burst 
compared to their mammalian counterparts (Wells et al., 1998). However, avian 
heterophils are quite effective at killing pathogens by phagocytosis and utilising anti-
microbial proteins, such as lysosomes, β-defensins and peptides (reviewed by 
Genovese et al., 2013). Heterophils are important mediators of the innate immune 
system, as highlighted by their ability to express a number of TLRs. Heterophils 
express chTLR1La, chTLR1Lb, chTLR2a, chTLR2b, chTLR3, chTLR4, chTLR5, 
chTLR7 and chTLR15 (Kogut et al., 2005a; Kogut et al., 2005b; Nerren et al., 2009) 
and probably chTLR21, as they respond to CpG stimulation (He et al., 2012). The 
engagement of heterophil receptors leads to their activation and expression of pro-
inflammatory cytokines and chemokines (Kogut et al., 2005a; He et al., 2005).  
NK cells have been identified in the chicken. To date, three subsets of 
chicken NK cells have been identified from the embryo, intestinal epithelial 
lymphocytes (IEL) and peripheral blood mononucleated cells (PBMC), distinguished 
by differential surface expression of antigens, such as CD8, CD25 and CD56 
(reviewed by Straub et al., 2013). The chicken leukocyte receptor complex has been 
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mapped to micro-chromosome 31 and so far only one multi-gene receptor family has 
been identified, called the chicken Ig-like receptors (CHIR) (Luan et al., 2006). 
CHIR have similar structure to mammalian KIR and Ly46 and have both positive 
and negative signalling capacities required for NK cell regulation and activation 
(Viertlboeck & Göbel, 2011).  
In 2010, the first non-mammalian bone marrow-derived DC (BMDC) were 
cultured from chicken bone marrow cells using recombinant chicken IL-4 (chIL-4) 
and GM-CSF (CSF-2) (Wu et al., 2010). Avian BMDC have the capacity to 
upregulate mRNA expression levels of pro-inflammatory cytokines upon LPS and 
CD40L stimulation, express maturation markers on their cell surface, such as MHC 
class II, CD40, CD86 and the chemokine receptor, CCR7, and are potent stimulators 
of T cells (Wu et al., 2010; Wu et al., 2011). Chicken BMDC express a variety of 
TLRs, such as chTLR2, chTLR4, chTLR5 and chTLR21 (Liang et al., 2013). 
Immature BMDC are highly phagocytic, like mammalian DC (Wu et al., 2010) and 
play a role against avian influenza virus in the chicken lung (De Geus et al., 2013). 
Recently, avian DC have been characterised from the chicken spleen (Quéré et al., 
2013). Chicken bone marrow-derived macrophages (BMDM) cultured with 
recombinant chicken CSF-1 (chCSF-1) to induce their differentiation have also been 
described; although functional studies were not as comprehensive as the BMDC 
study, the cells were capable of phagocytosis (Garceau et al., 2010). 
1.3.3  Chicken B and T cell receptors 
In contrast to bone marrow models of B cell development in human and 
mouse, avian species differ both in the anatomical location and method of generation 
of BCR diversity. In 1954, Glick and colleagues identified the requirement of the 
bursa of Fabricius for antibody production against Salmonella type O-antigen, and so 
these antibody-producing cells became known as B (for bursa) cells. Primary 
antibody generation in the chicken occurs through somatic gene conversion rather 
than the V(D)J recombination process seen in human and mouse. The chicken light 
chain locus contains 25 VL genes upstream from the functional VL. All 25 VL genes 
are pseudogenes (ψVL) due to the lack of functional RS, out of frame deletions or 
truncations. The locus also expresses only one CL and one JL segment (Reynaud et 
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al., 1987). The chicken also lacks the κ light chain locus so it would seem that its 
antibody diversity is much more limited than mammals. However, chickens display 
considerable heterogeneity in their circulating light chains (Jalkanen et al., 1984). 
The same applies for the chicken heavy chain locus, where single functional VH and 
JH genes are present with 15 functional DH genes with similar sequence patterns 
(Reynaud et al., 1991). Like the light chain locus, the heavy chain locus also contains 
VH pseudogenes upstream from its functional VH gene (Reynaud et al., 1989). 
Interestingly, the heavy chain pseudogene sequences are homologous to VH and DH 
genes suggesting that these genes fused together and multiplied by gene duplication 
at some point in evolutionary time (Ota & Nei, 1995). Like mammals, gene 
rearrangement takes place using the RAG-1 and RAG-2 proteins with rearrangement 
of the chicken light chain being straightforward. The VL and JL are flanked by RS 
sequences and are joined together using the 12/23 rule, meaning all chicken B cells 
express the same IgL chain. However, diversity does occur within the light chain in 
the junctional sequence between the VJ segments in terms of length (McCormack et 
al., 1989). The chicken does not process deoxyribonucleotidyl transferase gene 
meaning that non-template (N) nucleotides are not added to the coding ends before 
joining as would occur in mammals. 
As for heavy chain rearrangement, the chicken possesses only three heavy 
chain isotypes-IgM, IgA and IgY. IgM and IgA are similar to their mammalian 
counterparts whereas chicken IgY, from a phylogenetic perspective, is similar to 
mammalian IgG and IgE. There appear to be no mammalian homologues of IgD or 
IgE or isotypes of IgG present in the chicken (Ratcliffe, 2006). Chicken heavy chain 
rearrangement is similar to mammalian V(D)J recombination events; the VDJ 
segments are joined together as in mammals but in the chicken DH-DH joining can 
occur. D2JH and D3JH segments have been identified in the chick embryo but not in 
hatched chickens making their biological functions uncertain (Reynaud et al., 1991). 
Diversity is created within the chicken light chains by somatic gene conversion. As 
mentioned previously, the light gene locus contains 25 ψVL genes upstream from 
their functional VL gene. The light chain ψVL genes have high diversity at sites of 
complementarity-determining regions (CDR) similar to VL regions that correspond to 
the variable region of the antibody. A stretch of the IgVL can be replaced by a 
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sequence derived from the ψVL genes of varying size (10-300 amino acids) leading to 
an extensive repertoire of diversity at the site of antigen recognition (McCormack & 
Thompson, 1990).  
With the chicken TCR, both αβ and γδ TCR-expressing T cells are conserved. 





) and CD8α-high 
(CD8α
+
) cells. The CD8α
+
 cells can be further sub-divided on the expression of 
either the homodimeric CD8αα or heterodimer CD8αβ (Berndt et al., 2006). Both 
these cell types produce Th1-associated cytokines upon Salmonella Typhimurium 
infection in chickens (Pieper et al., 2011).  
Unlike mammals, where three distinct CD3 proteins, CD3γ, CD3δ and CD3ε 
signal upon TCR engagement, the chicken possesses a CD3ε-like protein and one 
gene that has high homology to both mammalian CD3γ and CD3δ, called chCD3γ/δ 
(Bernot & Auffray, 1991). It is postulated that mammalian CD3γ and CD3δ arose 
from gene duplication over 230 million years ago after separation of the mammalian 
and avian lineages (Bernot & Auffray, 1991). Recently, NMR studies have 
determined the heterodimer composition of the chCD3ε-chCD3γ/δ complex and their 
unusual juxtapositioning that is not seen in the mammalian CD3 complex. Two 
copies of the chCD3ε-chCD3γ/δ interact with the αβ TCR and signalling is thought 
to be similar to the mammalian CD3 complex, due to conservation of ITAM motifs 
in the chicken CD3 proteins (Berry et al., 2014).  
1.3.4  Chicken T helper cells 
The Th1 and Th2 arms of immunity are vital to control infection with 
intracellular and extracellular pathogens, respectively. The signature cytokines and 
transcription factors required in mammals for Th1 and Th2 responses have been 
identified in the chicken genome (Kaiser et al., 2005) and some functional analysis, 
such as for IL-12 (Degen et al., 2005), IFN-γ (Digby & Lowenthal, 1995) and the 
Th2 gene cluster (Avery et al., 2004), has been carried out. In 2004, the ability of a 
non-mammalian species to mount a Th1 and Th2 immune response was 
demonstrated in the chicken through the quantification of signature cytokines during 
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intracellular and extracellular infection (Degen et al., 2005; Avery et al., 2005). 
However, during a chicken’s Th2 immune response, IL-5 transcription is not 
activated (Powell et al., 2009). This could be linked to chickens lacking functional 
eosinophils and basophils, as in mammals, IL-5 is required for the activation of these 
cells after IL-4 induces IgE production. In mammals, IgE is the first line of defence 
against parasites, such as helminths, and its inappropriate production is associated 
with allergic diseases (Gould & Sutton, 2008).  
The existence of Th17 and Th9 cells in the chicken is still unresolved. 
However, Th17 effector cytokines, IL-17A (Min & Lillehoj, 2002), IL-17F (Kim et 
al., 2012), IL-23 (Louise Welch, unpublished results) and IL-21 (Rothwell et al., 
2012) have been identified in the chicken genome. IL-17A mRNA expression levels 
are upregulated during Eimeria tenella infection and chickens treated with anti-IL-
17A antibody have increased body weight and enhanced production of Th1 cytokines 
during infection (Zhang et al., 2013; Min et al., 2013). IL-9 and IL-10 have also been 
identified and cloned in the chicken (Rothwell et al., 2004; Lisa Rothwell, 
unpublished results) and our laboratory is currently carrying out functional analyses 
to identify Th9 cells in chickens.  
During an infection, the immune system concentrates effector cells to the site 
of inflammation. When the infection subsides, an influx of Treg cells occurs to 
deactivate immune cells to protect the host against excessive cytokine production and 





cells have been identified through surface markers and their ability to express high 
levels of IL-10 and TGF-β4 mRNA. These cells do not express IL-2 
(Shanmugasundaram & Selvara, 2011). Avian Treg cells are similar to mammalian 
Treg cells, they develop in the thymus and are stored in the bone marrow. Chicken 
Treg cells express a number of TLRs similar to mammalian Treg cells, such as 
chTLR2b and chTLR4 (Shanmugasundaram & Selvaraj, 2011). They also express 
CTLA-4 and LAP3, known to have a role in contact-dependent immunosuppressive 
functions against DC activation in mammals (Wing et al., 2008; Shevach, 2009). 
One important piece of the puzzle missing for avian Treg cells is the lack of 
identification of an ortholog of FoxP3. In silico analysis and degenerate primers 
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designed to span various species, such as cows, human, mouse and fish FoxP3 
cDNA, have all failed to identify FoxP3 in any avian species. However, two other 
members of the FoxP family, FoxP1 and FoxP2, are present in the chicken genome 
and appear during these searches indicating high sequence identities between these 
genes in the chicken (Selvaraj, 2013).  
 Although some important differences exist between mammals and chickens, 
such as the repertoire of cytokines, transcription factors, the process of BCR/TCR 
variability selection and the organs of immunity, the chicken can induce a robust 
immune response upon pathogen exposure.  
1.4  Tumour necrosis factor superfamily 
Members of the TNF superfamily are key regulators of the activities of a 
variety of pathways associated with the regulation and modulation of the immune 
system. The TNF superfamily is made up of TNF ligands and their respective 
receptors, the TNFR superfamily. The signals from TNFR superfamily members 
control survival versus death signals but they also have a role in regulatory events, 
such as controlling cytokine and chemokine expression. The activation of T cells 
requires ligation of costimulatory molecules and many members of the TNF 
superfamily play this role in T cell activation. Death-inducing TNFR family 
members are also expressed on T cells, such as FAS, TNF-related apoptosis-inducing 
ligand receptor 1 (TRAILR1), TRAILR2 and TNFR1, all of which negatively 
regulate T cell survival. TNF ligands are also expressed on the surface of T cells, 
such as CD40L, LT-β, CD27 and 4-1BBL, which interact and signal through their 
cognate receptors expressed on APC, neighbouring T cells or non-lymphoid cells. 
These signals are associated with the upregulation of costimulatory molecules and 
pro-inflammatory cytokine expression. TNF members can send both bidirectional 
and reverse signals, enhancing their own expression on the surface of cells. 
1.4.1  Features of the TNF superfamily  
The mammalian TNF superfamily orchestrates a variety of functions both in 
the architecture of immune organs and the development of immunity (Locksley et 
al., 2001). The receptor family are characteristically type I transmembrane proteins 
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that have low degrees of homology and are grouped due to the presence of conserved 
cysteine-rich domains (CRD) in their extracellular ligand-binding domain (Naismith 
& Sprang, 1998). These CRDs are typically defined by three intra-chain disulphide 
bridges generated by highly conserved cysteine residues that act as a scaffold to 
produce an elongated structure protruding from the cell (Smith et al., 1994). They are 
believed to be involved with specific ligand-binding and generation of a pre-
assembly site for the docking of the ligand. The TNFR superfamily can be further 
categorised into TRAF motif-expressing receptors or death domain (DD)-containing 
receptors. The DD receptors are characterised by the presence of ~80 amino acids of 
cytoplasmic sequence necessary for apoptosis (Nagata, 1997). In mammals, eight 
DD-expressing TNFR have been identified and are further categorised into four 
homologous groups or clades. The p75
NTR
 clade consists of ectodysplasin A receptor 
(EDAR), death receptor 6 (DR6) and p75 neurotrophin  (NTR), the TNFR1 clade 
consists of TNFR1 and DR3, the FAS clade and the TRAIL clade consisting of 
TRAILR1 and TRAILR2, respectively (Sessler et al., 2013). Although their names 
may imply death-inducing molecules, many members of the DD-containing TNFR 
family have roles in development. For example, EDAR is required for hair follicle 
development (Monreal et al., 1999) and DR6 is strongly expressed in the brain and 
upregulated during neuron injury and is involved in regulating inappropriate axonal 
branches (Nikolaev et al., 2009). 
TNF superfamily ligands are mostly type II transmembrane proteins with an 
extracellular site for proteolytic cleavage to release a soluble protein from the 
membrane. All TNF cytokines share a common structural core, a scaffold of ten 
hydrogen bonds that assume a jellyroll β-sandwich fold. Each member of the TNF 
superfamily has varying lengths and composition of residues on the surface of the 
loops connecting the β-strands (Naismith & Sprang, 1998). These molecules are 
predominantly expressed as non-covalent trimers and the core β-strands are intrinsic 
to these structures as monomers oligomerize around the axis of the strands (Lam et 
al., 2001). 
1.4.2  Mammalian and chicken TNF superfamily members 
 Studies on the functions of members of the mammalian TNF superfamily are 
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exhaustive, with many studies identifying both negative and positive roles of each 
member in development, immunity and disease, and have been reviewed extensively 
(e.g Watts, 2005; Croft, 2014). Previous analysis of the chicken genome has 
identified the presence and absence of a number of the TNF superfamily members 
(Kaiser et al., 2005) (Table 1.2). This phenomena is not only restricted to the TNF 
superfamily in the chicken but has been identified in the IFN, IL-1, IL-10, IL-12 and 
the chemokine CCL families (Table 1.3) (Kaiser, 2010; Kaiser, 2012). Table 1.2 
identifies the members of the TNF superfamily that are “missing” from the chicken 
genome. When a ligand and its respective receptor are not present in the chicken, it is 
assumed that these members are really non-existent rather than not annotated in the 
chicken genome (Kaiser et al., 2012). Out of the 19 ligand and 29 receptors TNF 
family members identified so far in mammals, the chicken genome only possesses 10 
ligands and 15 receptors.  
The TNF superfamily members are present as sub-families that are physically 
adjacent to one or two additional TNF superfamily genes on the same loci. In 
humans, eleven out of the nineteen TNF superfamily members are clustered with the 
MHC or paralogous regions of the MHC on chromosomes 1, 6, 9 and 19.  These 
paralogous regions may have resulted from en bloc duplication over 500-800 million 
years ago in vertebrates (Abi-Rached et al., 2002). The first sub-family missing from 
the chicken genome is that containing LT-α, TNF-α and LT-β. These TNF family 
members are tightly linked with the MHC on chromosome 6p21.3 in humans and 
chromosome 17qB1 in the mouse (Browning et al., 1993; Lawton et al., 1995). Bony 
fish also have this chromosomal organisation suggesting a gene duplication event 
occurred before the divergence of fish and amphibians (Glenney & Wiens, 2007). 
LT-α can form homotrimers and heterotimers with LT-β at the membrane surface in 
a 1:2 stoichiometric ratio (LT-α1LT-β2). LT-α1LT-β2 binds and signals through the 
LT-βR while TNF-α and LT-α3 bind to two receptors, TNFR1 and TNFR2 
(Browning et al., 1993). LT-α1LT-β2 is expressed on a number of lymphoid cells, 
from T to B cells and innate lymphoid cells. The LT-βR is expressed on DC, 
macrophages and stromal cells (Upadhyay & Fu, 2014). In addition to binding to 




Table 1.2 The TNF superfamily members present in the human and the chicken 
genomes. The chromosomal location and presence of TNF superfamily members in 
human are shown along with the chromosomal locations and presence of the chicken 
TNF family members and their receptors (adapted from Kaiser et al., 2012).  
 
recent study demonstrated that LT-α3 and TNF-α bind with the same affinity to 
TNFR1 and induce similar downstream activities (Etemadi et al., 2013). It is 
believed that the lack of the lymphotoxin genes in the chicken genome is linked to 
the lack of lymph nodes in chickens. For example, LT-α
-/-
 mice have defects in 
lymph node development and splenic architecture (Banks et al., 1995). On the other 
hand, TNF-α
-/- 





Table 1.3 Cytokine and chemokine family members present in mammalian and 
chicken genomes. The number of cytokine and chemokine family members in 
mammals is shown along with the number of chicken family members present 
(adapted from Kaiser et al., 2012). 
 
(Pasparakis et al., 1996). There is evidence of the presence of the two receptors for 
TNF-α, TNFR1 (Bridgham & Johnson, 2001) and TNFR2 (Abdalla et al., 2004a), in 
the chicken genome. The second human sub-family missing in the chicken genome 
contains 4-1BBL, CD27 and lymphotoxin-like inhibits inducible expression and 
competes with HSV glycoprotein D for HVEM a receptor expressed by T 
lymphocytes (LIGHT), which all reside on chromosome 19 in humans and 
chromosome 17 in mice. When first identified, the receptor for 4-1BBL, 4-1BB, was 
thought to be a costimulatory molecule on T cells but its expression has since been 
identified on CD8
+
 T cells, Treg cells, follicular DC, eosinophils, NK T cells and NK 
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cells (Wilcox et al., 2002). 4-1BB is essential for the control of T cell proliferation, 
as 4-1BB
-/-
 T cells are hyperproliferative (Lee et al., 2005). 4-1BBL is expressed in 
CD40L-stimulated B cells, DC and LPS-stimulated macrophages driving pro-
inflammatory cytokine production upon activation (Wang et al., 2009). Genetically 
modified DC expressing high levels of 4-1BBL enhance cytotoxic T cells (CTL), 
making it a potential DC adjuvant against pathogens and tumours (Asai et al., 2007).  
CD27 is closely related to CD40L and is expressed in defined subsets of T 
and B cells (Camerini et al., 1991). In mammals around 30% of blood- and tonsil-
derived and all mutated IgV B cells express CD27 and it is therefore considered an 
important developmental B cell marker (Maurer et al., 1990). However, CD27 is not 
a potent inducer of B cell proliferation or isotype switching like CD40L. CD27 has 
minimal proliferative effects and can only induce IgG1 isotype switching (Agematsu 
et al., 1998). The ligand for CD27, CD70, is expressed on CD45RO
+ 
T cells, 
medullary thymic epithelial cells (mTEC), DC and B cells (Bossen et al., 2006). 





 T cells is hampered by the loss of CD27 upon influenza virus 
infection (Hendriks et al., 2000).  
LIGHT can bind to three receptors, HVEM, LT-βR and a decoy receptor, 
DcR3. HVEM can also bind to LT-α3, and two members of the Ig superfamily, 
CD160 and BTLA, which deliver coinhibitory signals (Zhai et al., 1998; Cai & 
Freeman, 2009). The interaction of LIGHT and HVEM leads to survival- and 
growth-producing signals, whereas LIGHT and LT-βR signals induce apoptosis 
(Chuang et al., 2007). LIGHT is expressed on T cells and its interaction with HVEM 
induces T cell proliferation and DC maturation, which can be enhanced by the 
presence of CD40L (Harrop et al., 1998). LIGHT
-/-
 mice have no defects in lymphoid 
organ development but have defects in CD8
+
 T cell activity (Tamada et al., 2002).  
The third missing sub-family consists of TNF-like weak inducer of apoptosis 
(TWEAK) and a proliferation-inducing ligand (APRIL). The two genes reside on 
human chromosome 17 within 700 bp of one another. An intergenic splicing event 
can occur between exon 6 of TWEAK and exon 2 of APRIL leading to a hybrid 
gene, called TWE-PRIL, in both human and mice. The protein consists of the NH2-
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terminal and transmembrane domain of TWEAK fused to the COOH-terminal 
domain of APRIL. TWE-PRIL can signal through the APRIL receptor and can be 
detected at the mRNA level in activated T cells (Pradet-Balade et al., 2002). 
TWEAK mRNA is expressed in a variety of tissues and cell types, such as the 
thymus, spleen and lymph nodes (Chicheportiche et al., 1997), and binds to the 
receptor TWEAKR, also known as Fn14 (Wiley et al., 2001). TWEAK signalling 
induces cell proliferation and has been implicated in monocyte-mediated cytotoxicity 
(Nakayama et al., 2000).  
APRIL shares receptors with the TNF superfamily member B-cell activating 
factor (BAFF). These receptors include transmembrane activator and CAML 
interactor (TACI), BAFFR and B-cell maturation antigen (BCMA), in a redundant 
and specific manner. TACI binds to both ligands whereas BAFFR binds specifically 
to BAFF and BCMA binds only to APRIL (Bossen & Schneider, 2006). APRIL-
BCMA interactions enhance plasma cell survival while APRIL-TACI interactions 
induce IgG and IgE class switching (Schneider, 2005). Unlike BAFF, APRIL is 
cleaved in the Golgi and expressed as a soluble protein from the cell (Lopez-Fraga et 
al., 2001). Recently, a transmembrane form of APRIL, APRIL-δ, mutated at the furin 
cleavage site, was identified and found to be highly expressed in leukaemia cell 
precursors (Maia et al., 2011).  
The absence of these TNF family members in the chicken indicates their 
possible redundancy in the mammalian immune system. The chicken TNF 
superfamily may represent the “minimal essential” TNF members needed to control 
and regulate lymphoid development and immunity. 
Of the ten TNF ligands present in the chicken genome, the biological activity 
of five members has so far been characterised. Cloning and RT-PCR analyses of 
chicken CD30 (chCD30) and chicken TRAIL (chTRAIL) demonstrated that both 
cytokines were highly conserved with their mammalian orthologues and mRNA 
transcripts were present in a number of chicken tissues and cells (Abdalla et al., 
2004b). Burgess et al. (2004) identified the enhanced expression of chCD30 on 
MDV-induced lymphomas. Mammalian CD30 promotes neoplastic cell survival in 
both Hodgkin’s and non-Hodgkin’s lymphoma disease (Pera et al., 1998). ChCD30 
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has four CRD domains while there are only three in mouse CD30 (Burgess et al., 
2004). ChCD30 also lacks an intracellular TRAF6-binding motif. However, TRAF6 
does not directly bind to the intracellular domain of CD30 in mammals (Ishida et al., 
1996). Chicken BAFF (chBAFF) is highly expressed in chicken B cells (Schneider et 
al., 2004). ChBAFF binds to its receptor, BAFFR, and enhances B cell survival 
(Schneider et al., 2004). TACI and BAFFR are present and functional in the chicken 
whereas the gene for BCMA is disrupted, implying functional differences in B cell 
survival in chickens compared to mammals (Reddy et al., 2008). 
Chicken CD40L (chCD40L) bioactivity was determined using mouse anti-
chicken CD40L monoclonal antibodies (mAb). The chCD40L receptor, chCD40, 
was detected in chicken B cells, monocytes and macrophages. ChCD40L had 
conserved biological activities with mammalian CD40L, inducing NO synthase in 
macrophages and enhancing the survival of B cells (Tregaskes et al., 2005). Chicken 
vascular endothelial growth inhibitor (chVEGI) (also called TL1A) has 50% 
homology with human VEGI and is expressed in a number of chicken tissues. Levels 
of chVEGI expression were significantly increased in LPS-stimulated splenocytes 
and induced cell cytotoxicity in chicken fibroblast cells (Takimoto et al., 2005). 
Overall, the functions of the TNF family members cloned in the chicken are 
evolutionarily conserved. 
In 1997, three new members of the mammalian TNF superfamily were 
identified; receptor activator of NF-κB ligand (RANKL) and its two receptors, 
RANK and osteoprotegerin (OPG). These three genes are present in the chicken 
genome.  
1.4.3  Mammalian RANKL, RANK and OPG 
In 1997, four independent groups isolated a type II TNF-like transmembrane 
protein using different experimental systems and each gave it a different name, i.e. 
TNF-related activation-induced cytokine (TRANCE) (Wong et al., 1997), receptor 
activator of NF-кB ligand (RANKL) (Anderson et al., 1997), osteoprotegerin ligand 
(OPGL) (Lacey et al., 1998) and osteoclast differentiation factor (ODF) (Yasuda et 
al., 1998). In recent years, RANKL is normally used as the receptor has been named 
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RANK. Mammalian RANKL is a transmembrane protein of 316 amino acids 
containing a COOH-terminal receptor-binding domain, a 20 amino acid hydrophobic 
transmembrane domain and a relatively long extracellular domain that contains a 
TNF-homologous domain that is the active receptor-binding site (Anderson et al., 
1997; Lam et al., 2001) (Figure 1.2). Human RANKL has 87% homology with 
murine RANKL (Lacey et al., 1998). Mammalian RANKL expression in the immune 
system is limited to the thymus and lymph nodes, a restricted pattern of expression 
not usually seen for TNF superfamily members. For example, FASL and TRAIL 
expression can be detected in both lymphoid and non-lymphoid organs (Anderson et 
al., 1997; Wong et al., 1997).  
 RANKL has two receptors, a signalling receptor, RANK, and a decoy 
receptor, OPG, which is a secreted TNF-related protein that inhibits RANKL-RANK 
interaction (Simonet et al., 1997). RANK, also known as TRANCEL and 
TNFRSF11a, is a relatively recent member of the TNFR superfamily. The RANK 
gene encodes a type I transmembrane protein of 616 amino acids, with an 
extracellular region (residues 30-194) comprised of four CRD (Anderson et al, 1997) 
(Figure 1.2). It has a high degree of amino acid homology with the extracellular 
region of CD40 (40%) and has the longest extracellular domain (residues 234-616) 
of all TNFR members identified so far (Figure 1.2). It is the only known signalling 
receptor for RANKL (Anderson et al., 1997; Wong et al., 1997). Originally 
identified in a bone marrow-derived myeloid DC cDNA library, RANK mRNA 
expression is widely detected in the lungs, spleen, skeletal muscle, brain, liver, 
kidney and surface protein expression is widely detected in cells of the 
myelomonocytic lineage ranging from osteoclast progenitor cells to DC (Anderson et 
al., 1997; Wong et al,. 1997).  
OPG was identified the same year as RANKL through sequence homology 
with the TNF superfamily (Simonet et al., 1997). OPG contains two COOH-terminal 
homologous death domains of TNFR1 that are not functional. OPG is a naturally 




Figure 1.2 Schematic diagrams of the features of mammalian RANKL, RANK 
and OPG proteins. Numbers indicate the amino acid length of the protein, SS signal 
sequence, TM transmembrane domain (adapted from Darnay et al., 1999).  
 
at position 22 to form a mature protein (Simonet et al., 1997) (Figure 1.2). In 
mammals, OPG mRNA was detected in the liver, lung, kidney, intestines, skin and 
stomach. Transgenic mice overexpressing OPG suffer from osteopetrosis and 
osteoclastogenesis can be inhibited by the addition of OPG to cell cultures (Simonet 
et al., 1997). Subsequently, the ligand for OPG was found to be RANKL and its 
affinity for RANKL is 1000-fold higher than that of RANK (Yasuda et al., 1998; 
Schneeweis et al., 2005). OPG binds to RANKL inhibiting its interaction with 
RANK. OPG also binds to and inhibits TRAIL-mediated apoptosis. TRAIL, a fellow 
TNF superfamily member, has four receptors; two DD-containing receptors, 
TRAILR1 and TRAILR2, and two membrane-bound decoy receptors, DcR1 and 
DcR2. OPG can bind and inhibit the interaction of TRAIL with its signalling 
receptors but its affinity is 10,000 times less than the OPG-RANKL interaction 
(Emery et al., 1998; Vitovski et al., 2007). TRAIL can detect tumour cells and 
induce apoptosis, therefore tumours expressing OPG may be an escape route from 
TRAIL-mediated cell death (Holen et al., 2002). 
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RANKL, RANK and OPG arose during the ontogeny of bony fish reflecting 
the presence of reabsorbing and mineralisation activity in these vertebrates. This 
triad of genes post-date the formation of the primordial immune system that 
comprised a primitive thymus and lymphoid structures but preceded the development 
of LT-β-mediated development of lymph nodes in amphibians (Witten & Huysseune, 





 deficient mice had entirely unexpected 
phenotypes: early defects in T and B cell development, complete absences of lymph 
nodes, severely reduced osteoclastogenesis and failure to develop mammary glands 
(Dougall et al., 1999; Kong et al., 1999a). 
1.4.4  The role of RANKL in lymphoid organ development  
Lymph nodes are highly organised structures found in higher vertebrates that 
provide the optimal environment for APC, immune effector cells and antigens to 
come in close proximity to induce an optimal immune response. It is also the location 
in which antigen-specific T and B cells differentiate into effector cells. Arrested 
lymph node development in RANKL
-/-
 mice is due to impaired colonisation of 
haematopoietic precursors cells in the lymph node anlage. Developing lymph nodes 






 cells that also express LT-α1-LT-β2, RANKL, 
RANK, IL-7Rα and IL-2Rγc, also known as lymphotoxin-inducer cells (LTi) (Kim 
et al., 2000). In RANKL
-/-
 mice, the percentage of LTi
 
cells and the expression of the 
mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) (target for α4β7) 
are reduced and endothelial cells are underdeveloped, in comparison to wild-type 
mice (Kim et al., 2000). LTi cells induce the expression of RANKL on lymphotoxin-
organiser cells (LTo) by interacting with LT-βR which also increases chemokine 
expression levels such as CXCL13, required for the influx of LTi cells to colonise 
and cluster with LTo cells to create the lymph node analage (Cupedo & Mebius, 
2005). 
1.4.5.  Medullary thymic epithelial cells  
 The thymus provides an environment of non-haematopoietic stromal cells and 
cells of haematopoietic origin for the development of self-tolerant and Treg cells 
(Gill et al., 2003). Thymic epithelial cells are central components of the thymic 
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microenvironment and are subdivided into two specialised cells associated with their 
location, cortical thymic epithelial cells (cTEC) and mTEC. Thymocytes develop and 
mature while migrating through the cortical and medullary compartments of the 
thymus.  Positive selection is mainly carried out by cTEC and negative selection is 
carried out by mTEC through associated MHC and self-antigens (Guerder et al., 
2012). TEC development is very complex, requiring a number of cell to cell contacts 
with thymocytes, fibroblast and mesenchymal cells that provide important extrinsic 
signals for TEC differentiation. mTEC express a number of TNF receptors, such as 
RANK, CD40 and LT-βR (Akiyama et al., 2012).  
RANKL-RANK interactions are essential for mTEC formation and 
maturation. During development, RANKL is expressed on LTi cells and dendritic 









 mTEC (Rossi et al., 2007). Furthermore, 
positively selected CD4
+
 T cells in the thymus also provide RANKL signals. The 
importance of RANKL-RANK interaction in mTEC development is evident in 
RANKL
-/-
 mice which have reduced mTEC numbers (Rossi et al., 2007). OPG is 
also expressed by mTEC, indicating its regulatory role in RANKL-RANK 
interactions in mTEC development (Hikosaka et al., 2008).  
1.4.6  M cells 
The intestine is distributed with various inductive sites that are required for 
the excretion of IgA and the generation of Treg cells to maintain haemostasis. 
Peyer’s patches and isolated lymphoid follicles (ILF) are surrounded by follicle-
associated epithelium that contain specialised epithelia called microfold cells (M 
cells) (Owen & Jones, 1974). M cells are phagocytic cells that differ from their 
neighbouring enterocytes. They lack the typical brush border but have variable 
microvilli and microfolds with large plasma membrane subdomains that are exposed 
to the lumen (Neutra et al., 1996). M cells can uptake particulate antigen by actin-
dependent phagocytosis, macropinocytosis and pinocytosis (Jones et al., 1994). 
Antigens that are acquired by M cells are transported to intraepithelial pockets within 
the M cells where DC and lymphocytes can access from the sub-epithelial domains 
(Neutra et al., 1996). Although described over 30 years ago, the mediators of M cell 
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differentiation and activation were only recently discovered to be RANKL and 
RANK. RANKL is expressed by stromal cells in the sub-epithelium and it was 
suggested that it may have a role in M cell development. RANKL
-/-
 mice have 
smaller Peyers’s patches and diminished numbers of M cells compared to wild-type 
mice (Knoop et al., 2009). Levels of expression of RANK were determined in apical 
and basolateral aspects of epithelial cells. RANKL production is required for the 
continuous development and activation of M cells in the intestine, as anti-RANKL 
treated mice were depleted of M cells within 4 days (Knoop et al., 2009). The data 
suggested that RANKL is secreted by the inner domes of the Payer’s patches and 
expressed on the outer reticular cells where it instructs newly emerging epithelial 
cells to undertake the M cell fate.  From this discovery, the ability to culture M cells 
was achieved using a 3-dimensional intestinal organoid culture system (mini-guts) 
and the transcription factor, SpiB, was identified as an essential requirement for M 
cell differentiation (de Lau et al., 2012).  
1.4.7  Bone metabolism  
Osteoclasts originate from haematopoietic multinucleated cells that have the 
capacity to reabsorb bone whereas osteoblasts are derived from bone marrow 
mesenchymal stem cells and are responsible for new bone formation. In humans, 
around 10% of bone is renewed each year (Baud’huin et al., 2007). Communication 
between osteoclasts and osteoblasts is mediated by soluble cytokines and growth 
factors that control the expression of genes and transcription factors. However, cell 
to cell contact is required for osteoclast differentiation and activation through 
membrane receptors (Yasuda et al., 1998). It took over 30 years to identify RANKL- 
RANK and OPG as key players in osteoclast function (Simonet et al., 1997, Yasuda 
et al., 1997). RANKL is expressed on osteoblasts and interacts with RANK-
expressing osteoclast progenitor cells. The interaction between RANKL and RANK 
is controlled by OPG which is expressed by osteoblasts and stromal cells. The 
progenitor cells of osteoclasts are chemotactically attracted to sites of bone 
resorption where they deposit in the mesenchyme surrounding the bone. Here, they 
proliferate and differentiate into mature osteoclasts. Mature osteoclasts are very large 
cells containing multiple nuclei and have abundant mitochondria, lysosomes and free 
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ribosomes (Li et al., 2006). When these cells reach the site of bone resorption, a 
complete alteration of their cytoskeleton occurs. The cells become tightly attached to 
the bone leading to various changes in plasma membrane domains such as a ruffle 
border and sealing zone. This sealing zone divides the plasma membrane, thereby 
producing a closed compartment between the ruffle membrane and the bone matrix, 
the resorptive lacunae. This zone is distinct to osteoclasts (Li et al., 2006). The 
balance between RANKL and OPG determines osteoclast activation, skeletal 
calcium levels and bone remodelling (Lacey et al., 1998). Abnormalities in the 
RANKL-RANK-OPG system can lead various bone diseases, such as Paget's disease 
(Chung et al., 2010) and crippling RA (Kong et al., 1999b; Takayanagi, 2007).  
1.5  RANKL, RANK, OPG and immunity 
 Before the discovery that RANKL, RANK and OPG were the key mediators 
of bone metabolism, research was aimed at identifying their roles in immunity. 
Mammalian RANK surface expression was shown to be restricted to the surface of 





mice expressed normal DC and macrophage numbers and functions (Darney et al., 
1999; Kong et al., 1999a), these cytokines were shown to have a role in driving pro-
inflammatory immune responses. In 1997, the novel TNF family member, RANKL, 
was shown to induce pro-inflammatory cytokine expression in mature DC (Anderson 
et al., 1997; Wong et al., 1997). Mammalian RANKL induces predominantly Th1 
effector cytokines, such as IL-1β, IL-1Ra, IL-6, IL-12 and IL-15, and had no effect 
on expression levels of IL-2, IL-4, IL-5 or IL-10 (Josien et al., 1999). In the same 
study, strong RANKL surface expression was predominantly found on activated 
murine Th1 clones compared to Th2 clones and its expression was inhibited by IL-4 
treatment (Josien et al., 1999). Interestingly, RANKL
-/-
 T cells produce higher levels 
of IL-4 and IL-5 compared to wild-type cells (Kong et al., 1999a). Schiano de 
Colella et al. (2008) demonstrated that RANKL had similar bioactivity on monocyte 
derived-DC (Mo-DC), where Th2 effector cytokine expression levels were unaltered 
by RANKL treatment. These studies strongly suggested that RANKL is a 
predominant Th1 surface marker. RANKL transcription is upregulated within 2 h of 
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TCR stimulation. Its expression on T cells is regulated by Ca
2+
 mobilisation and is 
enhanced by protein kinase C (PKC) activation (Wang et al., 2002).  
Further studies indicated the role of RANKL in CD40L-independent 
induction of IL-12. CD40L is expressed on activated T cells and interacts with 
CD40-expressing DC. Their interaction leads to the upregulation of a number of 
cytokines required for the activation of a Th1 response. CD40L
-/-
 mice are capable of 
mounting a Th1 immune response upon infection albeit at a weaker level than wild-
type mice, which led to the hypothesis that a fellow member of the TNF superfamily 
induces IL-12 expression independent of CD40L signalling. Padigel et al. (2003) 




 mice and induced an immune 
response by infecting mice with Leishmania major and treating them with RANKL. 
The dual treated mice controlled the infection, compared to untreated mice, which 
did not (Padigel et al., 2003). Blocking of RANKL with RANK-Fc inhibited the 
ability of DC to produce IL-12 and hindered Th1 polarisation. Bachmann et al. 
(1999) also demonstrated that an alternative pathway for IL-12 production in CD40
-/-
 
mice was due to RANKL-RANK interaction.  
Various mucosal-derived DC express surface RANK and can interact with 
RANKL. However, RANKL does not activate similar downstream pathways in 
stimulated mucosal-derived DC. Peyer’s patches treated with RANKL expressed 
enhanced levels of IL-10 and low levels of IL-12β expression in contrast to spleen-
derived DC, where IL-12β was expressed at higher levels than IL-10 (Williamson et 
al., 2002). More recently the bioactivity of RANKL was analysed in macrophages 
(Park et al., 2005). BMDM treated with RANKL induced low levels of pro-
inflammatory cytokine expression but cells co-stimulated with RANKL and LPS or 
IFN-γ were more potent inducers of pro-inflammatory cytokine expression (Park et 
al., 2005), indicating that RANKL signals more efficiently on mature APC.  
Various members of the TNF superfamily can upregulate the expression of 
costimulatory molecules on the surface of target cells. RANKL does not significantly 
increase the surface expression of MHC class II, CD80 and CD86 on DC but does 
upregulate the expression of a fellow TNF superfamily member, CD40 (Anderson et 
al., 1997; Wong et al., 1997). Mo-DC treated with RANKL induced partial 
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maturation of cells and enhanced the levels of CD83 and CD86 expression (Schiano 
de Colella et al., 2008). Macrophages upregulate MHC class II and CD86 when 
stimulated with RANKL and can further increase surface expression by synergising 
with LPS and IFN-γ (Park et al., 2005).  
RANKL is a survival factor for APC. Treatment of DC and macrophages 
with RANKL encourages cell survival, upregulating the anti-apoptotic molecule Bcl-
XL, a mitochondrial transmembrane protein involved in signal transduction (Wong et 
al., 1999; Park et al., 2005). The decision between cell death and survival is 
fundamental to shaping the immune response. Immature interstitial tissue-derived 
DC express both RANKL and RANK but lose RANKL expression upon maturation. 
Using RANK-Fc, interstitial tissue-derived DC undergo spontaneous apoptosis due 
the blockade of RANKL-RANK signalling (Cremer et al., 2002). The ability of 
RANKL to protect DC from spontaneous apoptosis is a potential avenue to improve 
the efficacy of vaccines and DC-based immunotherapy. DC that migrate to the 
draining lymph nodes upon infection to activate antigen-specific T cells have a very 
limited life span (Pugh et al., 1983). RANKL-treated, PPD-pulsed DC can enhance 
the levels of IFN- expression compared to non-treated PPD-pulsed cells and were 
found for up to five days in the draining lymph nodes of injected mice (Josien et al., 
2000).  
Polymorphonuclear neutrophils express surface and intracellular RANK in 
vesicles and specific granules enhanced by Ca
2+
 mobilisation (Riegel et al., 2012). 
Monocytes expressing RANK are chemoattracted to RANKL-expressing cells, which 
leads to the activation of Src kinases, a family of proteins implicated in a number of 
signalling pathways associated with cellular migration, growth and survival 
(Mosheimer et al., 2004). Monocyte-derived multipotential cells, expressing CD14, 
CD34 and CD45, are circulating cells that have the potential to spontaneously induce 
the expression of RANKL upon clustering. These cells were capable of 
differentiating into osteoclasts without endogenous osteoclastogenic factors which 
may contribute to pathological conditions, such as RA (Seta et al., 2008).  
OPG not only regulates the interaction between RANKL and RANK in bone 





 mice produce enhanced levels of pro-inflammatory cytokine 
expression compared to DC from wild-type mice and had significantly increased 
survival rates (Chino et al., 2009). OPG is expressed by mature DC and its 
expression is dependent on NF-κB activation (Schoppet et al., 2007). Therefore, 
OPG also provides a molecular brake between RANKL-RANK signalling in 
immunity.  
1.5.2  RANKL, RANK, OPG in non-mammalian species  
Bone metabolism increases due to movement in a site-specific manner (Rubin 
et al., 2001). Teleost fish are a good model to understand the cell to cell interactions 
required for the activation of osteoclastogenesis (Yoshikubo et al., 2005; Sanuki et 
al., 2007). Teleost fish, which include zebrafish, goldfish and Japanese rice fish, 
have scales with calcified tissues, such as osteoblasts and osteoclasts and bone matrix 
proteins (Yano et al., 2013). When scales were removed and underwent static or 
dynamic centrifugation, expression levels of RANKL were significantly decreased 
after 3 and 6 h, whereas OPG expression levels were increased at 12 and 18 h in 
dynamic movement experiments, indicating inhibition of bone metabolism (Kitamura 
et al., 2013). Goldfish RANKL had increased mRNA expression levels during scale 
regeneration. However, this study could not differentiate between osteoblasts or pro-
inflammatory cells expressing RANKL at the site of scale damage (Thamamongood 
et al., 2012). 
1.6  RANKL-RANK signalling  
The selectivity of RANKL binding to RANK is due to 46 buried polar 
interactions upon trimer formation, the highest number of polar interactions found in 
any TNF ligand and receptor pair (Lam et al., 2001). It is accepted that TNFR 
binding is carried out by an elongated receptor molecule, along each of the three 
clefts of the neighbouring monomers of the homotrimer (Hymowitz et al., 1999). 
This interaction induces the intracellular domain of RANK to recruit a number of 
TNF receptor-associated factors (TRAF) (Darnay et al., 1998; Wong et al., 1998; 
Kim et al., 1999). The TNFR superfamily members do not possess catalytic domains 
and rely on the recruitment of adaptor proteins to signal and activate downstream 
42 
 
protein kinase cascades. The activation of the extracellular domain of RANK recruits 
five members of the mammalian TRAF family, TRAF1, TRAF2, TRAF3, TRAF5 
and TRAF6, to the intracellular domain, triggering downstream signalling events, 
such as activation of the NF-кB, Jun-N terminal kinase (JNK), extracellular signal 
regulated kinase 1 (ERK1) and p38 signalling pathways (Wong et al., 1998).  
 TRAFs are a group of homologous intracellular molecules originally 
characterised in mammals but recently extensive research has been carried out in fish 
(Qiu et al., 2009; Kim et al., 2011; Huang et al., 2012; Li et al., 2014), insects, slime 
moulds and nematodes (Regnier et al., 1995). This group of adaptor proteins 
emerged as the key downstream signal transducers for the TNFR and TLR/IL-1R 
superfamilies. The hallmark feature of TRAF proteins is their COOH-terminal TRAF 
domain of approximately 230 amino acids (Figure 1.3). The COOH-terminal domain 
can be subdivided into more divergent NH2-proximal (TRAF-N) and highly 
conserved COOH-proximal (TRAF-C) sub-domains. TRAF-N contains a coiled-coil 
domain, responsible for homo- and hetero-dimerisation of the TRAF proteins, as well 
as for indirect and direct interactions with cognate surface receptors (Park et al., 
1999). TRAF7 does not conform to the canonical TRAF-C domain but instead 
expresses seven WD40-repeat domains (Bouwmeester et al., 2004). All TRAF 
family members, except TRAF1, possess an NH2-terminal really interesting new 
gene (RING) domain which is highly conserved throughout TRAF2-TRAF7 at the 
amino acid level. Deletion of the RING domain in mammalian TRAF2, TRAF5 and 
TRAF6 led to the generation of dominant-negative (DN) TRAF mutants, suggesting 
that the RING domain is critical for downstream signalling (Hsu, 1996). The RING 
domain is followed by five to seven zinc finger motifs, depending on the TRAF 
(Figure 1.3). 
Previous biochemical and structural analyses have identified two sequence 
motifs for TRAF binding: a major, (P/S/A/T)X(Q/E)E, and a minor, PXQXXD (X 
representing any amino acid). TRAF signalling predominantly leads to the activation 
of the canonical NF-κB (NF-κB) or non-canonical (NF-κB2) pathways which can 




Figure 1.3 Schematic diagrams of mammalian TRAF family members (adapted 
from Xie, 2013). 
 
differentiation, but also involved in the activation of mitogen-activated protein 
kinases (MAPK), such as JNK, p38, ERK1 and ERK2 (Arch et al., 1998).  
 The NF-κB family of proteins are evolutionarily conserved master regulators 
of the immune system. They were first described as transcription factors in B cells 
that bound to the enhancer elements that control expression of the immunoglobulin 
kappa light chain (Sen & Baltimore, 1986). NF-κB regulates a number of mediators 
of immunity, such as cytokines, growth factors and effector enzymes. A large 
number of unstimulated cell types express NF-κB which correlates with a huge 
number of genes having promoter/enhancer sites for NF-κB binding. The mammalian 
NF-κB family consists of five members: p65 (RelA), RelB, c-Rel, p50/p105 (NF-
κB1) and p52/p100 (NF-κB2). Both p50 and p52 are synthesized as precursor 
proteins (p100/p105) which are processed in vivo to release the active forms (Bours 
et al., 1990). All members have a characteristic ~300 amino acid NH2-terminal 
DNA-binding domain called the Rel homology region (RHR) (Baldwin, 1996). This 
RHR domain binds to the consensus sequence 5'-GGGPuNNPyPyCC-3' present in 
the regulatory elements of NF-κB target genes and is required for homo- and 
heterodimerisation and interaction with their regulatory proteins. NF-κB is kept 
inactive in the cytoplasm through association with its inhibitor IκBα. NF-κB is 
activated by the phosphorylation and degradation of IκBα by IKK, which is a 
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regulatory subunit of NF-κB essential modulator (NEMO) (Silverman & Maniatis, 
2001).  
Genome-wide analysis of the mRNA transcripts induced by osteoclast 
progenitor cells incubated with or without RANKL previously cultured with CSF-1 
found that RANKL treatment led to the upregulation of nuclear activator of T cells 1 
(NFATc1) transcription that was dependent upon c-Fos and TRAF6. The increase 
expression of NFATc1 was followed by an increase in Ca
2+
 oscillations, indicating 
the vital role of this transcription factor in osteoclast differentiation (Takayanagi et 
al., 2002). RANKL-RANK signalling also activates phospholipase C, which 
enhances the release of intracellular stores of Ca
2+
 (Komarova et al., 2003). TRAF6 
is vital for RANKL-mediated osteoclastogenesis, as TRAF6
-/-
 mice suffering from 
severe osteoporosis (Lomaga et al., 1999; Naito et al., 1999). 
1.6.2  The mammalian TRAF family 
TRAF1 
TRAF1 was one of the first TRAF family members to be identified by its 
ability to bind to the intracellular domain of TNFR2 (Rothe et al., 1994). In contrast 
to the other TRAF members, TRAF1 does not possess a RING domain or E3 ligase 
activity and only has one zinc finger motif (Wajant et al., 2003). Its expression is 
restricted to the testis and the spleen (Rothe et al., 1994). TRAF1 can bind to a 
number of TNFR family members, such as OX40 (Kawamata et al., 1998), CD30 
(Tsitsikov et al., 1997), RANK (Wang et al., 1998) and CD27 (Yamamoto et al., 
1998). TRAF1 both positively and negatively regulates NF-κB depending on the 
nature of the ligand. For example, TNF-α and IL-1-mediated NF-κB activation is 
repressed in TRAF1 overexpression studies (Carpentier & Beyaert, 1999). TRAF1
-/-
 
mice have dysregulated T cell functions (Tsitsikov et al., 2001) and it is required for 
4-1BBL-mediated NF-κB activation (McPhearson et al., 2012). TRAF1 can form 
heterodimers with TRAF2 at the expense of TRAF2 homodimers and may be a 
regulatory mechanism, as the recruitment of TRAF1/TRAF2 complex to CD40 
reduces NF-κB activation (Zheng et al., 2010).  
45 
 
In the hydroid, Hydractinia echinata, a homologue of TRAF1 has been 
identified that does not contain a coiled-coil region (Mali & Frank, 2004). A TRAF1 
splice isoform missing the zinc finger was also identified. mRNA expression of this 
splice isoform was only detected in the larva and early metamorphosis stages, 
suggesting different functions for the two TRAF1 proteins in Hydractinia echinata 
development which have yet to be characterised. The existence of TRAF molecules 
in Hydractinia echinata again suggests ancient functions for the TNFR/Toll-IL-1R 
pathways in development and immunity.  
TRAF2 
TRAF2 is one of the best studied TRAF family members, first identified with 
TRAF1 by Rothe et al. (1994). Mammalian TRAF2 is ubiquitously expressed in all 
tissues (Rothe et al., 1994). TRAF2
-/-
 mice have a lethal phenotype complicating the 
use of this model to delineate its functions (Yeh et al., 1997). Using the dominant 
negative form of TRAF2 (TRAF2DN), this adaptor protein was shown to be required 
for both TNF-α- and CD40-mediated JNK and NF-κB activation (Lee et al., 1997). 
TRAF2 can interact with a number of intracellular adaptor proteins that both 
negatively and positively regulate NF-κB activity, such as A20, TRAF-interacting 
protein (TRIP) and NF-κB-inducing kinase (NIK) (Takeuchi et al., 1996; Hsu et al., 
1997). TRAF2 is vital for both CD40- and BAFF-regulated B cell proliferation 
(Grech et al., 2004). TRAF2KO MEF display enhanced cell death upon TNF-α 
treatment and TRAF2 inhibits apoptosis by targeting caspase-8 ubiquitination 
(Gonzalvez et al., 2012).  
A novel isoform of murine TRAF2, TRAF2A, contains an additional seven 
amino acids located within the RING domain and is incapable of mediating NF-κB 
activation (Brink & Lodish, 1998) but could activate JNK (Dadgostar & Cheng, 
1998). Both isoform transcripts are expressed across a range of murine tissues, with 
TRAF2A expressed at much lower levels than TRAF2 (Brink & Lodish, 1998). 
TRAF2A may work to regulate TRAF2-mediated activation of downstream 
signalling pathways by competitively binding to TRAF2-binding motifs.  
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The rock bream TRAF2 (rbTRAF2) homologue was cloned and characterised 
by Kim et al. (2011). The full-length protein has 56% identity with both mouse and 
human TRAF2. Its biological activity was analysed in cells harbouring an NF-κB 
reporter gene. Upon TNF-α exposure, cells expressing rbTRAF2 induced higher 
levels of NF-κB activation compared to control cells. 
TRAF3 
TRAF3 was first identified in 1994 as binding to CD40 (Hu et al., 1994). 
TRAF3 can bind to almost all TNFR superfamily members that do not express DD 
and is ubiquitously expressed. TRAF3 is a negative regulator of CD40-mediated NF-
κB activation but a positive regulator of Epstein-Barr virus latent membrane protein 
1 (LMP1)-mediated NF-κB activation in B cells (Xie et al., 2004). This is due to 
TRAF3 binding to the different TRAF-motifs within these receptors (Graham et al., 
2009). TRAF3
-/-
 mice die prematurely at around day 10 with no gross morphology of 
immune organs. The spleens of TRAF3
-/-
 mice are structurally intact, but cellularity 
is around 1% compared to the cellularity of wild-type spleens. The percentages of B 
lineage precursors in the bone marrow were significantly reduced in TRAF3
-/-
 mice 
indicating that TRAF3 may have a role in B cell development (Xu et al., 1996). 
Using a conditional gene targeting approach, TRAF3 was disrupted in murine B cells 
and these had increased survival rates independent of BAFF and CD40 signalling 
(Xie et al., 2007). Prolonged survival rates were linked to the upregulation of the 
non-canonical NF-κB2 (p52/RelB) pathway which is required for BAFF-R 
downstream pro-survival signalling. The NF-κB2 pathway is tightly regulated and its 
dysregulation is linked to many haematological malignancies (Courtois & Gilmore, 
2006). Loss of function mutations in TRAF3 have been observed in different sub-
types of B cell lymphomas and Waldenström’s macroglobulinaemia, defined by 
lymphoplasmacytic infiltrates in the bone marrow and IgM paraprotein production, 
and are linked to the upregulation of NF-κB2 activation (Braggio et al., 2009). There 
is evidence that TRAF3 regulates NIK but the relationship between TRAF3 and the 
negative regulation of B cell survival is still very complex (Lin et al., 2013).  
Several isoforms of mammalian TRAF3 have been described in which all or 
some of the zinc finger motifs are missing due to polyadenylation and exon-skipping 
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events (van Eyndhoven et al., 1998; 1999). All isoforms, except for TRAF3Δ5-10 
(numbers represent missing exons), were capable of activating NF-κB in a reporter 
gene assay and augmented its activation when co-transfected with full-length TRAF3 
(van Eyndhoven et al., 1999). In T cells, two isoforms of TRAF3 were expressed, the 
full-length gene and an isoform lacking exon 8, representing a zinc finger motif 
(TRAF3Δ8), previously described by van Eyndhoven et al. (1999). Levels of 
TRAF3Δ8 protein expression increased in PMA-stimulated T cells and were linked 
to the upregulation of NF-κB2 activation in a time-dependent manner (Michel et al., 
2014). T cell activity is known to be controlled by splice-dependent mechanisms as 
seen with CD45 splicing events (Lynch, 2004). It is proposed that splicing events are 
required for the response of immune cells to challenging environments (Heyd & 
Lynch, 2010).  
TRAF4 
Mammalian TRAF4 was first identified by differential screening of a cDNA 
library of metastatic lymph nodes derived from breast cancer cells (Régnier et al., 
1995). Its transcripts were not detected in a number of healthy tissues but were 
identified in four carcinoma cell lines and appeared to be mainly expressed in the cell 
nucleus (Régnier et al., 1995). However, similar studies identified a low basal level 
of TRAF4 expression in a number of lymphoid tissues, such as the spleen and 
thymus (Cherfils-Vicini et al., 2008). TRAF4 has a number of unique characteristics 
that differ from the other TRAF family members. It contains multiple nuclear 
localisation signal peptides (Régnier et al., 1995). Pull-down assays and yeast two-
hybrid systems have failed to identify a TNFR superfamily member that binds 
TRAF4 (Régnier et al., 2002). Murine TRAF4 is highly expressed during the 
development of the central and peripheral nervous systems and is required for the 
development of the axial skeleton, trachea and neurons (Régnier et al., 2002). There 
are limited studies identifying the role of TRAF4 in immune cells.   
TRAF4
-/-
 mice develop normally but only on a mixed genetic background 
(129/SvJ x C57Bl/6). However, these mice are still born with a constricted upper 
trachea at the site of the tracheal junction with the larynx (Shiels et al., 2000). 
TRAF4
-/-
 mice had no defects in lymphoid organ development, T cell, B cell or DC 
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numbers (Cherfils-Vicini et al., 2008). However, DC migration was affected by the 
loss of TRAF4 expression, not due to the loss of CCR7 expression but possibly due 
to defects in actin polymerisation (Cherfils-Vicini et al., 2008). TRAF4 also 
complexes with TRAF6, IL-1 receptor-associated kinase 1 (IRAK1) and TIR-domain 
containing adaptor-inducing interferon-β (TRIF), and negatively regulates the 
capacity of this signalling complex to activate NF-κB (Takeshita et al., 2005). In a 
more recent study, TRAF4
 
overexpression attenuated IL-17-mediated 
phosphorylation of ERK1/2 and JNK (Zepp et al., 2012).  
TRAF5 
 The fifth member of the TRAF family, TRAF5, was identified by 
coimmunoprecipitation studies using CD40 or LT-βR as bait (Ishida et al., 1996; 
Nakano et al., 1996). TRAF5 can associate with other TNFR family members, such 
as CD27 (Akiba et al., 1998), CD30 (Aizawa et al., 1997), LMP-1 (HVEM) 
(Marsters et al., 1997), OX40 (Kawamata et al., 1998) and RANK (Darnay et al., 
1999). TRAF5 mRNA was detected in the thymus, spleen and kidney with low levels 
detected in the brain and liver, but not in the skeletal muscle, heart, testis or small 
intestine by Northern blot analysis (Ishida et al., 1996). Although structurally more 
similar to TRAF3 (Ishida et al., 1996), TRAF5 shares many biological functions, and 
binding motifs in a number of receptors, with TRAF2 (Aizawa et al., 1997; Darnay 
et al., 1999). Targeted disruption of the murine TRAF5 RING domain does not lead 
to abnormal development or defects in lymph nodes or lymphocyte numbers. 
However, CD40-mediated upregulation of CD23, CD54 and costimulatory 
molecules, CD80 and CD86, along with IgM and IgG1 production were substantially 
reduced in TRAF5
-/-
 B cells (Nakano et al., 1999). LMP-1, a fellow member of the 
TNFR superfamily, is a functional mimic of CD40 (Fennewald et al., 1984) and 
requires TRAFs for downstream signaling. Although both CD40 and LMP-1 bind to 
the same TRAFs, they induce different responses (Xie et al., 2004). LMP-1 requires 
TRAF5 more than CD40 for B cell biology as it is vital for LMP-1-mediated IL-6 
expression (Kraus et al., 2009). 
The requirement of TRAF5 for TLR signalling was recently described in 
TRAF5
-/-










 B cells were stimulated with agonists 
for TLR4, TLR7 or TLR9, mRNA expression levels of IL-6, IL-10, TNF-α and IL-
12p40, were enhanced compared to levels in wild-type cells. TRAF5 negatively 
regulates TLR signalling in B cells by interacting with and inhibiting the adaptor 
proteins, MyD88 and TAB2, known positive regulators of TLR downstream 
signalling cascades and NF-κB activators (Buchta & Bishop, 2014). TAB2 links 
TRAF6 to the transforming growth factor-β activated kinase 1 (TAK1), facilitating 
the downstream activation of MAPKs (Takaesu et al., 2000).  
TRAF5 also functions as a limiting step in the differentiation of the Th2 
response. TRAF5
-/-
 T cells induced higher levels of IL-4 and IL-5 after CD3/28 and 
OX40 costimulation. OX40 signalling promotes both Th1 and Th2 immune 
responses and the knockout of TRAF5 in mice induced a more robust Th2 response 
in vitro and in vivo to experimental OVA-induced allergic-inflammation (So et al., 
2004). It is hypothesized that, like TRAF2, TRAF5 interacts with and inhibits the 
NFAT-interacting protein, NIP45, which is required for the transcription of IL-4 
(Lieberson et al., 2001). More recently, TRAF5 was identified as a negative 
regulator of IL-6-mediated induction of Th17 cells by binding to gp130 (Nagashima 
et al., 2014). 
TRAF6 
 TRAF6 is considered one of the oldest members of the TRAF family and has 
the most divergent TRAF-C domain which binds to a number of cytoplasmic tails of 
receptors and upstream molecules. The TRAF-C domain of TRAF6 does not interact 
with the peptide motifs used by TRAF1, TRAF2, TRAF3 and TRAF5 (Park et al., 
1999). The Drosophila ortholog of TRAF6, DTRAF2, has a major role in gene 
expression and control of the NF-κB pathway and is required for antimicrobial 
activity (Grech et al., 2000). TRAF6 is the only member of the TRAF family to 
signal for the Toll/IL-1R superfamily. However, it does not directly bind to their 
intracellular domains but instead binds to signalling complexes mediated by MyD88 
which recruits two serine/threonine kinases, IRAK1 and IRAK4, or TRIF, which 
recruits TRAF6 with receptor-interacting protein-1 (RIP-1) and tyrosine-based 
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activation motif ITAM expressing proteins (Li et al., 2002). TRAF6 has ubiquitin 
ligase activity; it can synthesise non-degradative K63-chains onto target proteins 
required for the phosphorylation of IκBα (Deng et al., 2000). TRAF6
-/- 
mice suffer 
from severe osteopetrosis and this was linked to RANKL-RANK interactions 




 T cells are hypersensitive to IL-2 treatment due to TRAF6 binding 
to and negatively regulating the IL-2Rβ-chain (Motegi et al., 2011) and they become 
resistant to Treg cells (King et al., 2006). TRAF6
-/-
 Tregs cells lose FoxP3 
expression and are skewed towards Th2-like cells (Muto et al., 2013). TRAF6 is 
essential for IL-17-mediated activation of NF-κB and MAPK as IL-17 cannot signal 
through IL-17RA in TRAF6
-/-
 MEF (Schwandner et al., 2000). The IL-17R is similar 
to the Toll/IL-1R superfamily but does not possess TIR domains or a TRAF6-
binding domain, so adaptor proteins are required for IL17RA-TRAF6 signalling 
(Novatchkova et al., 2003; Chang & Dong, 2011).  
TRAF6 homologues have been identified in a number of fish species, such as 
the Zhikong scallop (Qiu et al., 2009), common carp (Kongchum et al., 2011), grass 
carp (Zhao et al., 2013), Epinephelus coioides (Li et al., 2014) and Epinephelus 
tauvina (Wei et al., 2014). Fish species rely heavily on the innate immune system as 
their fundamental defence against pathogens. All fish TRAF6 proteins are highly 
conserved (65-98%) and tissue expression is highest in the stomach, blood and 
intestine (Li et al., 2014; Wei et al., 2014). The liver is one of the most important 
innate lymphoid organs of the fish. Various bacterial and viral antigens were used to 
infect fish and liver cells which were then analysed for the levels of TRAF6 
expression. Vibrio alginolyticus-challenged fish had increased levels of TRAF6 
mRNA expression, significantly higher than levels induced by other antigens (Wei et 
al., 2014). 
TRAF7 
TRAF7 is the most recently identified member of the TRAF protein family 
and was only discovered in a screening for protein-protein interactions around the 
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known components of the TNF-α/NF-κB pathway (Bouwmeester et al., 2004). 
TRAF7 differs from other TRAF members in that it does not possess a TRAF-C 
domain but instead has seven WD40-repeat domains. However, TRAF7 does express 
a RING domain and one zinc-finger motif (Xu et al., 2004). TRAF7 mRNA was 
detected in the skeletal muscle, heart, brain, lung, thymus, spleen, colon, small 
intestine and peripheral blood leukocytes. TRAF7 requires its WD40-repeat domains 
to interact with and activate MEKK3 (Xu et al., 2004) and inhibits the transactivation 
of c-Myb by activating its sumoylation (Morita et al., 2005). TRAF7 also negatively 
regulates TNF-α-mediated activation of NF-κB by binding to NEMO and NF-κB 
sub-unit p65 and targeting each for K29 polyubiquitination (Zotti et al., 2011). It also 
degrades the anti-apoptotic protein c-FLIP (Scudiero et al., 2012) which appears to 
be a function of its RING domain since deletion of this domain no longer confers cell 
death (Zotti et al., 2011).  
TRAF7 E3 ubiquitin ligase activity has also been linked to stabilizing p53, a 
key tumour repressor and master regulator of several signalling pathways. TRAF7 
protein expression was downregulated in breast cancer samples with no 
dysfunctional p53 gene (Wang et al., 2013). In similar studies examining 300 cases 
of primary brain tumors, TRAF7 was mutated in its WD40-repeat domains in nearly 
a fourth of all samples examined (Clark et al., 2013; Reuss et al., 2013). Currently no 
TRAF7
-/-
 mice, which could provide more insight into its role in cancer and NF-κB 
signaling, have been generated.   
Acting alone or in combination, TRAFs are versatile regulators of cellular 
responses, including survival, cytokine production, differentiation and activation.  
1.7  Aims and hypothesis of this study 
 Mammalian RANKL, RANK and OPG have vital roles in lymph node and 
thymocyte development, bone metabolism and APC biology. The chicken appears to 
have the “minimal essential” TNF superfamily, with fewer members than the same 
family in mammals. Those missing from the chicken genome have vital roles in 
mammalian T and B cell proliferation, activation and lymphoid organ development 
and it is therefore necessary to investigate the biological roles of the members that 
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are present in the chicken genome. Like mammals, chickens mediate a Th1/Th2 
immune response upon infection with intracellular and extracellular pathogens, 
respectively, and possess DC and macrophages. Members of the TNF superfamily 
require a number of TRAF adaptor proteins to activate downstream signalling 
pathways, such as NF-κB. Our hypotheses are that chicken RANKL, RANK and 
OPG have evolutionarily conserved functions in driving pro-inflammatory cytokine 
expression, cell survival and other functions in DC and macrophages, similar to 
mammalian RANKL, RANK and OPG, and that the signalling molecules required 
for mammalian RANK signalling are conserved, along with their expression patterns, 
in chicken immune organs and cells.  
The aim of this project was therefore to clone and characterise the roles of 
chicken RANKL, RANK and OPG in avian APC biology and to determine the 
presence and degree of conservation of the RANK adaptor proteins, TRAF2, 
















2.1  In silico materials 
2.1.1  BLAST 
Sequence similarly searches were used for all genes cloned. The BLAST 
program was used to analyse the similarity of nucleotide and amino acid sequences 
with the chicken and mammalian genomes and their genomic locations were 
identified.  
2.1.2  Signal P4 
Signal P4.1 (Center for Biological Sequence Analysis, Technical University 
of Denmark DTU (http://www.cbs.dtu.dk/services/SignalP/)) is an online server that 
allows the prediction of the presence and cleavage site of signal peptides present in 
an amino acid sequence from different organisms (Bendtsen et al., 2004). 
2.1.3  CLUSTALX2 
This software creates alignments of multiple amino acid and nucleotide 
sequences, allowing the identification of homologous genes between different 
species and variants of genes from the same species. It identifies residues within a 
gene of high conservation by colour coding (the darker the shading the higher the 
conservation of residues between species and variants) and has been used for all 
amino acid alignments in this study. 
2.1.4  SMART 
Simple molecular architecture research tool (SMART) is online software that 
allows the rapid identification of signalling domains and structure of proteins and 
genomes (Ponting et al., 1999). SMART version 7 was released in 2011 and contains 
1009 manually curated models of protein domains. The database also has genome 
sequence data of 1133 different species therefore allowing the identification of 




2.2  Vectors 
2.2.1  pGEM-T Easy  
pGEM-T Easy is a 3.015 kb vector used for cloning complementary DNA 
(cDNA) (Figure 2.1). It is a linearised plasmid with a single 3' deoxythymidine 
overhang at both ends. The thymidine prevents the recirculation of the plasmid and 
improves ligation of cDNA clones produced by Taq polymerases, which add 
adenosines to the ends of the PCR product, complimenting the T base, thus allowing 
for efficient ligation. The advantage of using pGEM-T Easy for cloning the cDNA of 
interest is its blue/white screening selection after transformation of the vector into 
appropriate bacteria. The vector is a high-number copy plasmid with T7 and Sp6 
RNA polymerase promoters flanking the multiple coding region (MCR). The MCR 
is located within a lacZ gene which encodes the α-peptide coding domain from the 
enzyme β-galactosidase. The β-galactosidase enzyme metabolises sugar producing a 
blue colour. When a product is inserted it shifts the reading frame, thereby 
inactivating the α-peptide protein and producing a non-functional β-galactosidase 
enzyme which will produce white colonies. However, when no insert in present blue 
colonies are formed as the α-peptide is produced and activated when exposed to 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal). This colour screening allows for the identification of 
positive colonies. The plasmid also contains an ampicillin resistance gene permitting 
the selection of positive colonies. Colony screening was also carried out to ensure no 
false positives were selected for further analysis.  
2.2.2  pCI-neo 
pCI-neo is a mammalian expression vector of 5.47 kb used for protein 
expression in mammalian cells (Figure 2.2). It can be used for both transient and 
stable transfection of cells and contains a number of features to accommodate these 
routes of expression. The vector contains the cytomegalovirus (CMV) immediate 
early enhancer/promoter region that is vital for expression of the protein of interest in 





Figure 2.1 Map of pGEM-T EASY vector 
 
2.2.3 pV20 and pV22  
 Two plasmids were designed for the expression of type II transmembrane 
proteins using the pCI-neo backbone (Tuan Jun Hu and John Young, IAH, UK, 
unpublished). The extracellular domains of type II transmembrane proteins are 
located at the COOH-terminal and interact with their cognate receptor. Therefore the 
plasmids were designed for the expression of an NH2-terminal FLAG-tag protein 
(Figure 2.3A). To generate soluble proteins the mouse CD8 signal peptide was 
intregated upstream of the gene sequence. Upstream from the FLAG sequence, an 
isoleucine zipper sequence was integrated to encourage formation of homotrimers. 
This plasmid was named pV20. The second plasmid, named pV22, was designed 
with a cysteine residue between the FLAG-tagged sequence and the gene sequence to 
encourage stabilisation of the protein structure (Figure 2.3B).  
2.2.4  Signal pKW06 and pKW06  
 Signal pKW06 and pKW06 are modified pCI-neo vectors (Staines et al., 
2013). Both plasmids were designed to express recombinant proteins in mammalian 
cells with a COOH-terminal human IgG Fc-tag. Signal pKW06-Ig differs in that it 




Figure 2.2 Map of pCI-neo 
 
soluble protein production. The pKW06-Ig allows the use of the natural signal 
peptide of the target gene or for the production of intracellular proteins. The MCR 
contains two restriction sites: a NheI site lies after the signal peptide sequence and a 
BgIll site lies between the gene of interest and the human IgFc domain (Figures 2.4A 
and B). 
2.2.5 pcDNA3-HA  
 pcDNA3-human influenza haemagglutinin (HA) is a modified version of 
pcDNA3 (Invitrogen) (Figure 2.5). HA is a surface glycoprotein and the HA tag 
corresponds to amino acids 98-106. pcDNA3 is a 6.5 kb plasmid containing the 
CMV promoter for mammalian protein expression. The MCR was modified to 
express the HA tag between the HindIII and EcoRI restriction enzyme sites (kind gift 
from James Pease, Imperial College London) (de Mendonca et al., 2005).  
2.2.6  pGL4.32-[luc2 P/NF-κB-RE/Hygro]  
 The pGL4 series of vectors were designed for genetic reporter systems to 
study gene expression (Promega) (Figure 2.6). The reporter gene system used is NF-
κB and upon activation leads to the production of Firefly luciferase. pGL4.32-




Figure 2.3 Map of pV20- and pV22-schRANKL vectors. A) pV20-schRANKL: the 
black underlined sequence indicates the mouse CD8 signal peptide, the dotted purple 
underline the isoleucine zipper sequence, the red box the NheI restriction site, the 
green box the Flag-tag sequence, the orange box the XhoI restriction site and the 
maroon box NotI restriction site. B) pV22-schRANKL: the boxed area indicates the 
sequence between the FLAG-tag and extracellular schRANKL domain, the green box 
the FLAG-tag and the grey box the extra cysteine residue. 
 
drive the transcription of the luciferase reporter gene luc2 P from the Photinus 
pyralis firefly. A hydromycin resistant gene is also expressed to allow for stable 







Figure 2.4 Map of pKW06 vector series A) Signal pKW06 expressing the mouse 
CD8 signal peptide for production of soluble proteins, B) pKW06 for expressing 
intracellular proteins or soluble proteins with natural signal peptides. These are 
mammalian expression vectors with COOH-terminal human IgG Fc tag. cDNA are 
cloned into the NheI and BglII restriction sites for expression of recombinant fusion 







Figure 2.5 Map of the pcDNA3 plasmid  
 
2.2.7 pEF1a-IRES-Neo 
 The pEF1a-IRES-neo plasmid is 5.6 kb in size and contains the human 
elongation factor-1 alpha sequence (Figure 2.7). The plasmid was designed for the 
ectopic expression of the 36 kDa Renilla Firefly protein. This plasmid was used as an 
internal control with the reporter assay system to investigate avian TRAF2 
bioactivity in mammalian cells (Section 2.13.2). There is a chimeric intron located 
adjacent to the MCR which augments the expression of the DNA insert. A simian 
virus 40 (SV40) enhancer/promoter region is present to allow the plasmid to be 
expressed in cell types containing the SV40 large T-antigen, e.g. COS-7 cells and 
HEK-293T cells. The MCR is flanked by T7 and T3 RNA polymerase promoters that 
allow for easy sequencing of the insert. Inserts for pCI-neo require directional 
insertion using restriction sites available in the MCR. It contains two antibiotic 
resistance genes for selection of positively transfected cells, ampicillin (β-lactamase) 
and G-418 (neomycin phosphotransferase), more commonly used for stable 





Figure 2.6 Map of pGL4.32-[luc2 P/NF-κB-RE/Hygro] 
 
 





2.2.8  Bacterial Strains  
Escherichia coli JM109 competent cells (Promega) were used in plasmid 
transformations. 
 
2.3  Cell lines 
2.3.1  Resurrection of COS-7 and HEK-293T cells. 
COS-7 or HEK-293T cells were removed from liquid nitrogen storage and 
quickly defrosted by placing in a pre-warmed 37°C water-bath. Cells were removed 
and resuspended in complete Dulbecco’s Modified Eagle’s medium (DMEM) 
(Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum (FCS), 200 mM 
L-glutamine, 100X non-essential amino acids, 1 U/ml of penicillin and 1 µg/ml of 
streptomycin. Cells were then washed and pelleted at 1200 g for 5 min. The 
supernatant was discarded, the cells resuspended in 15 ml of complete DMEM 
placed in a 75 cm
2
 culture flask (Niclon) and incubated at 37°C, 5% CO2. The cells 
take up to 3 days to become 70-80% confluent and ready for passage. 
To passage, the cell layer was washed twice with pre-warmed PBS. The cells 
were then washed with 5 ml of 10% (w/w) trypsin/versene solution. Another 5 ml of 
trypsin/versene solution was then added to the cells for 5 min at 37°C, 5% CO2. The 
flask was tapped three times to dislodge any cells attached to the surface. Complete 
DMEM was then added to the flask to quench the trypsin enzymatic activity. Cells 
were then transferred to a 20 ml Universal and pelleted at 1200 g for 5 min. The 
supernatant was then removed and cells resuspended in 10 ml of complete DMEM. 
The total number of cells were counted using a haemocytometer and seeded at 7.5 X 
10
5
 cells/ml in 75 cm
2
 flasks.  
2.3.2  Cell culture reagents  
All cell culture reagents were sourced from Sigma-Aldrich Ltd (Dorset, UK). 




2.4  Transfecting cells with plasmid DNA 
2.4.1  DEAE-dextran transient transfection method for COS-7 cells 
Negatively charged plasmid DNA binds to the positively charged DEAE-
dextran polymer creating a complex with an overall net positive charge, thus 
allowing for the uptake of this complex by the negatively charged cell membrane by 
endocytosis. Chloroquine is also added with the mixture to prevent the DNA being 
acidified and degraded in the endosomes upon endocytosis.  
Twenty-four hours prior to transfection, COS-7 cells were passaged and 




 flask with complete DMEM. Medium was removed from 
the cells and replaced with serum-free media containing the following for one 25 cm
2
 
flask; chloroquine (0.1 μm), plasmid DNA (37.5 μg), DEAE-dextran (600 µg/ml). 
Cells were then incubated for 3–3.5 h at 37°C, 5% CO2 after which the cells were 
given a further shock to uptake the plasmid DNA with dimethyl sulphoxide (DMSO) 
(10% in PBS) for 2 min. Cells were allowed to recover for 24 h in complete DMEM 
at 37°C, 5% CO2. To collect recombinant protein, serum-containing media was 
replaced with serum-free media and supernatant was harvested 72 h later. The 
supernatants were centrifuged at 1200 g to remove cell debris and stored at 4°C until 
use.  
2.4.2  Calcium phosphate transient transfection method for HEK-293T cells 
This approach to introduce plasmid DNA into mammalian cells is based on 
the formation of calcium-DNA precipitates that bind to the cell membrane leading to 
endocytosis. Calcium phosphate transfection was carried out according to the 
manufacturer’s instructions. Twenty-four hours prior to transfection, HEK-293T 
cells were seeded at 1.5 X 10
4
/ml in 96-flat well-plates in complete DMEM. Three h 
prior to transfection, the cell supernatant was removed and replaced with fresh 
complete DMEM. The kit components were defrosted at room temperature; calcium 
chloride (CaCl2) (2 M), 2X HEPES buffer and tissue culture water. The following 
were added to tube A: 18 μl of CaCl2, plasmid DNA (4-8 μg) and dH2O to a volume 
of 150 μl. This mixture was added drop-wise to tube B containing 150 μl of 2X 
HEPES, while bubbling air through the mixture to ensure the formation of a fine 
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CaCl2-DNA precipitate and allowed to incubate at room temperature for 30 min. The 
CaCl2-DNA precipitate was added to each well of a 96-well plate. Supernatants and 
cell lysates were harvested 48 h later and stored at 4°C or -20°C. 
2.4.3  Production of recombinant chIL-4, chCSF-2 and chCSF-1 
ChIL-4 and chCSF-2 induce the differentiation of chicken bone marrow-
derived cells into DC (Wu et al., 2010). Plasmids expressing both chIL-4 and 
chCSF-2 were available as glycerol stocks. ChCSF-1 differentiates chicken bone 
marrow cells into macrophages (Garceau et al., 2010) and a plasmid expressing 
chCSF-1 was also available as a glycerol stock. Each glycerol was streaked on LB 
agar plates with 100 μg/ml ampicillin (LBAmp100) overnight at 37°C. Single colonies 
were picked from each plate and inoculated in 5 ml of LBAmp100 broth overnight at 
37°C with shaking at 200 rpm. Two and half ml of the inoculum were removed, 
placed in 250 ml of LB-Amp100 broth and cultured for 18 h at 37°C with shaking at 
200 rpm. The bacteria were pelleted at 3000 g for 30 min and stored at -20°C. DNA 
for transfections were later isolated using Maxi prep kits (QIAGEN) (Section 2.9.2).  
 
2.5.  Analysis of tagged recombinant proteins 
2.5.1  Dot blot  
Recombinant tagged proteins were initially tested by the dot blot approach 
allowing for quick detection of the expression of the protein of interest.  All the 
proteins generated were indirectly detected by antibodies against the tag protein 
(Appendix 4, Table 5). Twenty-five to 50 μl aliquots of proteins were dotted onto 
nitrocellulose membrane along with positive (known protein with the relevant tag) 
and negative controls (PBS or dH2O). The membrane was washed with PBS-
Tween20 (PBST) and blocked for 1 h with 0.2% casein (PBS) (blocking buffer) on a 
rotating platform at room temperature. The membrane was then probed with the 
appropriate dilution of the primary antibody in blocking buffer for 1 h on a rotating 
platform. The membranes were washed once with PBST for 15 min, followed by two 
washes for 5 min. A secondary conjugated antibody (horseradish peroxidise (HRP)) 
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was added to detect the primary antibody for 1 h on a rotating platform and washed 3 
times for 5 min. To detect the proteins, ECL
TM
 Western Blotting Detection Reagents 
were used (GE Healthcare Life Sciences, Little Chalfont, UK). The membrane was 
covered with equal volumes of detection reagent solutions 1 and 2 and incubated for 
1 min. The membrane was covered in clingfilm and visualised using a G-Box. 
2.5.2  SDS-PAGE 
SDS-PAGE analysis of exCOS-7 or exHEK-293T supernatants was carried 
out using the MINI PROTEAN®-Tetra system (Bio-Rad). Samples were prepared by 
mixing 20 μl of sample protein with an equal volume of 2X reducing or non-
reducing sample buffer (Appendix 1) and denaturation at 95°C for 5 min before 
being placed on ice. Samples were loaded into a precast Tris-HCI Mini PROTEAN® 
TGX
TM
 4-20% gel (Bio-Rad), which was clamped into the electrophoresis cell. 
Running buffer, containing Tris, glycine and SDS (Bio-Rad), was added to the 
chambers at 1X concentration. Samples were electrophoresed alongside the Precision 
Plus Protein Standards dual colour ladder (Bio-Rad) at 100 V for 1.5 h. Proteins were 
either analysed by western blotting or stained with Coomassie Blue stain (National 
Diagnostics, Hessle, UK), which was added to the gels for 2 h on a rotating platform. 
Digital images were taken of the gel using a scanner (EPSON Perfection V700). 
2.5.3  Western blot  
Following electrophoresis, proteins were electro-blotted onto nitrocellulose 
membrane (GE Healthcare Life Sciences, UK) using a Transblot Turbo-Transfer 
system (Bio-Rad). The gel was removed from the cassette and washed with dH2O. 
Four 3MM filter papers (Bio-Rad) were pre-soaked in transfer buffer along with the 
nitrocellulose membrane. Two pieces of filter paper were placed on the bottom of the 
cassette holder and the nitrocellulose membrane was placed on top. To this the SDS-
PAGE gel was added and sandwiched with two more pieces of filter paper before 5 
ml of transfer buffer were added to the cassette which was then placed into the 
Transblot Turbo system. The protein was electrophoresed at 100 V for 40 min at 1.5 
A. The nitrocellulose membrane was removed from the cassette and washed with 
PBST and then blocked with 0.2% casein at room temperature for 1 h on a rotating 
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platform. The appropriate primary antibody was diluted in 0.2% casein and added to 
the membrane for 1 h at room temperature on a rotating platform, followed by a 15 
min wash with PBST and a further two 5 min washes. The secondary antibody was 
diluted in PBST and incubated with the membrane for 1 h, followed by three 10 min 
washes. Proteins were detected by enhanced chemiluminescence using ECL
TM
 
Western Blotting Detection Reagents. The membrane was covered with equal 
volumes of detection reagent solutions 1 and 2 and incubated for 1 min. The 
membrane was covered in clingfilm and visualised using a G-Box. For weak 
staining, membranes were visualised using an AEC substrate kit (BD Pharmingen, 
UK). The AEC substrate solution was made up by diluting 1 drop of AEC 
chromogen, 2 drops of acetate buffer and 1 drop of 3% hydrogen peroxide in 4 ml of 
H2O. The membrane was incubated with the solution at room temperature for 1 h on 
a rotating platform. Digital images were taken using a scanner (EPSON Perfection 
V700). 
2.5.4  Capture ELISA 
 To detect the expression of the recombinant proteins tagged with the human 
IgFc, capture ELISAs were carried out. A 96-well flat bottom plate (Falcon) was 
coated with mouse anti-human IgG antibody diluted in coating buffer for 24 h at 
4°C. Each well was washed twice with PBS-T and 50 μl of blocking buffer (0.2% 
casein-PBS) were added to each well for 1 h at room temperature. Recombinant 
protein supernatants were added to the wells serially diluted from neat to 10
-9
 in PBS. 
A standard control was added to quantify the protein concentration; this was purified 
bovine IL-2 IgFc protein (kind gift from Dr. Zhiguang Wu). The proteins were 
incubated for 1 h at room temperature. The wells were washed 5 times with PBS-T 
and goat anti-human IgG-HRP-conjugated secondary antibody was added to the 
wells at a 1:1000 dilution in PBS-T. The plate was incubated for 1 h and washed 5 
times with PBS-T. To detect the HRP enzyme, o-phenylenediamine dihydrochloride 
(OPD) (Sigma) was used. It utilises the HRP conjugates to produce a soluble brown-
orange product that can be measured by spectrometry at 450 nm. The detection 
buffer containing OPD was added to each well and the reaction was allowed to stand 
for 1-2 min. The reaction was stopped by the addition of 50 μl of 2 N H2SO4 to each 
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well and readings were taken on a Spectra Max Plus (Molecular Devices, Berkshire, 
UK).  
 
2.6  Primary Cells  
All the animals used in the work reported in this thesis were handled and 
killed in accordance with the Animals (Scientific Procedure) Act 1986. The chickens 
used in the following experiments were Brown Leghorn J line which were housed in 
the Poultry Unit, The Roslin Institute.  
2.6.1  Generation of bone marrow-derived dendritic cells (BMDC) 
Femurs and tibias from 4-6 weeks old birds were removed ascetically and 
submerged in PBS on ice till use. Both ends of the bones were cut with a bone-cutter 
and flushed with 10 ml of PBS with a 0.8 x 40 mm diameter needle (21 G x 1.5 
Terumo). To remove debris and large cells, the cell suspensions were poured through 
70 μm nylon mesh cell strainers (Fisher Scientific) into 50 ml Falcon tubes. Cells 
were pelleted by centrifugation at 400 g for 5 min at 4°C. The supernatants were 
discarded and cells were resuspended in 10 ml of PBS and overlaid on Histopaque-
1.077 (Sigma) at room temperature. To separate the cells, the Histopaque overlay 
was centrifuged at 1200 g for 20 min at room temperature with brakes and 
acceleration switched off. The cells residing on the interface were carefully removed 
using a Pasteur pipette and placed in a 20 ml Universal. Cells were then washed with 
complete Roswell Park Memorial Institute (RPMI) medium supplemented with 10% 
foetal chicken serum (FChS), 200 mM L-glutamine, 100X non-essential amino acids, 
1 U/ml of penicillin and 1 µg/ml of streptomycin) at 400 g for 5 min. The 
supernatants were removed and cells were washed in 10 ml of complete RPMI at 400 
g for 5 min. Cell numbers and viability were assessed by haemocytometer and trypan 
blue staining (Sigma-Aldrich) and adjusted to 1 X 10
6
 cells/ml with pre-warmed 
complete RPMI media containing the appropriate dilutions of chIL-4 and chCSF-2 
(exCOS-7). Cells were cultured on 6-well plates (Thermo Scientific) with 3 ml per 
well and incubated at 41°C, 5% CO2. On day two and four of culture, 75% of the 
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media were removed and replaced with 2 ml of fresh complete RPMI containing the 
appropriate dilutions of chIL-4 and chCSF-2.  
2.6.2  Generation of bone marrow-derived macrophages (BMDM) 
Macrophage progenitor cells were isolated from bone marrow using a similar 
procedure as that for BMDC in section 2.6.1. Cells were adjusted to 1 X 10
6
 cells/ml 
with pre-warmed complete macrophage RPMI (2% FChS, 3% FCS, 200 mM L-
glutamine, 100X non-essential amino acids, 1 U/ml of penicillin and 1 µg/ml of 
streptomycin). Cells were cultured in 25-well chamber plates (Thermo Scientific) 
with appropriate dilutions of chCSF-1 (exCOS-7) and incubated at 41°C, 5% CO2. 
Cells were differentiated for 6 days without replacing media or cytokines. 
2.6.3  Pilot Study: Generation of chicken osteoclasts 
 Macrophage cells were routinely grown as outlined in section 2.6.2. On day 2 
of culture, cells were removed from the plate by gentle pipetting and pelleted at 300 
g for 5 min at 4°C. Cells were counted by haemocytometer and trypan blue staining 
and adjusted to 5 X 10
4
 cells/ml in complete macrophage RPMI. Cells were 
incubated on 6-well plates (Thermo Scientific) with or without various dilutions of 
schRANKL at 41°C, 5% CO2 for up to 8 days.  
2.6.4  Tissues and primary cells  
Tissues were removed from three 6-week old birds using sterile scissors and 
forceps and were immediately stabilised in RNAlater (Sigma). Lymphoid tissues 
taken were the bursa of Fabricius, bone marrow, spleen, thymus, caecal tonsils, crop, 
gizzard, Meckel’s diverticulum, Harderian gland, caecum, mid- and upper-gut. Non-
lymphoid tissues taken were brain, muscle, heart, lung, liver, skin and kidney. 
Tissues were stored at 4°C or -20°C for long term storage. 
Further tissues were taken from three 6-week old birds. Spleen, thymus and 
bursa of Fabricius were removed aseptically and placed in PBS on ice till use. Cells 
were purified as follows; each tissue was torn apart using forceps and pressed 
through a 40 μm nylon mesh (Fisher Scientific) with chilled RPMI. Spleen cells were 
overlaid on Histopaque-1.077 and centrifuged at 500 g for 20 min with brakes and 
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acceleration switched off. Cells residing at the interface were removed using a 
Pasteur pipette and placed in a 20 ml Universal and washed twice in complete RPMI 
at 400 g for 5 min. Thymocytes and bursal cells were allowed to stand in PBS for 20 
min, allowing the cells to segregate to the bottom of a 50 ml Falcon tube. 
Supernatants were carefully removed and cells were washed twice in complete 
RPMI. Cell numbers and viability were assessed by haemocytometer and trypan blue 
staining (Sigma-Aldrich), adjusted to 5 X 10
6
 cells/ml with pre-warmed complete 
RPMI and cultured in 25 mm
2
 flasks for 2, 4, 18 and 24 h either unstimulated or 
stimulated as follows: splenocytes with 1 μg/ml Concanavalin A (ConA), bursal cells 
with 500 ng/ml phorbal myristate acetate (PMA) and ionomycin (1 μg/ml) and 
thymocytes with 25 μg/ml phytohaemagluttinin (PHA). Cells were pelleted after the 
specified time-point and lysed using RNeasy RLT lysis buffer (QIAGEN) and stored 
at -20°C until use.  
2.6.5  Purification of chicken splenocyte subsets 
Three whole spleens were removed from 6-week old birds and purified as 
outlined above. To separate the population of cells of interest, positive selection was 
carried out. After cells had been counted and cell numbers adjusted as appropriate, 
500 μl of primary mouse anti-chicken antibody (Appendix 4, Table 6) were added for 
30 min on ice in 15 ml Falcon tubes. Cells were washed twice in AutoMac Pro
TM 
Rinsing Solution (wash buffer) at 300 g for 10 min. After removal of the supernatant, 
cells were resuspended in 80 μl of wash buffer and 20 μl of mouse anti-IgG labelled 
magnetic beads for 30 min on ice. Cells were washed twice with 1 ml of wash buffer 
at 300 g for 10 min and resuspended in 500 μl of wash buffer and placed into a 15 
tube chilled rack for positive selection separation using the AutoMac Pro
TM
 Cell 
Separator (Miltenyi, Biotech). Twenty microliters of cells were retained prior to 
separation to compare sorted and unsorted cells by FACS and stored in a 96-well U-
bottomed plate on ice.  
During cell separation, the AutoMac Separator places the cells over a 
magnetic column which is placed within a magnetic field. Here, magnetic IgG- 
positive cells are captured. The column is washed multiple times to remove non-
specific bound cells and the negative cells are released. The column is then removed 
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from the magnetic field to release positive cells and undergoes multiple washes to 
elute 500 μl of the positive cell population. 50 μl aliquot of each population was 
retained for FACS analyses. Cells numbers were counted (Appendix 4, Table 6) and 
adjusted to 5 X 10
5
 cells/ml. Cells retained for FACS analysis are pelleted at 300 g 
for 2 min and were stained with 50 μl of goat anti-mouse secondary conjugated 
antibody for 20 min on ice. Cells were washed twice and resuspended with 300 μl of 
FACS buffer and analysed using the FACS Calibur machine (BD Biosciences) 
(Appendix 4, Figure 2) 
2.6.6  Control of RANKL transcription in chicken spleenocytes 
Whole spleens were aseptically removed from three 6-week old birds and 
purified as previously described in section 2.6.1. Cells numbers were adjusted to 5 X 
10
6
 and stimulated as follows: medium alone, ionomycin (3 μg/ml), ionomycin (3 





inhibitor 3, 4, 5-trimethoxybenzoic acid 8-(diethylamino)octyl 
ester (TMB-8) (Sigma) for 18 h at 41°C in 96-well U-bottomed plates. Cells were 
harvested by gentle pipetting and pelleted with centrifugation at 500 g for 5 min. Cell 
pellets were resuspended in lysis buffer, RLT, and stored at -20°C until use.  
 
2.7  Purification of nuclei acids  
2.7.1  Purifying total RNA from chicken tissues 
 Total RNA was purified from chicken tissues using the RNeasy mini kit 
(QIAGEN) following the manufacturer’s instructions. Tissues stored at -20°C in 
RNAlater were removed and allowed to thaw. Using sterile forceps and scissors, 30 
mg of each tissue were placed into a lysing matrix tube containing 1.4 mm ceramic 
spheres (MD Biomedicals). To this, 600 μl of RLT buffer containing β-
mercaptoethanol were added to protect the RNA from RNases. Tubes were placed 
into a homogenizer (FAST-PREP, Thermo Savant) and agitated vigorously for 20 
sec at 20 Hz to release cellular RNA and shear genomic DNA. The lysates were 
removed and placed in a clean 1.5 ml tube to which 600 μl of 70% ethanol were 
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added. This mixture was then placed over an RNeasy silica membrane (spin 
columns) and centrifuged for 15 sec at 1300 g. The flow through was discarded and 
the column was washed once with RW1 buffer and twice with ethanol-containing 
RPE buffer for 15 sec at 1300 g to remove contaminants. A final 2 min RPE wash 
was carried out followed by a 1 min centrifugation to remove residual ethanol. The 
spin columns were placed into clean 1.5 ml tubes and RNA was eluted from the 
silica membrane by the addition of 50 μl of RNase-free H2O. 
2.7.2  Purifying total RNA from chicken cells and cell lines 
 Total RNA was purified from chicken cells (BMDC, BMDM, splenocytes, 
thymocytes and bursal cells) and cell lines (COS-7 and HEK-293T) using RNeasy 
mini kits following the manufacturer’s protocol as in section 2.7.1.  
 
2.8  DNA and RNA amplification  
2.8.1  Oligonucleotide primer design 
 All oligonucleotides for cDNA amplification were designed using the 
predicted cDNA templates from the Ensembl (www.ensembl.org) or NCBI 
(http://www.ncbi.nlm.nih.gov/gene/) databases using Primer3 software and are given 
in Appendix 2, Table 2. 
2.8.2  Two-step RT-PCR 
  cDNA for cloning and reverse transcription-polymerase chain reaction (RT-
PCR) analysis were generated from various mRNA sources using Superscript III 
(Invitrogen) following the manufacturer’s instructions. The reverse transcription is 
carried out in two steps. First the oligo(dT) primer or gene-specific reverse primer is 
annealed to the mRNA by adding oligo(dT)20 (500 ng), mRNA sample (100 ng), 
dNTP (10 μM) and dH2O to a total volume of 13 μl and heating the mixture to 65°C 
for 5 min. In the second reaction, 4 μl of 4X first-strand buffer containing MgCl2, 1 
μl of dithiothreitol (DTT) reducing agent, 1 μl of RNaseOUT (Promega) and 1 μl of 
Superscript III reverse transcriptase (RT) were added and incubated at 50°C, or 55°C 
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for gene-specific primers, for 55 min. Finally, the RT enzyme is inactivated by 
heating to 70°C for 15 min. All samples were stored at -20°C until use.  
2.8.3  DNA amplification by PCR 
Double-stranded DNA was amplified by PCR in standard 20 or 50 μl 
reactions. Each reaction consisted of 50-100 ng of cDNA template, 0.1 μm dNTPs, 
0.75 mM MgCl2, 1X PCR buffer, 0.1 μm of primers and 1.25 U of Taq polymerase 
(Invitrogen). PCR were performed on either the G-storm or MJ machine thermal 
cycler. 
Thermal cycling conditions: 
95°C for 5 min 
95°C for 40 sec 
*X°C/ for 40 sec 
**72°C for 1 to 1.5 min 
95°C for 40 sec 
*X°C/ for 40 sec 
**72°C for 1 to 1.5 min 
*Annealing temperatures were dependent on the Tm of the each set of primers and 
ranged from 50-70°C. 
**The length of the elongation steps was dependent on the size of the product. For 
every kb, 1 min was added.  
2.8.4  Quantitative Real-time RT-PCR (TaqMan) 
Quantitative real-time RT-PCR (qRT-PCR) was used to quantitatively 
measure cytokine mRNA expression levels in a range of chicken tissues and cells. To 
account for variation and to normalise the data, the housekeeping gene, 28S, was also 
measured for each sample. The 28S ribosomal RNA gene encodes for the large 
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subunit of ribosomes and is abundantly expressed in eukaryotic cells making it an 
appropriate gene to normalise the expression levels of the target gene.  
For each gene analysed, a pair of primers and a probe were designed against 
the template for the target gene using the Primer Express software package (Applied 
Biosystems). All primers were acquired from Sigma and probes from Eurogentec 
(Belgium). The probes were labelled at the 5' end with the fluorophore 5-
carboxyfluorescein (FAM) and the 3' end with the quencher dye 
tetramethylrhodamine (TAMRA). Primers and probes for chRANKL, chRANK and 
chOPG were designed under seven strict conditions. The melting temperature of the 
primers was between 58°C and 60°C, with the probes being 10°C higher. Both the 
primers and probes were designed to be no longer than 30 nucleotides and have a GC 
content in the range of 30-80%. To reduce non-specific priming, the five last 
nucleotides at the 3' end of the primers did not contain G or C residues and 
amplicons were ideally between 50-150 bp. To design an optimal probe, there were 
no G or C residues at the 5' end as this could quench the FAM fluorophore and, to 
prevent its mis-priming, probes were designed to have less than four identical 
nucleotides in a row. Finally, all primer and probe sets were designed so that at least 
one component overlapped an intron/exon boundary so that no genomic DNA was 
amplified producing “false positives”. 
Detection of a specific product is based on the fluorescence released due to 
hydrolysis of the target-specific probes by the 5' exonuclease activity of the DNA 
polymerase. The close proximity of the 5' reporter fluorophore allows the 3' quencher 
to inhibit the fluorescence of the reporter dye. During the PCR stage of RT-PCR, the 
primers anneal to the template and the probe anneals at a position between the 
forward and reverse primer. When the primers are extended during PCR the DNA 
polymerase moves along the template. However, when the polymerase encounters 
the bound probe, its 5'-3' exonuclease activity degrades the probe releasing the 
reporter from the inhibition of the quencher. This leads to an increase in the 
fluorescence intensity which can be measured. The greater the fluorescence intensity, 
the greater the abundance of the target gene in each sample. The results are presented 
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as the cycle threshold (Ct) value, the number of cycles at which the fluorescence 
emission of the reporter minus the background passes the threshold of detection.  
The optimal concentration of each primer set needs to be determined before 
examining the expression of the target gene. For IL-1β, IL-6, IL-10, IL-12α and 28S, 
primer optimisations were previously determined (Wu et al., 2010; 2011). For 
chRANKL, chRANK and chOPG, optimal primer concentrations were determined as 
follows; COS-7 cells were transfected with the pV22-exRANKL, pKW06-RANK or 
pKW07-OPG constructs by the DEAE-dextran approach as in section 2.4.1. RNA 
was extracted using an RNeasy mini kit according to the manufacturer’s instructions 
(Section 2.7.1). These RNA samples were used as positive standard controls. The 




 and primers were used 
at concentrations between 0.25-2.5 μM to determine the optimal concentration. For 
chRANKL, chRANK and chOPG, 0.4 μM primer concentrations were optimal for 
detection of each cytokine and was used for all analyses.   
 All RT-PCR reactions were performed using the TaqMan FAST Universal 
PCR Master Mix and the One-step RT-PCR Multiscribe enzyme (Applied 
Biosystems). Samples were analysed in a 10 μl reaction volume consisting of 5 μl of 
2X FAST Master mix, 0.5 μl of primer mix, 0.25 μl (125 nM) of probe, 0.25 μl 40X 
Multiscribe enzyme, 1.5 μl of DEPC-H2O and 2.5 μl of diluted RNA. For 28S 
analysis, RNA samples were diluted 1:500 and RNA test samples used for detection 
of target gene were diluted at 1:5. All assays were done in triplicate wells. For 
positive standard RNA for 28S detection, RNA from HD11 cells stimulated with 
LPS (200 ng/ml) for 6 h was used. Amplification and detection of products was 
carried out using the 7500FAST TaqMan machine (Applied Biosystems).The 
thermal cycling conditions were as follows. RT steps: 48°C for 30 min, 95°C for 20 
sec followed by PCR steps: 95°C for 3 sec, 60°C for 30 sec repeated for 40 cycles. 
Primers and probe sequences and concentrations for all target genes tested are given 
in Appendix 2, Table 4. 
To calculate the corrected 40-Ct values for all target genes, the following 
formulas were used: standard curves were created using the Ct values of the serially 
diluted standard RNA of the specific gene. The slope of the line (y=mx+c) allows for 
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the examination of the efficacy of the reaction using the following formula E= (10(-
1/slope))-1 (E=efficacy). To calculate the corrected 40-Ct values the following 
equation was used: normalised Ct= Ct+(N’t-C’t)*(S/S’) where N’t is the mean Ct 
value for 28S RNA among all samples, C’t is the mean value for 28S RNA in the 
sample and the S and S’ are the slopes of regression of the standard plots for the 
cytokine mRNA and the 28S RNA, respectively. Corrected 40-Ct is calculated by 
40- normalised Ct. 
2.8.5  Agarose gel electrolysis  
All DNA was visualised using agarose gels. DNA agarose gels were prepared 
by adding agarose at a (w/v)% dependent on the size of the expected PCR product in 
TAE. TAE is made up of Tris-buffer, acetic acid and EDTA which works to 
sequester divalent cations. Although TAE is not a stable as TBE, linear, double-
stranded DNA runs faster through agar dissolved in TAE buffer. The mixture was 
heated until agarose powder was fully dissolved and allowed to cool to 50°C.  The 
DNA intercalating dye, SYBR Safe® (Invitrogen) was added to the mixture and 
poured into a plastic mould to set with appropriate comb sizes inserted.  
2.8.6  PCR purification  
When a single band was visualized on a DNA agarose gel, the remaining 
PCR product was cleaned up using the QIAquick PCR Clean-up kit (QIAGEN) 
according to the manufacturer’s instructions, as follows. PB binding buffer was 
added at 5 times the volume of the PCR mix and placed in spin column with a 2 ml 
collection tube. The DNA was bound to the silica membrane by centrifugation at 
1300 g for 1 min. The flow through was discarded and the column washed twice with 
ethanol-containing PE buffer. To ensure all ethanol was removed before elution, the 
column was given a dry spin at 1300 g for 1 min. The DNA was eluted in 30 μl of 
H20, allowed to stand for 1 min for optimal absorption and spun at 1300 g for a 
further 1 min to elute the DNA. Samples were stored at -20°C or used immediately 




2.8.7  Gel extraction  
 PCR reactions that contained multiple bands were purified using a QIAquick 
Gel Elution kit (QIAGEN) according to the manufacturer’s instructions, as follows. 
The bands of interest were excised using a disposal scalpel blade from the gel under 
a UV transilluminator. QG dissolving buffer was added at 5 times the volume of the 
excised gel portion. This was allowed to dissolve for 15 min at 56°C on a heating 
block after which it was vortexed repeatedly. The QG buffer also contains a pH 
colour and salt indicator which, when orange, indicates the pH is <7.5 and salt 
concentration is high for optimal DNA absorption to the silica membrane of the spin 
column. Sodium acetate (pH 5.0) was added to samples that needed adjusting for 
optimal absorption. The dissolved gel was mixed 1:1 with isopropanol, applied to a 
spin column and centrifuged for 1 min at 1300 g. The flow-through was discarded 
and the column was washed using PE buffer at 1300 g for 1 min. The column was 
washed for an additional min to ensure any residue of ethanol was removed. The 
column was transferred to a clean 1.5 ml microcentrifuge tube and the DNA was 
eluted using 30 μl of autoclaved H20, allowed to stand for 1 min for optimal 
absorption and spun at 1300 g for a further 1 min. Samples were stored at -20°C or 
used immediately for ligation into the appropriate vector.  
2.8.8  Ligation 
Ligation is a method which allows the covalent bonds at the ends of DNA 
fragments to be joined together. This process requires three components: DNA 
fragments that have compatible or sticky ends, buffer containing ATP which is a 
vital co-factor for the bioactivity of the last component and T4 ligase. The T4 ligase 
is from the bacteriophage T4 and works to fix nicks in the phophodiester backbone 
of DNA. T4 ligase works across a broad range of temperatures with 16°C being the 
most optimal.  However, 4°C overnight incubation works efficiently. All sub-cloning 
procedures were carried out using T4 ligase buffer (Promega).  
2.8.9  Directional sticky-end cloning into expression vectors 
To directionally ligate DNA into expression vectors, primers were designed 
to integrate the appropriate restriction sites at the 5' and 3' end of the cDNA. The 
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empty expression vectors were cut using the same restriction enzymes as the sites 
incorporated into the cDNA sequence. The restriction enzymes create overhanging 
ends on the vector and cDNA that complement one another, allowing T4 ligase to 
join them together creating a closed circular plasmid.   
2.8.10  Restriction digestion 
Restriction digestion was carried out using the restriction enzymes and their 
appropriate buffers (Appendix 1) to release the DNA inserts from pGEM-T Easy or 
to cut the cDNA after gel or PCR purification. The same restriction enzymes used to 
cut the cDNA were used to linearize the empty expression vectors (pKW06, 
pcDNA3-HA, etc.). All digestions were carried out in 10 μl reactions containing 1 μl 
of DNA, 1 μl of 10X reaction buffer and 1 μl of restriction enzyme. Reactions were 
incubated at 37°C overnight. For double digestions, the initial digest was incubated 
overnight at 37°C, after which the mixture was cleaned up to remove the original 
restriction enzyme and buffer using a PCR clean-up kit (QIAGEN), as described in 
section 2.8.6, and the second restriction enzyme added for a further 8 h incubation at 
37°C. 
2.8.11  Transformation  
Escherichia coli JM109 competent cells were removed from -80°C storage 
and defrosted on ice for 5 min. A 45 μl aliquot of the cells was added to a chilled 1.5 
ml eppendorf tube containing 2 μl of ligation reaction and gently flicked before 
incubating on ice for 20 min. The mixture was then placed in a water-bath heated to 
42°C for 50 sec. This heat-shock approach creates small holes in the wall of the 
bacteria allowing the uptake of the DNA/plasmid. The cells were then returned to ice 
for a further 2 min. A 950 μl aliquot of room temperature SOB media was added to 
the cells and incubated at 37°C with shaking (2000 rpm) for 90 min. The cells were 
gently pelleted at 200 g for 3 min and supernatants discarded. The cell pellets were 





2.8.12  Screening bacterial colonies by colony PCR 
Bacterial colonies were screened for gene inserts by PCR using either gene- 
specific primers, those used to clone the gene, or plasmid-specific primers, designed 
to overlap the MCR of the plasmid. Using a pipette tip, colonies were individually 
picked and streaked in a small numbered area of a Luria broth (LB) agar plate 
supplemented with 100 mg of ampicillin (LBamp100). The same tip was then incubated 
in 50 μl of dH2O for 1 min. These samples were then boiled for 5 min at 95°C and 10 
μl were used as template in PCR. The LBamp100 agar plates were incubated at 37°C 
for 24 h. Positive colonies were identified by PCR and picked from overnight agar 
plate into 5 ml of LBamp100 broth for plasmid purification.  
 
2.9 Plasmid DNA purification 
2.9.1  Small-scale plasmid purification  
 For sequencing, plasmid DNA from E. coli cells was purified using a Mini 
Prep kit from QIAGEN following the manufacturer’s instructions as follows. A 
single colony was grown overnight in 5 ml LBamp100 broth at 37°C with shaking at 
200 rpm. Cells were pelleted for 15 min at 3000 g and supernatants were discarded. 
Cells were resuspended in 250 μl of buffer P1 containing Lysis Blue (colour 
indicator to ensure optimal buffer mixing) and placed in a 1.5 ml tube. Next, 250 μl 
of lysis buffer P2 were added and the tube was inverted 4-6 times. A 350 μl aliquot 
of neutralising N3 buffer was added to the mixture and inverted 4-6 times to degrade 
the cell components, leaving the DNA in the supernatant. To compact the cell debris, 
the mixture was centrifuged at 1300 g for 10 min. The supernatant was applied to a 
spin column and centrifuged at 1300 g for 1 min to capture the DNA in the silica 
membrane. To remove endonucleases and ensure no degradation of the DNA, the 
membrane was washed with 500 μl of PB buffer. The flow through was discarded 
and the column washed twice with ethanol-containing wash buffer with a further dry 
spin to remove residual ethanol. The spin column was placed in a new 1.5 ml tube 
and the DNA eluted using 50 μl of dH2O and centrifugation at 1300 g for 1 min. The 
concentration of the plasmid DNA was analysed using a Nanodrop.  
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2.9.2  Large-scale endotoxin-free plasmid purification  
To acquire a high yield of plasmid DNA for transfection and protein 
production, an endotoxin-free Maxi prep kit (QIAGEN) was used according to the 
manufacturer’s instructions as follows. Single colonies previously sequenced verified 
were grown in 5 ml of LB amp100 broth at 37°C with shaking at 200 rpm for 8-12 h. A 
2.5 ml aliquot was added to 250 ml of LB amp100 broth and incubated at 37°C with 
shaking at 200 rpm. Cells were pelleted at 3000 g for 30 min. The cell pellets were 
either stored at -20°C until use or immediately resuspended with 10 ml of P1 buffer 
containing Lysis Blue. The cells were lysed by addition of 10 ml of buffer P2, mixed 
by inversion and incubated at room temperature for 5 min. Chilled P3 buffer was 
added to the mixture to precipitate cell debris, genomic DNA and proteins. To 
compact the cell debris the mixture was centrifuged for 15 min at 4000 g. The lysates 
were removed and placed in a clean 50 ml Falcon tube to which 5 ml of ER buffer 
were added to remove endotoxins and incubated on ice for 30 min. A 30 ml 
QIAGEN-100 column was equilibrated with 10 ml of QBT buffer; to this the lysate 
mixture was added and allowed to flow through. The column was washed twice with 
30 ml of QC buffer and DNA was eluted with elution buffer QF into a clean 50 ml 
Flacon tube. To precipitate the DNA, 10.5 ml of isopropanol were added and mixed 
by vigorous inversion. The DNA was pelleted by centrifugation at 4000 g for 1 h at 
4°C. The supernatant was removed and the DNA was washed once with 5 ml of 70% 
ethanol at 4000 g for 1 h at 4°C. The ethanol was removed and the DNA pellet was 
air-dried for 15-20 min at room temperature. The DNA pellet was resuspended in 
500 μl of dH2O and stored at -20°C until use.  
2.9.3  Sequencing plasmid DNA 
Sequencing of all genes for verification was carried out using a Big Dye 
Sequencing Kit (Applied Biosystems) and analysed using the Applied Biosystems 






2.10  Optimising bioassay conditions 
2.10.1  Optimising LPS concentration for stimulating BMDC and BMDM 
 Preliminary assays were carried out to determine the concentration of 
lipopolysaccharide (LPS) to induce sub-optimal maturation of antigen-presenting 
cells (APCs). BMDC and BMDM were differentiated from bone marrow cells as 
described in section 2.6.1. Cells were stimulated on day 6 of culture with various 
amounts of LPS (E. coli serotype 055:B5, Sigma) (1-200 ng/ml) for 3, 6 and 9 h, 
after which the cells were removed from wells by gentle pipetting and pelleted at 500 
g for 5 min. The cells were then lysed using RLT lysis buffer from the RNeasy mini 
kit (QIAGEN) and stored at -20°C until use. RNA was purified for each sample 
following the manufacturer’s protocol as described in section 2.7.1. For cell surface 
expression of activation markers on BMDC and BMDM, various amounts of LPS (1-
200 ng/ml) and exCOS-7 IFN-γ dilutions were tested to identify the optimal 
concentration to induce maturation in APCs, as determined by flow cytometry using 
a FACs Calibur (BD Biosciences) as described in section 2.11.1. For BMDC, 2 
ng/ml, and for BMDM, 1 ng/ml of LPS were sufficient to induce expression of cell 
surface molecules after 24 h. For BMDM, the more potent activator IFN-γ was 
optimal at a 1:100 dilution of exCOS-7 cell supernatant.  
2.10.2  Optimising schRANKL concentrations for stimulating BMDC and BMDM 
Two similar plasmids differ in the location of cysteine residues were designed 
to express of type II transmembrane proteins (Section 2.2.4). To determine which 
recombinant chRANKL was expressed from both vectors for further studies and 
bioassays, BMDC were differentiated from bone marrow cells as described in section 
2.6.1.  Cells were stimulated on day 6 of culture with LPS (2 ng/ml) with or without 
various dilutions of pV20- or pV22-schRANKL for 3, 6, 24 and 48 h.  To determine 
the bioactivity of each protein, RNA was extracted from each sample and pro-





2.11  Flow cytometry 
2.11.1  Cell surface analysis of proteins expressed by chicken APC 
Flow cytometry allows analysis of the expression of specific proteins on the 
surface of cells or intracellularly. Due to the relatively small number of chicken 
APC- specific mAb available, single staining of BMDC and BMDM was carried out 
for this study. Cells were harvested after the specified time-point by addition of 
EDTA (0.5 mM) for 2 min at room temperature. Cells were removed by gentle 
pipetting using a Pasteur pipette and placed in a 20 ml Universal tube. Cells were 
pelleted at 350 g for 5 min and resuspended in the appropriate amount of FACS 
buffer (PBS, 0.005% bovine serum albumin and 0.001% azide). All antibodies were 
diluted in FACS buffer with dilutions and further information is given in Appendix 
4, Table 7. In a 96-well U-bottomed plate, 50 μl of cells were added to each well. 
Cell were washed with 150 μl of FACS buffer and centrifuged at 350 g for 3 min at 
4°C. The plate was quickly inverted to release the supernatant and the cell pellet 
dispersed using a plate shaker. The cells were resuspended in 50 μl of the appropriate 
primary mAb on ice for 20 min. Cells were washed twice with FACS buffer and 
shaken to disperse the cell pellet. The appropriate secondary conjugated antibody 
was added to the cells for a further 20 min after which the cells were washed twice 
and resuspended in 400 μl of FACS buffer. To distinguish between live and dead 
cells, the 7-AAD viability dye (Biolegend) was added to cells prior to analyses on the 
FACS Calibur (BD Biosciences).  
2.11.2  Flow cytometry-based survival assay 
During the different stages of apoptosis, the cell membrane undergoes a 
number of changes such as expression of thrombospondin-binding sites and exposure 
of phosphatidylserine (PS).  PS is usually found on the inner membrane of the cell 
and upon apoptosis-inducing signals, this negatively charged phospholipid flips to 
the outer membrane (Fadok et al., 1992). This occurs at the early stages of apoptosis 
and is not linked to membrane leakage, unlike the necrosis form of cell death. 
Annexin-V is part of large family of calcium-dependent proteins that recognise and 
bind to a wide variety of phospholipids. However, Annexin-V only binds to PS 
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which makes it appropriate for staining early apoptotic cells. To differentiate 
between early and late stages of apoptosis and necrosis, propidium iodine (PI) is used 
to stain DNA which becomes exposed during cell death by cell membrane leakage.  
To analyse cells undergoing early or late apoptosis, BMDC and BMDM were 
treated on day 6 of culture with media alone or with various dilutions of ex-COS-7 
exRANKL for 24 and 48 h. Cells were harvested from the plates by gently pipetting 
as EDTA inhibits the calcium-dependent annexin-V binding. Cells were pelleted at 
350 g for 5 min and washed twice with annexin-V binding buffer (eBioscience- 
Affymetrix). Cells were resuspended in 190 μl of binding buffer to which 10 μl of 
recombinant annexin-V-biotin were added at room temperature for 20 min. Cells 
were washed twice with binding buffer at 350 g for 3 min. Streptavidin-Alexa-647 
was added to the cells for 30 min at room temperature in the dark. Cells were washed 
twice with binding buffer and resuspended in 350 μl of buffer. Prior to FACS 
analysis, 20 μg of PI were added to the appropriate wells and FACs analysis was 
performed on a FACS Calibur (BD Biosciences). 
2.11.3  Phagocytosis assay 
 Immature DC and macrophages can engulf solid particles to form internal 
phagosomes. As the cells mature they lose the ability to endocytose particles. On day 
6 of BMDC culture, the media were removed and replaced with fresh media or a 
1:50 dilution of schRANKL for 24 h, after which 100 particles/well of Zymosan A 
BioParticles labelled with fluorescein isothiocyanate (FITC) (Molecular Probes), 
except in control wells, were added for 1 h. Experiments were carried out in 
duplicate with one plate incubated at 41°C, 5% CO2, and a control plate at 4°C to 
inhibit phagocytosis. Phagocytosis was stopped by the addition of 550 μl of ice-cold 
PBS followed by 4 washes with cold PBS. The cells were fixed with 4% PFA for 20 
min at room temperature, followed by two washes with PBS containing 2% FBS, and 
analysed under the Zeiss Axiovert fluoresence
 
microscope with attached camera or 





2.12  Dual-Luciferase Reporter system 
Dual-Luciferase Reporter system (Promega) are widely used for the study of 
eukaryotic gene expression and allows a number of biological processes to be 
analysed, e.g. transcription factors, intracellular signalling, RNA processing and 
protein folding. The dual reporter approach allows for the simultaneous expression 
and detection of two individual reporter enzymes. The Firefly luciferase-containing 
vector, pGL4.32-[luc2 P/NF-κB-RE/Hygro] (section 2.2.7), is a reporter plasmid that 
is affected by specific experimental conditions while the co-transfected control 
Renilla luciferase plasmid, pEF1a-IRES-Neo (section 2.2.8), serves to provide a 
baseline response. Firefly and Renilla luciferase have distinct evolutionary origins, 
different enzyme structure and have different substrate requirements, giving them 
utility in these assays. 
The pGL4.32-[luc2 P/NF-κB-RE/Hygro] vector contains NF-κB response 
elements that drive the transcription of the luciferase reporter gene luc2 P from the 
Photinus pyralis Firefly when the NF-κB pathway is activated. The Firefly luciferase 
is a 61 kDa monomeric protein that can be oxidised through a luciferyl-AMP 
intermediate that requires ATP, Mg
2+
 and O2 upon which it releases a “flash” of light 
that can be detected by a luminometer (Figure 2.6). Renilla luciferase on the other 
hand is a 36 kDa monomeric protein from Renilla reniforms. The luminescent 
reaction is catalysed by the coelenterate-luciferin and O2 (Figure 2.6). To distinguish 
between the luminescent of the two luciferases, the Dual-Luciferase reporter system 
provides two substrate kits; a Luciferase Assay Reagent II kit to activate the Firefly 
luciferase and a Stop & Glo® Reagent kit which inhibits the Firefly luciferase and 
activates the Renilla luciferase.  
 HEK-293T cells were grown and passaged as described in section 2.3.2. Cells 
were seeded at 1.5 X 10
4 
cells/ml and grown on 96-well flat bottomed plates at 37°C, 
5% CO2 for 48 h to allow cells to become 80% confluent. Cells were then co-
transfected using the calcium-phosphate method (section 2.3.4). To each well, 40 
ng/ml of pGL4.32-[luc2 P/NF-κB-RE/Hygro] vector were added along with 10 ng/ml 




Figure 2.6 Bioluminescent reactions catalysed by Firefly and Renilla luciferases.  
 
plasmids at 75 or 150 ng/ml. Cells were grown for 48 h and media were removed and 
replaced with 30 µl of 1X Passive Lysis buffer (Promega) for 10 min at room 
temperature on a rotating platform to release intracellular protein. To detect 
luciferase activity of the firefly luciferase, 50 µl of Luciferase Assay Reagent II were 
added to each well and luminescence was detected immediately using the GloMax® 
96 luminometer (Promega). To quench the firefly luminescence and activate the 
Renilla luciferase, 50 µl of Stop & Glo® Reagent was added to each well and a 
second reading of luminescence detected using the GloMax® 96 luminometer 
(Promega). To normalise the data, the luminescence of the Firefly luciferase was 
divided by the Renilla luciferase data and expressed as relative luciferase activity. 
2.13  Statistical analysis 
 All data were checked for normality and statistical analyses were carried out 
using either Mann Whitney-U test or Student’s t-test as indicated in Minitab 16.1.0 
(State College, USA). Statistical significance was determined as p<0.05 (significant) 











Cloning and expression of chicken receptor activator of NF-κB 




3.1  Introduction 
The mammalian TNF receptors and their ligands orchestrate a variety of 
functions in the architecture of immune organs, development, inflammation, 
invasion, proliferation and angiogenesis (Locksley et al., 2001; Aggarwal, 2003). 
The receptor family are characteristically type I transmembrane proteins that have 
low degrees of homology and are grouped due to the presence of conserved CRD in 
their extracellular ligand-binding domain (Naismith & Sprang, 1998). The ligand 
family has 19 members which interact with their cognate receptor(s). This family of 
cytokines are typically type II transmembrane proteins with highly conserved 
COOH-terminal TNF homology domains. Members of the TNF superfamily usually 
share 20-30% sequence identity within this domain. The hallmark of ligand:receptor 
interactions is their three-fold symmetry. The ligands self-assemble into non-
covalent trimers, whose individual chains form a β-sheet “jelly-roll” fold (Jones et 
al., 1990).  
 To date, 19 ligands and 29 receptors have been identified in mammalian 
species. However, only 10 ligands and 15 receptors have been identified in the avian 
genome. One of the most recent members of the mammalian TNF superfamily to be 
identified was RANKL along with its signalling receptor, RANK (Anderson et al., 
1997; Wong et al., 1997). RANKL is a transmembrane protein of 316 amino acids 
containing a COOH-terminal receptor-binding domain, a 20 amino acid hydrophobic 
transmembrane domain and a relatively long extracellular region that contains a TNF 
homologous domain (Anderson et al., 1997; Lam et al., 2001). RANKL 
predominantly exists as a membrane-bound form but soluble protein can be 
generated by enzymatic cleavage and alternative splicing (Ikeda et al., 2001; Walsh 
et al., 2013). At the cell surface, RANKL aggregates into trimers through conserved 
residues in the extracellular domain and this three-fold symmetry is required for the 
activation of its cognate receptor, RANK. RANKL interacts with RANK on the 
surface of DC, enhancing pro-inflammatory cytokine expression and survival of cells 
(Anderson et al., 1997; Wong et al., 1997). Around the same time as RANKL was 
cloned and identified, various other groups identified the inhibitory effects of 
osteoprotegerin (OPG) on osteoclast cells (Simonet et al., 1997). Using OPG as bait, 
two independent groups identified its ability to interact with RANKL and inhibit its 
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bioactivity (Simonet et al., 1997; Yasuda et al., 1998). OPG functions to limit the 
interaction between RANKL and RANK, working as a decoy receptor. Further 





 deficient mice had entirely unexpected phenotypes: early 
defects in T and B cell development, complete absence of lymph nodes, severely 
reduced osteoclastogenesis and failure to develop mammary glands (Dougall et al., 
1999; Kong et al., 1999a; Perlot & Penninger, 2012). RANKL-RANK interaction is 
critical for a number of important biological activities required for development, 
immunity and bone metabolism. Their role in T cell and DC communication was at 
the forefront of research until the discovery that these cytokines drive interactions 
between the immune system and bone turnover, leading to an interdisciplinary 
research field, coined osteoimmunology by Arron & Choi (2000).  
With the TNF superfamily playing vital roles in immunity it is important to 
understand the bioactivity of the family members present in the chicken genome.                                                                                                                                                                                                                                                                                                                                                                      
To date, of the 11 TNF ligands identified in the avian genome, research has been 
carried out on 5; CD30L and TRAIL (Abdalla et al., 2004b), BAFF (Schneider et al., 
2004), CD40L (Tregaskes et al., 2005) and VEGI (T1A) (Takimoto et al., 2005). 
These studies identified the conserved bioactivity of each gene in the chicken. To 
begin examining the bioactivity of chicken RANKL, RANK and OPG, their 
sequences were examined for conservation with their mammalian orthologues. In this 
Chapter, the molecular cloning of the full-length and extracellular domains of 
chRANKL, chRANK and full-length chOPG is described. The ability of chRANKL 
to form trimers, along with the ability of chOPG to form dimers, was analysed with 




3.2.  Methods 
3.2.1  In silico analysis 
Mammalian RANKL and RANK are type II and type I transmembrane 
proteins, respectively. To identify the various domains within the chicken proteins, 
the SMART prediction program was used to compare them to the known human and 
mouse sequences. Signal peptide sequences, N-glycosylation sites and domain 
structures were analysed using SignalP4, NetNGly, TMHMM and PSIPRED 
programs Amino acid conservation between mammalian and chicken genes were 
analysed using CLUSTALX V2 (Chapter 2, section 2.1).  
3.2.2  In vitro methods 
The full-length and extracellular domains of chRANKL and chRANK were 
cloned, along with the full-length sequence of chOPG, using RNA from ConA-
stimulated splenocytes or bone marrow cells as template by RT-PCR. Each gene was 
sub-cloned into their respective expression vectors to produce recombinant proteins 
(Chapter 2, section 2.2). To express chRANKL, two plasmids were specifically 
designed to induce the correct folding of the protein, called pV20-schRANKL and 
pV22-schRANKL (Chapter 2, section 2.2). Recombinant fusion proteins were 
generated from COS-7 cells transfected with the respective expression vectors by a 
DEAE-dextran-based approach (Chapter 2, section 2.4). The TNF family form 
dimeric or trimeric proteins and to investigate the ability of the chicken TNF 
superfamily members to fold correctly, protein structures were analysed by western 
blot. Preliminary experiments were carried out to investigate the bioactivity of the 
pV20- and pV22-schRANKL. BMDC were generated and stimulated with LPS or 
chCD40L, with or without pV20- and pV22-schRANKL, and pro-inflammatory 






3.3  Results 
3.3.1  Identification of the genes for RANKL, RANK and OPG in the chicken 
 genome 
To characterise the biological roles of chRANKL, chRANK and chOPG, the 
cDNA for all three were cloned and sequence verified. All three genes are present in 
the chicken genome with chRANK (NP_001076830.1) being the only sequence that 
is currently predicted. Using the chicken genome sequence v4.0, the location of each 
gene was identified. The chRANKL gene is located on chromosome 1 and has 
conserved synteny with both the human (chromosome 13) and mouse (chromosome 
14) genes (Kaiser et al., 2005). ChRANK and chOPG both lie on chromosome 2 and 
also have conserved synteny with both the human (chromosomes 18 and 8 
respectively) and mouse genes (chromosomes 1 and 15, respectively) (Kaiser et al., 
2005). Wang et al. (2008a) characterised the ability of chRANKL to activate 
osteoclasts from chicken bone marrow preparations.  However, that study does not 
indicate whether the full-length or extracellular domain of the protein was used. It 
refers to another paper (Wang et al., 2008), stating that the protocol to clone 
chRANKL is in this other paper. However, this other paper does not exist in any 
searchable database.  
To verify the sequence identified was chRANKL, the human RANKL protein 
sequence (NP_003692.1) was blasted against the chicken genome. Human RANKL 
has 61% identity to chRANKL (NP_001076830.1) and therefore this chicken 
sequence was used for further analyses. In the chicken genome, the chRANK cDNA 
sequence was predicted and was verified by blasting the human protein RANK 
sequence against the chicken genome sequence. Human RANK has the highest 
similarity to the predicted chRANK protein (~44%). In 2003, a group identifying the 
expression of TNF decoy receptors during follicle development and atresia in 
chickens cloned a partial sequence of chOPG. This partial sequence contained the 
CRD but not the COOH-terminal domain (Bridgham & Johnson, 2003). Several 
years later an independent group cloned the full-length sequence of chOPG (Hou et 
al., 2011). Their sequence was added to the NCBI database in 2012 
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(NM_001033641.1) and was used for the design of forward and reverse primers to 
clone chOPG cDNA. 
3.3.2  Signal peptide analysis of chRANKL, chRANK and chOPG 
 To verify the position, presence and cleavage sites of signal peptides in 
chRANKL, chRANK and chOPG, their predicted amino acid sequences were 
analysed with SignalP4 (Figure 3.1). Mammalian RANKL is a type II 
transmembrane protein; therefore its COOH-terminal is exposed to the extracellular 
space. Type II transmembrane proteins do not contain signal peptides but possess 
long hydrophobic residues that have the dual function of targeting and harbouring the 
protein within the endoplasmic reticulum. The chRANKL predicted protein sequence 
was analysed for the presence of a signal peptide using SignalP4 (Figure 3.1). The 
signal peptide analysis was negative, strongly suggesting a type II protein structure.  
RANK is a type I transmembrane protein and therefore contains a signal 
peptide at its NH2-terminal region. The predicted signal peptide for chRANK is from 
position 1 to 19 (Figure 3.1). The first 20 bases in chRANK contain a high 
percentage of G/C residues making it difficult to design appropriate primer pairs. It 
was therefore decided to design primers omitting the signal peptide as the designated 
protein expression plasmid vector contained a signal peptide.  
OPG is produced as a soluble protein and therefore contains a signal peptide 
to ensure the protein is processed for transport to the cell membrane, where upon 
appropriate signals it will be exported outside the cell. The predicted amino acid 
sequence of chOPG has a signal peptide of 19 amino acids (Figure 3.1) which was 
included in the primer design. 
3.3.3  Identification of the extracellular domains of chRANKL and chRANK  
 To express chRANKL as a soluble recombinant protein, its extracellular 
domain was identified using the known human and mouse sequences. The 
extracellular portions of the TNF superfamily contain conserved canonical ‘TNF 
homology domains’ required for trimerisation and are responsible for receptor 
















Figure 3.1 SignalP4 predictions for the presence of signal peptides in 
chRANKL, chRANK and chOPG. The predicted chRANKL protein was analysed 
for signal peptide sequence, chRANK predicted signal peptide sequence and 
cleavage site, and chOPG predicted signal peptide sequence and cleavage site. Max 
C values represent the C-score, which identifies the position of the first amino acid of 
the mature protein. Max S values represent the S-score of the positions within the 
signal peptide from those in the mature protein. The Max Y values are the 
combinations of the slope of the Max S and the Max C-score to predict a more 





Max C 42 
Max Y 42 
Max S 34 




Max C 24 
Max Y 20 
Max S 14 
Mean S 1-19 
D 1-19 
 
Measure  Position 
Max C 20 
Max Y 20 
Max S 17 



















Figure 3.2 SMART predictions of the structure of human, mouse and chicken 
RANKL proteins. The pink boxes show low complexity regions with unknown 
functions, blue boxes the transmembrane domains and pink diamonds the TNF 
homology domains. The locations of each domain within the protein are indicated by 
the amino acid scale below each protein.  
 
domains of proteins can be identified. In Figure 3.2, SMART prediction using the 
human and mouse RANKL sequences identified the location and presence of the 
transmembrane domain and TNF homology domain. Interestingly, when the 
chRANKL SMART prediction was analysed, there was no predicted transmembrane 
domain. The TMHMM transmembrane prediction model was also used to identify 
this region in chRANKL, and, like the SMART prediction, this model did not predict 









Figure 3.3 Amino acid alignment of human, mouse and predicted chicken 
RANKL. Shaded areas represent conservation of amino acid – the darker the 
shading, the more conserved the residue across species: black shading indicates 
conservation between all species, dark grey with white lettering indicates 
conservation between 2 species. Dots indicate gaps in the alignment. The black box 
indicates the mammalian transmembrane domains and the grey underlined sequence 
represents the TNF homology domains. 
 
To further validate the extracellular domain of chRANKL, the amino acid 
sequences of human and mouse RANKL were aligned with the predicted chRANKL 
sequence to analyse conservation between the species within the TNF homology 
domain (Figure 3.3). The NH2-terminal of chRANKL was longer in comparison to 
human and mouse proteins. There is low conservation of residues within this region 
compared to the mammalian counterparts. When the mammalian RANKL 
transmembrane domains were identified in the comparison, it became obvious that 
this region of the chRANKL gene was not predicted correctly. The domain with the 
92 
 
most conservation and similarity was the extracellular, TNF homology, domain. The 
correct chRANKL sequence was obtained by blasting the human RANKL protein 
against the chicken genome V4. Analysis indicated that the first two exons of the 
predicted chRANKL were incorrect and that the correct sequence was present in 
various EST. The full-length sequence of chRANKL was retrieved and further 
analysed using the SMART prediction model (Figure 3.4). The annotated chRANKL 
sequence was incorrect as the new sequence contained a predicted transmembrane 
domain (Figure 3.4). It is clear that this is the correct chRANKL sequence and was 
added to the Ensembl database (Accession Number: LM999949). The full-length 
cDNA sequence was cloned and, to produce soluble recombinant proteins, the 
extracellular domain of chRANKL was cloned and expressed as a FLAG-tagged 
protein to examine its bioactivity in chickens (Chapter 4). The extracellular domain 
of RANKL is bioactive in human, mouse (Anderson et al., 1997; Wong et al., 1997; 
Simonet et al., 1997; Park et al., 2005) and pig (Böcker et al., 2012).  
The TNFR superfamily members are characteristically type I transmembrane 
proteins, with their NH2-terminal domains exposed to the extracellular space. Using 
the SMART prediction program, the various domains of the human and mouse 
RANK proteins were identified and used to locate these domains in the predicted 
chRANK gene (Figure 3.5). SMART prediction was also carried out on the predicted 
chRANK sequence to analyse whether these domains were conserved. It is clear that 
the chRANK contains a signal peptide, transmembrane and TNFR domains, also 
known as CRD (Figure 3.5). 
3.3.4  Amplification and molecular cloning of chRANKL, chRANK and chOPG 
Primers were designed against the full-length and extracellular domains of 
both chRANKL and chRANK and full-length chOPG, using the sequences deposited 
in the NCBI database. To clone the full-length and extracellular domains of 
chRANKL and chRANK, cDNA was amplified by RT-PCR using RNA from ConA-
stimulated splenocytes as template. The resulting products were a ~954 bp cDNA 
fragment corresponding to 318 amino acids for full-length chRANKL and a 735 bp 
cDNA fragment, corresponding to 244 amino acids (chRANKL
75-318
) for the 





Figure 3.4 SMART prediction of the structure of the corrected predicted 
chicken RANKL protein. The blue box indicates the transmembrane domain and 
the pink diamond the TNF homology domain. 
 
 For the extracellular domain of chRANK, a 498 bp cDNA fragment, which 
corresponded to 166 amino acids (chRANK
24-195
) (Figure 3.6B), was cloned. Primers 
were also designed to amplify the cDNA of the full-length sequence of chRANK, 
without the signal peptide. Various primer combinations were used to try and clone 
the full-length sequence, without success. However, primers designed to clone the 
intracellular and transmembrane domains generated a ~1.5 kb product, corresponding 
to 465 amino acids (chRANKL
190-655
), using cDNA from ConA-stimulated 
splenocytes as template. There was an 18 base-pair cDNA overlap between the 
cloned extracellular and transmembrane domains, allowing the full-length cDNA 
sequence of chRANK to be verified. Full-length chOPG cDNA was generated from 
RNA derived from bone marrow cells. The expected band of 1.2 kb was identified 
after agarose gel electrophoresis (Figure 3.6C). All three cDNAs were ligated into 
the pGEM-T Easy vector and sequences were verified for three individual clones.  
 For protein expression, all genes were sub-cloned into their appropriate 
expression vectors. To sub-clone the genes directionally, primers were designed to 
integrate restriction enzyme sites at the 5' and 3' ends of the cDNAs. For chRANKL, 
primers were designed to place XhoI and NotI sites at either end of the cDNA. For 
chRANK and chOPG, NheI and BgIll sites were included (primer sequences are 
given in Appendix 2, Table 2). PCR reactions contained a 1:100 dilution of the 












Figure 3.5 SMART predictions of the structure of human, mouse and predicted 
chicken RANK proteins. The red boxes indicate the predicted signal peptide 
sequences, the triangles the TNFR domains (CRD), the blue boxes the 
transmembrane domains and the pink boxes regions of highly conserved, unknown 
structure. 
 
gel purified and restriction digestion was carried out with appropriate restriction 
enzymes before ligation into linearized expression plasmids. All sub-cloning was 
verified by sequencing.  
3.3.5  In silico analysis of chRANKL 
The full-length corrected cDNA of chRANKL was cloned and its predicted 
amino acid sequence was aligned with human and mouse RANKL (Figure 3.7). The 
correct chRANKL sequence shares 61-64% amino acid identity with mammalian 
RANKL, is similar in size and possesses a transmembrane domain (Figure 3.7). The 
core TNF homology domain (residues 160-388) is required for receptor interaction 
and trimerisation. Mammalian RANKL are composed of β-strands and loops 











Figure 3.6 Gel electrophoresis of chRANKL, chRANK and chOPG. A) RT-PCR 
generated a ~954 bp product corresponding to the full-length cDNA of chRANKL 
and an 800 bp product corresponding to the extracellular domain of chRANKL from 
ConA-stimulated splenocytes; B) RT-PCR generated a ~500 bp product 
corresponding to the extracellular domain of chRANK and a 1.5 kb product for the 
transmembrane and intracellular domains, both from ConA-stimulated splenocytes; 
C) RT-PCR generated a 1.2 kb product for the full-length sequence of chOPG from 
bone marrow cDNA. L = 1 kb DNA ladder (Invitrogen).  
 
al., 2001). To investigate the conservation of these β-strands in chRANKL, each β-
strand was identified in the human and mouse proteins (Lam et al., 2001; Cheng et 
al., 2009) and PSIPRED was used to predict the secondary structure of chRANKL. 







Figure 3.7 Amino acid alignment of the human, mouse and chicken RANKL. 
Shaded areas represent conservation of amino acid – the darker the shading, the 
more conserved the residue across species: black shading indicates conservation 
between all species, dark grey with white lettering indicates conservation between 2 
species. Dots indicate gaps in the alignment. The box indicates the transmembrane 
domains, the arrow the start of the extracellular domains, the dark grey underline 
the TNF homology domains, asterisks the conserved cysteine residues, the light grey 
boxes the chicken RANKL predicted N-linked glycosylation sites and the black box 
the N-linked glycosylation site conserved across all species. The open triangle 
indicates the murine TACE cleavage site, and the black lines above the sequence the 
location of the 10 highly conserved β-strands involved in the “β-jelly” roll structure. 
The surface loops are shown as grey lines between the β-strands, labelled AA’, CD, 
DE and EF. 
 
in its mammalian counterparts, suggesting it folds in the “jelly-roll” conformation. 
Mouse RANKL is cleaved from the membrane surface by TACE converting enzyme 
at position 140 (Lum et al., 1999). The cleavage site is not conserved in chRANKL. 
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3.3.6  In silico analysis of chRANK 
ChRANK was cloned in two parts; the extracellular domain and the 
transmembrane domain with the intracellular domain. The whole sequence was 
combined and aligned with the known human and mouse RANK proteins using 
CLUSTALX2 software (Figure 3.8). ChRANK shows relatively high amino acid 
identity with the mammalian orthologues, with 40-42% sequence identity with 
human and mouse. ChRANK is larger than both the mammalian proteins by 39-48 
amino acids. The predicted signal peptide is slightly larger in the chicken and there is 
an 11 amino acid insert in the intracellular domain between residues 450-461. 
Members of the TNFR superfamily are grouped due to the presence of conserved 
CRD in their extracellular ligand-binding domain (Naismith & Sprang, 1998). These 
CRDs are typically defined by three intra-chain disulphide bridges generated by 
highly conserved cysteine residues that act as a scaffold to produce an elongated 
structure protruding from the cell (Smith et al., 1994). They are believed to be 
involved with specific ligand binding and generation of a pre-assembly site for the 
docking of the ligand (Chan et al., 2000). All four CRD are present in chRANK 
(labelled I-IV) and the cysteine residues are conserved between all species (Figure 
3.8).  
The extracellular domains of RANK are highly conserved across all species 
which could indicate conserved bioactivity. RANK has one of the largest 
intracellular domains of all TNFR family members yet identified. The TNFR family 
do not possess catalytic domains and require adaptor proteins for downstream 
signalling called TNF receptor-associated factors (TRAFs). This family of adaptor 
proteins are made up of seven members (TRAF1-7). Previous biochemical and 
structural analysis have identified two amino acid sequence motifs for TRAF1, 
TRAF2, TRAF3, and TRAF5 binding: a major one, (P/S/A/T)X(Q/E)E and the 
minor one, PXQXXD (X being any amino acid) (Ishida et al., 1996). TRAF6 has a 
specific binding motif, PXXGXX.  Numerous studies have identified the specific 
TRAF-binding domains required for RANK activity (Wong et al., 1998; Galibert et  
98 
 
Figure 3.8 Amino acid alignment of the human, mouse and chicken RANK. 
Shaded areas represent conservation of amino acid – the darker the shading, the 
more conserved the residue across species: black shading indicates conservation 
between all species, dark grey with white lettering indicates conservation between 2 
species. Dots indicate gaps in the alignment. The black arrows indicate the cloned 
extracellular domain of chRANK. The CRD domains are numbered I-IV. Asterisks 
indicate conserved cysteine residues, the grey box the transmembrane domains, the 
green boxes conserved TRAF6-binding motifs, blue box the “missing” chicken 
TRAF6-binding motif, the red boxes TRAF1-, TRAF2-, TRAF3- and TRAF5-binding 
motifs and the black box the highly conserved domain (HCD).  
 
al., 1998; Darnay et al., 1999). Using site-directed mutagenesis on previously 
identified TRAF-binding motifs found in CD40, CD30, HVEM and OX40, three 
TRAF6-specific binding motifs were identified at the COOH-terminal region of 
RANK. Two TRAF1, TRAF2, TRAF3 and TRAF5-binding motifs were identified at 
the membrane-distal domain of the cytoplasmic tail in mammalian RANK (Darnay et 
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al., 1999). Using the published data available for TRAF-binding motifs found in 
human and mouse RANK (Galibert et al., 1998; Darnay et al., 1999; Wong et al., 
1998), four out of five TRAF-binding motifs were identified in chRANK (Figure 
3.7). Surprisingly the “missing” TRAF-binding domain is a TRAF6-specific binding 
motif (residues 452-463). RANK also requires a region of its intracellular domain to 
signal in osteoclastogenesis. This domain is called the highly conserved region 
(HCR) and within this region there is an IVVY motif required for osteoclastogenesis 
(Xu et al., 2006). Both the HCR and IVVY motifs are conserved in chRANK 
suggesting conserved bioactivity for osteoclastogenesis in the chicken. 
3.3.7  In silico analysis of ChOPG  
The full-length cDNA sequence of chOPG was cloned and the predicted 
amino acid sequence was aligned with human and mouse OPG (Figure 3.9). ChOPG 
has 64-69% amino acid identity with mammalian OPG. ChOPG possesses four CRD 
domains (labelled I-IV) with 17 out of 18 cysteine residues in them conserved 
(Figure 3.9). Using NetNGly software to predict N-linked glycosylation sites in all 
species, chOPG has two potential sites whereas there are five in human and four in 
the mouse. OPG contains two DD with no known function and these domains are 
conserved between all species. ChOPG contains a cysteine residue at position 401 
which is conserved in human and mouse. This cysteine is vital for dimer formation in 
mammalian OPG. 
3.3.8  Protein expression and analysis of FLAG-chRANKL 
 To produce soluble fusion proteins of chRANKL, the extracellular domain 
was sub-cloned into expression vectors as described in section 2.2.3 and transfected 
into COS-7 cells using the well-described DEAE-dextran approach (Rothwell et al., 
2004). The cell supernatants were collected after 72 h of incubation in serum-free 
DMEM. To analyse the composition of chRANKL, protein produced in COS-7 cells 
was subjected to SDS-PAGE under both reducing and non-reducing conditions and 
analysed by western blot using antibodies against the FLAG-tag (Figure 3.10). In 
reducing conditions, prominent bands are evident at ~37 kDa and ~75 kDa; the 




Figure 3.9 Amino acid alignment of human, mouse and the predicted chicken 
OPG. Shaded areas represent conservation of amino acid – the darker the shading, 
the more conserved the residue across species: black shading indicates conservation 
between all species, dark grey with white lettering indicates conservation between 2 
species. Dots indicate gaps in the alignment. The CRD domains are numbered I-IV 
(grey underline), asterisks indicate the conserved cysteine residues, the open triangle 
the conserved cysteine residue in mammals absent in the chicken, the light grey 
underline DD regions, the light grey boxes chOPG predicted N-linked glycosylation 






Figure 3.10 Western blot analysis of pV20- and pV22-schRANKL. COS-7 cells 
were transfected with pV20- or pV22-chRANK using the DEAE-dextran approach 
and cell supernatants were collected 72 h later. The expression of the FLAG-
chRANK was analysed under both reducing (R) and non-reducing (NR) conditions 
and the FLAG-tag was detected using mouse anti-Flag (M2) antibody. M = 
Precision plus protein standard (BioRad). 
 
respectively. Protein analysis under non-reducing conditions, in which higher order 
structures of proteins are not disturbed, showed three predominant bands; dimers at 
~75 kDa, trimers at ~120 kDa and  tetramers/hexamers at ~185 kDa (Figure 3.10). 
3.3.9  Protein expression and analysis of recombinant chRANK-Fc 
 Plasmids expressing the extracellular domain of chRANK were transfected 
into COS-7 cells using the DEAE-dextran-based approach. The resulting cell 
supernatants were analysed by western blot to investigate the expression of chRANK 
protein, using antibodies against the IgFc tag. The extracellular domain of chRANK 
consists of 4 CRD which each consist of five irregular β-strands that are linked by 
three inter-strand disulphide bonds (Naismith & Sprang, 1998). Although bioactivity 
of the TNFR superfamily requires trimerisation to form heterohexamers with their 
102 
 
ligands, RANK dimers can partially induce osteoclast activation (Iwamoto et al., 
2004). ChRANK protein was analysed under both reducing and non-reducing 
conditions (Figure 3.11). In non-reducing conditions, using AEC staining to analyse 
structures with weak staining, three bands were present for chRANK (Figure 3.11). 
As an IgFc-tagged monomer, the predicted molecular mass of chRANK is ~43 kDa. 
The extracellular domain of chRANK has two potential N-glycosylation sites. 
Glycosylation at target asparagines contributes to the molecular mass of the protein. 
In non-reducing conditions, bands corresponding to ~100, ~160 and ~200 kDa were 
present. These bands could represent dimeric, trimeric and tetrameric structures. In 
reducing conditions, no intense band was evident which may be due to weak staining 
of the monomeric proteins. 
3.3.10  Protein expression and analysis of recombinant chOPG-Fc  
 The full-length sequence of chOPG was sub-cloned into pKW06-Ig and 
transfected into COS-7 cells to produce an IgFc fusion protein. To detect the 
expression of recombinant proteins, the COS-7 cell supernatants were treated with 
reducing or non-reducing buffer and analysed by western blot using antibodies 
against the Fc tag (Figure 3.12). The chOPG-Fc monomer has a predicted molecular 
mass of ~72 kDa. In reducing conditions, a ~75 kDa band was evident whereas in 
non-reducing conditions there was a strong band at ~150 kDa, suggesting the 
formation of homodimers. 
3.3.11  Assessment of BMDC and BMDM functions 
 The main aim of the study was to characterise the role of chRANKL, 
chRANK and chOPG in the biology of chicken APC. DC play key roles in host 
defence by recognizing, engulfing and presenting microbial peptides to effector T 
cells.  
 BMDM were stimulated and pro-inflammatory cytokine mRNA expression 
levels and cell surface markers were analysed. Chicken BMDC were the first non- 
mammalian DC to be differentiated using recombinant chIL-4 and chCSF-2 and 
characterised (Wu et al., 2010). Since then, studies using these cells have measured 




Figure 3.11 Western blot analysis of chRANK-Fc. COS-7 cells were transfected 
with pKW06-chRANK using the DEAE-dextran approach and cell supernatants were 
collected 72 h later. The expression of chRANK-Fc was analysed under both 
reducing (R) and non-reducing (NR) conditions and detected using a goat-anti 
mouse Ig Fc-HRP antibody. M = Precision plus protein standard (BioRad). 
 
Rothwell et al., 2012). They have also paved the way to understanding how chicken 
BMDC react upon pathogen exposure (De Geus et al., 2013; Quéré et al., 2013; 
Liang et al., 2013; Vervelde et al., 2013). However, in comparison to mammals, 
there are limited cell surface markers available to differentiate between BMDC and 
BMDM in the chicken.  
 In Wu et al. (2010), the optimal concentration of LPS required to induce 
maturation of BMDC after 24 h culture was 200 ng/ml. In initial experiments in this 
study, this amount of LPS was too strong a stimulant and masked any potential effect 
of chRANKL on pro-inflammatory cytokine mRNA expression levels but also 
induced cell death within 9-10 h of treatment. Therefore, LPS was titrated to identify 
the optimal concentration to induce sub-optimal activation of BMDC, i.e. activation 
but not a strong pro-inflammatory cytokine response. Various amounts of LPS were 




Figure 3.12 Western blot analysis of chOPG-Fc. COS-7 cells were transfected 
with pKW06-chOPG using the DEAE-dextran approach and cell supernatants were 
collected 72 h later. The expression of chOPG-Fc was analysed under both reducing 
(R) and non-reducing (NR) conditions and detected using a goat-anti mouse IgFc-
HRP antibody. Western blots were visualised using an ECL detection system (left) 
and AEC staining (right). M = Precision plus protein standard (BioRad). 
 
analysed by qRT-PCR (Figure 3.13). IL-12α mRNA expression was not detected in 
non-stimulated BMDC and therefore its expression is a good indicator of BMDC 
activation. A concentration of LPS of 2 ng/ml led to an increase in IL-12α mRNA 
expression levels at both time-points, whereas at 1 ng/ml, IL-12α expression was not 
detectable (Figure 3.13). 
 To determine if this concentration of LPS could alter the expression of cell 
surface markers on BMDC, cells were stimulated with LPS (2 ng/ml) for 24 h. Cells 
were removed from the culture plates and stained with mouse anti-chicken mAb 
against cell surface markers associated with cell activation: MHC class II, CD40 and 
the mononuclear phagocyte marker, KUL01 (Mast et al., 1998), and analysed by 
FACs (Figure 3.14). As the chRANKL fusion protein was not purified but exCOS-7 
cell supernatant, cells were also treated with supernatant from COS-7 cells 




Figure 3.13 IL-12α mRNA expression levels in BMDC as measured by qRT-
PCR. BMDC were unstimulated (C) or stimulated with LPS at 200, 100, 50, 20, 2 
and 1 ng/ml for 3 and 6 h. Data are presented as corrected 40-Ct ± SEM of triplicate 
wells.  
 
itself did not activate the cells. The upregulation of CD40 on the surface of BMDC is 
an indication of cell activation. In unstimulated and mock-treated cells, the surface 
expression of CD40 was negative. When the cells were treated with LPS for 24 h, the 
cell surface expression levels of CD40 increased in comparison to controls. KUL01 
expression decreases as BMDC mature (Wu et al., 2010; De Geus et al., 2013). 
Unstimulated and mock-treated cells expressed KUL01. However, in LPS-stimulated 
cells there was a mixed population, with a portion of cells expressing KUL01 on 
their surface and a portion which were not (Figure 3.14). This could suggest that 2 
ng/ml of LPS induces partial cell activation. For MHC class II expression, there was 
very little change in expression between control and LPS-stimulated cells. This could 
mean that the cells do not upregulate the expression of MHC class II after 
stimulation. However, chicken BMDC constitutively express MHC class II on their 
cell surface (Wu et al., 2009). The ability of LPS to activate BMDM was  




Figure 3.14 FACS analysis of cell surface markers on BMDC stimulated with 
LPS (2 ng/ml). BMDC were unstimulated (black lines), treated with mock 
supernatant (pCI-neo empty vector exCOS-7) (grey lines) and LPS (2 ng/ml) (dotted 
grey lines) for 24 h. Cell surface expression of CD40, KUL01 and MHC class II was 
analysed by FACs. Analyses are shown as histograms with cell count versus FL1-
staining and data represents one of three experiments with similar results. 
 
investigated next. Previous data available for BMDM were minimal. ChCSF-1 drives 
the differentiation of bone marrow cells to BMDM (Garceau et al., 2010). However, 
this study differentiated the cells at 37°C for 10 days rather than at the physiological 
temperature of chicken cells of 41°C. The initial studies for BMDM were to identify 
the sub-optimal concentration of LPS that could induce pro-inflammatory cytokine 
mRNA expression. The optimal concentration of LPS and IFN-γ needed to 
upregulate cell surface markers on BMDM grown at the appropriate temperature, 
41°C, was also determined.  
To identify the concentration of LPS to induce sub-optimal activation of 
BMDM, cells were grown with recombinant chCSF-1 (exCOS-7) for 6 days and then 
stimulated with various amounts of LPS for 3 and 6 h. RNA was purified and qRT-
PCR was carried out to detect IL-12α mRNA expression levels. IL-12α was not 
detectable in any samples tested (data not shown), therefore IL-6 mRNA expression 
levels were analysed (Figure 3.15). At 3 h, there was very little difference in the 




Figure 3.15 IL-6 mRNA expression levels in stimulated BMDM as measured by 
qRT-PCR. BMDM were unstimulated or stimulated with LPS at 100, 50, 20, 10 and 
1 ng/ml for 3 and 6 h. RNA was purified and IL-6 mRNA expression levels were 
detected by qRT-PCR. Data are shown as fold change between levels in unstimulated 
cells ± SEM of three replicate wells. 
 
However, a further 3 h stimulation led to an increase in IL-6 mRNA expression 
levels by ~4-5-fold. Interestingly, 10 ng/ml of LPS induced maximal expression of 
IL-6. From these initial studies, 1 ng/ml of LPS was chosen to induce sub-optimal 
maturation of BMDM. The expression of cell surface markers were also assessed in 
BMDC stimulated with 1 ng/ml LPS to investigate the ability of sub-optimal 
activation of cells to increase surface protein expression in BMDM. Cells were 
stimulated with LPS for 24 h and cell surface expression of MHC class II, KUL01 
and CD40 were analysed by FACs (Figure 3.16). LPS-stimulated BMDM for 24 h, 
increased surface expression of CD40 compared to unstimulated cells and mock-
treated cells. The expression of KUL01 was slightly decreased in LPS-stimulated 
cells. MHC class II expression levels were not altered by the addition of  




Figure 3.16 FACS analysis of cell surface markers of BMDM stimulated with 
LPS (1 ng/ml) for 24 h. BMDM were unstimulated (black lines), treated with mock 
supernatant (1:5 pCI-neo exCOS-7) (grey lines) or LPS (1 ng/ml) (dotted grey lines) 
for 24 h. Cell surface expression of CD40, KUL01 and MHC class II were analysed 
by FACs. Analyses are shown as histograms with cell count versus FL1-staining and 
represent data from one of three independent experiments with similar results. 
 
LPS at 1 ng/ml for 24 h. This could be due to the sub-optimal concentration of LPS 
used to induce BMDM maturation. 
3.3.12  Pilot Study: Bioactivity of pV20- and pV22-schRANKL 
 As described in section 3.3.9, two plasmids were designed to express soluble 
chRANKL. Western blot analyses indicated that both pV20- and pV22- schRANKL 
can form trimers, required for the interaction of RANKL with RANK in mammals. 
To verify the bioactivity of each protein, BMDC were stimulated with LPS (2 ng/ml) 
or CD40L (3 μg/ml) alone or in combination with a 1:50 dilution of exCOS-7 
supernatant of pV20- or pV22-schRANKL protein for 3, 6, 24 or 48 h. Pro-
inflammatory cytokine mRNA expression levels were analysed by qRT-PCR 
(Figures 3.17 and 3.18). This pilot study was carried out as a single experiment to 
determine which protein was more bioactive for the following experiments in 
Chapter 4, and therefore no statistical analysis was carried out.  
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 As stated previously, IL-12α mRNA was not detected in immature BMDC 
and therefore the data are presented as corrected 40-Ct. At 3 h, LPS and LPS/V20 
schRANKL-stimulated cells had similar levels of IL-12α mRNA expression (Figure 
3.17). However, LPS/pV22-schRANKL-stimulated cells expressed higher levels of 
IL-12α mRNA in comparison to LPS or LPS/pV20-schRANKL stimulated cells 
(Figure 3.17). At 6 h, IL-12α mRNA expression was not detected in either LPS or 
LPS/pV20-schRANKL-stimulated cells. Cells stimulated with LPS/pV22-
schRANKL had increased mRNA expression levels of IL-12α. This could suggest 
that pV22-schRANKL is more bioactive than pV20-schRANKL. At 24 and 48 h, IL-
12α mRNA expression was not detectable in any sample (data not shown).  
ChCD40L-stimulated BMDC had increased mRNA expression levels of pro-
inflammatory cytokines (Wu et al., 2010). To analyse the bioactivity of schRANKL 
with this stimulant, cells were stimulated with CD40L alone or with either pV20- or 
pV22-schRANKL and were analysed for IL-12α mRNA expression levels at 3 and 6 
h (Figure 3.17). At 3 h, the levels of IL-12α mRNA expression were similar between 
the CD40L/pV20- and CD40L/pV22-schRANKL-stimulated cells. CD40L-
stimulated cells did not induce IL-12α mRNA expression levels at 3 h but did, 
however, at 6 h. At 6 h, IL-12α mRNA expression was not detectable in 
CD40L/pV20-schRANKL-stimulated cells. However, CD40L/pV22-schRANKL-
stimulated cells have increased levels of IL-12α mRNA expression but not to the 
level of CD40L-stimulated cells. These data suggest that pV22-schRANKL is more 
bioactive than pV20-schRANKL. 
 The mRNA expression levels of IL-1β and IL-6 were analysed in the above 
samples to investigate the effect of schRANKL on other pro-inflammatory cytokines 
(Figure 3.18). As both IL-1β and IL-6 mRNA were detectable in unstimulated cells, 
data are presented as fold change between the levels in control and stimulated cells. 
For IL-1β mRNA expression levels, LPS-stimulated cells increased expression by 
~5-fold at 3 h which was increased to ~6 fold in LPS/pV22-schRANKL-stimulated 




Figure 3.17 IL-12α mRNA expression levels in BMDC, as measured by qRT-
PCR. BMDC were unstimulated or stimulated with LPS (2 ng/ml) or LPS with either 
pV20- or pV22-schRANKL (1:50 ex-COS) for 3 and 6 h. RNA was purified and IL-
12α mRNA expression levels were detected by qRT-PCR. Data are shown as 
corrected 40-Ct ± SEM of three replicate wells. 
 
expression levels by ~3-fold. At 6 h, the mRNA expression levels of IL-1β were 
decreased across all the stimulated cells. At 24 and 48 h, IL-1β mRNA expression 
levels were quiet low with no difference between LPS, LPS/pV20- or LPS/pV22-
schRANKL-stimulated cells (Figure 3.18). For CD40L-stimulated cells, 
CD40L/pV22-schRANKL treatment enhanced IL-1β mRNA expression levels at 3, 6 
and 24 h compared to CD40L- and CD40L/pV20-stimulated cells (Figure 3.18). 
 For IL-6 mRNA expression levels, LPS-stimulated cells increased expression 
by ~100-fold after 3 h. Neither LPS/pV20-schRANKL nor LPS/pV22-schRANKL-
stimulated cells enhanced IL-6 expression levels above levels in LPS-stimulated cells 
(Figure 3.18). At 6 h, LPS/pV20-schRANKL-stimulated cells had a ~50 fold 
increase in IL-6 mRNA expression levels whereas LPS- and LPS/pV22-schRANKL-
stimualated cells had low mRNA expression levels. At 24 and 48 h, IL-6 mRNA 
expression levels were similar between all stimulated cells. Similar to the IL-1β data,  
  






Figure 3.18 IL-1β and IL-6 mRNA expression levels in BMDC, as measured by 
qRT-PCR. RNA was purified and IL-1β and IL-6 mRNA expression levels were 
analysed by qRT-PCR. Data are shown as fold change between levels in 
unstimulated and stimulated cells at specific time-points ± SEM of three replicate 
wells. 
 
CD40L/pV22-schRANKL enhanced the levels of IL-6 mRNA expression at 3 and 48 
h. At 6 h, CD40L-stimulated cells had increased IL-6 mRNA expression levels above 
those of the other treatments. CD40L/pV22-schRANKL-stimulated cells induce 







not to the levels of CD40L-stimulated cells. Overall these data suggest that pV22-
schRANKL may be more bioactive than pV20-schRANKL. It was therefore decided 
that pV22-schRANKL (named schRANKL) would be used to further study the 




3.4  Discussion 
  The repertoire of TNF superfamily members is different between chicken 
and mammals. To date, 19 ligands have been identified in the mammalian genome 
whereas only 11 have been identified in the chicken genome. Those that are absent in 
the chicken genome, exist as small sub-families in multigene loci on the same 
chromosomes in the human and mouse genomes (Kaiser et al., 2005). The absence of 
the lymphotoxin genes, LT-α and LT-β, has been attributed to the lack of lymph 
nodes in the chicken. However, the absence of TNF superfamily members such as 4-
IBBL, CD27L, HVEM, TWEAK and APRIL have not yet been linked to any 
abnormal development or differences in the chickens ability to mount an immune 
response, although knock-out mice have defective T and B cell responses (Locksley 
et al., 2001). One of the most recent TNF superfamily members to be identified was 
RANKL and since its discovery it has been implicated in a number of biological 
systems, e.g. osteoclastogenesis and DC-T cell interactions (Simonet et al., 1997; 
Anderson et al., 1997). RANKL has two receptors, a signalling receptor, RANK and 
a decoy receptor, OPG. In the chicken genome, all three genes are present and 
homologues for each have been found from human to fish (O’Brien, 2010).  
Sequence analysis of chRANKL indicates that the NH2-terminal is incorrectly 
annotated in the genome. SMART and TMHMM prediction programs identified the 
lack of a transmembrane domain in the predicted chRANKL sequence. Although 
mammalian RANKL can exist in various forms, such as membrane-bound or soluble 
(Ikeda et al., 2001; Walsh et al., 2013), when aligned with the human and mouse 
genes, the extracellular domain was highly conserved across all species. Chicken 
immune proteins are usually similar in size to their mammalian counterparts. 
However, for chRANKL the annotated intracellular domain is large, having 96 more 
amino acids than the human RANKL protein. To identify the correct chRANKL 
sequence, the human RANKL sequence was blasted against the chicken genome to 
mine for the correct sequence. The results indicated that the first two exons of the 
predicted chRANKL sequence were incorrect and the correct sequence was extracted 
and primers were designed to clone the full-length correct cDNA. The extracellular 
domains of the TNF superfamily across species usually have between 20-30% 
homology, which would have helped the correct annotation of the extracellular 
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domain. Various studies have shown the ability of the extracellular domains of the 
TNF superfamily to retain their bioactivity. For example, the extracellular domain of 
CD40L retains its ability to stimulate B cell proliferation and drive immunoglobulin 
isotype switching (Armitage et al., 1992) although CD40L is rarely found as a 
soluble protein in vivo (Aggarwal et al., 2012). Mammalian RANKL can function 
either as membrane-bound or secreted form (Ikeda et al., 2001; Walsh et al., 2013) 
and there is no functional difference between these two forms of RANKL 
(Nakashima et al., 2000). The extracellular domain of chRANKL was cloned and 
called schRANKL. An amino acid alignment of chRANKL with human and mouse 
RANKL showed high conservation across all species. Internal hydrophobic residues 
within the extracellular domains of the TNF superfamily members are required for 
monomer folding and trimer assembly. The RANKL monomer consists of two anti-
parallel β-sheets. The two β-sheets are formed by various β-strands (Lam et al., 
2001). The PSIPRED prediction program was used to verify the location of the 
residues involved in β-sheet formation in chRANKL. SchRANKL contains 10 β-
strands and the 4 loops required for the assembly of a trimer (Figure 3.7). The 
extracellular domains of the TNF superfamily contain TNF homology domains and 
this region is conserved between mammals and birds. Mutations within the TNF 
homology domain have been linked to the genetically rare bone disorder, autosomal 
recessive osteoporosis (ARO) in mammals. For example, a mutation at residue V
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leads to a frameshift which introduces a stop codon forming a non-functional 
truncated RANKL protein (Frattini et al., 2007; Sobacchi et al., 2007). Mutational 
analysis of the TNF homology domain shows its requirement for RANK signalling 
but not RANK interaction (Cheng et al., 2009). In particular, a RANKL mutant 
protein expressing only residues 248 to 316 can block RANKL induction of 
osteoclast activation by binding to RANK but not activating downstream signalling 
pathways (Cheng et al., 2009). SchRANKL was sub-cloned downstream of the 
mouse CD8 signal peptide to facilitate secretion of the protein from COS-7 cells. The 
plasmid also contained two more elements: an isoleucine zipper to encourage the 
formation of trimer proteins and a FLAG-tag for recombinant protein detection.  
RANKL is one of the few TNF superfamily members with two receptors, one 
for downstream signalling, RANK, and the second working as a decoy receptor, 
115 
 
called OPG (Anderson et al., 1997; Simonet et al., 1997). Both receptors are present 
in the chicken genome with both residing on chromosome 2. RANK is a type I 
transmembrane protein with highly conserved CRD domains characteristic of 
members of the TNFR superfamily. The chRANK sequence was predicted and 
therefore the location and prediction of various domains were analysed using 
SignalP4 and SMART prediction models. The predicted chRANK contains an NH2-
terminal signal peptide, four CRDs, a transmembrane and a large intracellular 
domain, similar to mammals (Figure 3.5) (Anderson et al., 1997). Using this 
sequence, primers were designed to clone the full-length sequence of the cDNA. To 
express chRANK as a soluble recombinant protein, primers were also designed to 
clone the extracellular domain. Attempts to clone the full-length sequence of 
chRANK in a single PCR were not successful. However, various primer pairs 
designed to clone partial pieces of the gene were successful. The extracellular 
domain was cloned with a second product containing the transmembrane and 
intracellular domains. Although chRANK was not cloned in one piece, the 18 base 
overlap allowed the full-length predicted protein sequence to be analysed. 
Conservation of RANK in non-mammalian species is relatively high with 40-42% 
sequence similarity with human and mouse RANK (Figure 3.8).  
Members of the TNFR superfamily do not possess intrinsic catalytic domains 
and therefore require adaptor proteins for downstream signalling. The TNFR 
superfamily can be further categorised as either containing intracellular TRAF- 
binding motifs or DD. TRAFs are a family of adaptor proteins made up of seven 
members (TRAF1-7). Most signalling by the TNF receptors through TRAFs leads to 
activation of NF-κB and JNK pathways, that are in turn associated with the 
activation of immune genes linked to pro-inflammatory cytokine expression, cell 
survival and differentiation (Lee & Lee, 2002). Signalling though DD (TNFR1, FAS, 
DR3, DR4, DR5 and DR6) leads to cell death by activating apoptosis. Distinct 
TRAF-binding motifs have been identified in a number of TNFR members, such as 
CD40 (Rothe et al., 1995; Ishida et al,. 1996a and Ishida et al,. 1996b), HVEM (Hsu 
et al., 1997), RANK (Darnay et al., 1998; Galibert et al., 1998; Kim et al., 1999), 
CD30 (Gedrich et al., 1996; Aizawa et al., 1997) and LMP-1 (Devergne et al., 1996). 
Using site-directed mutagenesis, various domains within these receptors were shown 
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to be required for specific TRAF binding. Two TRAF1, TRAF2, TRAF3 and TRAF5 
binding motifs have been identified; a major one, (P/S/A/T)X(Q/E)E and a minor 
one, PXQXXD (X being any amino acid) (Devergne et al., 1996). The binding sites 
for TRAF6, however, differ from the motifs described above. TRAF6 is the only 
member of the TRAF family that participates in signalling for both the TNFR and the 
Toll/IL-1R superfamilies. The TRAF6-specific binding motif is the peptide PXEXX 
(X being aromatic/acidic residue), which is present in CD40, RANK and three IRAK 
adaptor proteins involved in Toll/IL-1R signalling (Ye et al., 2002).  
Two independent groups first identified the location of TRAF-binding motifs 
in mammalian RANK (Darney et al., 1998; Gilbert et al., 1998). Deletion constructs 
of the intracellular domain of RANK at potential TRAF binding motifs allowed for 
the identification of TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6 binding to 
RANK and which of these were required for downstream NF-κB activation (Darney 
et al., 1998; Galibert et al., 1998; Wong et al., 1999). Two membrane-distal TRAF 
binding motifs and three membrane-proximal TRAF6-specific motifs were identified 
in mammalian RANK. To verify the presence of these binding motifs in chRANK, 
the TRAF binding motifs in human and mouse were identified in an amino acid 
alignment. Interestingly, of the 5 mammalian TRAF-binding motifs, chRANK only 
contained four. The “missing” motif is one of the TRAF6-specific binding sites 
(Figure 3.8). TRAF6
-/-





 mice (Lomaga et al., 1999; Naito et al., 1999). 
In mammalian studies, the requirement for three TRAF6-binding motifs in 
RANK was analysed by expressing a chimeric protein consisting of the ectodomain 
of human CD40 with the transmembrane and intracellular domains of mouse RANK 
(hCD40/mRK) with or without mutations in one, two or three of the TRAF6-binding 
sites (Gohda et al., 2005). These chimeric and mutational studies identified the 
requirement for at least one functional TRAF6-binding site in RANK for osteoclast 
cell activation, although a similar study identified the need for two sites for 
osteoclastogenesis (Kadono et al., 2005). Interestingly, the TRAF6-binding motif in 
the membrane-proximal domain was more efficient than the other two sites (Gohda 
et al., 2005). CD40, a fellow member of the TNFR superfamily, is the only other 
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receptor within this family with a TRAF6-binding motif (Tsukamoto et al., 1999; 
Walsh & Choi, 2003). Although RANK and CD40 activate the NF-κB, MAPK and 
JNK pathways, CD40 cannot differentiate or activate osteoclasts (Gohda et al., 
2005). To understand which different signalling pathways were being activated by 
RANK and not CD40 to drive osteoclastogenesis, various signalling pathways were 
analysed in bone marrow cells expressing the chimeric hCD40/mRANK protein or 
hCD40 stimulated with anti-CD40. The intracellular domain of RANK could activate 
the nuclear activator of T cells 1 (NFATc1) transcription factor and Ca
2+
 oscillation 
(Gohda et al., 2005). NFATc1 is the master regulator for the differentiation and 
activation of osteoclasts (Ishida et al., 2002) and was first identified as a transcription 
factor required for the production of IL-2 upon T cell activation (Rao et al., 1997; 
Serfling at al., 2000). Studies carried out by both Kadono et al. (2005) and Gohda et 
al. (2005) showed that overexpression of CD40 in bone marrow cells, or the addition 
of more TRAF6-binding motifs within the intracellular domain of CD40, could lead 
to the activation of osteoclastogenesis. It is therefore assumed that RANK, having 
three TRAF6-binding sites, leads to a quantitative recruitment of TRAF6 proteins, 
activating p38 and NFATc1 phosphorylation (Kadono et al., 2005). Currently there 
is little knowledge surrounding avian TRAFs and it was therefore decided to identify 
and clone those involved in RANK signalling to investigate whether they were 
conserved in the chicken (Chapter 5). 
To further understand the ability of RANK and not CD40 to activate 
osteoclastogenesis, even though both have TRAF6-binding motifs, Taguchi et al., 
(2009) set out to identify if there was another domain within the cytoplasmic region 
of RANK required for osteoclastogenesis. To identify regions within the RANK 
cytoplasmic tail with high conservation, an amino acid alignment of mouse, rat, 
chicken, dog and chimpanzee RANK was analysed by CLUSTALX. The analyses 




 that was highly conserved between all 
species, which was named the highly conserved region (HCR) (Taguchi et al., 2009). 
To understand the molecular requirement of this region for RANK signalling, 
mutational analyses were carried out omitting this domain. As mentioned earlier, 
RANK can activate Ca
2+
 oscillation leading to the activation of NFATc1 (Gohda et 
al., 2005). Ca
2+
 oscillation requires the phospholipase Cγ2 (PCγ2), which is activated 
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by immune receptors of tyrosine activation motifs (ITAM) harbouring adaptors, 
DNAX-activating protein (DAP) 12 and the γ-chain of the Fc receptor (FcRγ) (Mao 
et al., 2006). Depletion of either of these in mice leads to profound osteopetrosis 
(Koga et al., 2004). BMDM were transfected with WT and mutant RANK and 
stimulated with RANKL. PCγ2 was activated along with NF-κB and MAPK at the 
early stages of osteoclastogenesis (20 min). However, after 6 h of stimulation, 
NFATc1 was barely detectable in HCR-mutant cells. It was suggested that the HCR 
is required for the late stages of osteoclastogenesis by maintaining the expression of 
PCγ2. To further investigate the necessity of this domain for RANK signalling 
during osteoclastogenesis the HCR was integrated into the cytoplasmic tail of CD40. 
HCR containing CD40 could induce osteoclastogenesis (Gohda et al., 2005). The 
role, if any, of HCR in RANK’s ability to induce pro-inflammatory cytokine 
expression and survival in APC has not been studied in mammalian species. To 
investigate the ability of soluble chRANK to block chRANKL bioactivity, the 
extracellular domain was sub-cloned into Signal pKW06-Ig to generate COOH-Fc-
tagged protein in COS-7 cells.  
Mammalian OPG cDNA encodes a 401 amino acid protein that is further 
processed to form a 380 amino acid mature protein after cleavage of the signal 
peptide. OPG is synthesised as a glycosylated 55 kDa protein which self-associates 
to form disulphide-linked dimers prior to secretion from cells. ChOPG had been 
previously cloned by Hou et al. (2007). However, no sequence alignment or analysis 
was carried out to investigate the conservation of the CRD, DD and penultimate 
cysteine residue required for chOPG dimer assembly. Using SignalP4, the presence 
and cleavage site of the chOPG signal peptide was identified (Figure 3.1) allowing 
prediction of the size of the mature chOPG protein. Amino acid alignment of chOPG 
with the human and mouse proteins identified the high conservation of the gene 
across species, with 64-65% amino acid identity (Figure 3.9). This percentage of 
conservation is relatively high for a chicken immune gene as usually conservation 
between mammalian and chicken cytokines is between 25-30% (Kaiser, 2011). Like 
RANK, OPG is composed of NH2-terminal CRDs. These are followed by two 
modules homologous to DD, a heparin-binding domain and a penultimate cysteine 
residue required for dimer formation (Yasuda et al., 1998). OPG can bind to heparin 
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and although it was once suggested that this domain contributes to dimer formation it 
does not appear to have much biological importance (Schneeweis et al., 2005). 
However, rats treated with heparin had a decrease in bone density (Muir et al., 1996) 
and this was due to heparin inhibiting the interaction of OPG with RANKL (Irie et 
al., 2007). OPG contains 4 CRD domains similar to RANK but does not possess a 
transmembrane domain. Instead, OPG contains two DD with no known function. All 
DD containing receptors are expressed intracellualarly, driving cell death through the 
accumulation of caspase activation. OPG is the only death-domain containing 
receptor which is soluble. The CRDs behave as an independent structural unit with 
the second and third CRD interacting with RANKL (Luan et al., 2012). This 
interaction is diminished by a mutation in OPG at position 117, where Phe was 
substituted to Leu. A subset of families with juvenile Paget’s disease have the 
OPG
F117L
 mutation which causes long bone deformities, fractures, skull enlargement 
and deafness associated with accelerated bone resorption (Chong et al., 2003). The 
cysteine residue at position 400 is required for dimer formation in mammals (Luan et 
al., 2012). It is believed that the OPG dimer is a Y-shaped structure with the CRD 
forming the arms and the death domains forming a stalk. The “arms” occupy two 
grooves in the RANKL trimer, blocking the site for RANK binding (Luan et al., 
2012) (Figure 3.19). ChOPG was sub-cloned into pKW06 to generate a soluble Fc-
tagged protein in COS-7 cells. 
 Having cloned the extracellular domains of chRANKL and chRANK along 
with the full-length sequence of chOPG, each was sub-cloned into expression vectors 
for recombinant fusion protein production in COS-7 cells and protein structures were 
analysed by western blot. Interaction and signalling between TNF and TNFR 
superfamily members is dependent on the obligatory 3-fold symmetry. In mammals, 
the crystal structure of TNF ligands alone or in complex with their receptors has 
provided insight into the regions of the ligand required for interaction. The first 
crystal structure of TNF-α was identified in 1990 and provided the first detailed 
identification of the ability of TNF superfamily members to form trimers (Jones et 





Figure 3.19 Schematic diagram of OPG and RANKL interaction. OPG is a Y-
shaped structure where the CRD form the arms and the DD the stalk of the protein. 
RANKL (grey) naturally forms trimers at the surface of the cell membrane. The 
“arms” of OPG accupy two groves inhibiting the docking of RANK. Picture adapted 
from Nelson et al. (2012).  
 
sheets. The β-sheets of three individual β-sandwiches lie parallel to the three-fold 
axis. The interaction between these sheets creates an edge-to-face stacking producing 
a tight association between the subunits (Figure 3.20A) (Jones et al., 1990). The 
interface between these subunits is formed by mainly aromatic residues (Karpusas et 
al., 1995; Lam et al., 2001). TNFR superfamily members express CRD in their 
extracellular ligand-binding domains. These four-cysteine-repeat motifs produce 
very elongated structures from the cell surface (Smith et al., 1994). The six cysteine 
residues of each CRD form three intra-domain disulphide bridges which are shaped 
like the rungs of a ladder that are evenly spaced and do not come into contact with 
one another (Banner et al., 1993). Recognition between the TNF ligand and their 
receptor(s) is highly specific with a dissociation constant in the nanomolar range 
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(Lam et al., 2001). The TNF ligand trimer structure allows the loops at the edge of 
the opposing monomers to from a cleft, the shape of which forms the specificity of 
the interacting receptor (Figure 3.20A). The conventional model of TNF receptor 
signalling proposes that the trimeric ligand recruits three separate chains of the 
receptor, bringing them within close proximity to form homotrimers themselves 
(Smith et al., 1994). The trimeric ligand inter-digitates between the receptor chains 
thus preventing their interaction with each other (Figure 3.20B) (Lam et al., 2001). 
RANK is more elongated than OPG but both share 34% amino acid identity 
in their CRD. RANK and OPG share similar structural frameworks but RANKL 
adopts a different conformation when in complex with either of them. OPG has 
higher affinity for RANKL than RANK (Nelson et al., 2012). To verify the protein 
structures of schRANKL, chRANK and chOPG, exCOS-7 supernatants containing 
FLAG-schRANKL, chRANK-Fc or chOPG-Fc were analysed by western blot.  
Two expression plasmids were designed for the expression of type II 
transmembrane proteins. Each plasmid contained the mouse CD8 signal peptide to 
drive soluble protein expression, a FLAG-tag for detection and an isoleucine zipper 
to facilitate trimerisation of schRANKL. The first initial study to identify the 
importance of TNF trimerisation was carried out by Morris et al. (1999), who 
identified enhancement of the biological activity of soluble CD40L expressed with 
an isoleucine zipper. It was suggested that the addition of the isoleucine zipper 
enhanced trimerisation and stability of the complex (Morris et al., 1999). More 
recently, studies of the bioactivity of TRAIL showed that although the extracellular 
domain could be produced as a soluble protein using the secretion signal from human 
fibrillin-1 protein, it was not bioactive (Kim et al., 2004). TRAIL requires 
trimerisation to induce apoptosis, as the trimer acquires a zinc ion essential for 
bioactivity. This zinc ion cannot be attracted by a TRAIL monomer (Hymowitz et 
al., 1999). To drive TRAIL trimerisation, the isoleucine zipper from the leucine 
trimerisation domain (Harbury et al., 1994) was integrated into pCR3 (Kim et al., 
2004). Two plasmids were designed to express the isoleucine zipper with a cleavable 
or non-cleavable signal peptide and proteins were produced in HEK-293T cells. Both 




Figure 3.20 Schematic diagrams of A) RANKL trimer, B) RANKL and RANK 
interaction. A) Ribbon diagram of the RANKL trimer shown down the axis of the 
three-fold symmetry. The three monomers are identified as monomers Z, Y and X, the 
β-strands and loops involved in trimerisation are lettered and the RANK binding 
clefts are shown with black arrows. B) Schematic diagram of RANKL trimers 
interacting with RANK monomers at the cell surface. Figures are adapted from Luan 






cell death in HeLa cells (Kim et al., 2004). To ensure schRANKL was 
predominantly produced as a trimeric protein, the isoleucine zipper was integrated 
into a modified pCI-neo vector called pV20-schRANKL. As cysteine residues are 
crucial for stabilisation of higher order protein structures, a second plasmid was 
designed with a cysteine residue at a different location. This cysteine was placed 
between the FLAG sequence and the schRANKL sequence and the vector was called 
pV22-schRANKL. The cysteine residue in pV20-schRANKL was placed between 
the isoleucine zipper and the FLAG-tag sequence. Each plasmid was transfected into 
COS-7 cells and structures of the expressed recombinant proteins were analysed by 
western blot. In reducing conditions, schRANKL appears as predominantly a 
monomeric protein at ~37 kDa with a weak band of ~75 kDa which is possibly a 
dimeric protein (Figure 3.10). Proteins analysed under non-reducing conditions 
produced bands at ~75, ~150 and ~180 kDa, suggesting the formation of dimeric 
trimeric and possibly a tetrameric protein structures (Figure 3.10). The data suggest 
the formation of trimeric protein for both pV20- and pV22-schRANKL.  
ChRANK was expressed in COS-7 cells to produce a COOH-terminal Fc-
tagged protein. Under non-reducing conditions a strong band was apparent at ~100 
kDa (Figure 3.11). The predicted chRANK-Fc monomer is ~52 kDa, and this larger 
band could represent glycosylated monomers. Mammalian RANK self-association 
requires the cytoplasmic domain but not the extracellular domain (Kanazawa & 
Kudo, 2005). Hakozaki et al. (2010) transfected murine RANK into COS-7 cells and 
examined the expression of RANK in both the cell lysates and supernatants. In the 
cell lysates ~85 and ~200 kDa bands were present, representing the trimeric and 
monomeric proteins, respectively. However, in the cell supernatant containing 
soluble cleaved RANK, the trimeric protein was not present, suggesting the 
cytoplasmic tail is required for RANK self-association (Hakozaki et al., 2010). 
Although the conventional view is that TNFR only trimerises upon ligand 
interaction, one study identified the ability of TRAILR1 and CD40 to preassembled 
oligomers at the cell surface serving as a pre-ligand binding assembly domain 
(PLAD) (Chan et al., 2000). It would be interesting to investigate the ability of the 
full-length chRANK protein to form a PLAD at the cell surface. ChOPG was 
expressed as Fc-tagged protein and shown to self-associate to form homodimers in 
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COS-7 cell supernatants, similarly to mammalian OPG (Yasuda et al., 1998) (Figure 
3.12).  
The ability of chicken TNF members to fold correctly after expression in 
mammalian COS-7 cells is important for the study of their bioactivity and 
interactions. Both pV20- and pV22-schRANKL can self-associate to form 
homotrimers, which in mammals is vital for RANK trimerisation and downstream 
signalling (Cheng et al., 2009). To begin identifying the role of chRANKL in avian 
DC and macrophage biology, the activity of chRANKL on the phenotypes of each 
cell type were investigated. In the current model of DC and macrophage 
differentiation, each subset is derived from haematopoietic stem cells with a 
restricted myeloid differentiation potential (Geissmann et al., 2010). Within the bone 
marrow, there are macrophage/DC progenitor cells (MDP) which are constantly 
proliferating. MDP have a similar phenotype to granulocyte-macrophage progenitor 










 cells but specifically express the 
cytokine receptor, colony stimulating factor-1 receptor (CSF-1R), and the chemokine 
receptor, CX3CR1. These cells differentiate into monocytes and common DC 
precursor cells (CDP). Monocytes leave the bone marrow through the blood and 
under inflammatory conditions enter tissues and differentiate into macrophages or 
inflammatory DC (Auffray et al., 2009). CDP, on the other hand, can differentiate 
into plasmacytoid DC (pDC) or pre-classical DC which travel to the lymph nodes 
where they acquire a mature DC phenotype and morphology (Greissmann et al., 
2010). Certain cytokines and transcription factors have been identified as crucial for 





 mice suffer osteopetrosis, have a reduced number 
of monocytes and have reproductive defects (Dai et al., 2003). Primary immature 
macrophage and DC can be generated from bone marrow cells using specific 
cytokines to drive their differentiation. For BMDC, IL-4 and CSF-2 drive their 
differentiation (Inaba et al., 1992; Sallusto et al., 1994) whereas BMDM differentiate 
in the presence of CSF-1 (Bonifer & Hume, 2008). The same pattern applies to the 
chicken where BMDC differentiate with recombinant chIL-4 and chCSF-2 (Wu et 
al., 2010) and BMDM with recombinant chCSF-1 (Garceau et al., 2010).  
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To induce sub-optimal maturation of APC, BMDC and BMDM were 
stimulated with various concentrations of LPS for 3 and 6 h. The mRNA expression 
levels of IL-12α were minimal in BMDC stimulated with LPS at 2 ng/ml (Figure 
3.13). This concentration was sufficient to upregulate the cell surface expression of 
CD40 and decrease the expression of the phagocytic marker, KUL01. However, 
MHC class II expression was not enhanced by LPS stimulation (Figure 3.14). In Wu 
et al. (2010), BMDC constitutively expressed MHC class II on their cell surface and 
neither LPS nor CD40L stimulation led to a significant increase in expression. 
BMDM were sub-optimally matured with LPS at 1 ng/ml for 3 and 6 h which 
increased IL-6 mRNA expression levels (Figure 3.15). This concentration was also 
sufficient to induce the cell surface expression of CD40, decreased KUL01 
expression but caused no change in MHC class II expression (Figure 3.16). 
Macrophages have two ways of being activated, by antigen exposure or by cytokines 
produced by activated Th
 
cells (Th1 and CD8
+
 cytotoxic T cells) and natural killer 
cells. Macrophage stimulated with IFN-γ undergo “classical activation” leading to 
pro-inflammatory cytokine expression, NO2 release and MHC class II expression 
(Gordon, 2002). Chicken IFN-γ-treated BMDM upregulated the expression of CD40 
and MHC class II suggesting the cells were activated. The qRT-PCR and FACs 
analyses indicated that bone marrow cells grown with chIL-4 and chCSF-2 were 
phenotypically BMDC, while chCSF-1 differentiated bone marrow cells into 
BMDM.  
To investigate the bioactivity of chRANKL on avian APC, two plasmids 
were designed to encourage the formation of trimeric chRANKL proteins. Each 
protein was tested for their ability to enhance pro-inflammatory cytokine mRNA 
expression levels in BMDC. The pilot study indicated that both proteins could 
enhance pro-inflammatory cytokine mRNA expression levels, with pV22-
schRANKL protein having slightly more bioactivity than pV20-schRANKL protein. 
Therefore pV22-schRANKL, referred to as schRANKL, was used for further 

















 In 1997, four independent groups isolated a type II TNF-like transmembrane 
protein using different experimental systems and provided various names for the 
novel protein, i.e. TNF-related activation-induced cytokine (TRANCE) (Wong et al., 
1997), RANKL (Anderson et al., 1997), osteoprotegerin ligand (OPGL) (Lacey et 
al., 1998) and osteoclast differentiation factor (ODF) (Yasuda et al., 1998). Both 
TRANCE and RANKL were isolated from immunology-based laboratories while 
OPGL and ODF were isolated from a myelomonocytic cell line and a bone marrow 
stromal cell line, respectively. In this thesis, this protein is called RANKL. 
Mammalian RANKL mRNA expression in the immune system is limited to the 
thymus and lymph nodes, a restricted pattern also demonstrated by LT-α which is 
expressed solely in the spleen, differing to the pattern of expression seen for other 
members of the TNF superfamily (Anderson et al., 1997; Wong et al., 1997). 
Mammalian RANKL surface expression is predominantly on Th1 cells, and is 
inhibited by IL-4, not surprisingly as IL-4 is a Th2 cytokine that inhibits IFN-γ 
production by Th1 cells. Stimulation of the TCR leads to the early onset of RANKL 
expression and its induction is believed to be regulated by calcium mobilisation and 
PKC activation (Wang et al., 2002; Fionda et al., 2007).  
RANKL is known to bind to two receptors: RANK and OPG, a secreted TNF-
related protein that inhibits RANKL and RANK interaction (Simonet et al., 1997; 
Yasuda et al., 1997). RANK was originally identified in a bone marrow-derived 
myeloid DC cDNA library. RANK mRNA expression is widely detected in the 
lungs, spleen, skeletal muscle, brain, liver, kidney and skin, while its surface 
expression is limited to mature DC and osteoclast progenitor cells (Anderson et al., 
1997; Wong et al,. 1997). Mammalian OPG mRNA is expressed in a number of 
tissues, such as the lung, kidney, heart, intestine and bone (Simonet et al., 1997; 
Yasuda et al., 1998). RANKL enhances the expression of pro-inflammatory 
cytokines in DC due to activation of the NF-κB pathway. Initial analyses 
demonstrated that RANKL does not alter the expression of costimulatory molecules, 
such as CD80, CD86 and the adhesion molecule, I-CAM, on the surface of murine 
DC (Anderson et al., 1997; Wong et al., 1997). However, human Mo-DC, treated 
with RANKL, increased the surface expression of CD83 and CD86 at low levels, 
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suggesting that RANKL induces partial maturation of DC (Schiano de Colella et al., 
2008). Currently, there is only one study analysing the bioactivity of RANKL on 
murine macrophages (Park et al., 2005). RANKL treatment induced low levels of 
pro-inflammatory cytokine expression but costimulating cells with LPS or IFN-γ 
induced more potent macrophage activity, such as pro-inflammatory cytokine 
expression, cell surface marker expression (MHC class II and CD86) and 
phagocytosis (Park et al., 2005).  
Mammalian RANKL is a survival factor for both DC and macrophages 
(Anderson et al., 1997, Cremer et al., 1999; Park et al., 2005). The ability to enhance 
the survival of DC is linked to the up-regulation of the anti-apoptotic molecule, Bcl-
XL (Wong et al., 1999). The ability of RANKL to protect DC from spontaneous 
apoptosis is a potential avenue to improve the efficacy of vaccines and DC-based 
immunotherapy. DC that migrate to the draining lymph nodes upon infection to 
activate antigen-specific T cells have a very limited life-span and it is difficult to 
identify DC in the efferent lymph two days after infection (Pugh et al., 1983). To 
investigate the ability of RANKL to enhance the adjuvant effects of DC, cells were 
antigen-pulsed with purified protein derivative (PPD) from Mycobacterium, a 
classical antigen for T cell-mediated immunity (Inaba et al., 1992). DC were pulsed 
with PPD to induce maturation and then treated with RANKL and injected into mice 
(Josien et al., 2000). Immunization with RANKL-treated, PPD-pulsed DCs increased 
the production of IFN- compared to PPD-pulsed DC untreated with RANKL. 
Importantly, RANKL-treated PPD-pulsed DC were capable of inducing delayed type 
hypersensitivity (DTH) up to nine weeks after treatment. Therefore, RANKL-treated 
DC could induce both primary and secondary immune responses (Josien et al., 
2000). These DC were also found up to five days post-injection in the draining 
lymph node, with a 5-10-fold increase in the number of cells than in those not treated 
with RANKL prior to injection. The ability of RANKL to enhance and improve the 
survival and capabilities of DC upon infection is an important aspect of the adjuvant 
properties of RANKL. If DC can survive for longer in the draining lymph nodes, 
they can therefore enhance T cell-DC interactions.  
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The main aim of this study was to characterise the biological effect of 
schRANKL on avian APCs, but since its discovery in mammals, the role of RANKL 
in bone metabolism has been at the forefront of research. Bone is a dynamic tissue 
that is constantly being remodelled by bone forming cells (osteoblasts), and bone 
reabsorbing cells (osteoclasts) (Katagiri & Takahashi, 2002). The skeletal and 
immune systems are closely related sharing several regulatory molecules, including 
cytokines, chemokines and transcription factors (Horowitz et al., 1984; Dewhirst et 
al., 1985). The evidence that the pathology of one system affects the other has led to 
the term osteoimmunology to cover these overlapping scientific fields (Arron & 
Choi, 2000). The most typical example of these systems interacting is the prolonged 
activation of the immune system, leading to bone erosion due to osteoclast activation 
causing RA (Sato & Takayanagi, 2006). RANKL is necessary for osteoclast 
differentiation and activation (Kong et al., 1999a) by binding to RANK on osteoclast 
progenitor cells leading to the activation of TRAF6, NF-κB, p38 and JNK MAPKs 
(Lomaga et al., 1999; Naito et al., 1999). 
This Chapter describes the expression of chRANKL, chRANK and chOPG 
mRNA in a number of lymphoid and non-lymphoid tissues and primary immune 
cells, and examines the kinetics of their expression in splenocytes, bursal cells and 
thymocytes following stimulation with mitogens associated with proliferation and 
activation. The bioactivity of schRANKL is studied in more detail in both BMDC 
and BMDM, by analysing mRNA expression levels of pro-inflammatory cytokines 
and the phenotype of cells untreated or treated with schRANKL. The conservation of 
the role of RANKL as a survival factor in chickens was also investigated in BMDC 
and BMDM. Preliminary data are also presented on the ability of schRANKL to 





4.2  Methods 
 4.2.1  Tissues and primary immune cells  
Primers and probes were designed to amplify small regions of chRANKL, 
chRANK and chOPG that lie across an intron-exon boundary to prevent false 
positives for qRT-PCR analysis. The kinetics of mRNA expression levels of 
chRANKL, chRANK and chOPG were analysed in purified splenocytes, bursal cells 
and thymocytes, either unstimulated or stimulated with various mitogens, such as 
ConA for splenocytes, PMA/ionomycin for bursal cells and PHA for thymocytes 
(Chapter 2, section 2.6). Splenocyte subsets were purified using mouse anti-chicken 
mAb against CD4, CD8β, TCRγδ and TCRαβ1/αβ2 using an AutoMACs pro 
separator (Chapter 2, section 2.6). To investigate the transcriptional control of 
chRANKL, splenocytes were purified and unstimulated or stimulated with 
ionomycin or ionomycin and PMA for 2, 4 and 18 h. To determine if chRANKL 
expression was due to Ca
2+
 mobilisation, splenocytes were further treated with 
ionomycin with or without a Ca
2+ 
channel blocker, TMB-8, for 18 h (Chapter 2, 
section 2.6). 
4.2.2  BMDC and BMDM primary cells 
To determine the effects of schRANKL on BMDC and BMDM, bone marrow 
cells were extracted from the tibias and femurs of 4-6-week-old birds. Bone marrow 
cells were cultured in the presence of chIL-4 and chCSF-2 for BMDC, and chCSF-1 
for BMDM, for 6 days (Chapter 2, section 2.6). Three separate experiments were 
carried out. 1) BMDC were stimulated with or without various concentrations of LPS 
for 3, 6 or 9 h. RNA was purified and mRNA expression levels of the chRANKL 
receptors, chRANK and chOPG, were analysed to understand the kinetics of their 
expression in avian DC. 2) To further validate the bioactivity of schRANKL, cells 
were either unstimulated or stimulated with LPS, CD40L, schRANKL or 
combinations thereof for 3, 6 or 24 h. To verify the bioactivity of schRANKL, 
chRANK-Fc and chOPG-Fc were pre-incubated with schRANKL for 3 h prior to 
stimulating cells with LPS. Pro-inflammatory cytokine mRNA expression levels 
were measured by qRT-PCR. 3) Pro-inflammatory cytokine mRNA expression levels 
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were also assessed in BMDM, either unstimulated or stimulated with LPS, 
schRANKL or both, for 3 and 6 h. 
 
4.2.3  Flow cytometric analysis 
 Using the same conditions as described in section 4.2.2, the effect of 
schRANKL treatment on the phenotype of BMDC and BMDM was assessed by flow 
cytometry. Cells were stained with mouse anti-chicken MHC class II, CD40 and 
KUL01 mAb or isotype control mAb and analysed by FACs. FACs analysis was also 
used to measure the uptake of FITC-labelled zymosan-A particles by BMDC in the 
presence or absence of schRANKL. The survival of BMDC and BMDM was 
analysed using flow cytometry. BMDC and BMDM were untreated or treated with 
various dilutions of schRANKL for 24 and 48 h and cells were stained with 
recombinant annexin-V and PI to distinguish between dead, apoptotic and viable 
cells, by flow cytometry (Chapter 2, section 2.11).   
4.2.4  Osteoclasts differentiation   
 To analyse the ability of schRANKL to drive osteoclast cell differentiation, 
bone marrow cells were purified from 6-week-old birds. Cells were cultured in the 
presence of chCSF-1 for 2 days, followed by 8 days of incubation with schRANKL. 
To verify the generation of osteoclasts, the presence of multinuclear cells was 
detected by Hoescht-33258 staining and analysed by UV illumination (Chapter 2, 




4.3  Results 
4.3.1  Tissue distribution of chRANKL, chRANK and chOPG mRNAs 
The mRNA expression profiles of chRANKL, chRANK and chOPG were 
determined in a broad range of non-lymphoid and lymphoid tissues by qRT-PCR. 
Primers and probes for chRANKL and chRANK were designed against their 
extracellular domains. In both non-lymphoid and lymphoid tissues, mRNA 
transcripts for each gene were detected, suggesting each is ubiquitously expressed in 
chicken tissues (Figure 4.1). In non-lymphoid organs, chRANKL and chRANK 
mRNA expression levels are highest in muscle tissue taken from the breast. 
Interestingly, the lowest level of chOPG mRNA expression was in the muscle tissue 
(Figure 4.1A). The lowest levels of chRANKL and chRANK mRNA expression 
were in the heart. Levels of mRNA expression of all three cytokine were consistent 
in the liver, kidney and lung and slightly lower in the skin and brain (Figure 4.1A). 
In chicken lymphoid tissues, the highest levels of mRNA expression for all 
three cytokines were in the thymus, followed by the bone marrow and the upper-gut 
(Figure 4.1B). Overall, mRNA expression levels of all three molecules were similar 
within a tissue. In the crop, chRANKL mRNA expression levels were higher (~16-
fold) than those of chRANK and chOPG. In the Harderian gland, chRANKL was 
more highly expressed than chRANK. In the majority of tissues tested, the levels of 
chRANKL mRNA expression were higher than those of its receptors.  
4.3.2  Kinetics of expression of chRANKL, chRANK and chOPG mRNAs in primary 
 chicken cells 
To understand the kinetics of expression of all three molecules in primary 
lymphoid cells, the spleen, thymus and bursa of Fabricius were removed from three 
individual J-line birds and cells were purified as described in section 2.6.4. Cells 
were seeded at 5 X 10
6
 per ml and either unstimulated or stimulated with various 
mitogens. Splenocytes were stimulated with ConA at 1 μg/ml for 2, 4, 18 and 24 h. 
The mRNA expression levels of chRANKL, chRANK and chOPG were quantified 




Figure 4.1 Expression profiles of chRANKL, chRANK and chOPG mRNA in A) 
non-lymphoid and B) lymphoid tissues, as measured by qRT-PCR. ChRANKL, 
chRANK and chOPG mRNA expression levels in A) non-lymphoid tissues: 1) brain, 
2) muscle, 3) heart, 4) liver, 5) kidney, 6) lung, 7) skin and  B) lymphoid tissues: 1) 
thymus, 2) spleen, 3) bursa of Fabricius, 4) caecal tonsils, 5) Harderian gland, 6) 
bone marrow, 7) Meckel’s diverticulum, 8) caeca, 9) mid-gut, 10) upper-gut, 11) 
crop, 12) gizzard.  Data are presented as the average corrected 40-Ct values of three 






Figure 4.2 Kinetics of chRANKL, chRANK and chOPG mRNA expression 
levels in primary immune cells, as measured by qRT-PCR. ChRANKL, chRANK 
and chOPG mRNA expression levels were analysed in unstimulated (U) or 
stimulated (S) primary immune cells at 2, 4, 18 and 24 h. Splenocytes were 
stimulated with ConA (1 μg/ml) and bursal cells were stimulated with ionomycin (3 
μg/ml) and PMA (500 ng/ml). Data are presented as the average corrected 40-Ct 
values of three individual birds ± SEM.  
 
slightly down-regulated in ConA-stimulated cells compared to levels in unstimulated 
cells. ChRANKL mRNA expression levels were not statistically significantly 
different between unstimulated and ConA-stimulated splenocytes at any time-point 
(Figure 4.2). ChRANK and chOPG mRNA expression levels were slightly 
downregulated after ConA stimulation compared to levels in unstimulated cells but 
again mRNA expression levels were not statistically significantly different between 
levels in unstimulated and stimulated cells at any time-point. Overall mRNA 
expression levels of all three molecules were not significantly different after ConA 
stimulation of splenocytes. 
2 h 
4 h  
18 h  
24 h  
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 The bursa of Fabricius is a specialised organ for the generation of the avian B 
cell receptor repertoire. Bursal cells were purified and co-stimulated with ionomycin 
and PMA for 2, 4, 18 or 24 h and examined for chRANKL, chRANK and chOPG 
mRNA expression levels by qRT-PCR (Figure 4.2). ChRANKL mRNA expression 
levels were high in unstimulated bursal cells at 2 and 4 h. When cells were 
stimulated with ionomycin and PMA, chRANKL mRNA expression levels were 
decreased at 2 h and increased at 4 h compared to levels in unstimulated cells. 
ChRANKL mRNA expression levels in stimulated bursal cells were not statistically 
significantly different between levels in unstimulated cells at any time-point 
examined. ChRANK and chOPG mRNA expression levels were lower compared to 
chRANKL mRNA expression levels in bursal cells. There was no statistically 
significant difference in the levels of chRANK and chOPG mRNA expression 
between unstimulated and stimulated bursal cells.  
Thymocytes were also examined for chRANKL, chRANK and chOPG 
mRNA expression levels in either unstimulated or PHA-stimulated cells for 2, 4, 18 
and 24 h (Figure 4.3). Similar to the previous data, PHA-stimulation did not 
significantly alter the levels of mRNA expression of any of the cytokines at all time-
points examined (Figure 4.3). Overall, there was no statistical difference in the levels 
of chRANKL, chRANK or chOPG mRNA expression between unstimulated or 
stimulated splenocytes, bursal cells or thymocytes over the four time-points 
examined. 
4.3.3  Expression of chRANKL, chRANK and chOPG mRNAs in chicken splenocyte 
 subsets   
 The data from section 4.3.2 suggest that stimulation of splenocytes with 
ConA had no effect on the levels of chRANKL, chRANK or chOPG mRNA 
expression levels. Further analysis was carried out to determine if expression varied 
in different splenocyte subsets. Spleens were removed from three individual birds 
and splenocytes were purified over Histopaque-1077 and sorted using AutoMacs 
technology. The purity of cell populations were analysed by FACs (Appendix 4, 
Figure 2) and the percentage of purity for all cell subsets was between ~89-99%. The 












Figure 4.3 Kinetics of chRANKL, chRANK and chOPG mRNA expression 
levels in primary thymocytes, as measured by qRT-PCR. ChRANKL, chRANK 
and chOPG mRNA expression levels were analysed in unstimulated (U) or PHA (25 
μg/ml)-stimulated (S) thymocytes at 2, 4, 18 and 24 h. Data are presented as the 
average corrected 40-Ct values of three individual birds ± SEM.  
 
expression levels of all three molecules was detected in all four cell subsets (Figure 
4.4). ChRANKL mRNA expression levels were generally higher across all subsets in 
comparison to those of its receptors, although there was no statistically significant 
difference in mRNA expression levels for any molecule across the subsets.  
4.3.4  ChRANK and chOPG mRNA expression levels in mature BMDC 
 In mammals, RANK surface expression is predominantly found on mature 
DC and osteoclasts (Anderson et al., 1997; Wang et al., 1997) while OPG expression 
is found on osteoblast cells (Yasuda et al., 1998), suggesting a role for the latter in 
regulating the interaction between RANKL-RANK in bone metabolism. A more 
2 h  
4 h  
18 h  




Figure 4.4 ChRANKL, chRANK and chOPG mRNA expression levels in 
purified splenocyte subsets as measured by qRT-PCR. Splenocyte subsets were 
purified by AutoMacs separation and mRNA expression levels of chRANKL, chRANK 









. Data are presented as the average corrected 40-Ct values of 
three individual birds ± SEM. 
 
recent study identified a similar role for OPG in human Mo-DC, where OPG 
expression levels increased as DC matured (Schoppet et al., 2007). This suggests that 
OPG is also a molecular brake for RANKL-RANK interactions in the immune 
system. Before examining the bioactivity of schRANKL, the mRNA expression 
levels of both of its receptors were analysed in mature BMDC. BMDC were 
unstimulated or stimulated with various concentrations of LPS for 3 to 9 h and the 
mRNA expression levels of the receptors analysed by qRT-PCR (Figure 4.5). At 3 h, 
LPS-stimulated (200 ng/ml) cells had a ~2-fold increase in chRANK mRNA 
expression levels which dropped to ~1.6-fold at the lower amounts of LPS used, 
compared to levels in unstimulated cells. In contrast, chOPG mRNA expression 




Figure 4.5 ChRANK and chOPG mRNA expression levels in mature BMDC, as 
measured by qRT-PCR. BMDC were unstimulated or stimulated with various 
amounts of LPS (200, 100 and 1 ng/ml) for 3, 6 and 9 h. ChRANK and chOPG 
mRNA expression levels were analysed by qRT-PCR. Data are presented as fold 
change between unstimulated cells and stimulated cells at indicated time-points and 
represent the average results of three independent experiments ± SEM. 
*p<0.05(Mann-Whitney U test).  
 
stimulation, chOPG mRNA expression levels were increased by nearly 3-fold while 
levels of chRANK mRNA expression were only increased by ~0.4-fold (200 ng/ml). 
At lower concentrations of LPS, chRANK mRNA expression levels decreased to 
basal unstimulated levels or lower (Figure 4.6). However, cells stimulated with 100 
ng/ml or 1ng/ml of LPS increased chOPG mRNA expression levels statistically 
significantly compared to chRANK mRNA expression levels (p<0.05). At 9 h, 
chOPG mRNA expression levels were statistically significantly higher than those of 
chRANK in all LPS-stimulated cells (p<0.05). There was no statistically 
significantly difference in chRANK or chOPG mRNA expression levels compared to 




4.3.5  Transcriptional control of chRANKL mRNA expression in avian splenocytes 
In mammals, RANKL is a regulator of the interactions between T cells and 
DC (Anderson et al., 1997; Wang et al., 1997a). The expression of RANKL by 
mammalian T cells is induced by their activation and is dependent on Ca
2+
 
mobilisation (Wang et al., 2002). Our previous data have shown that ConA 
stimulation has no effect on chRANKL mRNA expression levels in chicken 
splenocytes (section 4.3.2). Therefore to further understand the regulation of 
chRANKL transcription, splenocytes were activated with the Ca
2+
-mobiliser/inducer, 
ionomycin, or ionomycin and the PKC activator, PMA, to mimic the signals initiated 
by TCR activation for 2, 4 and 18 h. Levels of chRANKL mRNA expression were 
analysed by qRT-PCR (Figure 4.6A).  
At 2 h, in ionomycin-stimulated splenocytes, chRANKL mRNA expression 
levels did not increase compared to those in unstimulated cells whereas costimulated 
cells had a ~2-3-fold increase in chRANKL mRNA expression levels (Figure 4.6A). 
At 4 h, ionomycin-stimulated cells statistically significantly increased chRANKL 
mRNA expression levels by ~5-fold compared to levels in unstimulated cells 
(p<0.05). Costimulated cells also significantly increased chRANKL mRNA 
expression levels at 4 h (p<0.05). At 18 h, chRANKL mRNA expression levels in 
ionomycin-stimulated cells decreased compared to expression levels at 4 h. This 
could suggest that ionomycin-mediated Ca
2+
-mobilisation declines over time and no 
longer induces chRANKL mRNA expression. ChRANKL mRNA expression levels 
were statistically significantly increased in costimulated cells compared to 
unstimulated cells (p<0.05), indicating that the concomitant activation of Ca
2+
 
mobilisation and the PKC pathway are necessary to drive the transcription of 
chRANKL in chicken splenocytes.  
To verify that the transcriptional regulation of chRANKL was linked to the 
activation and mobilisation of Ca
2+
, splenocytes were stimulated with ionomycin or 
ionomycin with various concentrations of the Ca
2+
 channel and PKC inhibitor, TMB-
8. The levels of chRANKL mRNA expression were analysed in these cells after 18 h 
of treatment by qRT-PCR (Figure 4.6B). ChRANKL mRNA expression levels were 




Figure 4.6 Transcriptional control of chRANKL expression in chicken 
splenocytes, as measured by qRT-PCR. A) Splenocytes were unstimulated or 
stimulated with ionomycin (3 μg/ml) or ionomycin and PMA (500 ng/ml) for 2, 4 and 
18 h. Levels of chRANKL mRNA expression levels were analysed by qRT-PCR. B) 
Splenocytes were unstimulated or stimulated with ionomycin or ionomycin with 
various concentrations of TMB-8 (10-50 μM) for 18 h and levels of chRANKL mRNA 
expression were analysed. Data are presented as the average of the fold change 
between unstimulated and stimulated cells of three individual birds ± SEM. Asterisks 
represent data that are statistically significantly different compared to levels in 




In the presence of TMB-8, chRANKL mRNA expression levels were reduced to 
those in unstimulated cells (Figure 4.6B). These data suggest that the 
pharmacological inhibitor of Ca
2+
 mobilisation and PKC activation, TMB-8, can 
block the transcription of chRANKL in chicken splenocytes and that the 
transcriptional control of chRANKL is regulated by these two biological pathways. 
4.3.6  The effects of chRANKL on pro-inflammatory cytokine mRNA expression 
levels in BMDC 
To examine the bioactivity of schRANKL, recombinant protein was produced 
in COS-7 cells and its effect on pro-inflammatory cytokine mRNA expression levels 
in BMDC was explored. On day 6 of culture, BMDC were unstimulated or 
stimulated with LPS, schRANKL or both, for 3 and 6 h. mRNA expression levels of 
the pro-inflammatory cytokines, IL-1β, IL-6 and IL-12α, were analysed by qRT-
PCR. At both time-points, LPS-stimulated cells had significantly upregulated IL-12α 
mRNA expression levels compared to levels in unstimulated cells (p<0.05). 
Costimulation with schRANKL had no effect at 3 h but did highly statistically 
significantly increase IL-12α mRNA expression levels compared to those in 
unstimulated cells at 6 h (p<0.01). However, in costimulated cells IL-12α mRNA 
expression levels were not statistically significantly altered compared to levels in 
LPS-stimulated cells at 6 h. Treatment of cells with schRANKL alone did not affect 
IL-12α mRNA expression levels (Figure 4.7). 
At 3 h, IL-1β mRNA expression levels were significantly increased (26-fold) 
in LPS-stimulated cells compared to those in unstimulated cells (p<0.05). 
Costimulated cells also had a significant increase in IL-1β mRNA expression levels 
compared to those in unstimulated cells (p<0.05) but not statistically significantly 
different to those in LPS-stimulated cells (p<0.07) (Figure 4.7), indicating that the 
addition of schRANKL did not enhanced IL-1β mRNA expression levels. At 6 h, 
LPS stimulation led to a significant (~52-fold) increase in IL-1β mRNA expression 
levels which were further statistically significantly enhanced to ~79-fold in co-
stimulated cells compared to levels in unstimulated cells (p<0.05) and statistically 
significantly compared to levels in LPS-stimulated cells (p<0.05) (Figure 4.7). 




Figure 4.7 Pro-inflammatory cytokine mRNA expression levels in BMDC 
stimulated with LPS, schRANKL or both for 3 and 6 h, as measured by qRT-
PCR. BMDC were unstimulated or stimulated with LPS (2 ng/ml), schRANKL (1:50 
ex-COS), or costimulated with both for 3 and 6 h. SchRANKL bioactivity was verified 
by pre-incubating with either chRANK-Fc (1:5 ex-COS) or chOPG-Fc (1:5 ex-COS) 
3 h prior to stimulation of BMDC. Pro-inflammatory cytokine mRNA expression 
levels (IL-1β, IL-6 and IL-12α) were analysed by qRT-PCR. IL-12α mRNA 
expression was not detectable in unstimulated cells and data are therefore presented 
as the average corrected 40-Ct values. IL-1β and IL-6 data are presented as average 
fold change between unstimulated cells and stimulated cells of six independent 
experiments ± SEM. a represents data that are statistically significant (p<0.05) 
compared to unstimulated cells, b represents data that are highly significant 
(p<0.01) compared to unstimulated cells, c represents data that are significant 
(p<0.05) compared to LPS-stimulated cells, d represents data that are significant 







this was not statistically significant compared to levels in unstimulated cells. At 3 
and 6 h, IL-6 mRNA expression levels were statistically significantly increased in 
LPS-stimulated cells. Co-stimulated cells statistically significantly increased IL-6 
mRNA expression levels compared to unstimulated cells at 3 and 6 h (p<0.05) 
(Figure 4.7). IL-6 mRNA expression levels in co-stimulated cells were statistically 
significantly increased compared to those in LPS-stimulated cells at 6 h (p<0.05), 
suggesting that schRANKL enhances IL-6 mRNA expression in mature BMDC. 
Cells treated with schRANKL alone had a non-significant increase (~5-fold) in IL-6 
mRNA expression levels at 3 h but there was no increase at 6 h (Figure 4.7).  
The antagonistic effects of soluble chRANK-Fc and chOPG-Fc were determined 
by their ability to inhibit the schRANKL-mediated upregulation of pro-inflammatory 
cytokines in BMDC. SchRANKL was pre-incubated with chRANK-Fc or chOPG-Fc 
3 h prior to stimulation of cells and IL-1β, IL-6 and IL-12α mRNA expression levels 
were analysed by qRT-PCR (Figure 4.7). Incubation of schRANKL with either 
chRANK-Fc or chOPG-Fc inhibited the enhanced pro-inflammatory cytokine mRNA 
expression levels induced by schRANKL and LPS (Figure 4.7). IL-12α mRNA 
expression levels were statistically significantly increased in cells co-stimulated with 
LPS, schRANKL and chRANK-Fc or chOPG-Fc, to those in unstimulated cells at 3 
and 6 h (p<0.05). The expression levels were not as high as LPS and schRANKL co-
stimulated cells. At 6 h, IL-1β mRNA expression levels were significantly increased 
in LPS, RANKL and chRANK-Fc or chOPG-Fc stimulated cells to those in 
unstimulated cells (p<0.05) and to LPS- or LPS and schRANKL co-stimulated cells 
(p<0.05). For IL-6 mRNA expression, cells stimulated with LPS, schRANKL and 
chRANK-Fc or chOPG-Fc, had significantly increased levels compared to those in 
unstimulated cells (p<0.05) at both 3 and 6 h and had significantly increased levels 
compared to those in LPS or costimulated cells (p<0.05). Overall, the pro-
inflammatory mRNA expression levels mediated by schRANKL in costimulated 
cells were inhibited by the addition of chRANK-Fc and chOPG-Fc. These data 
suggest that the soluble receptors of chRANKL can interact with their ligand and 
block its activity.  
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SchRANKL-treated cells did not significantly alter pro-inflammatory cytokine 
mRNA expression levels in BMDC (Figure 4.7). To investigate the possibility that 
the mRNA expression levels of the anti-inflammatory cytokine, IL-10, were altered 
by schRANKL treatment, levels were analysed in stimulated BMDC. IL-10 mRNA 
expression levels was not statistically significantly altered in schRANKL-, LPS- and 
co-stimulated cells compared to those in unstimulated cells at either 3 or 6 h (Figure 
4.8). This ruled out IL-10 for inhibiting of the ability of schRANKL to ehance pro-
inflammatory cytokine mRNA expression levels. Next, the mRNA expression levels 
of chRANKL’s receptors, chRANK and chOPG, were analysed by qRT-PCR (Figure 
4.8). At 3 h, chOPG mRNA expression levels were increased by ~8-fold in 
schRANKL-treated cells but were not statistically significantly different compared to 
levels in unstimulated cells. ChRANK mRNA expression levels were decreased in 
schRANKL-treated cells levels were not statistically significantly different to levels 
in unstimulated cells. The data suggest that chRANKL enhances pro-inflammatory 
cytokine mRNA expression levels in mature rather than immature BMDC. 
4.3.7  The effects of chRANKL on pro-inflammatory cytokine mRNA expression 
levels in BMDM 
 The bioactivity of schRANKL on BMDM was analysed by examining pro-
inflammatory cytokine mRNA expression levels. Cells were unstimulated or 
simulated with LPS, schRANKL or both, for 3 and 6 h, similarly as previously 
described for BMDC. IL-12α mRNA expression was not detected in any sample, 
which may be due to the low concentration of LPS (1 ng/ml) used for this study (data 
not shown). At 3 h, LPS-stimulated cells increased IL-1β mRNA expression levels 
significantly by ~50-fold compared to those in unstimulated cells (p<0.05) (Figure 
4.9). Co-stimulation with LPS and schRANKL increased IL-1β mRNA levels 
statistically significantly compared to levels in unstimulated cells (p<0.05) but not 
those in LPS-stimulated cells. At 6 h, IL-1β mRNA expression levels were lower in 
LPS-stimulated cells. Co-stimulated cells had increased IL-1β mRNA expression 
levels but levels were not statistically significantly different compared to those in 
unstimulated or LPS-stimulated cells. IL-6 mRNA expression levels were increased 




Figure 4.8 IL-10, chRANK and chOPG mRNA expression levels in BMDC 
stimulated with LPS, schRANKL or both, for 3 and 6 h, as measured by qRT-
PCR. BMDC were stimulated with LPS (2 ng/ml), schRANKL (1:50 ex-COS), or co-
stimulated with both, for 3 and 6 h. mRNA expression levels of the anti-inflammatory 
cytokine, IL-10 and the chRANKL receptors, chRANK and chOPG, were analysed by 
qRT-PCR. Data are presented as average fold change between unstimulated and 
stimulated cells of three independent experiments ± SEM.  
 
statistically significantly different compared to those in unstimulated cells. Similar to 
BMDC, stimulation of immature BMDM with schRANKL had no effect on the 






Figure 4.9 Pro-inflammatory cytokine mRNA expression levels in BMDM 
stimulated with LPS, schRANKL or both, for 3 and 6 h, as measured by qRT-
PCR. BMDM were unstimulated or stimulated with LPS (1 ng/ml), schRANKL (1:50 
ex-COS) or both for 3 and 6 h. Pro-inflammatory cytokines (IL-1β and IL-6) were 
analysed by qRT-PCR. Data are presented as the average fold change between 
unstimulated and stimulated cells of three individual experiments ± SEM. * 
represents data that are statistically significant (p<0.05) compared to unstimulated 
cells at 3 h (Mann-Whitney U test).  
 
4.3.8  ChCD40L and schRANKL do not have synergistic effects on pro-
inflammatory cytokine mRNA expression levels in BMDC 
CD40L-CD40 interactions have similar characteristics as RANKL-RANK 
interactions, such as inducing pro-inflammatory cytokine expression in DC. To 
examine whether stimulating BMDC with two members of the chicken TNF ligand 
family, chCD40L and schRANKL, could have synergistic effects on pro-
inflammatory cytokine mRNA expression levels, BMDC were unstimulated or 
stimulated with chCD40L or chCD40L and schRANKL for 3, 6 and 24 h (Figure 
4.10). Previous data indicated that schRANKL has no effect on pro-inflammatory 
cytokine mRNA expression levels in immature BMDC; therefore data are not shown. 
IL-12α mRNA expression was not detected in any sample (data not shown). 






Figure 4.10 Lack of synergistic effects on pro-inflammatory cytokine mRNA 
expression levels in BMDC stimulated with chCD40L and schRANKL, as 
measured by qRT-PCR. BMDC were unstimulated or stimulated with chCD40L (3 
μg/ml) or chCD40L and schRANKL (1:50 ex-COS) for 3, 6 and 24 h. IL-1β, IL-6 and 
chRANK mRNA expression levels were analysed by qRT-PCR. Data are presented as 
the average of the fold changes between unstimulated cells and stimulated cells of 
three independent experiments ± SEM.  
 
time-points (Figure 4.10). Co-stimulated cells had increased IL-1β mRNA 
expression levels (~3-fold) but these were not statistically significantly different to 
levels in unstimulated cells or chCD40L-stimulated cells (Figure 4.10). IL-6 mRNA 
expression levels were increased in co-stimulated cells but were not statistically 





levels were not significantly altered by chCD40L stimulation or co-stimulation at any 
time-point (Figure 4.10). 
4.3.9  Phenotype of BMDC treated with schRANKL 
To investigate the ability of schRANKL to alter the expression of cell surface 
markers on BMDC, cells were treated with LPS (2 ng/ml), schRANKL (1:5 exCOS-
7) or both, for 24 h (Figure 4.11). Cells were removed from culture plates and stained 
for the following chicken APC activation markers; MHC class II, CD40 and the 
chicken mononuclear phagocyte marker, KUL01 (Mast et al., 1997). Cells were 
stained with a viability dye, 7-AAD, prior to FACs to exclude dead cells from the 
data analysis (Appendix 4, figure 3). The histograms compare antigen staining with 
isotype controls (Figure 4.11A) while barcharts indicate the average geometric mean 
fluorescence intensity of four individual experiments (Figure 4.11B). Although a 
previous study demonstrated that MHC class II was constitutively expressed on 
chicken BMDC, either unstimulated or stimulated with LPS (200 ng/ml) (Wu et al., 
2010), the expression of MHC class II was not altered by the sub-optimal maturation 
of BMDC with the  LPS concentration (1 ng/ml) used in this study (Figure 4.11). Co-
stimulation of cells with LPS and schRANKL or with schRANKL alone did not 
increase the surface expression levels of MHC class II. CD40 expression levels were 
increased in LPS-stimulated cells and were slightly enhanced by the addition of 
schRANKL but not to a statsically significant level (p=0.4) (Figure 4.11). The 
expression of KUL01 decreases as BMDC mature (Wu et al., 2010) and this was 
evident in the LPS-stimulated cells where a portion of the cell population lost the 
expression of KUL01. Co-stimulated cells had similar levels of KUL01 expression as 
the LPS-stimulated cells, indicating that schRANKL may not contribute to enhancing 
the maturity of BMDC. Overall there no statistically significant alternation in the 
phenotype of BMDC treated with schRANKL. 
4.3.10  Phenotype of BMDM treated with schRANKL 
BMDM were stimulated with LPS (1 ng/ml), schRANKL (1:5 exCOS-7) or 
both, for 24 h and analysed by FACS (Figure 4.12). Similar to BMDC, MHC class II 





Figure 4.11 FACS analysis of BMDC stimulated with LPS and schRANKL for 
24 h. BMDC were unstimulated or stimulated with LPS (2 ng/ml), schRANKL (1:5 
ex-COS) or both for 24 h. Cells were stained for activation markers (MHC class II, 
CD40 and KUL01) using mouse anti-chicken monoclonal antibodies and isotype 
controls and analysed by FACs. A) Data are represented as histograms comparing 
isotype controls (black lines) to surface staining (grey lines) and are representative 
of four independent experiments with similar results. B) Data are represented as the 






BMDM with LPS (1 ng/ml) alone or in combination with schRANKL (Figure 4.12). 
CD40 expression levels were increased in LPS-stimulated cells but were not 
enhanced by the addition of schRANKL (Figure 4.12A). KUL01 expression levels 
were decreased in LPS-stimulated cells compared to unstimulated cells and were not 
altered by the addition of schRANKL. Similarly to BMDC, schRANKL alone did 
not affect the expression levels of cell surface activation markers on BMDM. As 
there was no major difference in the expression levels of surface markers on BMDM 
stimulated with LPS and schRANKL, a more potent activator of macrophages, IFN-
γ, was used to analyse the effects of schRANKL on mature BMDM.  
As previous data indicated (Figure 4.12), schRANKL alone has no effect on 
the phenotype of BMDM and therefore this analysis is not shown. BMDM were 
unstimulated or stimulated with IFN-γ (1:100 exCOS) or IFN-γ and schRANKL, for 
24 h and analysed by FACS. BMDM stimulated with IFN-γ increased surface 
expression of MHC class II indicating the potency of IFN-γ in stimulation of chicken 
macrophages (Figure 4.13). MHC class II expression levels on co-stimulated cells 
were increased compared to levels on unstimulated cells but were not significantly 
enhanced compared to levels on IFN-γ-stimulated cells (Figure 4.13). CD40 
expression levels were increased in IFN-γ-stimulated cells and statistically 
significantly increased in co-stimulated cells compared to levels in unstimulated cells 
(p=0.03) (Figure 4.13). However, co-stimulated cells CD40 expression levels were 
slightly increased but were not statistically significantly altered compared to levels in 
IFN-γ-stimulated cells (Figure 4.13). KUL01 expression levels were statistically 
significantly decreased on IFN-γ and costimulated cells compare to levels in 
unstimulated cells. There were no statistically significant differences in levels 
between co-stimulated cells and IFN-γ-stimulated cells. Overall the data suggest that 
schRANKL does not stimulate differential expression of surface activation markers 
on BMDM. 
4.3.11  Survival of BMDC treated with schRANKL 
RANKL was first identified as a survival factor for DC (Anderson et al., 
1997; Wong et al., 1997; Josien et al., 2000) through the anti-apoptotic 





Figure 4.12 FACS analysis of BMDM stimulated with LPS and schRANKL for 
24 h. BMDM were unstimulated (control) or stimulated with LPS (1 ng/ml), 
schRANKL (1:5 ex-COS) or both for 24 h. A) Data are presented as histograms 
comparing isotype controls (black lines) to surface staining (grey lines) and are 
representative of four independent experiments with similar results. B) Data are 
represented as the average geometric-mean fluorescence intensity (GEO-MFI) of 







Figure 4.13 FACS analysis of BMDM stimulated with LPS and schRANKL for 
24 h. BMDM were unstimulated (control) and stimulated with LPS (1 ng/ml), 
schRANKL (1:5 ex-COS) or both for 24 h. A) Data are presented as histograms 
comparing isotype controls (black lines) to surface staining (grey lines) and are 
representative of six independent experiments with similar results. B) Data are 
represented as the average geometric-mean fluorescence intensity (GEO-MFI)  





examine whether chRANKL was a survival factor for BMDC, cells were treated with 
or without schRANKL (1:5 and 1:10 exCOS-7) for 24 and 48 h (Figure 4.14). Cell 
death and apoptosis were measured by Annexin-V and PI staining and analysed by 
FACs. Annexin-V and PI staining are commonly used to determine viable, apoptotic, 
necrotic and dead cells by flow cytometry. The PI stain can only enter cells that have 
damaged cellular membranes, so viable cells or cells undergoing early apoptosis 
cannot be stained with PI due to the nature of the cell death mechanism. Annexin-V 
can only bind to PS, which is usually found on the inner membrane of the cell and 
upon apoptosis-inducing signals flips to the outer membrane. This occurs at the early 
stages of apoptosis (Fadok et al., 1992).  




) and 42.8% 






) (Figure 4.14). This indicates 
that nearly half of the cell population analysed under normal conditions were 
undergoing apoptosis. In contrast, 1:5 schRANKL-treated cells had 56.2% viable 
cells and 29.7% undergoing apoptosis. The 1:10 schRANKL-treated cells had similar 
levels of live cells (45.3%) and cells undergoing apoptosis (41.4%) as the untreated 
cells, indicating that the ability of schRANKL to enhance cell survival is dose- 
dependent. Although not statistically significant (n=3) (p=0.07), it is clear that 
schRANKL does enhance the survival of BMDC after 24 h of treatment compared to 
untreated cells. After 2 days (48 h), the number of viable untreated cells fell to 28.9% 
in comparison to schRANKL-treated cells where 37.2% were viable (Figure 4.14). 
The survival rates of 1:10 schRANKL-treated cells were similar to untreated cells at 
48 h (Figure 4.14). Cells undergoing apoptosis in untreated cells increased to 56.4% 
but for schRANKL-treated cells apoptotic cells were 48.5%. Cells undergoing 
apoptosis reached 63% in 1:10 schRANKL-treated cells. Overall the data suggest 
that schRANKL acts as a survival factor for chicken BMDC. 
4.3.12  Survival of BMDM treated with schRANKL 
BMDM survival rates were analysed after 24 and 48 h of schRANKL 
treatment by FACs (Figure 4.15). After 24 h, cells untreated with schRANKL had 





Figure 4.14 Survival of BMDC treated with schRANKL for 24 and 48 h. BMDC 
were untreated or treated with schRANKL (1:5 or 1:10 ex-COS) for 24 and 48 h and 
cell survival was analysed by FACS after staining cells for Annexin-V (Alexa-647) 
and PI. Individual data are presented as dot plots (top) and data are summarised as 
bar charts representing the average percentages of Annexin-V
+





 (viable) cells of three independent experiments ± SEM (bottom). 
24 h 48 h 
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BMDM viability numbers were 29.5% and 30.2%, respectively. However, when 
apoptotic cell numbers were analysed in these cells, untreated and schRANKL-
treated cells had similar percentages of cells undergoing cell death (Figure 4.15). A 
further 24 h of cell culture led to similar numbers of viable and apoptotic cells 
between untreated and schRANKL-treated cells. The average of three independent 
experiments indicates that after 48 h, cells treated with schRANKL had higher 
percentages of annexin-V
+
 cells compare to control cells (Figure 4.15). Although the 
data are not statistically significant (n=3), there is evidence that schRANKL can 
enhance the survival of BMDM after 24 h of exposure but this enhanced survival is 
short-lived, as cells begin to undergo normal rates of apoptosis after 48 h. 
4.3.13  Phagocytosis  
As APCs, phagocytosis is an important function for DC. The effect of 
schRANKL on the phagocytic activity of BMDC was analysed by treating cells with 
schRANKL 24 h prior to exposure to zymosan A-FITC particles. The particles were 
incubated with untreated or schRANKL-treated cells for 1 h at 4°C or 41°C. 
Phagocytosis was inhibited by the addition of ice-cold PBS to the cells and the cells 
were then washed with trypan blue to quench external FITC expression. Cells were 
washed several times with PBS and the presence of ingested particles analysed by 
flow cytometry.  
Cells incubated at 4°C did not phagocytose the zymosan A particles (control 
for surface binding) (Figure 4.16). When cells were exposed to the particles and 
incubated at 41°C, both untreated and treated BMDC ingested the particles. Cells 
pre-treated with schRANKL for 24 h had statistically significantly higher uptake of 
particles in comparison to the untreated cells (p<0.01). Although the previous data 
indicated that schRANKL did not enhance surface expression of antigen presenting 
MHC class II surface molecules, schRANKL can augment the phagocytic activity of 
BMDC. Murine BMDM can commit to the osteoclast lineage after 24 h of RANKL 
treatment and still have phagocytic potential (Mochizuki et al., 2006). The BMDC 
cultures treated with schRANKL formed cluster of cells, whereas the untreated cells 
did not (Figure 4.17). BMDC cultures are heterogeneous and there could potentially 





Figure 4.15 Survival of BMDM treated with schRANKL for 24 and 48 h. BMDM 
were untreated or treated with schRANKL (1:5 or 1:10 ex-COS) for 24 and 48 h and 
cell survival was analysed by FACS after staining cells for Annexin-V (Alexa-647) 
and PI. Individual data are presented as dot plots (top) and bar charts representing 
the average percentages of Annexin-V
+





cells of three independent experiments ± SEM (bottom). 
24 h 48 h 
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4.3.14  Pilot study: ChRANKL and osteoclasts 
 Since the discovery of mammalian RANKL, several studies have identified 
its requirement for osteoclast differentiation and activation (e.g. Simonet et al., 1997; 
Yasuda et al., 1998). Although the aim of this study was to investigate the bioactivity 
of chRANKL on chicken APCs, preliminary experiments were carried out towards 
establishing a protocol for differentiating chicken bone marrow cells into 
multinucleated osteoclasts. Osteoclast cells are derived from the 
mononuclear/macrophage lineage. Therefore, to drive bone marrow cells towards 
this lineage, cells were incubated with chCSF-1 for 2 days. On day 2, cells were 
removed from cultured plates, reseeded at 5 X 10
4
 cells/well in 6-well plates and 
either untreated or treated with schRANKL (1:10 ex-COS) for 8 days. Twenty-four h 
after reseeding, an adherent monolayer of cells formed on the cultured plates (Figure 
4.18A). There was no difference in cell numbers or cell clumping between untreated 
and schRANKL-treated cells (Figure 4.18A). After 4 days of culture, untreated cells 
became less confluent compared to schRANKL-treated cells. This could be linked to 
schRANKL being a survival factor for these undifferentiated cells, as it is for 
BMDC. On day eight, non-adherent cells were removed by gentle washing with PBS 
and stained with the nuclear stain Hoescht-33258. Stained cells were analysed by UV 
illumination to visualise multinucleated cells (Figure 4.18B). Untreated cells did not 
have multinucleated cells. However, schRANKL-treated cells had numerous large, 
multinucleated cells (Figure 4.18B). Although no functional studies were carried out 
on these cells for this study, these cells do express high amounts of chRANK mRNA 
and absorb bone (Garcia-Morales, unpublished results). This preliminary study 





Figure 4.16 Phagocytosis by BMDC treated with schRANKL, analysed by 
FACS. BMDC were untreated or pre-treated with schRANKL (1:50 exCOS-7) 24 h 
prior to exposure to zymosan A-FITC particles for 1 h at 4°C or 41°C. Particle 
ingestion was analysed by FACs. Data are presented as the average geometric-mean 
fluorescence intensity (GEO-MFI) of four independent experiments ± SEM. 
**p<0.01 (Student’s t-test). 
 
 
Figure 4.17 BMDC treated with schRANKL for 24 h. BMDC were A) untreated 
or B) treated with schRANKL (1:50 ex-COS-7) for 24 h. Arrows indicate large cells 






4.4  Discussion  
ChRANKL, chRANK and chOPG mRNA expression levels were ubiquitous 
across a range of lymphoid and non-lymphoid tissues and immune cells in the 
chicken. Studies examining the mRNA expression levels of mammalian RANKL are 
based on northern blot analysis. RANKL mRNA transcripts were only detected in the 
thymus and lymph nodes of mice (Wong et al., 1997). Mammalian OPG expression 
was not observed in the brain, muscle, thymocytes or naïve T and B cells (Yun et al., 
1998). qRT-PCR is more sensitive than northern blot, and it would be interesting to 
revisit the expression of these molecules in mammals. 
In the bone marrow, all three molecules were highly expressed at the mRNA 
level, which was not surprising as all three have vital roles in bone metabolism in 
mammalian species (Simonet et al., 1997; Yasuda et al., 1998). In non-lymphoid 
organs, chRANKL and chRANK mRNA expression levels were highest in muscle 
tissue, similar to mammalian RANKL and RANK (Anderson et al., 1997; Wong et 
al., 1997). The heart had the lowest mRNA expression levels of all three molecules 
amongst the non-lymphoid tissues examined. In contrast, mammalian OPG 
expression was strongest in smooth muscle tissue and the heart, which suggested that 
it may have a role in vascular development (Simonet et al., 1997; Yun et al., 1998). 
OPG
-/-
 mice suffer from calcification of the renal arteries and aorta (Bucay et al., 
1998), due to OPG regulating RANKL-dependent IL-6 expression which promotes 
calcification (Callegari et al., 2014).  
In the spleen, mRNA expression levels of chRANKL, chRANK and chOPG 
levels were all similar. The chicken spleen contains a heterogeneous mix of T and B 
lymphocytes, macrophages and DC (Jeurissen, 1993; Quéré et al., 2013). Purified 
splenocytes were also examined for the levels of chRANKL, chRANK and chOPG 
mRNA expression, either in unstimulated or in ConA-stimulated cells over four 
time-points. ConA stimulation did not significantly alter the mRNA expression levels 
of the three molecules compared to the levels in unstimulated cells (Figure 4.2A) but 
the culture conditions led to an increase in expression of all these molecules after 18 
and 24 h. It may be as cells are cultured in media they undergo physiological 







Figure 4.18 Differentiation of bone marrow cells into osteoclast cells by 
schRANKL. A) Bone marrow cells were incubated for 2 days with rchCSF-1 and 
reseeded at 5 X 10
4
 cells/ml with schRANKL (1:10 ex-COS) for up to 8 days. B) 





these TNF and TNFR superfamily members. In mice, the co-culture of T cells and 
splenocytes stimulated with ConA induces osteoclast differentiation (Horwood et al., 
1999). It was not determined if this occurred in the chicken cultures but it could be 
the cause of the increase in the mRNA expression levels of the three molecules over 
time.  
The mRNA expression levels of chRANKL, chRANK and chOPG were 
analysed in T cell subsets purified from chicken spleens (Figure 4.4). qRT-PCR 
analysis indicated that chRANKL mRNA expression levels were higher compared to 








 cells. In 





 T cells but was expressed in CD44
+
 memory T cells (Josien et al., 
1999). Mammalian RANKL cell surface expression was also identified on both 
stimulated murine Th1 and Th2 cell clones, with expression levels higher on Th1 cell 
clones. IL-4 treatment decreases the surface expression of RANKL, verifying that it 
is predominantly a Th1 surface marker (Josien et al., 1999; Chen et al., 2001). 
RANK surface expression was also detected on T cells but at much lower levels than 
its ligand (Josien et al., 1999). RANKL and RANK are not required for Th1/Th2 
dichotomy but are required for optimal cytokine production in antigen receptor-




 T cells 
produce lower levels of IL-4, IL-5, IL-6, IFN-γ and IL-2 (Kong et al., 1999a). 
RANKL reverse-signalling has been linked to enhanced production of IFN-γ in Th1 
cells, which in turn has been linked to activation of the p38 MAPK pathway (Chen et 
al., 2001). Mammalian CD4
+
 T cells express both the membrane and soluble forms 
of RANKL, and both can induce osteoclastogenesis (Kong et al., 1999b). Various 
studies have shown that T cell-mediated inflammation is linked to arthritis in humans 
with symptoms of cartilage and bone erosion, severe joint pain and crippling 
(reviewed by Feldmann et al., 1996). Having identified RANKL expression on the 
surface of activated CD4
+
 T cells, Kong et al. (1999b) examined the expression of 
RANKL in adjuvant-induced arthritis in rats (Lewis rats). Within the hind paw of 
these rats, synovial and inflammatory cells expressed RANKL mRNA and CD4
+
 
inflammatory T cells expressed surface RANKL. When RANKL was blocked using 
OPG, bone and cartilage erosion were inhibited but not pro-inflammatory cytokine 
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expression, indicating that RANKL was the key mediator of joint destruction and 
bone loss in adjuvant arthritis (Kong et al., 1999b). Although there is a lack of Th 
cell clones in the chicken, antibodies against chRANKL could help identify and 
differentiate between Th subsets.  
ChRANKL mRNA expression levels were much higher than those of its 
receptors in both the upper-gut and Harderian gland (Figure 4.1). The intestinal 
surface is physically protected by tightly joined epithelial cells preventing enteric 
antigen from penetrating the host. Along the intestinal tract there are nodules or 
lymphoid follicles, such as Peyer’s patches, Meckel’s diverticulum and caecal 
tonsils, which are overlaid with epithelia required for immune surveillance. In the 
gut-associated lymphoid tissues (GALT), sampling of lumenal pathogens is achieved 
by M cells (reviewed by Mabbott et al., 2013). M cells are highly efficient 
phagocytic cells that uptake bacterial antigen from the lumen into the Payer’s 
patches, priming CD4
+
 T cells and IgA
+
-committed B cells (VanCott et al., 1996). 
RANKL is necessary for the differentiation of RANK expressing enterocytes into M 
cells (Knoop et al., 2009). It would be interesting to determine if the high levels of 
chRANKL mRNA expressed in the upper gut correlated with the presence of large 
numbers of M cells in this tissue.  
The Harderian gland is the major eye-associated lymphoid tissue and is rich 
in plasma cells at different stages of maturation. Birds used for the study were 6-
weeks of age, coincident with high rates of plasma cell proliferation in the Harderian 
gland. In the chicken, the bursa of Fabricius is a specialised organ containing naïve B 
cells. qRT-PCR analysis indicated that all three molecules were similarly expressed 
in the bursa of Fabricius (Figure 4.1). Interestingly, in the kinetic studies where B 
cells were stimulated with ionomycin and PMA to activate MAPK kinases and the 
PKC pathway, inducing B cell proliferation, differentiation and effector functions, 
chRANK and chOPG mRNA expression levels were much lower than the levels of 
chRANKL mRNA expression. Notably, bursal cells had the highest levels of 
chRANKL mRNA expression compared to purified splenocytes and thymocytes. 
Early studies on bursal development found that epithelial tuffs overlaying the B cell 
follicles appear to be structurally and functionally similar to M cells (Bockman & 
162 
 
Copper, 1973). Mice with a germline deletion of either RANK or RANKL have 
serious defects in B cell development (Dougall et al., 1999; Kong et al., 1999) and 
mammalian RANKL is expressed on the surface of pre-B cells, where its expression 
is controlled by IL-7 (Kato et al., 2003). OPG
-/-
 B cells have greater responses to IL-
7 stimulation and higher numbers of pro-B cells and peripheral B cells compared to 
OPG
+/-
 mice (Yun et al., 2001). In a more recent study in RANK
-/-
 mice (Perlot & 
Penninger, 2012), B cells were present in both the bone marrow and spleen and were 
of similar frequencies and types compared to B cells in wild-type mice. This strongly 




mice, defective B cell 
development may be due to the nature of osteoporosis where bones are denser and 
lack cavities, therefore creating secondary disorders not directly linked to RANKL-
RANK signalling. In the chicken, B cell lymphopoiesis occurs in the bursa of 
Fabricius but early B cell progenitors have been identified in the embryonic, but not 
the adult, bone marrow. Two other TNF superfamily members are required for 
chicken B cell survival and proliferation, BAFF (Schneider et al., 2004) and CD40L 
(Kothlow et al., 2008). ChRANKL may be a potential marker for identifying pro-B 
cells in the chicken, along with monoclonal antibodies against chicken IL-7Rα (van 
Haarlem et al., 2009).  
In the chicken the highest levels of chRANKL mRNA expression were 
detected in the thymus, similarly to mammalian RANKL (Wong et al., 1997). The 
development of T cells within the thymus depends on two cell types, cTEC and 
mTEC. TCR-expressing T cells are presented with peptide antigens expressed on 
both cell types, with cTEC required for positive selection and mTEC required for 
negative selection (Nitta et al., 2008). mTEC are distinguished by the expression of 
the autoimmune regulator (AIRE), a transcriptional regulator required for the 
expression of tissue-specific antigens (TSA) and clonal deletion (Derbinski et al., 
2001; reviewed by Kyewski & Klein, 2006), and are also distinguished by surface 
expression of MHC class II, CD80 and UEA-1 (Rossi et al., 2007). mTEC express a 
wide range of TSA that bind to the TCR with either high affinity leading to apoptosis 
(negative selection) or with intermediate affinity which are then diverted to the 
regulatory T cell pool. A number of cytokines are involved in the development of 
mTEC including LT-β, CD40L (Dunn et al., 1997) and RANKL (Rossi et al., 2007). 
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TRAF6-dependent downstream NF-κB activation is required for mTEC development 
(Akiyama et al., 2005) and the cell surface receptor required for that signalling is 
RANK (Rossi et al., 2007). Although the development of the medullary region of the 
thymus does not require RANKL-RANK interaction, AIRE
+
 mTEC do require these 
cytokines in adult mice (Akiyama et al., 2008). Mammalian RANKL is not 

















thymocytes but is expressed on LTi cells (Rossi et al., 2007). Although LTi cells 
have yet to be identified in the chicken, their identification may be possible in the 
future with the use of monoclonal antibodies against chRANKL. 
The initial data suggested that ConA stimulation of splenocytes had no 
significant effect on the transcription of chRANKL. The expression of RANKL by 
mammalian T cells is induced by their activation and dependent on Ca
2+
 mobilisation 
(Wang et al., 2002). To understand whether the mechanism of chRANKL expression 
was conserved between mammals and birds, chicken splenocytes were stimulated 
with the intracellular calcium modulator, ionomycin, and the PKC activator, PMA, 
which mimic TCR activation, for 2, 4 and 18 h and levels of chRANKL mRNA 
expression were analysed by qRT-PCR (Figure 4.6A). In co-stimulated cell the levels 
of chRANKL mRNA expression were significantly increased at 4 and 18 h 
indicating that ionomycin and PMA work in synergy to induce chRANKL mRNA 
expression. In murine T cells, ionomycin alone was sufficient to induce RANKL 
expression and no synergy was found when cells were costimulated with ionomycin 
and PMA, although northern blot analysis was used and levels were not quantified 
(Wang et al., 2002). In similar studies, murine T cell hybridomas weakly induced 
RANKL after PMA stimulation but a combination of PMA and ionomycin 
synergised and induced higher levels of RANKL expression (Fionda et al., 2007; 
Bishop et al., 2011). TCR activation induced RANKL expression in T cells 2 h after 
activation and lasted up till 96 h (Josien et al., 1999). 
 Calcium levels control a number of biological activities, such as gene 
expression, proliferation, differentiation and apoptosis. Two genes in particular that 
are upregulated by calcium levels in T cells are NFATc1 and NFATc3 (Lee et al., 
2011). NFAT are a family of transcription factors (NFAT1-5) that express highly 
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conserved Rel/NF-κB DNA-binding domains. When either NFATc1 or NFATc3 
were knocked down by siRNA in osteoblast cells, RANKL expression was ablated 
(Lee et al., 2011). There is no conclusive evidence that NFAT plays a role in 
transcriptional regulation of RANKL in mammalian lymphocytes (O’Brien, 2010). 
The transcriptional control of chRANKL and mammalian RANKL by Ca
2+
 
modulation and PKC activation is conserved between species, as indicated by the 
inhibition studies (Figure 4.6B). 
Since DC were first generated from chicken bone marrow cells, various 
markers and cytokines have be shown to be upregulated in mature BMDC, such as 
CCR7, TLRs and cell surface activation markers, after LPS, CpG or bacterial 
exposure (Wu et al., 2010; Wu et al., 2011; Lang et al., 2013; Rajput et al., 2014; Fu 
et al., 2014). CD40, a fellow TNF superfamily member with similar characteristics to 
RANK, is expressed on the surface of mature chicken BMDC (Wu et al., 2010) and 
mammalian RANK surface expression is predominantly found on mature DC in 
mammals (Anderson et al., 1997; Wong et al., 1997; Josien et al., 1999). To 
investigate the expression patterns of the chRANKL receptors on chicken BMDC, 
cells were unstimulated or stimulated with various amounts of LPS and the levels of 
chRANK and chOPG mRNA expressions analysed by qRT-PCR (Figure 4.5). The 
data suggest that the mRNA expression levels of chRANK and chOPG in BMDC are 
both dose- and time-dependent. The more the cells matured, the lower the levels of 
chRANK expression and the higher the levels of chOPG expression observed. Also 
the dose of LPS used to stimulate BMDC affected the mRNA expression levels of 
chRANK and chOPG; lower concentrations led to lower mRNA expression levels of 
each receptor (Figure 4.5). Mammalian OPG expression is dependent on NF-κB 
pathway activation and increases as DC mature (Schoppet et al., 2007). It is therefore 
possible that mature chicken BMDC increase levels of chOPG expression to regulate 
the magnitude of chRANKL
+
 T cells interacting with chRANK
+
 DC.  
 The ability of schRANKL to induce or enhance pro-inflammatory cytokine 
expression in immature or mature chicken APC was analysed by qRT-PCR. The 
exposure of chicken BMDC to LPS or chCD40L increased pro-inflammatory 
cytokine mRNA expression levels compared to those in unstimulated BMDC (Wu et 
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al., 2010). To examine whether schRANKL contributed to changes in pro-
inflammatory cytokine levels, cells were either unstimulated or stimulated with LPS 
or chCD40L, schRANKL or both for 3, 6 or 24 h. Costimulation of cells with 
schRANKL and LPS led to a significant increase in pro-inflammatory cytokine 
mRNA expression levels compared to those in unstimulated cells, and in some cases, 
LPS-stimulated cells (Figure 4.7). The ability of schRANKL to drive IL-12α mRNA 
expression in costimulated cells could suggest that chRANKL enhances the 
differentiation of Th0 cells to the Th1 phenotype. SchRANKL-treatment alone did 
not alter the levels of IL-12α expression but did increase expression of IL-1β after 6 
h of stimulation and IL-6 after 3 h of stimulation. Because schRANKL did not 
induce a large increase in pro-inflammatory cytokine mRNA expression levels in 
BMDC, anti-inflammatory cytokine mRNA expression levels were examined. Levels 
of IL-10 mRNA expression were low in schRANKL-treated cells (Figure 4.8), 
similar to the effects of mammalian RANKL (Izawa et al., 2007), and it was 
therefore not likely to explain the inability of schRANKL alone to induce pro-
inflammatory cytokine mRNA expression in BMDC. The mRNA expression levels 
of the receptors of chRANKL, chRANK and chOPG, were analysed to identify if 
their mRNA expression levels correlated with the lack of pro-inflammatory cytokine 
mRNA expression in schRANKL-treated cells. Interestingly, levels of chOPG 
expression were increased in schRANKL-treated cells at 3 h and decreased at 6 h 
(Figure 4.8), whereas levels of chRANK mRNA expression were very low in 
schRANKL-treated cells at both 3 and 6 h (Figure 4.8). Various studies have shown 
that in mammals DC surface expression levels of RANK were not altered by 
RANKL treatment (Wong et al., 1999; Chino et al., 2001; Williamson et al., 2002). 
It is possible that immature BMDC express higher levels of chOPG to ensure DC do 
not mature under non-pathological conditions which could led to autoimmune 
disorders, as shown in  OPG
-/- 
mice which produce greater levels of IL-23, a cytokine 
associated with the induction of experimental autoimmune encephalomyelitis (EAE) 
due to activation of pro-inflammatory macrophages (Cua et al., 2003). 
To verify that schRANKL was a key mediator of enhanced pro-inflammatory 
cytokine expression in mature BMDC, soluble fusion proteins of chRANK-Fc or 
chOPG-Fc were pre-incubated with schRANKL prior to costimulating cells. Pre-
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incubation with both chRANK-Fc and chOPG-Fc downregulated the schRANKL-
mediated increase in pro-inflammatory cytokine mRNA expression levels (Figure 
4.8). This also indicated that the soluble receptors of chRANKL were capable of 
interacting with their ligand. In mammalian studies, the bioactivity of RANKL is 
commonly verified by the ability of the soluble forms of either RANK or OPG to 
block its activity (Anderson et al., 1997; Wong et al, 1999; Yun et al., 2001).  
In mammals, RANKL increases the levels of pro-inflammatory cytokine  
mRNA expression in mature BMDC, such as IL-1β, IL-6, IL-12 (p70), IL-15 and 
TNF-α (Josien et al., 1999), whereas RANKL-treated Mo-DC did not alter the 
mRNA expression levels of IL-3, IL-4, IL-6, IL-10, or IL-13 but did increase levels 
of IL-12β (Schiano de Colella et al., 2008). In a similar study, RANKL-treated 
BMDC did not alter the mRNA expression levels of IFN-γ, IL-10 or IL-12β. 
However, Fas
-/-
 BMDC significantly increased levels of IFN-γ and IL-12β mRNA 
expression when treated with RANKL, indicating the regulatory role of the death 
receptor on fellow TNF members (Izawa et al., 2007). Mucosal-derived DC purified 
from spleen, Peyer’s patches, mesenteric and peripheral lymph nodes of Flt-3L-
injected mice all expressed surface RANK. However, the DC from these various 
anatomical sites reacted differently when incubated with RANKL for 18 h. Spleen-
derived DC expressed the highest amounts of IL-12β and the lowest amounts of IL-
10, whereas DC derived from Peyer’s patches expressed the highest levels of IL-10. 
Levels of IL-18 mRNA expression were consistent across all mucosal-derived DC 
after RANKL treatment (Williamson et al., 2002). It is important to note that DC 
may express RANK but react differently in their response to RANKL depending on 
their tissue of origin.  
The synergistic effects of stimulation with two chicken TNF superfamily 
members, chCD40L and schRANKL, on the levels of pro-inflammatory cytokine 
mRNA expression by BMDC were investigated (Figure 4.10). BMDC costimulated 
with chCD40L and schRANKL had consistent levels of IL-1β mRNA expression at 
3, 6 or 24 h and no significant difference was identified between unstimulated or 
chCD40L-stimulated cells. Levels of IL-6 mRNA expression were not statistically 
enhanced in costimulated cells. Similarly, levels of chRANK mRNA expression 
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were not significantly altered in either chCD40L- or co-stimulated cells. In 
mammals, the cooperation of CD40L and RANKL has been examined in survival 
assays and DC maturation (Josien et al., 1999; Yu et al., 2003). Treatment of Mo-DC 
with RANKL caused no change in the phenotype of cells but cells costimulated with 
CD40L and RANKL upregulated MHC class II and CD80 surface expression, which 
was further enhanced by the addition of TNF-α (Yu et al., 2003). Various studies 
identifying the biological effect of mammalian RANKL in DC have produced 
contrasting evidence as to its effect on their phenotype. One of the first studies 
examining the biological role of mammalian RANKL proposed that RANKL-treated 
murine BMDC did not significantly increase the levels of MHC class II, CD80 or 
CD86 but did slightly (not significantly) upregulate the expression of CD40 after 48 
h of stimulation (Anderson et al., 1997). Surprisingly, this paper did not present the 
FACs data, making it difficult to assess their conclusions. A similar study followed 
(Wong et al., 1997) in which RANKL-treated BMDC in vitro slightly down-
regulated MHC class II, had no change in CD80 or CD86, CD11b or CD11c but 
increased CD40 expression, with similar data at 24 and 48 h of RANKL treatment. 
Mo-DC, cultured with IL-4 and CSF-2, treated with RANKL increased surface 
expression of MHC class II, CD80 and CD86 (Seshasayee et al., 2004), suggesting 
that DC derived from various sources react differently to RANKL exposure, as 
previously identified in mucosal-derived DC (Williamson et al., 2002). However, all 
three of the previous studies induced DC maturation prior to RANKL treatment by 
culturing cells for up to 7-8 days. Maturing BMDC by prolonged culturing only led 
50% of the cell population to mature and express surface RANK (Wong et al., 1999). 
Also, RANKL-treated BMDC do not increase the surface expression of RANK 
(Wong et al., 1998). This may explain the different results seen for RANKL-
mediated changes to DC phenotype in mammalian studies. Mo-DC, cultured with IL-
4 and CSF-2, were stimulated with LTK murine cells previously transfected with 
full-length murine RANKL, or CD40L as a positive control. These cells were mixed 
with Mo-DC for 72 h and flow cytometric analysis indicated that RANKL-treated 
DC upregulated CD83, CD86, MHC class II and CD40 but not CD80 (Schiano de 
Colella et al., 2008).  
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For chicken BMDC, schRANKL treatment did not affect the expression 
levels of MHC class II either alone or in combination with LPS (Figure 4.11). CD40 
expression levels were increased in LPS-stimulated cells but its expression levels 
were not enhanced by the addition of schRANKL. The expression pattern of KUL01 
was also analysed; although it is not an activation marker like CD40 and MHC class 
II, KUL01 expression decreases as chicken APC mature (Wu et al., 2010). This was 
therefore a good marker to identify the ability of schRANKL to induce cell 
maturation. As expected, at 24 h LPS-treated cells had decreased KUL01 expression 
but were unaltered by schRANKL treatment. Overall schRANKL does not mediate 
the upregulation of cell surface activation markers in chicken BMDC, similarly to 
mammalian RANKL (Anderson et al., 1997; Wong et al., 1997).  
BMDM cell phenotypes were analysed, similarly to BMDC, for 24 h (Figure 
4.12). There were no changes in MHC class II or KUL01 expression in the presence 
of schRANKL alone or in co-stimulated cells. CD40 expression levels were 
increased in LPS-stimulated cells but not enhanced by the addition of schRANKL. A 
more potent activator of BMDM, IFN-γ, was also assessed for its ability to enhance 
surface expression of MHC class II, CD40 and KUL01, with schRANKL, after 24 h. 
IFN-γ-stimulated cells increased MHC class II expression but this was not enhanced 
in co-stimulated cells (Figure 4.13). Co-stimulated cells increased CD40 expression 
levels and decreased KUL01 expression levels but were not significantly different 
when compared to IFN-γ-stimulated cells. One study (Park et al., 2005) of the 
bioactivity of mammalian RANKL on macrophages suggested that RANKL-treated 
cells upregulated MHC class II expression which was enhanced when cells were co-
stimulated with LPS but not with IFN-γ. CD86 expression was also upregulated in 
cells costimulated with RANKL and LPS or IFN-γ (Park et al., 2005). There are 
contrasting data on the ability of mammalian RANKL to alter the expression of the 
costimulatory molecules, CD80 and CD86. These are two of the best-characterised 
mammalian costimulatory molecules and are strongly and rapidly upregulated on 





T cells. Ligation of CD28 facilitates the progression of the cell-cycle and production 
of IL-2 (Sharpe & Freeman, 2002). Currently, a mouse anti-chicken CD86 
monoclonal antibody is commercially available. However, this antibody is not very 
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efficient and studies using this antibody show little detection of surface chCD86 on 
BMDC (Wu et al., 2010; Liang et al., 2013), although chCD86 mRNA expression 
levels are increased in stimulated BMDC (Rajput et al., 2014).  
The lifespan of DC can influence the duration of lymphocyte activation, 
thereby affecting the outcome of immune responses. Limiting the lifespan of DC by 
inducing apoptosis is a means of regulating the interaction between antigen-bearing 
DC with T cells. Apoptosis is a physiological process of cell death that is required 
for tissue remodelling, development and homeostasis (Kerr et al., 1972). The 
survival of DC is affected by mediators of innate and adaptive immune responses, 
such as PAMPs interacting with their TLR ligands and co-stimulatory molecules 
expressed by T cells, such as CD40L (Hou & Parijs, 2004). Using trypan blue 
staining, Anderson et al. (1997) and Wong et al. (1997) concluded that cultures of 
murine DC treated with RANKL had more viable cells after 24 h of treatment. Park 
et al. (2005) analysed cell death and apoptosis by double-staining BMDM for 
annexin-V and PI after 24 h of RANKL treatment and found that treatment 
significantly increased the survival rates of cells but did not work in synergy with 
either LPS or IFN-γ. To determine the ability of schRANKL to enhance the survival 
rates of BMDC and BMDM, cells were untreated or treated with 1:5 or 1:10 (ex-
COS) of schRANKL for 24 and 48 h (Figures 4.14 and 4.15). BMDC survival rates 
were increased in schRANKL-treated cells compared to untreated cells after 24 h and 
48 h (Figure 4.14). After 24 h, the number of viable cells was increased in 
schRANKL-treated BMDM compared to untreated cells. However, after 48 h 
schRANKL-treated cells had fewer viable cells compared to untreated cells. It seems 
that the ability of schRANKL to enhance the survival of BMDM is short-lived. 
Although overall the data were not significant for either BMDC or BMDM (n=3), 
cells did undergo less apoptosis after 24 h of schRANKL treatment. The analysis did 
not identify the anti-apoptotic gene(s) linked to this enhanced survival, although 
various mammalian studies have shown that the upregulation of the Bcl-2 family 
members, Bcl-XL and Bcl-2, is linked to RANKL-mediated cell survival (Wong et 
al., 1998; Josien et al., 1999; Cremer et al, 2002; Hou & Parijs, 2004; Izawa et al., 
2007). Bcl-2 and Bcl-XL function to antagonise pro-apoptotic proteins such as BIM 
and BAX, regulate mitochondrial conductance and inhibit cell cycle progression. 
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Transgenic overexpression of Bcl-2 can prolong the survival of DC and is required 
for CD40L-mediated survival in murine BMDC (Hou & Parijs, 2004). Genetic and 
molecular analysis from nematodes to humans indicates that programmed cell death 
is highly conserved (Ellis et al., 1991), so it is therefore plausible that chRANKL 
may upregulate the levels of anti-apoptotic chicken Bcl-2 family members in BMDC 
and BMDM.  
 The overall data suggest that schRANKL alone induces partial maturation of 
BMDC, by inducing low levels of pro-inflammatory cytokine mRNA expression and 
down-regulating KUL01. DC reside in the peripheral tissues in an immature state for 
optimal uptake and response to inflammatory signals (Banchereau & Steinman, 
1998). The maintenance of DC, including apoptosis, cell growth and activation in the 
periphery, is in some ways regulated by RANKL and FAS (Izawa et al., 2007). 
Chicken BMDC significantly phagocytosed more zymosan-A particles in the 
presence of schRANKL (Figure 4.16), although there was no change in MHC class II 
expression in schRANKL-stimulated BMDC. However, these cell cultures are 
heterogeneous and large cells can be seen in these cultures after 24 h of schRANKL-
treatment (Figure 4.17). Osteoclast cells have APC properties, inducing expression of 
pro-inflammatory cytokines and cell surface markers and increasing phagocytosis (Li 
et al., 2010). BMDM commit to the osteoclast lineage after 24 h of RANKL 
treatment and still have phagocytic potential (Mochizuki et al., 2006). This may be 
the cause for the increased uptake of zymosan particles by schRANKL-treated 
chicken BMDC. 
In a pilot study to investigate the ability of schRANKL protein to drive 
osteoclast differentiation, bone marrow cells were treated with chCSF-1 for 2 days to 
enrich for the monocyte/macrophage cell population (as described in mice by 
Takeshita et al., 2000) and reseeded to ensure cells were in close proximity to fuse 
and generate multinucleated cells, in the presence of schRANKL for 8 days. The 
progenitor cells of osteoclasts are chemotactically attracted to sites of bone 
resorption, where they deposit in the mesenchyme surrounding the bone and 
proliferate and differentiate into mature osteoclasts by interacting with RANKL-
expressing osteoblasts. Mature osteoclasts are very large cells containing multiple 
171 
 
nuclei, have abundant mitochondria, lysosomes and free ribosomes (Li et al., 2006) 
and have unique characteristics, such as expressing titrate-resistant acid phosphatase 
(TRAP), matrix metalloproteinases (MMP) and calcitonin and vitronectin  receptors 
(Miyamoto & Suda, 2003). In preliminary studies, the presence of multinucleated 
cells was identified in chicken cell cultures using the nuclear stain Hoechst-33258. 
After 8 days of culture, schRANKL-treated cells had a variable morphology, from 
small to large cells. The large cells had a typical osteoclast morphology, large in size, 
flat and multinucleated. This study was not aimed to further characterise these cells 
but was carried out to identify an in vitro protocol for osteoclast differentiation using 
chCSF-1 and schRANKL and may be used in the future to understand osteoclast 
function in the chicken.  
In summary, chRANKL, chRANK and chOPG mRNA expression levels have 
been analysed in different tissues and cells in the chicken. Of the triad of molecules, 
the ligand, chRANKL, is expressed at higher levels across a wider range of organs 
and cells in the chicken than its receptors, chRANK and chOPG. Both of the 
receptors for chRANKL are differentially expressed in mature BMDC. The 
bioactivity of chRANKL has been analysed in both BMDC and BMDM and has 
















Cloning and molecular characterisation of chicken TRAF2 






5.1  Introduction   
The TNFR superfamily members signal using adaptor proteins that bind 
directly to their cytoplasmic domains. TRAF1 and TRAF2 were first identified as 
signal transducers of TNFR2 (Rothe et al., 1994). Four additional members of the 
TRAF family, TRAF3, TRAF4, TRAF5 and TRAF6, were identified in both mouse 
and human using yeast two-hybrid systems (Rothe et al., 1994; Hu et al., 1994; 
Regnier et al., 1995; Nakano et al., 1996; Cao et al., 1996). A seventh potential 
member of the mammalian TRAF family was identified, TRAF7: potential as it does 
not contain a TRAF-C domain, but instead has seven WD40 repeat domains (Xu et 
al., 2004).  In vitro binding experiments revealed that TRAFs not only bind to and 
signal for TNFR superfamily members but also for Toll/IL-1R superfamily members 
via MyD88 or TRIF (Cao et al., 1996; Naito et al., 1999), NLR family members via 
RIP2 and RLR family members via MAVS (Paz et al., 2011; Marinis et al., 2011). 
The hallmark feature of TRAF family members is their highly conserved COOH-
terminal TRAF domain of approximately 230 amino acids. The COOH-terminal 
domain can be subdivided into more divergent NH2-proximal (TRAF-N) and highly 
conserved COOH-proximal (TRAF-C) subdomains. TRAF-N possesses a coiled-coil 
domain responsible for homo- and hetero-oligomerisation of TRAF proteins as well 
as for indirect and direct interactions with cognate surface receptors (Park et al., 
1999). TRAF proteins also possess an NH2-terminal RING finger domain (TRAF2-
TRAF7) which is highly conserved at the amino acid level. The RING finger domain 
is followed by several zinc finger motifs. These two domains are vital for activation 
of downstream signalling pathways, such as MAPK and NF-κB (Baud et al., 1999).  
As described in Chapter 3, chRANK contains only four of the five TRAF peptide-
binding motifs identified in mammalian RANK (Darnay et al., 1998; Wong et al., 
1998). Importantly the “missing” TRAF peptide-binding motif was one of the three 
TRAF6-specific binding motifs. TRAF6 is vital for RANKL-mediated differentiation 
and activation of osteoclasts (Lomaga et al., 1999; Naito et al., 1999). Here, the 
chRANK-specific signalling TRAFs, TRAF2, TRAF5, and TRAF6, were cloned and 
characterised, as well as the chicken orthologue of the newest member of the 
mammalian TRAF family, TRAF7.   
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5.2  Methods 
5.2.1  In silico analysis 
To identify the various domains within chicken TRAF proteins, the SMART 
prediction program was used to compare each to the known human and mouse 
sequences. Amino acid conservation and phylogenetic analyses were carried out 
using CLUSTALX v2 and MEGA v5, respectively (Chapter 2, section 2.1). 
5.2.2  In vitro analysis  
ChTRAF2, chTRAF5, chTRAF6 and chTRAF7 were cloned, using RNA 
from ConA-stimulated splenocytes as template by RT-PCR. The mRNA expression 
patterns of all TRAFs were analysed in a number of lymphoid and non-lymphoid 
organs by RT-PCR. RNA (100 ng) from each tissue was reverse-transcribed using 
Superscript III and analysed for the expression of the housekeeping gene, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primers were designed to 
overlap intron-exon boundaries for the detection of mRNA for chTRAF2, chTRAF5, 
chTRAF6 and chTRAF7 (Chapter 2, section 2.8). Splenocyte subsets were purified 
and analysed for the mRNA expression of each TRAF and the kinetics of their 
mRNA expression levels were analysed in a time-course experiment comparing 
unstimulated and ConA-stimulated splenocytes. ChTRAF2 and chTRAF2S were 
sub-cloned into a modified pcDNA3-haemagglutinin (HA) vector to express NH2-
terminal-tagged HA-fusion proteins (Chapter 2, section 2.2). HEK-293T cells were 
transiently transfected with the chTRAF2 constructs and HA-tagged recombinant 
protein expression was analysed by dot blot (Chapter 2, section 2.4 & 2.5). Protein 
structures were analysed by SDS-PAGE under both reducing and non-reducing 
conditions. The bioactivity of the chTRAF2 isoforms were investigated using NF-κB 




5.3  Results   
5.3.1  Identification of the genes representing chTRAF2, chTRAF5, chTRAF6 and 
chTRAF7 in the chicken genome 
ChTRAF5 had been previously cloned (Adballa et al., 2004a). The Ensembl 
database (www.ensembl.org) was searched for chTRAF2, chTRAF6 and chTRAF7 
cDNA sequences. All were present as predicted cDNA (Accession Numbers are 
given in Appendix 2, Table 5). 
5.3.2  Amplification and molecular cloning of chTRAF5, chTRAF6 and chTRAF7 
Primers were designed against the predicted full-length cDNAs of chTRAF5, 
chTRAF6 and chTRAF7 using the sequences available in the Ensembl database. 
cDNA was amplified using RNA from ConA-stimulated splenocytes as template for 
RT-PCR. The resulting products were a 1.7 kb cDNA product, corresponding to 557 
amino acids for chTRAF5, a 1.6 kb cDNA product, corresponding to 545 amino 
acids for chTRAF6, and a 1.9 kb cDNA product, corresponding to 670 amino acids 
for chTRAF7 (Figure 5.1). Each band was excised and purified from the gel. All 
individual cDNA were ligated into the vector pGEM-T Easy. Sequences were 
verified for each for three individual clones and deposited into the Ensembl database 
(Accession Numbers: TRAF6, LM999953 and TRAF7, LM999954).  
 5.3.3  In silico analysis of chTRAF5, chTRAF6 and chTRAF7 
TRAF proteins are composed of several highly conserved domains, such as a 
RING domain, several zinc finger motifs, a coiled-coil region and a TRAF-C 
domain. To determine the location and presence of these domains in chTRAF5, 
chTRAF6 and chTRAF7, SMART was used to graphically identify these regions in 
the chicken and human proteins (Figure 5.2). ChTRAF5 contains all regions 
characteristic of TRAF family members and has a longer coiled-coil region 
compared to human TRAF5 (Figure 5.2). The SMART prediction for chTRAF6 was 
very similar to that for human TRAF6 (Figure 5.2), indicating that the protein 
structures are conserved between the two species. TRAF7 does not express a TRAF-




Figure 5.1 Gel electrophoresis of 1) chTRAF5, 2) chTRAF6 and 3) chTRAF7. 
RT-PCR products of chTRAF5, chTRAF6 and chTRAF7 amplified from RNA from 
ConA-stimulated splenocytes. L = 5 kb DNA ladder (Invitrogen).  
 
predicted in the chTRAF7 protein along with a RING domain and one zinc finger  
motif (Figure 5.2).The degree of conservation between mammalian and chicken 
TRAF5, TRAF6 and TRAF7 proteins was analysed by CLUSTAL X. The consensus 
sequence for TRAF RING finger motifs is the CX2
 
CX11 CX1 HX2 CX2 CX9 CX2C 
motif (X being any amino acid). The TRAF zinc finger motif typical patterns are 
CX2/3 CX11/12  HX3C or CX6 CX11 HX3C with the last zinc finger motif differing 
slightly (CX6 CX12 HX8). Sequence motifs for both the RING and zinc finger 
domains were identified in the mammalian and chicken TRAF proteins. ChTRAF5 
has high identity with its mammalian counterparts (68-70%) with a highly conserved 
RING domain and five zinc finger motifs (Figure 5.3). ChTRAF6 shows relatively 
high amino acid similarity with its mammalian orthologues (70-72%) (Figure 5.4). 
The presence and location of five zinc finger motifs and the RING domain were 
conserved. Interestingly, chTRAF6 is slightly larger than mouse and human TRAF6 
proteins. In the RING domain, chTRAF6 has three extra amino acids and an extra 23 
amino acids within the coiled-coil, TRAF-N, domain. 
ChTRAF7 is highly conserved across species (Figure 5.5), with 88% amino 
acid identity to human and mouse TRAF7 proteins. ChTRAF7 is slightly smaller 
than its mammalian orthologues, missing a small region before the first WD40 repeat 
domain. Overall, TRAF5, TRAF6 and TRAF7 are highly conserved across mammals 




Figure 5.2 SMART prediction models of human and chicken TRAF5, TRAF6 
and TRAF7 proteins. Red triangles indicate RING domains, black boxes zinc finger 
motif regions, green boxes coiled-coil regions (TRAF-N), blue triangles MATH 
(TRAF-C) domains and green triangles the seven WD40 repeat domains in TRAF7.  
 
5.3.4  RT-PCR analysis of chTRAF5, chTRAF6 and chTRAF7 mRNA in chicken 
tissues  
The mRNA expression of chTRAF5, chTRAF6 and chTRAF7 was analysed 
by RT-PCR. RNA (100 ng per sample) from various lymphoid and non-lymphoid 
organs was reverse-transcribed using Superscript III and an oligo dT20 primer to 
generate cDNA. To amplify regions of chTRAF5, chTRAF6 and chTRAF7, primers 
were designed to overlap intron and exon boundaries to generate a small amplicon of 
each gene (Appendix 2, Table 3). ChTRAF5 mRNA expression was detected in all 
lymphoid tissues examined except in the thymus (Figure 5.6). In the lymphoid tissue 




Figure 5.3 Amino acid alignment of the human, mouse and chicken TRAF5. 
Shaded areas represent conservation of amino acids – the darker the shading, the 
more conserved the residue across species: black shading indicates conservation 
between all species, dark grey with white lettering indicates conservation between 2 
species. Dots indicate gaps in the alignment. Black line above the sequence indicates 
the RING domain, asterisks conserved cysteine residues and open triangles 
conserved histidine residues characteristic of TRAF zinc finger motifs. Grey boxes 
above the sequence indicate the conserved zinc finger motif regions, the dashed line 
TRAF-N domains and the blue line the TRAF-C domains. 
 
tonsils, Meckel’s diverticulum, caeca and upper-gut (Figure 5.6). ChTRAF6 mRNA 
expression was also not detected in the thymus but its expression was detected in all 




Figure 5.4 Amino acid alignment of the human, mouse and predicted chicken 
TRAF6. Shaded areas represent conservation of amino acids – the darker the 
shading, the more conserved the residue across species: black shading indicates 
conservation between all species, dark grey with white lettering indicates 
conservation between 2 species. Dots indicate gaps in the alignment. Black line 
above the sequence indicates the RING domain, asterisks indicate conserved cysteine 
residues and open triangles conserved histidine residues characteristic of TRAF zinc 
finger motifs. Grey boxes above the sequence indicate the conserved zinc finger motif 
region, the dashed line TRAF-N domains and the blue line the TRAF-C domains. 
 
expression levels were in the spleen, bursa of Fabricius, Meckel’s diverticulum, 
caeca and mid-gut. ChTRAF7 mRNA expression was ubiquitous across the 




Figure 5.5 Amino acid alignment of the human, mouse and predicted chicken 
TRAF7. Shaded areas represent conservation of amino acid – the darker the 
shading, the more conserved the residue across species: black shading indicates 
conservation between all species, dark grey with white lettering indicates 
conservation between 2 species. Dots indicate gaps in the alignment. Black line 
above the sequence indicates the RING domain, asterisks indicate conserved cysteine 
residues and open triangles conserved histidine residues characteristic of TRAF zinc 
finger motif regions. Grey boxes above the sequence indicate the conserved zinc 




Figure 5.6 RT-PCR analysis of chTRAF5, chTRAF6 and chTRAF7 mRNA 
expression in lymphoid tissues. ChTRAF5, chTRAF6 and chTRAF7 mRNA 
expression was measured by RT-PCR in lymphoid tissues: 1) thymus, 2) spleen, 3) 
bursa of Fabricius, 4) caecal tonsils, 5) bone marrow, 6) Meckel’s diverticulum, 7) 
Harderian gland, 8) caeca, 9) mid-gut, 10) upper-gut, 11) crop, 12) gizzard. L = 1 
kb DNA ladder (Invitrogen). Data represent results from one of three individual 
birds with similar results. 
 
levels were lower (Figure 5.6). 
 In non-lymphoid tissues, chTRAF5 mRNA expression was detected in all 
tissues except the muscle and the skin (Figure 5.7). ChTRAF5 mRNA expression 
was highest in the lung, consistent in the brain, heart, liver and kidney, and lowest in 
the heart (Figure 5.7). ChTRAF6 mRNA expression was detected in all non-
lymphoid tissues examined (Figure 5.7), albeit only faintly in the brain. ChTRAF7 
was ubiquitously expressed in non-lymphoid tissues (Figure 5.7). 
5.3.5  RT-PCR analysis of chTRAF5, chTRAF6 and chTRAF7 mRNA in chicken cells 
 The mRNA expression of chTRAF5, chTRAF6 and chTRAF7 was examined 




Figure 5.7 RT-PCR analysis of chTRAF5, chTRAF6 and chTRAF7 mRNA 
expression in non-lymphoid tissues. ChTRAF5, chTRAF6 and chTRAF7 mRNA 
expression was measured by RT-PCR in non-lymphoid tissues; 1) brain, 2) muscle, 
3) heart, 4) liver, 5) kidney, 6) lung, 7) skin. L = 1 kb DNA ladder (Invitrogen). Data 
represent results from one of three individual birds with similar results. 
 
TCRγδ, TCRαβ1, TCRαβ2, KUL01 and Bu1 mAb using an AutoMacs pro-separator 
and purity verified by FACs analysis (Appendix 4, Figure 2). ChTRAF5 mRNA 
expression was detected in all cell subsets except KUL01
+
 cells. KUL01 is a marker 
for phagocytic cells and will predominantly represent DC and macrophages in the 
spleen. ChTRAF5 mRNA expression was highest in TCRγδ
+
 cells.  
ChTRAF6 mRNA expression was detected in all cells analysed. ChTRAF6 











 cells (Figure 5.8A). ChTRAF7 mRNA expression 
levels were similar in all cell subsets examined (Figure 5.8A) Next, the mRNA 
expression of chTRAF5, chTRAF6 and chTRAF7 was analysed in unstimulated or 
LPS-stimulated BMDC and BMDM, again by RT-PCR (Figure 5.8B). In BMDC, 
chTRAF5 mRNA expression levels were not altered between unstimulated and LPS-
stimulated cells.  In contrast, chTRAF5 mRNA expression levels were increased in 




Figure 5.8 RT-PCR analysis of chTRAF5, chTRAF6 and chTRAF7 mRNA 
expression in chicken immune cells. ChTRAF5, chTRAF6 and chTRAF7 mRNA 















 and B) BMDC 
and BMDM unstimulated or stimulated with LPS (200 ng/ml) for 24 h.  L = 1 kb 
DNA ladder (Invitrogen). Data represent results from one of three individual birds 





mRNA expression levels of chTRAF6 and chTRAF7 were not altered between 
unstimulated or LPS-stimulated BMDC or BMDM (Figure 5.8B). 
5.3.6  Kinetics of chTRAF5, chTRAF6 and chTRAF7 in stimulated splenocytes  
The kinetics of mRNA expression of chTRAF5, chTRAF6 and chTRAF7 
were analysed in splenocytes either unstimulated or stimulated with ConA (1 μg/ml) 
over a time-course of 2, 4, 6, 12, 18 and 24 h (Figure 5.9). ChTRAF5 mRNA 
expression was not altered in ConA-stimulated cells compared to unstimulated cells 
from 2 to 12 h. (Figure 5.9) At 18 and 24 h, chTRAF5 mRNA expression was low in 
unstimulated cells and was increased in Con-A stimulated cells. ChTRAF6 mRNA 
expression levels were similar between unstimulated and stimulated cells at 2 and 4 h 
(Figure 5.9). At 6 h, chTRAF6 mRNA expression was barely detectable in 
unstimulated cells but detectable in ConA-stimulated cells. At 12, 18 and 24 h, 
chTRAF6 mRNA expression was detected in unstimulated and was increased in 
ConA-stimulated cells (Figure 5.9). ChTRAF7 mRNA expression was detected in 
both unstimulated and stimulated cells at similar levels (Figure 5.9). 
 
5.4  Identification of a novel chTRAF2 isoform 
5.4.1  Amplification and molecular cloning of chTRAF2 and identification of a 
novel chTRAF2 isoform, chTRAF2S  
 Primers were designed to clone the full-length cDNA of chTRAF2 from the 
5' ATG start codon to the 3' stop codon using the sequence extracted from the 
Ensembl database (Appendix 2, Table 5). RNA from ConA-stimulated splenocytes 
was used as template for RT-PCR. Gel electrophoresis of the PCR product revealed 
two distinct bands, an expected band at ~1.5 kb and a smaller band at ~1.4 kb (Figure 
5.10). Both bands were gel purified and TA-cloned into pGEM-T Easy. Three 
independent clones of each cDNA were sequenced using the T7 forward and Sp6 
reverse primers (Appendix 2, Table 1). Analyses of the cloned sequences of the large 
band indicated that the 1584 bp band was a 100% match to the predicted full-length 




Figure 5.9 RT-PCR analysis of chTRAF5, chTRAF6 and chTRAF7 mRNA 
expression in unstimulated and ConA-stimulated splenocytes for 2, 4, 6, 12, 18 
or 24 h. ChTRAF5, chTRAF6 and chTRAF7 mRNA expression was measured by RT-
PCR in splenocytes unstimulated (U) or stimulated (S) with ConA (1 µg/ml) for 2, 4, 
6, 12, 18 or 24 h. L = 1 kb DNA ladder (Invitrogen). Data represent results from one 
of three individual birds with similar results. 
 
smaller band revealed the existence of a smaller chTRAF2 isoform 1422 bp in 
length, 162 bp smaller than the full-length cDNA of chTRAF2. 
5.4.2  Analysis of conserved synteny of mammalian and avian TRAF2 genes 
 To date, very little information on the existence, conservation and bioactivity 
of avian TRAFs is available. Using the Ensembl database, the TRAF2 genes were 
identified in human, mouse and chicken (Figure 5.11). Genes that lie upstream and 
downstream of TRAF2 were conserved in synteny between the chicken and 
mammals (Figure 5.11). There was no evidence of gene duplication events 
suggesting that the smaller chTRAF2 isoform was generated by alternative splicing.  
5.4.3  Identification of alternative splicing of chTRAF2 




Figure 5.10 Gel electrophoresis of chTRAF2. ChTRAF2 cDNA products from 
ConA-stimulated splenocytes. L = 5 kb DNA ladder (Invitrogen). 
 
different enzymatic activity, substrate specificity, subcellular localisation and altered 
abilities to interact with other proteins (Möröy & Heyd, 2007). To identify the type 
of splicing event that occurred for the generation of the smaller chTRAF2 isoform, 
the locations of each exon were identified. Using the SMART prediction model and 
the Ensembl database, the locations of the ten exons encoding chTRAF2 were 
identified in the cDNA sequence (Figure 5.12). The smaller chTRAF2 isoform lacks 
exon 4 (Figure 5.12). This suggests that the smaller chTRAF2 isoform is generated 
due to exon cassette splicing, characterised by an entire exon being skipped in the 
middle of the mRNA precursor, generating alternative isoforms of the same protein. 
SMART was used to identify if a protein domain would be in the region missing in 
the smaller TRAF2 isoform (Figure 5.13). Analysis of the two chTRAF2 proteins 
indicate that exon four translates into a portion of the zinc finger domain, and the 
smaller chTRAF2 isoform is therefore missing some zinc finger motifs. There is an 
alternative isoform of mouse TRAF2, TRAF2A, which has an additional seven 
amino acids in the RING domain. The chicken alternative isoform is obviously 




Figure 5.11 Conserved synteny of mammalian and chicken TRAF2 genes. The 
location of genes upstream and downstream of mammalian and chicken TRAF2 were 
analysed using the Ensembl database. 
 
5.4.4  In silico analysis of chTRAF2 and chTRAF2S 
 To determine the amino acid conservation of chTRAF2 with its mammalian 
orthologues, sequence data for human TRAF2 (ENSP00000247668.2) and both of 
the mouse TRAF2 isoforms, TRAF2 (ENSMUSP00000028311) and TRAF2A 
(ENSMUSP00000109872), were extracted from the Ensembl database. TRAF family 
members are intracellular proteins and therefore do not possess a signal peptide 
cleavage site or a transmembrane domain. The amino acid sequences of the two 
chTRAF2 isoforms were predicted. The smaller chTRAF2 isoform translates into a 
protein with a stop codon in the same position as chTRAF2 (Figure 5.14). The two 
isoforms encode predicted proteins of 527 and 473 amino acids, respectively. When 
aligned with the mammalian TRAF2 sequences, chTRAF2 shares high amino acid 
identity (~66-69%) (Figure 5.14). Using the SMART prediction model, the locations 
of the various domains were identified within mammalian and chicken TRAF2 
proteins (Figure 5.14). Mammalian TRAF2 contains an NH2-terminal RING domain, 
five zinc finger motifs, a coiled-coil, TRAF-N, domain and a TRAF-C domain. 
ChTRAF2 also has these regions with high degrees of conservation. In contrast, 




Figure 5.12 Nucleotide alignment of the chTRAF2 isoforms. Using the SMART 
program and the Ensembl database, the ten chTRAF2 exons were annotated in the 
chicken cDNA sequence, labelled exons 1-10. Vertical lines indicate exon boundaries 
 
finger motif and a portion of the third zinc finger motif but has an intact RING 
domain, zinc finger motifs 4 and 5 and both of the TRAF-N and TRAF-C domains. 
The splicing of exon four from chTRAF2S would lead to the formation of a protein 




Figure 5.13 Genomic structure of the chTRAF2 isoforms. Red triangles indicate 
the RING domains, black boxes the zinc finger motifs, green boxes the coiled-coil 
regions (TRAF-N) and blue triangles the MATH (TRAF-C) domain. In the gene 
model (centre) the grey boxes represent the ten exons and the numbers indicate the 
size (bp) of the exons and introns. 
 
terminal portion of zinc finger motif three (Figure 5.14). These two portions linked 
together may form a hybrid functional zinc finger. 
5.4.5  Construction of pcDNA3-HA containing chTRAF2 or chTRAF2S  
The two chTRAF2 isoforms were sub-cloned into a modified pcDNA3 vector 
containing a HA epitope (pcDNA3-HA) upstream of the cloning site (Poh et al., 
2008). Primers were designed to integrate an EcoR1 restriction site at the 5' end and 
an XbaI restriction site at the 3' end, downstream of the stop codon. The ATG start 
codon was removed from the chTRAF2 forward primer to generate NH2-terminal 
tagged proteins with an ATG start codon upstream of the HA tag. The sub-cloning 
primers (Appendix 2, Table 2) were used in PCR using a 1:1000 dilution of plasmid 





Figure 5.14 Amino acid alignment of mammalian and chicken TRAF2. Shaded 
areas represent conservation of amino acid – the darker the shading, the more 
conserved the residue across species; black shading indicates conservation between 
all species, dark grey with white lettering indicates conservation between 2 species. 
Dots indicate gaps in the alignment. The red box indicates the 7 additional amino 
acids in the murine TRAF2A isoform. Asterisks indicate the conserved cysteine 
residues and open triangles conserved histidine residues characteristic of zinc finger 
motifs. Grey boxes above the sequence indicate the five conserved zinc finger motif 




PCR products were gel electrophoresed and the resulting bands were gel purified. 
Both cDNAs were subjected to double restriction digestion using EcoR1 and XbaI 
restriction enzymes. The restriction product was visualised on an agarose gel and 
bands were excised and purified. The resulting products were ligated into linearized 
pcDNA3-HA and transformed into E. coli JM109 cells. Three independent colonies 
were sequenced and verified for chTRAF2 and chTRAF2S directional sub-cloning 
into pcDNA3-HA (Appendix 3, Figure 1). 
 
5.3.6  Protein expression and analysis of chTRAF2 and chTRAF2S 
To analyse the bioactivity of chTRAF2 and chTRAF2S, both cDNAs were 
sub-cloned separately into the modified pcDNA3-HA vector to examine protein 
expression. To generate recombinant proteins, each plasmid was transfected into 
HEK-293T cells using the calcium phosphate approach. Cells were transiently 
transfected and cell supernatants and lysates were collected after 48 h. The cell 
supernatants and lysates were examined for protein expression using mouse anti-HA 
mAb by western blot analysis. However, the expression of HA-tagged fusion 
proteins could not be detected. The samples were then analysed by dot blot, which 
allows concentration of the sample protein onto a small area of nitrocellulose 
membrane, and the HA-tagged recombinant proteins were then detected (Figure 
5.15A). There was little or no detection of HA-tagged recombinant proteins in the 
cell supernatants, but expression was detected in the cell lysates of cells transfected 
with both isoforms, indicating that each protein is expressed intracellularly.   
 Cell lysates from transfected HEK-293T cells were analysed by SDS-PAGE 
followed by Coomassee blue staining under both reducing and non-reducing 
conditions (Figure 5.15B). The predicted molecular weight of the HA-chTRAF2 
recombinant protein was 60.32 kDa and that of the HA-chTRAF2S recombinant 
protein was 54 kDa. Both bands were evident under both reducing and non-reducing 
conditions. No predominant larger proteins were identified on the gel indicating that 




Figure 5.15 Protein expression analyses of HA-chTRAF2 and HA-chTRAF2S.  
A) Dot blot analyses of cell supernatants and lysates from HEK-293T cells 
transiently transfected with pcDNA-HA-chTRAF2 and pcDNA-HA-chTRAF2S 
constructs. Protein expression was detected using mouse anti-HA mAb and goat anti-
mouse HRP-conjugated mAb. B) SDS-PAGE analyses of cell lysates from HEK-293T 
cells transiently transfected with pcDNA-HA-chTRAF2 (lanes 2 and 4) and pcDNA-
HA-chTRAF2S (lanes 1 and 3) under reducing (R) and non-reducing conditions 
(NR). M = Precision plus protein standard (BioRad).  
 
5.4.7  RT-PCR analysis of chTRAF2 and chTRAF2S mRNA expression in lymphoid 
and non-lymphoid tissues 
 The majority of eukaryotic genes are estimated to express several 
alternatively spliced forms that contribute to the complexity of the proteome. Protein 





pattern. RT-PCR analysis was carried out to examine the mRNA expression of 
chTRAF2 and chTRAF2S in lymphoid and non-lymphoid tissues. RNA samples 
(100 ng) were reverse-transcribed using an oligo-dT primer and then amplified by 
RT-PCR. A set of primers was designed for the amplification of both of the 
chTRAF2 isoforms (Appendix 2, Table 3). These primers overlapped exon 3 and 
exon 5 to amplify two bands, a large band at 350 bp representing chTRAF2 and a 
small band at 190 bp representing chTRAF2S.  
In all the lymphoid tissues examined, both chTRAF2 and chTRAF2S mRNA 
expression were detected (Figure 5.16). ChTRAF2 mRNA expression levels was 
predominant compared to chTRAF2S mRNA expression in the lymphoid tissue 
panel (Figure 5.16). ChTRAF2S mRNA expression levels were low in the thymus, 
caecal tonsils, bone marrow, spleen, bursa of Fabricius and the crop and highest in 
Meckel’s diverticulum (Figure 5.16). These data suggest that chTRAF2S mRNA 
expression levels are not as ubiquitous as those of chTRAF2 in a number of chicken 
lymphoid tissues.  
In non-lymphoid tissues, chTRAF2 mRNA expression was not detected in the 
brain. ChTRAF2 and chTRAF2S mRNA expression was detected in the muscle, 
heart, liver, kidney, lung and skin (Figure 5.17). Interestingly, in the liver, kidney 
and lung, chTRAF2S mRNA expression was predominant compared to chTRAF2. In 
contrast, chTRAF2 mRNA expression levels were higher in the muscle and skin 
compared to those of chTRAF2S. These data suggest that chTRAF2 isoforms have 
differential expression in non-lymphoid tissues. 
5.4.8  RT-PCR analysis of chTRAF2 and chTRAF2S mRNA expression in chicken 
immune cells 
To examine whether there was a differences in expression of the two 
chTRAF2 isoforms in chicken splenocyte subsets, CD4, CD8β, TCRγδ, TCRαβ1, 
TCRαβ2, KUL01 and Bu1 cells were purified as previously described in section 
5.3.6. RNA from these cell subsets were reverse-transcribed and chTRAF2 and 









Figure 5.16 RT-PCR analysis of chTRAF2 and chTRAF2S mRNA expression in 
lymphoid tissues. Primers were designed to overlap exon three and five of chTRAF2 
to generate two cDNA products, a 350 bp product, representing chTRAF2, and a 190 
bp product, representing chTRAF2S. ChTRAF2 and chTRAF2S mRNA expression 
was measured by RT-PCR in lymphoid tissues: 1) thymus, 2) spleen, 3) bursa of 
Fabricius, 4) caecal tonsils, 5) bone marrow, 6) Meckel’s diverticulum, 7) Harderian 
gland, 8) caeca, 9) mid-gut, 10) upper-gut, 11) crop, 12) gizzard. L = 1 kb DNA 
ladder (Invitrogen). Data represent results from one of three individual birds with 
similar result. 
 




subsets. Both chTRAF2 









subsets (Figure 5.18A). ChTRAF2 and chTRAF2S mRNA expression was 
examined in BMDC and BMDM either unstimulated or stimulated with LPS for 24 
h, by RT-PCR (Figure 5.18B). In BMDC, there was no difference in the mRNA 
expression levels of either chTRAF2 isoform with or without stimulation. BMDM 
stimulated with LPS for 24 h had decreased chTRAF2 mRNA expression levels 
compared to those in unstimulated cells (Figure 5.18B), whereas chTRAF2S mRNA 




Figure 5.17 RT-PCR analysis of chTRAF2 and chTRAF2S mRNA expression in 
non-lymphoid tissues. ChTRAF2 and chTRAF2S mRNA expression was analysed by 
RT-PCR in non-lymphoid tissues: 1) brain, 2) muscle, 3) heart, 4) liver, 5) kidney, 6) 
lung, 7) skin. L = 1 kb DNA ladder (Invitrogen). Data represent results from one of 
three individual birds with similar results. 
  
5.4.9  Kinetics of chTRAF2 and chTRAF2S mRNA expression in stimulated 
splenocytes  
The kinetics of chTRAF2 and chTRAF2S mRNA expression in splenocytes 
unstimulated or stimulated with ConA for 2, 4, 6, 12, 18 or 24 h were examined by 
RT-PCR (Figure 5.19). ChTRAF2 mRNA expression levels were higher than 
chTRAF2S mRNA expression levels at all time-points examined (Figure 5.19). At all 
time-points, chTRAF2 mRNA expression levels were increased following 
stimulation. ChTRAF2S mRNA expression levels were increased in ConA-
stimulated cells at most time-points but not as strongly as chTRAF2 mRNA.  
5.4.10  Analysis of chTRAF2 and chTRAF2S bioactivity  
To investigate the bioactivity of both chTRAF2 isoforms, NF-κB reporter 
assays were carried out in HEK-293T cells. The overexpression of receptors or 
signalling molecules can lead to the activation of their downstream signalling 
pathways in mammalian cells. Certain mammalian TRAFs positively regulate the 
NF-κB pathway, leading to its release from its inhibitor, IκB, in the cytoplasm and 
allowing it to translocate into the nuclease to bind to NF-κB DNA-binding motifs. 
HEK-293T cells were seeded at 1.5 X 10
4




Figure 5.18 RT-PCR analysis of chTRAF2 and chTRAF2S mRNA expression in 
chicken immune cells. ChTRAF2 and chTRAF2S mRNA expression was analysed by 















and in B) BMDC and BMDM 
unstimulated or stimulated with LPS (200 ng/ml) for 24 h. L = 1 kb DNA ladder 
(Invitrogen). Data represent results from one of three individual birds with similar 
results. 
 
later with pGL4-NF-κB-Luc expressing the Firefly luciferase and the pcDNA3-HA 
constructs encoding chTRAF2 or/and chTRAF2S. To control for transfection 
efficiency and background signals, cells were cotransfected with a plasmid 
expressing Renilla luciferase. For each transfection, total DNA was adjusted to 200 
ng using empty pcDNA3. To determine whether chTRAF2 or chTRAF2S could 
activate NF-κB in a dose-dependent manner, cells were transfected with 75 ng or 150 






Figure 5.19 RT-PCR analysis of chTRAF2 and chTRAF2S mRNA expression in 
unstimulated and ConA-stimulated splenocytes for 2, 4, 6, 12, 18 or 24 h. 
ChTRAF2 and chTRAF2S mRNA expression was analysed by RT-PCR in splenocytes 
unstimulated (U) or stimulated (S) with ConA (1 µg/ml) for 2, 4, 6, 12, 18 or 24 h L 
= 1 kb DNA ladder (Invitrogen). Data represent results from one of three individual 
birds with similar results. 
 
or inhibit NF-κB activation, cells were cotransfected with both chTRAF2 constructs 
at a total concentration of 75 ng (37.5 ng each) or 150 ng (75 ng each). Firefly and 
Renilla luciferase activation was analysed using a GloxMAX luminometer 
(Promega).  
HEK-293T cells overexpressing either chTRAF2 or chTRAF2S significantly 
upregulated NF-κB activity in a dose-dependent manner compared to vector control 
cells (Figure 5.20). Cells transfected with empty pcDNA3 did not activate Firefly 
luciferase indicating that the vector did not contribute to the activation of NF-κB. 
ChTRAF2S activated NF-κB at higher levels that chTRAF2 but not to a statistically 
significant level. It is surprising that chTRAF2S can activate NF-κB as it does not 
express an intact primary zinc finger motif, lacks zinc finger motif two and a portion 
of the third zinc finger motif. Cotransfected cells significantly increased NF-κB 
activation in comparison to vector control cells at the two different DNA 
concentrations. However, NF-κB activation levels were not statistically significantly 




Figure 5.20 NF-κB reporter assays in HEK-293T cells. The biological activity of 
chTRAF2 and chTRAF2S were determined using NF-κB reporter assays. Cells were 
transfected with 75 ng (white bars) or 150 ng of chTRAF2 and/or chTRAF2S (grey 
bars). Firefly and Renilla luciferase were detected in cell lysates 24 h after 
transfection. Data are presented as relative luciferase activity by normalising the 
data with Renilla luciferase activity. Data represent the average of four independent 
experiments and asterisks represents data that is statistically significantly (p<0.05) 
different compared to levels in pcDNA-3 empty control cells ± SEM (Mann-Whitney 
U test).  
 
(Figure 5.20). This suggests that the full-length chTRAF2 and chTRAF2S do not 
work in synergy to enhance the activation of NF-κB. 
5.4.11  Phylogenetic analysis 
 In phylogenetic analysis, the TRAF family members are classified into five 
distinct clades (Figure 5.21). TRAF7 proteins cluster together, as do TRAF6 proteins 
and TRAF3 proteins. TRAF1 and TRAF2 proteins cluster separately but in the same 
clade, and TRAF4 and TRAF5 proteins also cluster separately but in a distinct clade. 






Figure 5.21 Phylogenetic tree showing the relationship between avian and 
mammalian TRAFs. Numbers on the branches represent the boot-strap values. 
Analyses were performed using MEGA v5.0. Ch, chicken; Hu, human; M, mouse; 
ZF, zebra finch; p, partial: A, B, S; isoforms. Accession numbers are given in 
Appendix 2, Table 5.  
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5.5  Discussion  
Intracellular signalling by TNFR and Toll/IL-1R superfamilies is carried out 
by a number of TRAF family members. With some members of both the TNFR and 
IL-1R superfamilies absent from the chicken genome (Kaiser et al., 2005), it is 
important to study the conservation of their downstream signalling proteins. Certain 
TRAF family members are important for development, as seen by the lethal 
phenotype in mice lacking TRAF2, TRAF3 and TRAF6 (Yeh et al., 1997; Lomaga et 
al., 1999). In the chicken, all members of the TRAF family (chTRAF1-chTRAF7) 
are present in the genome. The TRAF family of proteins are grouped together due to 
the presence of various domains such as a RING domain, zinc finger domains and 
the highly conserved TRAF-N and TRAF-C domains. The TRAF-N domain contains 
a coiled-coil region that mediates homo- or hetero-oligomerisation while the TRAF-
C domains are involved in receptor binding (Pullen et al., 1998). Despite sequence 
homology, each TRAF protein signals different outcomes which are non-redundant 
(Chung et al., 2002). To begin to understand the downstream signalling pathways 
activated by chRANK, the cloning and molecular characterisation of chTRAF2, 
chTRAF5, chTRAF6 and chTRAF7 were attempted.  
Mammalian TRAF5 shares similar functions to TRAF2 but is homologous to 
TRAF3 (Ishida et al., 1996; Aizawa et al., 1997). TRAF5
-/- 
mice show no 
developmental abnormalities and survive as healthy adults. These mice do exhibit 
defects in CD40- and CD27-mediated activation of B cells (Nakano et al., 1999) and 
GITR-mediated activation of NF-κB in T cells (Esparza et al., 2006). TRAF5 
overexpressed in the experimental rat model of inflammatory bowel disease was 
linked to the overexpression of the TNF-α receptors, TNFR1 and TNFR2, both of 
which bind to TRAF5 (Rojas-Cartagena et al., 2005). It also regulates the expression 
of adhesion molecules and pro-inflammatory cytokines during early atherogenesis by 
enhancing JNK activation. TRAF5
-/-
 BMDM can significantly uptake particulates 
more than wild-type cells by enhanced actin polymerisation (Missiou et al., 2010). 
Crystal structure analysis of mammalian TRAF5 indicates that it can form 
homotrimers with the typical mushroom-shaped structure that is characteristic of 
TRAF proteins (Zhang et al., 2012). Although TRAF5 is not required for lymphoid 
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organ or immune cell development, it is necessary for a number of biological 
activities in mammals. ChTRAF5 is highly conserved with its mammalian 
orthologues (Figure 5.3). 
ChTRAF5 was cloned by Abdalla et al. (2004a), who analysed the expression 
pattern of chTRAF5 in a number of chicken tissues and cell types. The work 
presented here includes a more comprehensive panel of lymphoid and non-lymphoid 
organs, purified splenocytes and kinetics of expression in unstimulated and ConA-
stimulated splenocytes. ChTRAF5 mRNA expression was detected in various organs 
of the chicken (Figure 5.6). ChTRAF5 mRNA expression was lowest in the thymus, 
as demonstrated by Abdalla et al. (2004a), bursa of Fabricius and the crop whereas 
the highest levels of mRNA expression were in the spleen, Meckel’s diverticulum, 
caeca and upper-gut. In mammals, TRAF5 mRNA expression is limited to a few 
organs, such as the thymus and spleen, and was not found in the small intestine 
(Ishida et al., 1996).  
In non-lymphoid organs, chTRAF5 mRNA expression was barely detectable 
in the muscle and the skin (Figure 5.7), similar to mammalian TRAF5 mRNA 
expression patterns (Ishida et al., 1996). In purified splenocytes, chTRAF5 mRNA 
expression was not detected in KUL01
+
 cells. This could suggest that chTRAF5 is 
not highly expressed in phagocytic cells. In mice, TRAF5
-/-
 DC have no defects in 
CD40- or TLR9-mediated activation of pro-inflammatory cytokine expression 
(Kraus et al., 2008). In chicken LPS-stimulated BMDC, chTRAF5 mRNA 
expression levels were not altered compared to levels in unstimulated cells. 
However, chTRAF5 mRNA expression levels were increased in LPS-stimulated 
BMDM (Figure 5.8B). This suggest that chTRAF5 may have a role in the TLR4 
downstream signalling pathway in BMDM. BMDM from TRAF5
-/-
 knockout mice 
induced higher levels of IL-6 expression after TLR7 stimulation and TRAF5 was 
demonstrated to have a regulatory role in TLR signalling in B cells by interacting 
with and inhibiting MyD88 and TAK1 (Buchta & Bishop, 2014). ChTRAF5 mRNA 
expression levels were highest in TCRγδ
+
 cells (Figure 5.8A). TCRγδ cells are the 
most abundant T cells in the chicken in contrast to mammals, where TCRαβ T cells 
are more abundant. TCRγδ
 
cells are innate-like cells that increase in numbers upon 
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bacterial infection in human and chickens (Hara et al., 1992; Berndt et al., 2006). 
While naïve TRAF5
-/-
 mice have normal lymphocyte cellularity, upon infection with 
intracellular pathogens, expansion of CD8
+
 T cells is defective (Kraus et al., 2008), 
linked to an increase in cell apoptosis (Kraus et al., 2008), and they have a skewed 
and more enhanced Th2 immune response (So et al., 2004). Mouse TRAF5 has a role 
in IL-17-mediated stabilisation of CXCL1 mRNA expression. This chemokine is 
released by neutrophils to attract cells to the site of injury and its long-term 
expression is required for an optimal immune response (Sun et al., 2011). In ConA-
stimulated splenocytes, chTRAF5 mRNA expression levels were increased at 18 and 
24 h compared to levels in unstimulated cells (Figure 5.9). Activation of splenocytes 
therefore activates a downstream signalling pathway that involves chTRAF5. TRAF5 
is involved in the regulation of T cell responses in mammals and it would be 
interesting to examine its role in chicken T cell biology.  
TRAF6 expresses one of the most divergent TRAF-C domains of the TRAF 
family and binds to separate TRAF-binding peptides not recognised by TRAF1, 
TRAF2, TRAF3 or TRAF5. TRAF6 is the only TRAF family member that is 
associated with activating downstream signalling pathways for both the TNFR and 
Toll/IL-1R superfamilies (Cao et al., 1996; Chung et al., 2007). Structural analysis of 
TRAF6 identified that its zinc finger domain but not its RING domain is required for 
NF-κB activation (Cao et al., 1996). ChTRAF6 mRNA expression was detected in 
all lymphoid organs examined except the thymus. The highest chTRAF6 mRNA 
expression levels were seen in the bursa of Fabricius and the mid- and upper-gut 
(Figure 5.6). The chicken intestine is rich in many cells of the innate immune system 
while the bursa of Fabricius is the site of development for the B cell receptor 
repertoire for chicken B cells, indicating that chTRAF6 may be involved in 
signalling in immune cells. It plays a vital role in CD40-mediated JNK activation in 
mammals (Rowland et al., 2007). CD40 is a major player in B cell survival and Ig 
class switching, by binding to a number of TRAF molecules, such as TRAF2, 
TRAF3, TRAF5 and TRAF6 (Pullen et al., 1998). TRAF6
-/-
 mice have a lethal 
phenotype; such mice survive up to 2-3 weeks of age, lack osteoclasts, tooth eruption 
and normal bone marrow cavities (Lomaga et al., 1999; Naito et al., 1999). To 
examine the role of TRAF6 in downstream signalling activities, mice were generated 
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to express mutations in the known TRAF-binding domains of CD40. The mutation of 
CD40 TRAF6-specific binding domains led to a 95% decrease in total plasma cell 
numbers (Ahonen et al., 2002) and a decrease in the levels of IL-6 expression 
(Jalukar et al., 2000). As described in Chapter 3, TRAF6 is necessary for RANKL-
mediated osteoclastogenesis (Lomaga et al., 1999).  
ChTRAF6 mRNA expression was detected in all non-lymphoid tissues 
examined with the lowest expression levels seen in the brain (Figure 5.7). In purified 
splenocytes, chTRAF6 mRNA expression levels were low in TCRαβ2
+
 cells and the 
highest chTRAF6 mRNA expression levels were detected in CD8β
+
 cells (Figure 
5.8A). In a time-course study of unstimulated and ConA-stimulated splenocytes, 
chTRAF6 mRNA expression levels were not altered between unstimulated or 
stimulated cells after 2 or 4 h (Figure 5.9). ChTRAF6 mRNA expression levels were 
increased in stimulated cells at 6, 12 and 18 h compared to levels in unstimulated 
cells, indicating that chTRAF6 mRNA expression levels are upregulated in activated 
splenocytes as they are in mammals (King et al., 2006).  TRAF6
-/- 
mice have 
increased expression levels of Th2 and Treg cytokines, IL-4, IL-10 and TGF-β, in 
multiple organs but were still capable of differentiating Th1 cells. However, TRAF6
-
/-
 T cells could not induce IFN-γ production upon exposure to IL-18 which signals 
though an IL-1R superfamily member, the IL-18R, which requires TRAF6 for the 
activation of downstream signalling cascades (Chiffoleau et al., 2003). TRAF6
-/-
  T 
cells express higher levels of IL-4 and IL-5 upon stimulation (King et al., 2006) and 
Treg cells lose the expression of FoxP3, becoming exFoxP3Treg cells, under 
inflammatory conditions (Muto et al., 2013). These data indicate that TRAF6 has a 
role in the maintenance of Treg cells. TRAF6
-/- 
 T cells differentiated under Th1, Th2 
or Th17 polarising conditions induced increased levels of the Th17 effector cytokine, 
IL-17, compared to Th1 (IFN-γ) and Th2 (IL-13) cells, due to the increase in ROR-γt 
transcription. The loss of Th17 regulation has been linked to a number of 
autoimmune diseases and the loss or malfunction of TRAF6 signalling may be linked 
to these diseases (Cejas et al., 2010).  
ChTRAF6 mRNA expression levels were not altered between unstimulated 
and LPS-stimulated BMDC and BMDM (Figure 5.8B). In mammals, TRAF6 is 
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required for the TLR- and CD40-mediated maturation of, pro-inflammatory cytokine 
production by and cell surface expression of CD80 and MHC class II in DC and is 
required for the development of CD11c
+
 splenic DC (Kobayashi et al., 2003). In a 
more recent study, TRAF6
-/- 
gut-associated DC showed a substantial increase in Th2 
immune responses. The main roles of mucosal DC are to control the induction and 
maintenance of iTreg cells (Pulendran et al., 2010). In TRAF6
-/-
 DC, the number of 
iTreg cells in the intestine was diminished due to the lack of IL-2 production by DC 
(Han et al., 2013). 
TRAF7 is the most recent member of the mammalian TRAF family to be 
identified (Bouwmeester et al., 2004). The designation of this protein as TRAF7 has 
been controversial as it does not possess a TRAF-C domain but instead contains 
several WD40-repeat domains. It has been designated TRAF7 due to the high 
homology of its RING, zinc finger motif and coiled-coil domains with those of other 
TRAF proteins (Xu et al., 2004).  WD40-repeat domains are conserved WD 
dipeptides of approximately 44-60 amino acids. Each repeat comprises a four strand 
anti-parallel β-sheet (Wu et al., 2010). The overall structure of WD40 domains is a 
β-propeller architecture which acts as a platform for multiple protein-protein 
interactions making these proteins good hubs in cellular interaction networks 
(Stirnimann et al., 2010). WD40 domains are among the most abundant domain 
types across eukaryotic genomes. These proteins are involved in a number of 
biological processes such as apoptosis, signal transduction, cell cycle control and 
transcriptional regulation (Xu & Min, 2011). ChTRAF7 contains all seven WD40 
repeat domains as found in mammalian TRAF7 (Xu et al., 2004; Morita et al., 2005). 
In mammals, TRAF7 WD40 domains are required for interacting with and driving 
the sumoylation of the transcription factor, c-Myb (Morita et al., 2005). C-Myb is 
vital for several stages of T cell development and activation and requires tight 
regulatory control as its pro-oncogene, v-myb, induces anti-apoptotic signals leading 
to the development of T cell lymphomas (Gewirtz et al., 1989).  
ChTRAF7 mRNA expression was ubiquitous across chicken tissues and 
organs similar to mammalian TRAF7 (Xu et al., 2004; Morita et al., 2005). 
ChTRAF7 mRNA expression levels were the lowest in the crop and its mRNA levels 
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were not different between unstimulated and ConA-stimulated splenocytes over the 
six time-points examined (Figure 5.9). To date, very little data are available on the 
role of mammalian TRAF7 in immunity. TRAF7
-/-
 mice which would provide more 
insight into its biological functions have yet to be generated. Mammalian TRAF7 has 
not yet been implicated in binding to and signaling for members of the TNFR 
superfamily.  Recently, an oyster homologue of TRAF7 was identified in 
Crassostrea hongkongensis (CrhTRAF7). Although no biological functions were 
examined, crhTRAF7 mRNA expression levels were significantly reduced in the first 
12 h after challenge of hepatocytes with the Gram-ve bacteria, Vibrio alginolyticus, 
indicating a role for crhTRAF7 in fish immunity (Fu et al., 2011).  
When the full-length chTRAF2 cDNA was cloned, a smaller isoform was 
identified (Figure 5.10). Sequence analyses and the SMART prediction program 
indicated that the smaller isoform of chTRAF2 was missing exon four due to exon 
skipping (Figures 5.11 & 5.12). ChTRAF2S differs from the murine TRAF2A 
isoform, which expresses seven additional amino acids within the RING domain due 
to differential usage of a splice donor site at the 3' end of exon one (Brink & Lodish, 
1998). Due to the difference between the murine and chicken TRAF2 isoforms, the 
chTRAF2 smaller isoform was named chTRAF2S. The splicing of exon four from 
chTRAF2 leads to a portion of the first zinc finger motif, the entire second zinc 
finger motif and a portion of the third zinc finger motif  being excluded from the 
translated protein, generating chTRAF2S. The partial NH2-terminal portion of zinc 
finger one may join to the partial COOH-terminal portion of zinc finger three to 
produce a slightly smaller hybrid zinc finger motif. Overall chTRAF2 showed high 
conservation with its mammalian orthologues and branched with the human and 
mouse TRAF2 proteins in phylogenetic analysis (Figure 5.21).  
In RT-PCR analyses, chTRAF2 and chTRAF2S mRNA expression was 
analysed in a number of chicken lymphoid and non-lymphoid tissues (Figure 5.16). 
Across the lymphoid tissues examined, chTRAF2 mRNA expression levels were 
higher than those of chTRAF2S. ChTRAF2S mRNA expression levels were low 
across all tissues examined with the highest found in Meckel’s diverticulum (Figure 
5.16). In non-lymphoid tissues, chTRAF2 and chTRAF2S mRNA expression 
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patterns differ; chTRAF2 mRNA expression levels were low in the brain, heart, liver, 
kidney and lung (Figure 5.18). In contrast, chTRAF2S mRNA expression levels were 
highest in the brain and lung (Figure 5.17). Interestingly, in mice, TRAF2 mRNA 
expression levels were highest in the brain and lung whereas those of TRAF2A 
mRNA were lowest in these organs (Brink & Lodish, 1998).  





 cells (Figure 5.18A). Interestingly, chTRAF2S mRNA 
expression levels were higher than chTRAF2 mRNA expression levels in KUL01
+
 
cells. ChTRAF2 mRNA expression levels decreased in LPS-stimulated BMDM 
compared to chTRAF2S mRNA expression levels (Figure 5.18B). However, 
chTRAF2 mRNA expression levels increased in LPS-stimulated BMDC (Figure 
5.18B). This indicates differential expression patterns between the chTRAF2 
isoforms in chicken APC. ChTRAF2 and chTRAF2S mRNA expression levels were 
examined in a time-course assay of unstimulated and ConA-stimulated splenocytes 
by RT-PCR. Over all the time-points examined, chTRAF2 mRNA expression levels 
were predominantly increased in ConA-stimulated cells in comparison to chTRAF2S 
levels and levels of both isoforms in unstimulated cells (Figure 5.19). ChTRAF2 
mRNA expression levels increased in cells stimulated with ConA, a lectin that non-
specifically activates T cells, suggesting that chTRAF2 is associated with a pathway 
activated in chicken T cells.  In mammals, TCR-activated T cells increase TRAF2 
expression in a time- and dose-dependent manner and TRAF2 is required for 
regulation of the NF-κB2 pathway. Uncontrolled upregulation of the NF-κB2 
pathway led to an increase in expression of Th17 cell effector cytokines, such as IL-
21, and the transcription factor, ROR-γt (Lin et al., 2011). The role of mammalian 
TRAF2 in Th17 cells was further demonstrated in TRAF2
-/-
 mice where IL-17-
producing T cell numbers were increased in the colonic lamina propria which led to 
colitis (Piao et al., 2011). In mammals, TRAF2 expression was increased in 





 T cells in the thymus but mice do exhibit an increase in B cell numbers when 
TRAF2 is expressed as a DNTRAF2 mutant (Lieberson et al., 2001). Due to the 
lethality of TRAF2
-/-
 mice, many studies have identified the role of TRAF2 
signalling by generating DNTRAF2 mice. By only expressing the TRAF-C domain, 
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the DNTRAF2 protein can bind to receptors but not signal to activate pathways. 
Using this approach, it was demonstrated that TRAF2 was required for IL-2 





cell activation during a secondary response to influenza, indicating TRAF2 has a role 
in T cell memory (Cannons et al., 2002). TRAF2 also regulates Th2 differentiation 
by binding to and inhibiting NIP45, a member of the NFAT family, required for the 
activation of IL-4 (Lieberson et al., 2001). Mammalian TRAF2 is required for a 
number of T cell activities and with high conservation between mammals and 
chickens, chTRAF2 may have similar roles.  
Mouse TRAF2 and TRAF3 isoforms have been identified and demonstrated 
to have a role in the regulation of NF-κB activation (van Eyndhoven et al., 1998; 
Brink & Lodish, 1998). The bioactivity of intracellular signalling proteins can be 
investigated by overexpressing these genes in non-immune, transformed cell lines, 
such as HEK-293T cells, in combination with reporter genes, signalling molecules or 
receptors. This approach was used to analyse the bioactivity of chTRAF2 and 
chTRAF2S using NF-κB as a reporter gene. The overexpression of chTRAF2 or 
chTRAF2S proteins in HEK-293T cells led to a significant upregulation of NF-κB 
activation in a dose-dependent manner, compared to levels in empty vector control 
cells (Figure 5.20). Cells cotransfected with both chTRAF2 constructs at a total 
concentration of 75 ng (37.5 ng each) significantly increased NF-κB activation 
compared to levels in vector control cells but not compared to levels in chTRAF2 or 
chTRAF2S singly transfected cells (Figure 5.20). Cells cotransfected with higher 
concentrations of the chTRAF2 constructs (75 ng each) only slightly enhanced NF-
κB activation compared to chTRAF2 and chTRAF2S levels (Figure 5.20). This 
suggests that chTRAF2 and chTRAF2S do not synergise to enhance NF-κB 
activation. ChTRAF2S overexpression induced higher levels of NF-κB activation 
than those induced by chTRAF2 but not to a statistically significant level (Figure 
5.20). The chTRAF2S isoform lacks internal zinc fingers compared to chTRAF2 
(Figures 5.12 & 5.14). Mammalian TRAF2 requires an intact RING domain and zinc 
finger domains for NF-κB activation (Takeuchi et al., 1996). In NF-κB reporter 
systems, the replacement of the RING and zinc finger motifs one and two of TRAF3 
with the TRAF2 equivalent domains induced NF-κB activation compared to wild-
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type TRAF3, which cannot activate NF-κB (Takeuchi et al., 1996), indicating the 
importance of TRAF2 RING domain and zinc finger motifs for activating 
downstream signalling cascades. In mice, the TRAF2 isoform, TRAF2A, does not 
activate NF-κB, due to an additional seven amino acids within the RING domain 
(Brink & Lodish, 1998). It is hypothesised that the non-signalling TRAF2A isoform 
competitively binds to TRAF-binding peptides, inhibiting TRAF2 and other TRAF 
members from binding and signalling downstream pathways. Thus TRAF2A 
regulates the activation of downstream NK-κB but can activate JNK (Dadgostar & 
Cheng, 1998), suggesting a regulatory role for this isoform on specific downstream 
signalling pathways. The data indicate that chTRAF2S is capable of activating NF-
κB. The absence of exon four from chTRAF2S generates a protein expressing three 
zinc finger motifs, as compared to the five expressed in mammalian TRAF2 and 
chTRAF2 (Figure 5.14). Exon 4 of chTRAF2 translates the COOH-terminal portion 
of zinc finger motif one and the NH2-terminal portion of zinc finger motif three. It is 
hypothesised that these two zinc finger portions form a hybrid zinc finger motif with 
biological functions similar to the chTRAF2 protein which expresses five zinc finger 
motifs. ChTRAF2S is biologically active and may competitively bind to TRAF-
binding motifs in the intracellular domains of members of the TNFR superfamily, 
where it could send a more enhanced signal downstream during certain cellular 
processes.   
Overall, this Chapter describes the cloning and molecular characterisation of 
a number of chicken TRAF family members. These intracellular proteins share high 
amino acid conservation with their mammalian orthologues which could indicate 
conserved bioactivities. Although this Chapter describes their mRNA expression in a 
number of lymphoid and non-lymphoid tissues, along with immune cells, by RT-
PCR, future work should be aimed at quantifying their mRNA expression levels in 
cells activated by various stimuli, such as TLR, TNFR or IL-1R. Analysis of TRAF 
family member mRNA expression levels in chicken immune responses will help 
















6.1  Overall perspective 
  The main aim of this thesis was to clone and characterise the TNF family 
members RANKL, RANK and OPG in the chicken. Once the three genes were 
cloned, their transcriptional regulation, protein structure and bioactivity were 
investigated. In mammals, the TNF superfamily is made up of 19 ligands and 29 
receptors that have multiple roles in lymphoid organ development and immunity. In 
2005, genomic analysis identified a reduced number of TNF family members in the 
chicken genome (Kaiser et al., 2005). The missing members have roles in T cell 
costimulation, activation and effector cytokine production. It is possible that the 
chicken genome expresses a minimal essential TNF superfamily. Prior to this study, 
avian orthologues of five members of the TNF superfamily- CD30L, TRAIL, BAFF, 
CD40L and VEGI- had been characterised. These studies indicated high conservation 
of biological activity of TNF family members between mammals and birds.  
 The chicken mounts a Th1 and Th2 immune response to infection with 
intracellular and extracellular pathogens, respectively (Degen et al., 2004; Powell et 
al., 2009). However, the tools and reagents required to identify polarised Th cells in 
the chicken are still largely not available. Certain members of the TNF superfamily 
are predominantly expressed on different CD4
+
 T cell subsets and can be used to 
help differentiate between them. Mammalian RANKL is predominantly expressed on 
the surface of Th1 cells and induces pro-inflammatory cytokine expression in 
RANK-expressing DC and macrophages. RANKL is a multitasking cytokine, having 
roles in immune organ development (lymph nodes, M cells, mTEC), pro-
inflammatory immune responses and bone remodelling. Its importance within human 
physiology is underscored by the use of monoclonal antibodies against RANKL 
(denosumab, Amgen Inc., USA) to treat post-menopausal osteoporosis and cancer-
related osteolysis. It is currently under phase IV clinical trials for use in alleviating 
RA (Lacey et al., 2012). The conservation of RANKL bioactivity in the chicken was 
identified in this study and therefore RANKL has a role in both chicken Th1 immune 




6.2  Cloning and analysis of chRANKL, chRANK and chOPG 
The presence of RANKL, RANK and OPG in the chicken genome indicates 
the conservation of these genes from before the divergence of mammals and birds 
from a common ancestor over 300 million years ago. Using the sequence data from 
the Ensembl database, chRANK and chOPG cDNA were amplified by RT-PCR 
(Chapter 3). The predicted chRANKL sequence in the Ensembl database was 
annotated incorrectly, lacking a predicted transmembrane domain. Using the human 
RANKL sequence, the full-length correct chRANKL sequence was mined from the 
chicken genome and cDNA cloned from RNA from ConA-stimulated splenocytes. 
Like mammals, chRANKL is a 318 amino acid, type II transmembrane protein with 
an extracellular, TNF homology, domain. ChRANK is a type I transmembrane 
protein with highly conserved extracellular CRDs, characteristic of TNFR 
superfamily members (Anderson et al., 1997). ChOPG is produced as a soluble 
protein that contains two DD and four CRD, similar to mammalian OPG (Yasuda et 
al., 1998).  
Protein-protein interactions are central to biological processes from cellular 
communication to programmed cell death. The correct folding and assembly of 
protein complexes are vital for ligand and receptor interactions. Members of the TNF 
superfamily characteristically form homotrimers to induce the oligomerisation of 
their respective receptor(s). The geometry of the resulting TNF ligand-receptor 
interaction is favourable for the recruitment of intracellular adaptor proteins. It is 
therefore important to ensure that members of the TNF family are folded correctly to 
interact with their receptor(s) and activate appropriate downstream signalling 
pathways. The extracellular, soluble domain of chRANKL predominantly forms 
homotrimers with the assistance of an isoleucine zipper sequence in the expression 
plasmid. Mammalian OPG is produced as a dimeric soluble protein excreted from 
cells to interrupt the interaction between RANKL and RANK (Yasuda et al., 1998). 
ChOPG shares these characteristic by being expressed as a secreted homodimeric 
protein.  
All three molecules were ubiquitously expressed across a number of 
lymphoid and non-lymphoid tissues in the chicken, as shown by qRT-PCR. Primary 
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immune cells stimulated with a number of mitogens associated with the activation 
and proliferation of T and B cells did not affect the mRNA expression levels of these 
molecules in the chicken, indicating their mRNA is transcriptionally regulated by 
specific biological pathways. In mammals, RANKL transcription is regulated in 
murine T cells by Ca
2+
 mobilisation and activation of the PKC pathway (Wang et al., 
2002; Fionda et al., 2007). Chicken splenocytes stimulated with ionomycin and PMA 
increased the mRNA expression levels of chRANKL which was verified by the 
blockade of Ca
2+
 mobilisation and PKC activation by TMB-8 treatment. The data 
indicate the conserved transcriptional regulation of RANKL in mammals and birds 
(Wang et al., 2002; Fionda et al., 2007; Bishop et al., 2011). Similar to mammals, 
chOPG is expressed in LPS-stimulated BMDC and its mRNA expression levels were 
increased in a time- and dose-dependent manner (Schoppet et al., 2007). The mRNA 
expression levels of chRANK were also affected by the level of BMDC maturation, 
with mRNA expression levels decreasing as the cells matured. The data suggest that 
chOPG mRNA expression levels increase as BMDC mature, possibly regulating the 
interaction between chRANKL-expressing T cells and chRANK-expressing DC, 
similar to mammals. In osteoblast cells, the OPG promoter region is transcriptionally 
regulated by activation of the PKC pathway (Yang et al., 2002). It would be 
interesting to investigate the transcriptional regulation of chRANKL and chOPG in 
chicken osteoblast and stromal cells.  
6.3  The biological activity of chRANKL 
 Mammalian RANKL enhances the expression levels of pro-inflammatory 
cytokines and the survival of DC and macrophages (Anderson et al., 1997; Wong et 
al., 1997; Park et al., 2005). In chicken BMDC, mRNA expression levels of the pro-
inflammatory cytokines IL-1β, IL-6 and IL-12α were enhanced in cells co-stimulated 
with LPS and schRANKL (Chapter 4). Mammalian IL-12 is a key player in 
governing the development of Th1 responses and is a cytokine that is largely 
produced by DC. IL-12 induces the activation of the Th1 transcription factor, 
STAT4, and synergises with IL-2 to drive Th1 differentiation (Athie-Morales et al., 
2004). Chicken IL-1β mRNA expression is increased in response to bacterial, viral 
and parasite infection, demonstrating its role as a rapidly induced pro-inflammatory 
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cytokine (Gibson et al., 2014). To verify that the enhanced pro-inflammatory 
cytokine mRNA expression levels were due to treatment of cells with schRANKL, 
schRANKL was pre-incubated with soluble chRANK-Fc and chOPG-Fc before 
addition to cells with LPS. The schRANKL-mediated increase in pro-inflammatory 
cytokine mRNA expression levels was inhibited by both soluble chRANK-Fc and 
chOPG-Fc. This provides evidence that the recombinant schRANKL protein is 
biologically active and that its receptors, recombinant chRANK-Fc and chOPG-Fc, 
are folded correctly and capable of interacting with their ligand. SchRANKL 
bioactivity was also investigated in BMDM. mRNA expression levels of the pro-
inflammatory cytokine, IL-1β, were enhanced by schRANKL and LPS co-
stimulation. However, IL-6 mRNA expression levels were not enhanced to a 
statistically significant level compared to those in unstimulated cells.  
BMDC and BMDM stimulated with schRANKL or co-stimulated with 
schRANKL and LPS did not enhance the expression levels of cell surface markers 
associated with antigen presentation (MHC class II) or costimulatory capacities 
(CD40) which is similar to various studies in mammals (Anderson et al., 1997; 
Wong et al., 1997). To investigate whether the stimulant was a factor in the inability 
of schRANKL to enhance cell surface marker expression levels, a more potent 
activator of macrophages, IFN-γ, was used to induce M1 (classical) macrophage 
activation. However, schRANKL did not affect surface expression of MHC class II 
or KUL01 and only slightly enhanced CD40 surface expression. The data suggest 
that chicken APC matured with microbial components (LPS) or cytokines (IFN-γ) do 
not alter the surface expression of activation markers when in the presence of 
schRANKL. In mammalian studies, the treatment of APC with RANKL induces 
different outcomes depending on the anatomical location of DC. For example, 
RANKL induces IL-12 expression in spleen-derived DC but not in Peyer’s patch-
derived DC (Williamson et al., 2002) and upregulated MHC class II, CD80 and 
CD86 expression levels in Mo-DC (Schiano de Colella et al., 2008) but not BMDC 
(Anderson et al., 1997; Wong et al., 1997). Although this study did not investigate 
the expression levels of chCD80 and chCD86, it cannot be ruled out that schRANKL 
does not alter the phenotype of APC in the chicken. Future work is required for the 
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analysis of chRANKL bioactivity on Mo-DC, spleen-derived DC and other various 
anatomical-derived DC in the chicken.  
Similar to mammalian RANKL, chRANKL is a survival factor for chicken 
BMDC and BMDM. Cells treated with schRANKL for 24 and 48 h had increased 
numbers of viable cells compared to untreated cells. This study did not measure the 
mRNA expression levels of the anti-apoptotic genes, Bcl-XL or Bcl-2, involved in 
mammalian RANKL-mediated cell survival (Cremer et al., 2002). Apoptosis is an 
evolutionary conserved form of programmed cell death and plays vital roles in 
development, tissue homeostasis and cell defence against pathogens. Apoptosis 
occurs by two signals, extrinsic and intrinsic (mitochondrial). Extrinsic apoptosis is 
initiated by ligand-receptor interaction, such as that of the DD-containing TNF 
family members, FASL and FAS, which leads to the formation of the death-inducing 
signalling complex (DISC) that can activate caspase-8 and caspase-3 (Lamkanfi et 
al., 2007). Intrinsic apoptosis is initiated by intracellular perturbations in 
homeostasis, such as DNA damage, Ca
2+
 overload and oxidative stress (Taylor et al., 
2008).  Mammalian Bcl-XL and Bcl-2 are localized to the membrane surface of ER, 
mitochondria and the nucleus. Both regulate Ca
2+
 levels by reducing the capacity of 
ER Ca
2+
 stores (Szegezdi et al., 2003; Distelhorst & Bootman, 2011). Both 
counteract the mitochondrial pore-forming activities of the pro-apoptotic molecules, 
BAK and BAX, whose function is to induce mitochondrial outer membrane 
permeabilisation that drives the loss of mitochondrial transmembrane potential 
(Michels et al., 2013). In osteoclast cells, a fellow member of the anti-apoptotic Bcl-
2 family, myeloid cell leukemia-1 (Mcl-1), has been implicated in RANKL-mediated 
osteoclast cell survival, rather than Bcl-XL or Bcl-2 (Sutherland et al., 2009; Masuda 
et al., 2014). Mcl-1 is essential for embryonic development and survival of a number 
of cell lineages in the adult, such as lymphocytes, neurons, cardiomyocytes, 
hepatocytes and immunoglobulin-secreting plasma cells. Mcl-1 expression is tightly 
regulated at the transcriptional, post-transcriptional and post-translational levels 
(Mojsa et al., 2014). 
 Similar to mammalian RANKL, chRANKL enhances the phagocytic activity 
of chicken BMDC. However, more research is required to fully investigate the ability 
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of schRANKL to differentiate BMDC into osteoclast cells which have phagocytic 
potential (Li et al., 2010). Murine RANKL signals the differentiation of 
macrophages and DC into osteoclasts, a process that requires NF-κB and NFATc1 
(Walsh et al., 2003). These cells have properties that include the expression of pro-
inflammatory cytokines, MHC class II and phagocytic potential (Li et al., 2010). 
BMDM commit to the osteoclast cell lineage after 24 h of RANKL treatment 
(Mochizuki et al., 2006). There are two types of macrophage-derived multinucleated 
giant cells (MNG), osteoclasts in bone and MNG in chronic inflammatory reactions 
(Anderson, 2000). Various proteins have been implicated in the cell-cell fusion 
required for MNG formation, such as DC-STAMP, RANKL, CD47 and CD36 (Yagi 
et al., 2005; Yu et al., 2011; Miyamoto, 2011). In a pilot study, bone marrow cells 
incubated with chCSF-1 prior to exposure to chRANKL were capable of 
differentiating into large multinucleated cells characteristic of osteoclasts. Although 
a more detailed analysis of these cells is required, the ability of chRANKL to induce 
osteoclast-like cell differentiation indicates its conserved bioactivity both in 
immunity and bone metabolism in the chicken.    
 Overall the data presented in this thesis suggest the conserved bioactivity of 
RANKL, RANK and OPG across mammals and birds. It provides a platform for 
understanding the roles of these TNF molecules in various biological processes in the 
chicken.  
6.4  The cloning of TRAF-binding proteins which bind intracellularly to RANK  
Members of the TNFR superfamily do not possess intracellular catalytic 
domains for downstream signalling upon ligand interaction; instead they rely on the 
recruitment of adaptor proteins called TNF receptor-associated factors (TRAFs). 
Differently to mammalian RANK, chRANK lacks one of three TRAF6-specific 
binding motifs. RANK-mediated TRAF6 signalling is crucial for osteoclastogenesis 
(Koda et al., 2004). TRAF2, TRAF3 and TRAF6 knockout mice are all 
phenotypically lethal indicating the important roles of these molecules in 
development (Xu et al., 1996; Yeh et al., 1997; Lomaga et al., 1999; Naito et al., 
1999). Specifically, TRAF2, TRAF5 and TRAF6 serve as adaptor proteins that link 
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cell surface receptors to downstream signalling cascades involved in activating 
transcription factors, such as NF-κB, resulting in cytokine expression.  
To date, the only member of the chicken TRAF family cloned and studied is 
chTRAF5 (Abdalla et al., 2004a). To begin to understand the biological effects of 
chRANK, which contains two out of the three mammalian TRAF6-binding motifs, 
and chRANK intracellular signalling, the identification and molecular 
characterisation of chicken TRAFs was required. All seven TRAF family members 
are present in the chicken genome and this study focused on three members involved 
in mammalian RANK signalling, TRAF2, TRAF5 and TRAF6 (Wong et al., 1999; 
Darnay et al., 1999) and the newest member, TRAF7 (Xu et al., 2004). 
Using the sequences from the Ensembl database, chTRAF5, chTRAF6 and 
chTRAF7 cDNA were cloned and found to be highly conserved across mammals and 
chickens (Chapter 5). The cloning of chTRAF2 led to the identification of a novel 
splice isoform missing exon four, named chTRAF2S (Chapter 5). ChTRAF5, 
chTRAF6 and chTRAF7 mRNA expression levels across a number of lymphoid and 
non-lymphoid tissues were similar to those in mammals. In kinetic experiments 
comparing unstimulated and ConA-stimulated splenocytes, chTRAF5 mRNA 
expression levels were increased at 18 and 24 h in stimulated cells, chTRAF6 mRNA 
expression levels were increased at 6 h in stimulated cells whereas chTRAF7 mRNA 
expression was constant in unstimulated and stimulated cells. This suggests that 
chTRAF5 and chTRAF6 may be involved in intracellular pathways associated with T 
cell activation and proliferation in the chicken. The biological role of mammalian 
TRAF7 in immunity has yet to be identified but it plays a role in fish immunity 
against bacterial infection (Fu et al., 2011). 
6.5  The identification of a novel chTRAF2 isoform  
Mammalian TRAF2 is one on the best characterised members of the TRAF 
family. As described in Chapter 5, chicken TRAF2 undergoes alternative splicing to 
produce a smaller isoform lacking exon 4, which encodes a partial portion of the first 
zinc finger motif, omits the entire second zinc finger motif and a partial portion of 
the third zinc finger motif. This splice isoform has not been reported in mammalian 
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species. A murine TRAF2 splice isoform has previously been described, TRAF2A, 
which contains an additional seven amino acids within the RING domain which 
affect its ability to activate the NF-κB pathway (Brink & Lodish, 1998) but not the 
JNK pathway (Dadgostar & Cheng, 1998). 
Messenger RNA is transcribed as a precursor containing intron sequences 
which are removed so that the flanking regions, exons, are spliced together to form a 
mature mRNA. Alternative splicing of mRNA precursors is a versatile mechanism 
that increases the complexity of the resulting protein localisation and/or function. 
There are a number of alternative splicing mechanisms, such as exon skipping, 
mutually exclusive exons, alternative acceptor and alternative donor sites. Exon 
skipping is one of the most common forms of alternative splicing. As the name 
implies, exon or exons are spliced out of the precursor mRNA resulting in a smaller 
mature mRNA being generated. The mutually exclusive exon approach sees one of 
two exons retained but never both exons in the final mature mRNA. Use of 
alternative acceptor and alternative donor sites is where an alternative 5' splice 
junction is used changing the 3' acceptor site of the upstream exon or an alternative 3' 
splice junction is used altering the 5' boundary of the downstream exon. It is clear 
that the chTRAF2S isoform is generated from exon skipping, splicing out exon 4 and 
joining exon 3 to exon 5.  
 RT-PCR analyses indicated that chTRAF2 is the constitutive form expressed 
in lymphoid tissues but not in non-lymphoid tissues, where chTRAF2S is 
predominantly expressed. In splenocyte subsets, the mRNA expression levels of 






 cells compared to chTRAF2 
(Chapter 5). ChTRAF2 mRNA expression levels increased to higher levels than 
chTRAF2S in ConA-stimulated splenocytes, indicating that chTRAF2 is the 
predominant form expressed in activated chicken lymphoid cells. In chicken BMDM, 
chTRAF2 mRNA expression levels were unaltered after stimulation. ChTRAF2S 
mRNA expression levels were increased in LPS-stimulated BMDM but not BMDC.  
 The bioactivity of chTRAF2 and chTRAF2S was investigated by analysing 
their ability to activate a reporter gene in HEK-293T cells. The reporter gene used for 
the analysis was NF-κB, known to be positively regulated by mammalian TRAF2 
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(Lee et al., 1997; Takeuchi et al., 1996). Interestingly, chTRAF2S activated NF-κB. 
It is surprising that chTRAF2S can activate NF-κB when lacking zinc finger motifs. 
Mammalian TRAF2 RING and zinc finger motifs one, two and three are vital for 
NF-κB activation (Takeuchi et al., 1996). It may be plausible that the joining of the 
NH2-terminal piece of zinc finger motif one with the COOH-terminal portion of zinc 
finger motif three in chTRAF2S creates a composite zinc finger motif with biological 
activity. Overexpressing chTRAF2 or chTRAF2S in HEK-293T cells increased 
levels of NF-κB activation in a dose-dependent manner. However, when both 
chTRAF2 isoforms were overexpressed together, enhanced levels of NF-κB was not 
observed. Although NF-κB expression levels were increased in cotransfected cells 
compared to vector control wells, levels were not statistically significantly different 
between chTRAF2- or chTRAF2S-mediated NF-κB activation levels. More likely, 
the two isoforms bind to the same adaptor proteins, and therefore one may block the 
other. However, the two isoforms could form homo- or heterodimers, and any such 
interaction could hamper their respective bioactivities.  
Overall the data suggest that chTRAF2, chTRAF5, chTRAF6 and chTRAF7 
are highly conserved between mammals and birds. Importantly, chicken TRAF2 is 
alternatively spliced to generate a protein that is bioactive, inducing NF-κB 
activation, which may be relevant during certain immune responses. 
6.6 Future experiments 
 Additional experiments could have been carried to better understand the role 
of chRANKL, chRANK and chOPG in avian immunity during these studies. One of 
the most informative approaches would have been the use of chOPG to detect 
chRANKL surface expression. Mammalian OPG binds to RANKL 1000-fold higher 
than RANK binds to RANKL (Lam et al., 2001) making it the more sensitive 
receptor to use. The purified chOPG-Fc could be used to detect the surface 
expression of chRANKL on a number of immune cells by FACS analysis and in a 
number of tissues by histology. These studies will give a broader understanding of 
the protein expression of chRANKL in the chicken. 
The mRNA expression levels of chTRAF2 isoforms should be quantified to 
give a better understanding of the differential expression of these adaptor proteins in 
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the chicken. Further analysis on the role of chTRAF2 and chTRAF2S during various 
biological processes would have provided more insight into the regulation of their 
mRNA expression in various signalling pathways, such as downstream signalling 
induced TLR and TCR activation in splenocytes, BMDC and BMDM. It would have 
also been interesting to test the ability of the chTRAF2 isoforms to form homo- or 
hetrodimers with themselves and other TRAF family members.  
 
6.7  ChRANKL and its potential application to chicken immunity 
6.7.1  ChRANKL as a potential marker for chicken Th1 cells  
 Mammalian RANKL is predominantly expressed on the surface of Th1 cells 
and increases the expression of Th1 effector cytokines, such as IL-12 and IFN-γ, in 
DC (Wong et al., 1999; Josien et al., 1999). This study identified the ability of 
chRANKL to enhance the mRNA expression levels of chIL-12α that may in turn 
enhance the Th1 immune response in the chicken. Due to the role of mammalian 
RANKL in bone metabolism, research into RANKL and immunity is angled towards 
CD4
+
 T cells expressing RANKL under pro-inflammatory conditions linked to 
autoimmune diseases, such as RA and periodontal infection (Terheyden et al., 2014). 
Mammalian CD4
+
 Th1 and Th17 cells express RANKL under inflammatory 
conditions that activate osteoclasts, which degrade and destroy bone and tissue 





Th17 cells that upregulate the expression of RANKL, 
thought to contribute to the pathogenesis of RA (Komatsu et al., 2014).  
In the future, mAb against chRANKL will be developed by the avian toolbox 
initiative at The Roslin Institute. Antibodies against chRANKL and chRANK will 
help further develop the understanding of DC and T cell interactions in the chicken. 
Antibodies against chRANKL could be used to isolate cells expressing this molecule 
during a Th1 infection model, to test if they are expressing other Th1-specfic 




6.7.2  Understanding M cells in the chicken  
 The self-renewing epithelial cells of the small intestine are organised into 
crypts and villi. A huge rate of cell production occurs in the crypts and is balanced by 
a large amount of apoptosis at the tips of the villi. In the crypts, self-renewing cells 
produce rapidly proliferating transit-amplifying cells that can differentiate into any of 
the four cell linages (Paneth cells, enterocytes, goblet cells and enteroendocrine cells) 
(Barker et al., 2008).  M cells are a unique set of epithelial cells restricted to the FAE 
which overlays the gut-associated lymphoid tissues (GALT), such as Peyer’s 
patches, ILF and tonsils. M cells are phagocytic and take up particulates from the 
luminal environment and present them to cells in immune-inductive Peyer’s patches, 
initiating the intestinal immune response. RANKL is necessity for murine M cell 
differentiation and maintenance (Knoop et al., 2009). Bacteria can exploit the 
plasticity of cells to alter their activity and transform them to suit their requirements. 
This has been demonstrated in intestinal epithelial cells, which can undergo a 
reversible epithelial-mesenchymal transition (EMT) after exposure to bacteria 
(Thiery et al., 2009). The potential for the understanding of the role of M cells in 
host-pathogen interactions in the intestine can be seen in a study by Tahoun et al. 
(2012). S. Typhimurium can bind to epithelial cells and engage effector proteins to 
alter the cell’s cytoskeleton to uptake the bacterium (Galan & Zhou, 2000) and it 
preferably targets M cells in the intestine (Jones et al., 1994). Tahoun et al. (2012) 
demonstrated that S. Typhimurium interacts with bovine intestinal cells expressing 
the M cell marker, vimentin, and vimentin
-
 cells. The exposure of M cells to S. 
Typhimurium increased expression levels of RANKL, RANK and vimentin that 
could be controlled by OPG treatment. S. Typhimurium-mediated upregulation of 
RANKL was associated with RANKL-induced transformation of epithelial cells into 
M cells, a process allowing the bacteria to cross the intestinal mucosa. Aging mice 
have a slow decline of M cell numbers in the gut, causing defects in the mucosal 
immune response (Kobayashi et al., 2013). These studies indicate the importance of 
M cells in intestinal immunity and that they are good candidates for the investigation 
of how microbes evade the mucosal immune response in the chicken. 
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There is a need for intestinal culture systems in the chicken to enable the 
understanding of host-pathogen interactions. There are methods that have existed for 
some time to culture primary epithelial cells from mice as three-dimensional 
structures, called organoids (Macartney et al., 2000; Sato et al., 2009) (Figure 6.1). 
Since the discovery of the leucine-rich repeat-containing G-protein coupled receptor 
5 (Lrg5), as a marker for intestinal stem cells (Barker et al., 2007; Barker et al., 
2008), there have been unprecedented developments in the use of human tissue 
surrogates in vitro (reviewed by Sachs & Clevers, 2014). Intestinal stem cells divide 
every 24 h generating rapidly proliferating progenitor cells that fill up pocket-like 
crypts. These cells migrate up the crypt becoming nutrient absorbing enterocytes, 
secretory cells and M cells (Koo & Clevers, 2014). Organoids were first identified by 
mimicking the intestinal environment, leading to the discovery of culture conditions 
for mouse Lgr5
+
 intestinal cells (Sato et al., 2009). R-spondin-1, Noggin, EGF and 
Matrigel are the minimal requirements for the culture of murine organoids which led 
to the generation of crypt-like domains harbouring all four of the common intestinal 
cell lineages (Figure 6.1). These cell cultures are unique compared to cell lines; they 
efficiently form, self-renew and are genetically stable in long-term cultures (Sato et 
al., 2011). Recently, M cells were differentiated in these organoid systems by the 
addition of RANKL (De Lau et al., 2012).  
The ability to culture M cells as organoids has great potential for 
understanding host-pathogen interactions in the chicken gut. Organoid systems are 
useful for modelling of disease. There are many examples of human organoids being 
used to examine diseases, such as cystic fibrosis. The clustered regularly interspaced 
short palindromic repeats (CRISPR) RNA-guided Cas9 nuclease system was applied 
to amend the missing amino acid in cystic fibrosis transmembrane conductor 
regulator (CFTR) (F508) protein, a mutation linked to the common form of cystic 
fibrosis in humans. In organoid cultures generated from two mutant-expressing 
patients, the induction of double-stranded breaks and the insertion of the correct 
sequence led to the resultant organoids to regain CFTR functionality (Schwank et al., 
2013). Organoid cultures can be used as experimental platforms, using transgenic 
and knockout organoid systems to understand and study a gene of interest. These 





Figure 6.1 Schematic diagram of intestinal organoid. Intestinal organoids can be 
generated from a single Lrg5
+
 cell or from a portion of a crypt. Differentiated cells 
are found in the villus domain while stem cells (red cells) and Paneth cells (green 
cells) are found in the crypt domain of the organoid similar to the gastro-intestinal 
architecture. Cells move up the crypt, differentiating as they reach the villus domain, 
and are shed into the lumen (grey cells) (adapted from Koo & Clevers, 2014). 
 
systems. Efforts are now being made to generate these organoids in the chicken in 
our laboratory. 
6.7.3  Understanding bone metabolism in the chicken 
Femoral head separation is a common bone disorder seen in broilers that can 
lead to bacterial chondronecrosis with osteomyelitis. Excessive weight gain is 
thought to be the main cause of femoral head separation, as the pressure of the ball 
and joint of the femur restricts the flow of blood. The rapid increase in body mass is 
linked to the inability of the femur to keep pace with bone formation, leading to 
excessive osteoclast activity (Prisby et al., 2014). Skeletal disorders in broilers are 
linked to the inability of the skeleton to mature at rates sufficient to support the rapid 
growth of body mass. In the EU, there are over 350 million laying hens producing 
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100 billion eggs, annually. Over a third of these hens are reared under free-range 
conditions while the remaining two thirds are housed in furnished cages, a number 
likely to decrease due to the 2012 EU directive banning battery cage systems 
(Tarlton et al., 2013). The main concern about the increase in free-range chicken 
numbers is that up to 95% of these animals suffer bone breakage due to bone 
weakness and hazards of housing (Wilkins et al., 2011). Laying hens also require 
high amounts of calcium for the formation of the eggshells and therefore undergo 
extraordinarily intense calcium metabolism. Laying hens use nearly 10% of their 
body calcium levels for egg formation and around 50% of this is dietary derived. 
Therefore a considerable amount of calcium is taken from skeletal stores. During 
oviposition, osteoblast activity alters from cortical bone formation to medullary bone 
formation, a characteristic unique to birds and dinosaurs. Medullary bone is a source 
of calcium for egg shell formation usually found in the long bones of hens (legs), 
thereby contributing to bone weakness causing fractures. These fractures cause 
considerable pain and discomfort to the chickens, a serious animal welfare issue. 
There is evidence that the deficiency of dietary fatty acids may contribute to bone 
loss (Das, 2000). In mice, the lack of omega-3 leads to a reduction in 
osteoclastogenesis (Rahman et al., 2009) and in a more recent study an increase in 
omega-3 in the diet of free range chickens led to reduction in bone breakages 
(Tarlton et al., 2013).  
Osteoblast and osteoclast cell culture systems can be used to investigate the 
mechanism of bone formation and metabolism, allowing researchers to probe the 
cellular and molecular basis of bone diseases. Osteoblasts originate from the 
mesenchymal cell precursors whereas osteoclasts are derived from haematopoietic 
precursors of the myeloid lineage, present in the bone marrow and circulation 
(Collin-Osdoby & Osdoby, 2012). The essential osteoclast differentiation signal 
comes from RANKL, expressed by osteoblast cells, stromal cells and various cells in 
the bone marrow, causing osteoclast precursor cells to fuse and differentiate into 
large multinucleated cells with morphological features, such as membrane 
polarisation, ion pumps, enzyme activities and antigenic potential (Hall et al., 1996; 
Roodman, 1996). Osteoclasts perform bone pit reabsorption which needs to be 
carefully balanced with bone-forming osteoblast activity. The chicken is used as a 
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model for adolescent idiopathic scoliosis (AIS), a disease characterised by the lateral 
curvature of the spine (Machida et al., 1993; Coillard & Rivard, 1996). Thillard et al. 
(1959) reported the development of AID in pinealectomized chickens at 2 to 3 days 
old, called experimental pinealectomy (PNX) birds. The PNX birds had increased 
osteoclast cell numbers at the front of the growth plate three days post-
pinealectomization, which disappeared by day 6. This osteoclast activity is linked to 
the degradation of chondrocytes, leaving minimal cartilage matrix for osteoblasts to 
form new bone. Hypertrophic and proliferative chondrocyte cell numbers are 
increased in PTX chickens, leading to the increase in the thickness of the growth 
plate, leading to AIS (Aota et al., 2013). 
This thesis describes the ability of schRANKL and chCSF-1 to induce 
primary osteoclast cell differentiation from bone marrow-derived cells. These culture 
systems can be used study osteoclast phenotypes associated with knockout culture 
systems and will allow researchers to use in vitro culture systems to understand bone 
metabolism and effects of treatments, biomaterial safety and therapies in the chicken.  
6.7.4  ChRANKL as a potential vaccine adjuvant  
 The emergence of antibiotic-resistant bacteria has led to the need for 
alternative treatments for poultry diseases. The previous strategies to control disease 
in poultry flocks worldwide included in-feed antibiotics whose use has now been 
banned by the EU, which now relies heavily on vaccination and biosecurity. Feed 
additives have been extensively explored in chickens with growth promoters, 
immunomodulators or both being used to control disease in large commercial flocks. 
However, they are not cost-effective and can be a waste of energy in non-challenged 
birds (Guo et al., 2003; Huff et al., 2006; Kumar et al., 2011). Vaccination is 
considered the most effective way to control diseases in chickens. In recent years the 
development and use of subunit vaccines has increased due to the evidence that in 
some cases vaccination with live attenuated vaccines lead to higher virulence 
(Witter. 1997). Sub-unit vaccines can express a number of antigens with their 
production simpler, faster and safer than conventional vaccines. However, subunit 
vaccines are less immunogenic than conventional vaccines. Numerous studies have 
revealed the importance of the local cytokine microenvironment for the quality and 
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magnitude of the initial and ongoing responses to subunit vaccines. Therefore, 
certain cytokines have great appeal as potential vaccine adjuvants. 
ChCD40L expressed with M2e, an integral membrane protein of influenza A 
viruses (Pinto et al., 1992), conferred protection against low pathogenic avian 
influenza virus in chickens (Layton et al., 2009) and also contributed to reduced 
Salmonella colonisation and organ invasion in turkeys (O’Meara et al., 2010). The 
fusion of chCD40L with extracellular segments of HA increased the humoral 
response of chickens to H5N1 infection (Pose et al., 2011). These studies indicate the 
potential adjuvant properties of TNF superfamily members in the chicken. ChIL-2 
adjuvant properties have been described for a number of sub-unit vaccines. For 
example, the Eimeria tenella rhomboid protein and chIL-2 vaccine conferred partial 
protection against Eimeria infection compared to the vaccine not expressing chIL-2 
(Min et al., 2001).  
DNA immunisation is another effective way of inducing specific innate and 
humoral immune responses against various pathogens (Dunachie et al., 2006; Keitel 
et al., 2009). The use of plasmid DNA allows for precise immunisation against a 
plasmid expressing the gene or genes encoding the antigen, driving the synthesis of 
the antigen protein within the vaccinated host that will induce the production of 
antibodies. Cytokine adjuvants enhance the efficacy of DNA immunisation 
improving the immune response to the candidate DNA vaccine. For example, CSF-2 
enhances the immunogenicity of a HIV-1P24-Nef vaccine by recruiting DC to the 
site of the immune response and increasing the number of CTL (Mahdavi et al., 
2011). Recently, the adjuvant properties of chIL-18 were analysed in chickens 
vaccinated with a DNA vaccine expressing the VP243 gene from infectious bursal 
disease virus (IBDV). Compared to chickens immunized with the plasmid expressing 
only VP243, the administration of a plasmid expressing both VP243 and chIL-18 
induced higher levels of antibody production and increased levels of IL-4 and IFN-γ 
expression (Li et al., 2013). ChIL-6 adjuvant properties were demonstrated in 
animals vaccinated with the fimbrail Fae gene from the enterotoxigenic E. coli K88 
strain. Co-administration of Fae and chIL-6 expressing plasmids induced higher titres 
of anti-Fae mAb over a longer period than immunizing with Fae-expressing plasmid 
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alone (Cho et al., 2004). The adjuvant potential of chIL-1β has been demonstrated 
with tetanus toxoid where increased antibody production levels were induced 
compared to levels in chickens administered the antigen alone (Schijns et al., 2000).  
The adjuvant properties of mammalian RANKL have been analysed in 
vaccination programs. Plasmids encoding murine RANKL and the epitope trans-
sialidase surface antigen from Trypanosoma cruzi (T. cruzi), enhanced the induction 
of CD8
+
 T cells and improved the survival of mice infected with lethal doses of T. 
cruzi (Miyahira et al., 2003). Using an adenoviral vector, a model tumour antigen 
was co-expressed with either RANKL or CD40L to generate transgenic mice. Mice 
immunised with transgenic DC co-expressing the antigen and RANKL increased 
IFN-γ-producing cells, RANKL and RANK expression and CTL cell numbers 
compared to antigen alone and antigen co-expressed with CD40L-transgenic DC 
(Wiethe et al., 2003). Mice immunised against the HIV-1 Gag gene vaccine co-
expressing RANKL induced higher numbers of CD8
+
 T cells, IFN-γ production and 
enhanced T cell memory compared to mice immunized with the HIV-1 Gag gene 
vaccine alone. However, co-expression of RANKL was not as effective at inducing 
higher levels of IL-2 and anti-Gag mAb production as co-expression of other TNF 
superfamily members, such as CD40L, LIGHT and OX40L, with that antigen 
(Kanagavelu et al., 2012).  
The use of subunit vaccination in chickens is evolving and recent 
developments in the understanding of chicken innate immunity have seen an increase 
in vaccine adjuvant-based research (Xu et al., 2013; Li et al., 2013; Gupta et al., 
2014a; Gupta et al., 2014b; Zhao et al., 2014). The ability of chRANKL to enhance 
the expression of pro-inflammatory cytokines and survival of DC makes it a good 
candidate as a vaccine adjuvant.  
6.7.5  Understanding TRAF intracellular signalling induced by TNFR and Toll/IL-
1R superfamilies in the chicken 
TRAF family members are required for a number of biological processes 
activated by TNFR, Toll/IL-1R, RLR and NLR family members, either by direct 
binding or indirect binding via adaptor proteins. TRAF family members are therefore 
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critically involved in inflammation, innate and adaptive immune responses, and cell 
death (Inoue et al., 2000). However, in exaggerated immune responses, TRAF-
mediated cytokine expression has been linked to multiorgan failure and shock. 
Hence, TRAF proteins have central roles in signal transduction involved in the 
transactivation of genes linked to a multitude of biological processes involved in 
immunity.  
Viruses and bacteria have developed a variety of mechanisms to hijack or 
target TRAF family members to invade the immune response. For example, 
Mycobacterium tuberculosis-infected macrophages have an increased lifespan due to 
the upregulation of TRAF1 and TRAF2, linked to the upregulation of NF-κB 
(Ordway et al., 2005). Leishmania donovani neutralises the macrophage defence 
machinery by inhibiting TRAF3-mediated ubquitination of TAK-1, which is required 
for the activation of the TLR4-MyD88-Ubc13-TAK-1-TRAF6-cIAP1/2 complex 
leading to downstream activation of the MAPK kinases, JNK, ERK and p38 (Gupta 
et al., 2014). T cell-specific oncoproteins encoded by the old world monkey viruses 
Herpesvirus saimiri and Herpesvirus ateles utilise TRAF proteins to drive NF-κB 
activation. The herpesvirus oncoprotein, Tio, induces T cell leukaemia in humans by 
recruiting TRAF6 and blocking TRAF3, leading to the concomitant activation of NF-
κB (de Jong et al., 2010; de Jong et al., 2013). The HIV-encoded protein, Nef, binds 
to TRAF2 which is necessary for Nef-mediated activation of NF-κB in macrophages 
(Mangino et al., 2011).  
The overexpression of TRAF family members has been linked to a number of 
mammalian diseases. CD30 is a characteristic cell surface marker for T cells and the 
malignant cells of Hodgkin’s disease. High expression of CD30 leads to its 
aggregation and recruitment of TRAF2 and TRAF5 to its intracellular domain, 
constitutively activating NF-κB, characteristic of Hodgkin’s disease (Izban et al., 
2000; Horie et al., 2002). In B cell-chronic lymphocytic leukaemia (B-CLL), the 
inhibition of B cell apoptosis is linked to the overexpression of TRAF1 and TRAF2, 
which mediate the activation of NF-κB (Munzert et al., 2002).  
Understanding the pathogenesis and the immune mechanisms of protection 
against the pathogen is a prerequisite for preventing the disease. Chicken TRAF 
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family members may be targeted by avian viruses and bacteria to evade chicken 
immune responses. Similar to Hodgkin’s disease, chCD30 overexpression is seen on 
MDV-infected cells (Burgess et al., 2004). The induction of lymphomas due to MDV 
infection may involve the enhanced recruitment of TRAF family members, 
chTRAF2 and chTRAF5, to the intracellular domain of chCD30 leading to the 
enhanced activation of NF-κB. Clostridium perfringens-infected chickens increased 
mRNA expression levels of chTRAF6 (Lu et al., 2009). In a recent study, chTLR7 
activation significantly increased chTRAF6 mRNA expression levels in the spleens 
of MDV-infected chickens after 14 days but no change in chTRAF3 mRNA 
expression levels was observed (Jie et al., 2013). In BMDC, chTRAF6 mRNA 
expression levels were also significantly increased by stimulation with LPS, Bacillus 
subtilis and Saccharomyces boulardii, demonstrating that chTRAF6 is involved in 
TLR signalling in chicken APC (Rajput et al., 2013).  
In avian research, the detection of TRAF family members is becoming a 
means to understand the downstream signalling pathways initiated by viruses, yeast 
and bacterial infections (Rajput et al., 2013; Jie et al., 2013). However, with the 
identification of a novel chTRAF2 isoform and various chTRAF3 isoforms 
(unpublished data, Kate Sutton), the avian research community needs to be cautious 
in measuring chicken TRAFs before the full repertoire has been cloned and 
characterised and potential alternative isoforms have been identified. Exploiting 
TNFR family members for control of avian diseases will require a precise 
understanding of their in vivo regulation and downstream signalling pathways for a 
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Restriction enzyme buffers 
1X NEBuffer 1:  10mM Bis-Tris-Propane-HCL 
    10 mM MgCl2 
    1mM Dithiothreitol 
    pH 7.0  
Buffer H: 50 mM Tris-HCL (pH 7.5), 10 mM MgCL2, 100 mM 
NaCl, 1 mM Dithioerythritol, pH 7.5 
Qiagen molecular biology kit buffers 
RNeasy Mini Kit 
Buffer RTL (Lysis buffer)  contains guanidine thiocyanate 
Buffer RW1 
Buffer RPE (Wash buffer)  contains ethanol 
 
QIAquick PCR Purification Kit 
Buffer PB (binding buffer)  guanidine hydrochloride and isopropanol 
Buffer PE (wash buffer)   contains ethanol 
 
QIAquick Gel Extraction Kit 
Buffer QG (dissolving buffer)  contains guanidine thiocyanate 
Buffer PE (Wash buffer)  contains ethanol 
 
QIAprep Spin Mini prep Kit 
Buffer P1 (dissolving buffer) 50mM Tris-Cl (pH 8.0), 10 mM EDTA and  
 100 μg/ml RNase AwBuffer P2 (lysis buffer)
  200 mM NaOH and 1% SDS 
(w/v) 
Buffer N3 (neutraliser buffer)  contains guanidine hydrochloride 
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Buffer PB (binding buffer)  contains guanidine hydrochloride  
Buffer PE (wash buffer)  contains guanidine hydrochloride and ethanol 
 
EndoFree®Plasmind Purification Kits (Maxi) 
Buffer P1  50mM Tris-Cl (pH 8.0), 10 mM EDTA and  
 100 μg/ml RNase A 
Buffer P2    200 mM NaOH and 1% SDS (w/v) 
Buffer P3    3 M potassium acetate (CH3CO2K), pH 5.5 
Buffer ER                                    contains isopropanol and polyethylene glycol 
octylphenyl ether 
 
Buffer QBT (equilibrium buffer) 750 nM NaCl, 50 mM MOPS, pH 7.0, 15% 
isopropanol (v/v) and 0.15% Triton®X-100 
Buffer QC (wash Buffer) 1 nM NaCl, 50 mM MOPS, pH 7.0 and 15% 
isopropanol (v/v) 
Buffer QN (elution buffer) 1.6 M NaCl, 50 mM MOPS, pH 7.0 and 15% 
isopropanol (v/v) 
General Buffers  
FACS Buffer PBS, 0.5% (w/v) Bovine Serum Albumin 
(Sigma) and 0.05% Azide 
Versene 0.25 g KCL, 1.437 g Na2HPO4, 0.25 g KH2PO4, 
0.2 g EDTA, H2O to 11, pH 7.2 
ELISA Buffers: 
Coating Buffer: 15 mM Sodium carbonate, 35 mM Sodium 
bicarbonate, 3 mM Sodium azide  
Blocking Buffer: 0.2 g of casein in 1 l of PBS 
Wash Buffer: PBS, 0.05% Tween-20 (PBST) 
Substrate Buffer: Buffer A: 0.1 M Citric Acid (10.5 g Citric acid in 500 ml 
     dH2O)  
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Buffer B: 0.2 M Disodium hydrogen orthophosphate 
(14.2 g Na2HPO4 in 500 ml dH2O) 
 
25.7 ml of Buffer A + 24.3 ml of Buffer B + 1 o-phenylenediamine dihydrochloride 
tablet (OPD) (SIGMA P-8787)  +  30 l fresh H2O2. 
 
Stop Solution:    2 N H2SO4       
Non-Reducing buffer H2O, 0.5 M Tris-HCl, Glycerol, 10% SDS, 0.05%  and       
Bromophenol Blue 
Reducing Buffer  H2O, 0.5M Tris-HCl, Glycerol, 10% SDS, 0.05%       
Bromophenol Blue and 2-mercaptoethanol 
 
AutoMacs ProTM Cell Separator Buffers 
AutoMacs Pro
TM




 Running Buffer (1.5 litre) Bovine Serum Albumin, EDTA, 
PBS, 0.009% Azide and pH 7.2 
(2 μm filtered) 
Cell Culture Reagents 
COS-7 cell growth media  
DMEM 
10% Foetal calf serum (FCS)  
1% 200 mM L-glutamine 
500 μl 1000X Penicillin/streptomycin 
1% 100X Non-essential amino acids  
 
Cos-7 cell transfection media 
1% 200 mM L-glutamine 
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500 μl 1000X Penicillin/streptomycin 
1% 100X Non-essential amino acids 
 
HEK-293T growth media  
DMEM 
2% Foetal calf serum (FCS)  
1% 200 mM L-glutamine 
500 μl 1000X Penicillin/streptomycin 
1% 100X Non-essential amino acids  
 
BMDC growth media 
RPMI 
10% Chicken Serum (CS) 
1% 200 mM L-glutamine 
500 μl 1000X Penicillin/streptomycin 
 
BMDM growth media 
RPMI 
2% Chicken Serum  
3% FCS 
1% 200 mM L-glutamine 
500 μl 1000X Penicillin/streptomycin 
 
Bone marrow-derived osteoclasts growth media  
5% Chicken Serum  
5% FCS  
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1% 200 mM L-glutamine 
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Table 1 Primers designed for sequencing cDNA and sub-cloned cDNA into 
sequencing and expression plasmids.  













extracellular domain of 
RANK for insertion into 

























extracellular domain of 












Primer name Plasmid name Sequence (5'-3') 
T7 pGEM T-EASY/pcDNA3-HA TAATACGACTCACTATAGG  
Sp6 (reverse) pGEM T-EASY ATTTAGGTGACACTATAG 
pKW06F pKW06/pKW07 CAGTTCAATTACAGCTCTTAA 



















































Table 2 Primers designed to clone and subclone chRANKL, chRANK, chOPG, 
chTRAF2, chTRAF5, chTRAF6 and chTRAF7. Italic and underline indicate the 
location of the intregated restriction digestion sites for subcloning.  





Exon 3 and exon 5 













Exon 1 and exon 6 
Table 3 Primers designed for RT-PCR analysis of chTRAF2, chTRAF5, chTRAF6 
and chTRAF7 mRNA expression levels. 























































Table 4 Primers and probes designed for qRT-PCR (TaqMan®). F=forward primer, 



























Table 5 Ensembl Accession Numbers of TRAF sequences used for phylogenetic 
analysis.  









































Appendix 3  





Figure 7.1 Subcloning of chTRAF2 cDNA into a modified pcDNA3 vector 
expressing an NH2~terminal HA-tag. ChTRAF2 was subcloned into the EcoR1 
(red) and XbaI (green) restriction sites of pcDNA-3-HA.The box indicates the HA-
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Table 6 The Primary and secondary monoclonal antibodies used for the separation 
of chicken splenocyte subsets using an AutoMacs pro-separator. Cell numbers before 
and after separation are indicated. 
 
Target Information Dilution Secondary  
 
MHC Class II 
Mouse anti-chicken 
MHC class II IgG1 (Gift 
from Colin Butter, IAH. 
UK) 






CD40/AV79 IgG2a  
(Serotec/MCA2836) 









1:500 Goat anti-mouse-IgG1-FITC 
(Southern Biotech/1070-02) 
at 1:2000 
Table 7 Monoclonal antibodies and dilutions used for analysis of cell surface 
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KUL01 Mouse anti-chicken 
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Figure 2 FACS analysis of splenocyte subsets purified using an AutoMacs pro- 
seperator. Unsorted cells (black lines) and sorted cells (grey lines) for CD4, CD8β, 
TCRγδ, TCRαβ1/αβ2, KUL01 and Bu1 subsets. Data represent the results of one of 









Figure 3 FACS gating strategy. Prior to FACS analysis of BMDC or BMDM the 
viability dye 7-AAD was added to cells. Cells stained with 7-AAD were removed for 
data analysis by gating around the large FL3
-
 cell population. Cells were also 
analysed for non-specific binding using isotype controls. In the example used above 
BMDC stimulated with LPS (1 ng/ml) for 24 h were stained with mouse anti-chicken 
CD40 mAb and expression levels were analysed using histograms comparing isotype 
control to CD40 surface expression. 
